Anteriormente	O	-
informamos	O	-
que	O	-
el	O	-
tratamiento	O	-
de	O	-
pacientes	O	-
con	O	-
cáncer	O	-
avanzado	O	-
de	O	-
pulmón	O	-
no	O	-
microcítico	O	-
sintomático	O	-
con	O	-
un	O	-
solo	O	-
agente	O	-
Gemcitabina	O	-
(	O	-
GEM	O	-
)	O	-
dio	O	-
lugar	O	-
a	O	-
una	O	-
tasa	O	-
de	O	-
respuesta	O	-
clínica-beneficio	O	-
superior	O	-
(RR	O	-
)	O	-
en	O	-
comparación	O	-
con	O	-
la	O	-
quimioterapia	O	-
combinada	O	-
basada	O	-
en	O	-
cisplatino.	O	-

Ahora	O	-
reportamos	O	-
el	O	-
análisis	O	-
individual	O	-
detallado	O	-
de	O	-
control	O	-
de	O	-
síntomas,	O	-
y	O	-
la	O	-
influencia	O	-
del	O	-
uso	O	-
de	O	-
cisplatino,	O	-
la	O	-
edad,	O	-
el	O	-
estado	O	-
de	O	-
rendimiento	O	-
(	O	-
PS	O	-
)	O	-
y	O	-
la	O	-
duración	O	-
del	O	-
tratamiento.	O	-

Los	O	-
pacientes	O	-
recibieron	O	-
GEM	O	-
(	O	-
1000	O	-
mg/m	O	-
(	O	-
2	O	-
),	O	-
días	O	-
1,	O	-
8	O	-
y	O	-
15	O	-
)	O	-
o	O	-
cisplatino	O	-
(	O	-
100	O	-
mg/m	O	-
(	O	-
2	O	-
),	O	-
día	O	-
1	O	-
)	O	-
más	O	-
Vindesina	O	-
(	O	-
3	O	-
mg/m	O	-
(	O	-
2	O	-
),	O	-
días	O	-
1	O	-
y	O	-
15	O	-
)	O	-
(	O	-
PV	O	-
),	O	-
ambos	O	-
cada	O	-
4	O	-
semanas.	O	-

Los	O	-
puntajes	O	-
de	O	-
9	O	-
síntomas	O	-
fueron	O	-
listados	O	-
semanalmente	O	-
por	O	-
el	O	-
paciente	O	-
en	O	-
escalas	O	-
analógicas	O	-
visuales.	O	-

La	O	-
mejoría	O	-
de	O	-
un	O	-
síntoma	O	-
se	O	-
definió	O	-
como	O	-
2	O	-
ciclos	O	-
consecutivos	O	-
de	O	-
mejoría	O	-
respecto	O	-
al	O	-
valor	O	-
basal.	O	-

Los	O	-
síntomas	O	-
basales	O	-
en	O	-
los	O	-
169	O	-
pacientes	O	-
estuvieron	O	-
bien	O	-
equilibrados	O	-
entre	O	-
los	O	-
2	O	-
brazos	O	-
(	O	-
84	O	-
GEM,	O	-
85	O	-
PV	O	-
).	O	-

Ambos	B-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
objetiva	I-Premise	HighQuality
y	I-Premise	HighQuality
estabilización	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
claramente	I-Premise	HighQuality
un	I-Premise	HighQuality
mejor	I-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
que	I-Premise	HighQuality
aquellos	I-Premise	HighQuality
con	I-Premise	HighQuality
progresión	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad.	I-Premise	HighQuality

El	B-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
brazos	I-Premise	HighQuality
fue	I-Premise	HighQuality
similar	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
específicos	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad,	I-Premise	HighQuality
como	I-Premise	HighQuality
tos,	I-Premise	HighQuality
disnea,	I-Premise	HighQuality
dolor	I-Premise	HighQuality
o	I-Premise	HighQuality
hemoptisis.	I-Premise	HighQuality

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
PV,	I-Premise	HighQuality
un	I-Premise	HighQuality
número	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
GEM	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
mejores	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
para	I-Premise	HighQuality
ítems	I-Premise	HighQuality
'constitucionales'	I-Premise	HighQuality
tales	I-Premise	HighQuality
como	I-Premise	HighQuality
anorexia	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,007	I-Premise	HighQuality
),	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
para	I-Premise	HighQuality
continuar	I-Premise	HighQuality
con	I-Premise	HighQuality
las	I-Premise	HighQuality
actividades	I-Premise	HighQuality
diarias	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,04	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
impresión	I-Premise	HighQuality
global	I-Premise	HighQuality
de	I-Premise	HighQuality
calidad	I-Premise	HighQuality
de	I-Premise	HighQuality
vida	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,008	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
fue	I-Premise	HighQuality
muy	I-Premise	HighQuality
similar	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
más	I-Premise	HighQuality
jóvenes	I-Premise	HighQuality
(	I-Premise	HighQuality
<	I-Premise	HighQuality
65	I-Premise	HighQuality
años	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
mayores	I-Premise	HighQuality
(	I-Premise	HighQuality
>	I-Premise	HighQuality
/	I-Premise	HighQuality
=	I-Premise	HighQuality
65	I-Premise	HighQuality
años	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
sólo	I-Premise	HighQuality
ligeramente	I-Premise	HighQuality
mejor	I-Premise	HighQuality
en	I-Premise	HighQuality
aquellos	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
PS	I-Premise	HighQuality
de	I-Premise	HighQuality
Karnofsky	I-Premise	HighQuality
>	I-Premise	HighQuality
/	I-Premise	HighQuality
=	I-Premise	HighQuality
80	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
<	I-Premise	HighQuality
80	I-Premise	HighQuality
%.	I-Premise	HighQuality

La	B-Premise	HighQuality
mayor	I-Premise	HighQuality
parte	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
ocurrió	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
primeros	I-Premise	HighQuality
3	I-Premise	HighQuality
ciclos,	I-Premise	HighQuality
con	I-Premise	HighQuality
alguna	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
adicional	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
GEM	I-Premise	HighQuality
solamente.	I-Premise	HighQuality

Tanto	B-Claim	HighQuality
el	I-Claim	HighQuality
GEM	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
PV	I-Claim	HighQuality
producen	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
muy	I-Claim	HighQuality
superior	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
esperada	I-Claim	HighQuality
por	I-Claim	HighQuality
el	I-Claim	HighQuality
tumor	I-Claim	HighQuality
objetivo	I-Claim	HighQuality
RR.	I-Claim	HighQuality

El	B-Claim	HighQuality
GEM	I-Claim	HighQuality
es	I-Claim	HighQuality
igualmente	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
"	I-Claim	HighQuality
específicos	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
enfermedad	I-Claim	HighQuality
",	I-Claim	HighQuality
pero	I-Claim	HighQuality
superior	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
"	I-Claim	HighQuality
constitucionales	I-Claim	HighQuality
".	I-Claim	HighQuality

La	B-Premise	HighQuality
mayor	I-Premise	HighQuality
parte	I-Premise	HighQuality
del	I-Premise	HighQuality
control	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
se	I-Premise	HighQuality
logró	I-Premise	HighQuality
durante	I-Premise	HighQuality
los	I-Premise	HighQuality
primeros	I-Premise	HighQuality
3	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
con	I-Premise	HighQuality
algunas	I-Premise	HighQuality
mejoras	I-Premise	HighQuality
posteriores	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
GEM	I-Premise	HighQuality
solamente.	I-Premise	HighQuality

Comparar	O	-
los	O	-
resultados	O	-
a	O	-
1	O	-
año	O	-
de	O	-
la	O	-
trabeculotomía	O	-
circunferencial	O	-
asistida	O	-
por	O	-
microcatéteres	O	-
iluminados	O	-
(	O	-
IMCT	O	-
)	O	-
frente	O	-
a	O	-
la	O	-
trabeculotomía	O	-
parcial	O	-
convencional	O	-
(	O	-
CPT	O	-
)	O	-
para	O	-
el	O	-
glaucoma	O	-
congénito	O	-
primario	O	-
(	O	-
PCG	O	-
).	O	-

Cuarenta	O	-
ojos	O	-
de	O	-
31	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
congénito	O	-
primario	O	-
unilateral	O	-
o	O	-
bilateral	O	-
de	O	-
menos	O	-
de	O	-
2	O	-
años	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
someterse	O	-
a	O	-
IMCT	O	-
(	O	-
20	O	-
ojos	O	-
)	O	-
o	O	-
CPT	O	-
(	O	-
20	O	-
ojos	O	-
).	O	-

La	O	-
medida	O	-
del	O	-
resultado	O	-
primario	O	-
fue	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
).	O	-

El	O	-
criterio	O	-
de	O	-
éxito	O	-
se	O	-
definió	O	-
como	O	-
PIO	O	-
≤	O	-
12	O	-
mm	O	-
Hg	O	-
sin	O	-
y	O	-
con	O	-
medicamentos	O	-
antiglaucoma	O	-
(éxito	O	-
absoluto	O	-
y	O	-
éxito	O	-
calificado,	O	-
respectivamente).	O	-

La	O	-
edad	O	-
media	O	-
de	O	-
nuestra	O	-
población	O	-
estudiada	O	-
fue	O	-
de	O	-
8,35	O	-
±	O	-
1,2	O	-
meses.	O	-

La	O	-
PIO	O	-
media	O	-
preoperatoria	O	-
fue	O	-
de	O	-
24,70	O	-
±	O	-
3,90	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
IMCT	O	-
y	O	-
24,60	O	-
±	O	-
3,31	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
CPT.	O	-

Ambos	O	-
grupos	O	-
fueron	O	-
comparables	O	-
con	O	-
respecto	O	-
a	O	-
la	O	-
PIO	O	-
preoperatoria,	O	-
claridad	O	-
corneal,	O	-
diámetro	O	-
corneal,	O	-
relación	O	-
vertical	O	-
taza-disco	O	-
y	O	-
error	O	-
refractivo.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
tratado	I-Premise	HighQuality
con	I-Premise	HighQuality
IMCT,	I-Premise	HighQuality
se	I-Premise	HighQuality
alcanzó	I-Premise	HighQuality
la	I-Premise	HighQuality
canulación	I-Premise	HighQuality
de	I-Premise	HighQuality
360	I-Premise	HighQuality
grados	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
80	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
16/20	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos.	I-Premise	HighQuality

Para	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
IMCT	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
CPT,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
éxito	I-Premise	HighQuality
absoluto	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
80	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
16/20	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
60	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
12/20	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
éxito	I-Premise	HighQuality
cualificadas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
90	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
18/20	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
70	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
14/20	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Ambos	B-Claim	HighQuality
procedimientos	I-Claim	HighQuality
produjeron	I-Claim	HighQuality
una	I-Claim	HighQuality
reducción	I-Claim	HighQuality
estadísticamente	I-Claim	HighQuality
significativa	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO,	I-Claim	HighQuality
y	O	-
los	B-Premise	HighQuality
ojos	I-Premise	HighQuality
sometidos	I-Premise	HighQuality
a	I-Premise	HighQuality
IMCT	I-Premise	HighQuality
alcanzaron	I-Premise	HighQuality
una	I-Premise	HighQuality
PIO	I-Premise	HighQuality
menor	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
PTC	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
(	I-Premise	HighQuality
9,5	I-Premise	HighQuality
±	I-Premise	HighQuality
2,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
y	I-Premise	HighQuality
11,7	I-Premise	HighQuality
±	I-Premise	HighQuality
2,1	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Claim	HighQuality
el	I-Claim	HighQuality
glaucoma	I-Claim	HighQuality
congencial	I-Claim	HighQuality
primario,	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculotomía	I-Claim	HighQuality
circunferencial	I-Claim	HighQuality
de	I-Claim	HighQuality
360	I-Claim	HighQuality
grados	I-Claim	HighQuality
asistida	I-Claim	HighQuality
por	I-Claim	HighQuality
microcatéter	I-Claim	HighQuality
iluminado	I-Claim	HighQuality
se	I-Claim	HighQuality
realizó	I-Claim	HighQuality
mejor	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculotomía	I-Claim	HighQuality
parcial	I-Claim	HighQuality
convencional	I-Claim	HighQuality
a	I-Claim	HighQuality
1	I-Claim	HighQuality
año	I-Claim	HighQuality
de	I-Claim	HighQuality
seguimiento	I-Claim	HighQuality
y	I-Claim	HighQuality
resultó	I-Claim	HighQuality
en	I-Claim	HighQuality
mediciones	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
más	I-Claim	HighQuality
bajas	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO.	I-Claim	HighQuality

El	O	-
receptor	O	-
oral	O	-
tipo	O	-
peaje	O	-
(TLR	O	-
)	O	-
7	O	-
agonista	O	-
GS-9620	O	-
tiene	O	-
efectos	O	-
antivirales	O	-
en	O	-
los	O	-
modelos	O	-
de	O	-
leña	O	-
y	O	-
chimpancés	O	-
de	O	-
infección	O	-
crónica	O	-
por	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB	O	-
).	O	-

Se	O	-
investigó,	O	-
en	O	-
un	O	-
ensayo	O	-
clínico,	O	-
la	O	-
capacidad	O	-
de	O	-
este	O	-
agente	O	-
para	O	-
reconstituir	O	-
la	O	-
inmunidad	O	-
protectora	O	-
en	O	-
pacientes	O	-
con	O	-
infección	O	-
crónica	O	-
por	O	-
VHB.	O	-

Se	O	-
realizó	O	-
un	O	-
estudio	O	-
prospectivo	O	-
de	O	-
28	O	-
pacientes	O	-
con	O	-
supresión	O	-
de	O	-
la	O	-
infección	O	-
por	O	-
VHB	O	-
mediante	O	-
terapia	O	-
analógica	O	-
de	O	-
nucleos	O	-
(t)	O	-
ide	O	-
y	O	-
que	O	-
dieron	O	-
negativo	O	-
para	O	-
el	O	-
antígeno	O	-
de	O	-
hepatitis	O	-
B	O	-
e	O	-
en	O	-
4	O	-
centros	O	-
médicos	O	-
de	O	-
Italia.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
(	O	-
1:3:3:3	O	-
)	O	-
a	O	-
grupos	O	-
tratados	O	-
con	O	-
placebo	O	-
o	O	-
a	O	-
diferentes	O	-
dosis	O	-
de	O	-
GS-9620	O	-
(	O	-
1,	O	-
2,	O	-
y	O	-
4	O	-
mg,	O	-
semanalmente	O	-
durante	O	-
12	O	-
semanas	O	-
).	O	-

Se	O	-
añadieron	O	-
datos	O	-
de	O	-
8	O	-
pacientes	O	-
tratados	O	-
con	O	-
nucleos	O	-
(	O	-
t	O	-
)	O	-
ide	O	-
análogo	O	-
al	O	-
grupo	O	-
placebo	O	-
(controles	O	-
)	O	-
;	O	-
13	O	-
pacientes	O	-
no	O	-
tratados	O	-
previamente	O	-
con	O	-
infección	O	-
crónica	O	-
por	O	-
el	O	-
VHB	O	-
y	O	-
15	O	-
sujetos	O	-
que	O	-
se	O	-
recuperaron	O	-
espontáneamente	O	-
de	O	-
una	O	-
infección	O	-
aguda	O	-
por	O	-
el	O	-
VHB	O	-
sirvieron	O	-
como	O	-
controles	O	-
adicionales.	O	-

Se	O	-
recogieron	O	-
células	O	-
mononucleares	O	-
de	O	-
sangre	O	-
periférica	O	-
al	O	-
inicio,	O	-
durante	O	-
la	O	-
administración	O	-
de	O	-
GS-9620	O	-
o	O	-
placebo	O	-
y	O	-
12	O	-
semanas	O	-
después.	O	-

El	O	-
fenotipo	O	-
y	O	-
la	O	-
función	O	-
de	O	-
las	O	-
células	O	-
T	O	-
naturales	O	-
asesinas	O	-
(	O	-
NK	O	-
)	O	-
y	O	-
específicas	O	-
del	O	-
VHB	O	-
fueron	O	-
analizados	O	-
por	O	-
citometría	O	-
de	O	-
flujo.	O	-

Las	O	-
células	O	-
T	O	-
fueron	O	-
expandidas	O	-
por	O	-
incubación	O	-
con	O	-
péptidos	O	-
de	O	-
todo	O	-
el	O	-
proteoma	O	-
del	O	-
VHB	O	-
y	O	-
estudiadas	O	-
después	O	-
de	O	-
la	O	-
noche	O	-
o	O	-
10	O	-
días	O	-
de	O	-
cultivo.	O	-

La	O	-
inhibición	O	-
de	O	-
células	O	-
NK	O	-
de	O	-
las	O	-
respuestas	O	-
de	O	-
células	O	-
T	O	-
se	O	-
midió	O	-
evaluando	O	-
la	O	-
producción	O	-
de	O	-
citocinas	O	-
por	O	-
células	O	-
T	O	-
estimuladas	O	-
con	O	-
péptidos	O	-
en	O	-
presencia	O	-
o	O	-
ausencia	O	-
de	O	-
células	O	-
NK.	O	-

Las	B-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
recogidas	I-Premise	HighQuality
al	I-Premise	HighQuality
inicio	I-Premise	HighQuality
antes	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
adición	I-Premise	HighQuality
de	I-Premise	HighQuality
GS-9620,	I-Premise	HighQuality
cuando	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
sólo	I-Premise	HighQuality
recibían	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
nucleos	I-Premise	HighQuality
(	I-Premise	HighQuality
t	I-Premise	HighQuality
)	I-Premise	HighQuality
ide,	I-Premise	HighQuality
tenían	I-Premise	HighQuality
respuestas	I-Premise	HighQuality
al	I-Premise	HighQuality
VHB	I-Premise	HighQuality
mayores	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
no	I-Premise	HighQuality
tratados	I-Premise	HighQuality
previamente,	I-Premise	HighQuality
basadas	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
producción	I-Premise	HighQuality
de	I-Premise	HighQuality
citocinas	I-Premise	HighQuality
en	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
péptidos	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB.	I-Premise	HighQuality

Sin	B-Premise	HighQuality
embargo,	I-Premise	HighQuality
durante	I-Premise	HighQuality
o	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
administración	I-Premise	HighQuality
de	I-Premise	HighQuality
GS-9620,	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
niveles	I-Premise	HighQuality
más	I-Premise	HighQuality
altos	I-Premise	HighQuality
de	I-Premise	HighQuality
citocinas	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal.	I-Premise	HighQuality

La	B-Premise	HighQuality
activación	I-Premise	HighQuality
y	I-Premise	HighQuality
función	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
NK	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
GS-9620,	I-Premise	HighQuality
pero	I-Premise	HighQuality
la	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
NK	I-Premise	HighQuality
para	I-Premise	HighQuality
suprimir	I-Premise	HighQuality
las	I-Premise	HighQuality
respuestas	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
fue	I-Premise	HighQuality
menor	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
GS-9620	I-Premise	HighQuality
que	I-Premise	HighQuality
antes.	I-Premise	HighQuality

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
función	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
T	I-Premise	HighQuality
o	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
células	I-Premise	HighQuality
NK	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
correlacionaron	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B.	I-Premise	HighQuality

Los	B-Premise	HighQuality
niveles	I-Premise	HighQuality
séricos	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
no	I-Premise	HighQuality
disminuyeron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
que	I-Premise	HighQuality
se	I-Premise	HighQuality
administró	I-Premise	HighQuality
ninguna	I-Premise	HighQuality
dosis	I-Premise	HighQuality
de	I-Premise	HighQuality
GS-9620.	I-Premise	HighQuality

La	B-Claim	HighQuality
administración	I-Claim	HighQuality
de	I-Claim	HighQuality
GS-9620	I-Claim	HighQuality
durante	I-Claim	HighQuality
12	I-Claim	HighQuality
semanas	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
ningún	I-Claim	HighQuality
efecto	I-Claim	HighQuality
significativo	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
niveles	I-Claim	HighQuality
séricos	I-Claim	HighQuality
de	I-Claim	HighQuality
antígenos	I-Claim	HighQuality
de	I-Claim	HighQuality
superficie	I-Claim	HighQuality
de	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B,	I-Claim	HighQuality
pero	I-Claim	HighQuality
pareció	I-Claim	HighQuality
aumentar	I-Claim	HighQuality
las	I-Claim	HighQuality
respuestas	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
T	I-Claim	HighQuality
y	I-Claim	HighQuality
células	I-Claim	HighQuality
NK	I-Claim	HighQuality
y	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
capacidad	I-Claim	HighQuality
de	I-Claim	HighQuality
NK	I-Claim	HighQuality
para	I-Claim	HighQuality
suprimir	I-Claim	HighQuality
las	I-Claim	HighQuality
células	I-Claim	HighQuality
T.	I-Claim	HighQuality

Por	B-Claim	HighQuality
lo	I-Claim	HighQuality
tanto,	I-Claim	HighQuality
la	I-Claim	HighQuality
GS-9620	I-Claim	HighQuality
podría	I-Claim	HighQuality
incluirse	I-Claim	HighQuality
en	I-Claim	HighQuality
terapias	I-Claim	HighQuality
para	I-Claim	HighQuality
aumentar	I-Claim	HighQuality
la	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
inmune	I-Claim	HighQuality
al	I-Claim	HighQuality
VHB.	I-Claim	HighQuality

La	O	-
adhesión	O	-
a	O	-
la	O	-
nutrición	O	-
adecuada	O	-
y	O	-
la	O	-
ingesta	O	-
de	O	-
líquidos	O	-
es	O	-
una	O	-
de	O	-
las	O	-
partes	O	-
esenciales	O	-
del	O	-
tratamiento	O	-
de	O	-
insuficiencia	O	-
renal	O	-
crónica	O	-
para	O	-
lograr	O	-
los	O	-
resultados	O	-
deseados	O	-
entre	O	-
los	O	-
pacientes	O	-
con	O	-
hemodiálisis.	O	-

Entre	O	-
los	O	-
diversos	O	-
métodos	O	-
de	O	-
capacitación,	O	-
el	O	-
método	O	-
de	O	-
los	O	-
"	O	-
grupos	O	-
pequeños	O	-
",	O	-
como	O	-
método	O	-
avanzado,	O	-
puede	O	-
ser	O	-
realizado	O	-
por	O	-
los	O	-
enfermeros	O	-
para	O	-
lograr	O	-
resultados	O	-
terapéuticos	O	-
deseables.	O	-

El	O	-
objetivo	O	-
del	O	-
presente	O	-
estudio	O	-
fue	O	-
investigar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
adecuada	O	-
formación	O	-
nutricional	O	-
en	O	-
pequeños	O	-
grupos	O	-
sobre	O	-
los	O	-
parámetros	O	-
de	O	-
laboratorio	O	-
en	O	-
pacientes	O	-
hemodiálisis.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico,	O	-
64	O	-
pacientes	O	-
que	O	-
cumplieron	O	-
los	O	-
criterios	O	-
de	O	-
inclusión	O	-
fueron	O	-
seleccionados	O	-
aleatoriamente	O	-
y	O	-
divididos	O	-
en	O	-
un	O	-
grupo	O	-
de	O	-
intervención	O	-
y	O	-
un	O	-
grupo	O	-
control.	O	-

Posteriormente,	O	-
se	O	-
realizó	O	-
un	O	-
programa	O	-
de	O	-
entrenamiento	O	-
nutricional	O	-
apropiado,	O	-
incluyendo	O	-
conferencias	O	-
junto	O	-
con	O	-
folletos	O	-
nutricionales	O	-
apropiados	O	-
en	O	-
tres	O	-
sesiones	O	-
de	O	-
preguntas	O	-
y	O	-
respuestas	O	-
de	O	-
una	O	-
hora.	O	-

Treinta	O	-
y	O	-
dos	O	-
pacientes	O	-
en	O	-
cada	O	-
grupo	O	-
fueron	O	-
asignados	O	-
a	O	-
grupos	O	-
de	O	-
intervención	O	-
de	O	-
cinco.	O	-

Luego,	O	-
los	O	-
indicadores	O	-
de	O	-
laboratorio	O	-
para	O	-
cada	O	-
paciente	O	-
fueron	O	-
medidos	O	-
en	O	-
cada	O	-
grupo	O	-
un	O	-
mes	O	-
después	O	-
del	O	-
entrenamiento.	O	-

Posteriormente,	O	-
el	O	-
análisis	O	-
de	O	-
los	O	-
datos	O	-
se	O	-
realizó	O	-
utilizando	O	-
estadísticas	O	-
descriptivas	O	-
y	O	-
analíticas	O	-
(	O	-
pruebas	O	-
estadísticas	O	-
que	O	-
incluyen	O	-
pruebas	O	-
t	O	-
independientes,	O	-
pruebas	O	-
t	O	-
emparejadas,	O	-
medidas	O	-
repetidas	O	-
y	O	-
ANOVA	O	-
)	O	-
en	O	-
el	O	-
software	O	-
SPSS	O	-
V.16.	O	-

La	O	-
edad	O	-
media	O	-
de	O	-
los	O	-
pacientes	O	-
fue	O	-
de	O	-
50,1	O	-
±	O	-
13,1	O	-
años	O	-
;	O	-
el	O	-
47,5%	O	-
de	O	-
ellos	O	-
habían	O	-
sido	O	-
sometidos	O	-
a	O	-
diálisis	O	-
por	O	-
hipertensión	O	-
arterial	O	-
y	O	-
el	O	-
55,7%	O	-
tenían	O	-
antecedentes	O	-
de	O	-
1-5	O	-
años	O	-
de	O	-
hemodiálisis.	O	-

Hubo	B-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
significativa	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
post-intervención	I-Premise	HighQuality
de	I-Premise	HighQuality
urea,	I-Premise	HighQuality
creatinina,	I-Premise	HighQuality
sodio,	I-Premise	HighQuality
potasio,	I-Premise	HighQuality
calcio	I-Premise	HighQuality
y	I-Premise	HighQuality
fósforo	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

Una	B-Claim	HighQuality
adecuada	I-Claim	HighQuality
formación	I-Claim	HighQuality
nutricional	I-Claim	HighQuality
a	I-Claim	HighQuality
través	I-Claim	HighQuality
del	I-Claim	HighQuality
método	I-Claim	HighQuality
de	I-Claim	HighQuality
grupos	I-Claim	HighQuality
pequeños	I-Claim	HighQuality
para	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
en	I-Claim	HighQuality
hemodiálisis	I-Claim	HighQuality
puede	I-Claim	HighQuality
imponer	I-Claim	HighQuality
efectos	I-Claim	HighQuality
positivos	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
parámetros	I-Claim	HighQuality
de	I-Claim	HighQuality
laboratorio.	I-Claim	HighQuality

En	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica,	I-Claim	HighQuality
el	I-Claim	HighQuality
tenofovir	I-Claim	HighQuality
disoproxil	I-Claim	HighQuality
fumarato	I-Claim	HighQuality
(	I-Claim	HighQuality
TDF	I-Claim	HighQuality
)	I-Claim	HighQuality
más	I-Claim	HighQuality
interferón	I-Claim	HighQuality
pegilado	I-Claim	HighQuality
(	I-Claim	HighQuality
PEG-IFN	I-Claim	HighQuality
)	I-Claim	HighQuality
durante	I-Claim	HighQuality
48	I-Claim	HighQuality
semanas	I-Claim	HighQuality
da	I-Claim	HighQuality
lugar	I-Claim	HighQuality
a	I-Claim	HighQuality
tasas	I-Claim	HighQuality
más	I-Claim	HighQuality
altas	I-Claim	HighQuality
de	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
del	I-Claim	HighQuality
antígeno	I-Claim	HighQuality
de	I-Claim	HighQuality
superficie	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
(	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
)	I-Claim	HighQuality
que	I-Claim	HighQuality
cualquiera	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
dos	I-Claim	HighQuality
monoterapias.	I-Claim	HighQuality

Identificar	O	-
los	O	-
factores	O	-
basales	O	-
y	O	-
durante	O	-
el	O	-
tratamiento	O	-
asociados	O	-
con	O	-
la	O	-
pérdida	O	-
de	O	-
HBsAg	O	-
en	O	-
la	O	-
Semana	O	-
72	O	-
y	O	-
proporcionar	O	-
un	O	-
modelo	O	-
para	O	-
predecir	O	-
la	O	-
pérdida	O	-
de	O	-
HBsAg	O	-
en	O	-
pacientes	O	-
que	O	-
reciben	O	-
terapia	O	-
de	O	-
combinación	O	-
durante	O	-
48	O	-
semanas.	O	-

Un	O	-
análisis	O	-
secundario	O	-
de	O	-
los	O	-
datos	O	-
de	O	-
un	O	-
ensayo	O	-
abierto	O	-
en	O	-
el	O	-
que	O	-
los	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
TDF	O	-
(	O	-
300	O	-
mg/día,	O	-
oral	O	-
)	O	-
más	O	-
PEG-IFN	O	-
(	O	-
IP,	O	-
180	O	-
μg/semana,	O	-
subcutáneo	O	-
)	O	-
durante	O	-
48	O	-
semanas	O	-
(	O	-
TDF/PI-48w	O	-
)	O	-
;	O	-
TDF	O	-
más	O	-
PEG-IFN	O	-
durante	O	-
16	O	-
semanas,	O	-
TDF	O	-
durante	O	-
32	O	-
semanas	O	-
(	O	-
TDF/PI-16w	O	-
+	O	-
TDF-32w	O	-
)	O	-
;	O	-
TDF	O	-
durante	O	-
120	O	-
semanas	O	-
(	O	-
TDF-120w	O	-
)	O	-
o	O	-
PEG-IFN	O	-
durante	O	-
48	O	-
semanas	O	-
(	O	-
PI-48w	O	-
).	O	-

Se	O	-
utilizaron	O	-
métodos	O	-
de	O	-
regresión	O	-
logística	O	-
para	O	-
identificar	O	-
modelos	O	-
que	O	-
predijeron	O	-
mejor	O	-
la	O	-
pérdida	O	-
de	O	-
HBsAg	O	-
en	O	-
la	O	-
Semana	O	-
72.	O	-

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
superiores	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF/PI-48w	I-Premise	HighQuality
(	I-Premise	HighQuality
6,5	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF/PI-16w+TDF-32w	I-Premise	HighQuality
(	I-Premise	HighQuality
0,5%	I-Premise	HighQuality
),	I-Premise	HighQuality
TDF-120w	I-Premise	HighQuality
(	I-Premise	HighQuality
0	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
PI-48w	I-Premise	HighQuality
(	I-Premise	HighQuality
2,2	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,09	I-Premise	HighQuality
).	I-Premise	HighQuality

El	O	-
único	O	-
factor	O	-
basal	O	-
asociado	O	-
a	O	-
la	O	-
respuesta	O	-
fue	O	-
el	O	-
genotipo	O	-
A.	O	-
La	B-Premise	HighQuality
disminución	I-Premise	HighQuality
del	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
12	I-Premise	HighQuality
ó	I-Premise	HighQuality
24	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
del	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
(p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
disminución	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
>	I-Premise	HighQuality
3,5	I-Premise	HighQuality
log10	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
24	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF/PI-48w	I-Premise	HighQuality
resultó	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
valor	I-Premise	HighQuality
predictivo	I-Premise	HighQuality
positivo	I-Premise	HighQuality
del	I-Premise	HighQuality
85	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
valor	I-Premise	HighQuality
predictivo	I-Premise	HighQuality
negativo	I-Premise	HighQuality
del	I-Premise	HighQuality
99	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72.	I-Premise	HighQuality

La	B-Claim	HighQuality
disminución	I-Claim	HighQuality
de	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
semana	I-Claim	HighQuality
24	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
combinado	I-Claim	HighQuality
TDF	I-Claim	HighQuality
más	I-Claim	HighQuality
PEG-IFN	I-Claim	HighQuality
puede	I-Claim	HighQuality
identificar	I-Claim	HighQuality
a	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
que,	I-Claim	HighQuality
después	I-Claim	HighQuality
de	I-Claim	HighQuality
completar	I-Claim	HighQuality
48	I-Claim	HighQuality
semanas	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento,	I-Claim	HighQuality
tienen	I-Claim	HighQuality
una	I-Claim	HighQuality
mayor	I-Claim	HighQuality
probabilidad	I-Claim	HighQuality
de	I-Claim	HighQuality
lograr	I-Claim	HighQuality
la	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
de	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
semana	I-Claim	HighQuality
72.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
trabajo	O	-
es	O	-
evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
tolerabilidad	O	-
del	O	-
conservante	O	-
que	O	-
contiene	O	-
0.0015	O	-
%	O	-
de	O	-
tafluprost	O	-
y	O	-
libre	O	-
de	O	-
conservantes	O	-
0.0015	O	-
%	O	-
de	O	-
tafluprost	O	-
utilizando	O	-
un	O	-
estudio	O	-
prospectivo	O	-
cruzado.	O	-

Los	O	-
pacientes	O	-
tratados	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
(POAG	O	-
)	O	-
y	O	-
glaucoma	O	-
normotensivo	O	-
(	O	-
NTG	O	-
)	O	-
fueron	O	-
aleatorizados.	O	-

Los	O	-
pacientes	O	-
del	O	-
grupo	O	-
1	O	-
(	O	-
"	O	-
NPT	O	-
to	O	-
PT	O	-
"	O	-
)	O	-
utilizaron	O	-
tafluprost	O	-
(	O	-
NPT	O	-
)	O	-
sin	O	-
conservantes	O	-
0,0015	O	-
%	O	-
durante	O	-
6	O	-
meses	O	-
y	O	-
luego	O	-
cambiaron	O	-
a	O	-
conservante	O	-
que	O	-
contenía	O	-
tafluprost	O	-
(	O	-
PT	O	-
)	O	-
un	O	-
0,0015	O	-
%	O	-
durante	O	-
6	O	-
meses.	O	-

Los	O	-
pacientes	O	-
del	O	-
grupo	O	-
2	O	-
(	O	-
"	O	-
PT	O	-
to	O	-
NPT	O	-
"	O	-
)	O	-
utilizaron	O	-
conservantes	O	-
que	O	-
contenían	O	-
0,0015	O	-
%	O	-
de	O	-
tafluprost	O	-
durante	O	-
6	O	-
meses	O	-
y	O	-
cambiaron	O	-
a	O	-
tafluprost	O	-
libre	O	-
de	O	-
conservantes	O	-
0,0015	O	-
%	O	-
durante	O	-
6	O	-
meses.	O	-

A	O	-
los	O	-
1,	O	-
3,	O	-
6,	O	-
7,	O	-
9,	O	-
y	O	-
12	O	-
meses,	O	-
se	O	-
midió	O	-
la	O	-
presión	O	-
intraocular	O	-
para	O	-
la	O	-
eficacia	O	-
y	O	-
la	O	-
erosión	O	-
corneal	O	-
graduada,	O	-
el	O	-
tiempo	O	-
de	O	-
ruptura	O	-
lágrima	O	-
(	O	-
TBUT	O	-
)	O	-
y	O	-
la	O	-
incomodidad	O	-
subjetiva.	O	-

Se	O	-
incluyeron	O	-
un	O	-
total	O	-
de	O	-
20	O	-
pacientes	O	-
y	O	-
20	O	-
ojos.	O	-

En	B-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
1	I-Premise	HighQuality
y	I-Premise	HighQuality
2,	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
intraocular	I-Premise	HighQuality
estuvo	I-Premise	HighQuality
bien	I-Premise	HighQuality
controlada	I-Premise	HighQuality
hasta	I-Premise	HighQuality
aproximadamente	I-Premise	HighQuality
14	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
(	I-Premise	HighQuality
disminución	I-Premise	HighQuality
del	I-Premise	HighQuality
9,38-18,46	I-Premise	HighQuality
%	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
general,	I-Premise	HighQuality
la	I-Premise	HighQuality
satisfacción	I-Premise	HighQuality
subjetiva	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
cambiar	I-Premise	HighQuality
de	I-Premise	HighQuality
PT	I-Premise	HighQuality
a	I-Premise	HighQuality
NPT	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
TBUT	I-Premise	HighQuality
utilizando	I-Premise	HighQuality
PT	I-Premise	HighQuality
fue	I-Premise	HighQuality
numéricamente	I-Premise	HighQuality
inferior	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
que	I-Premise	HighQuality
se	I-Premise	HighQuality
utilizó	I-Premise	HighQuality
NPT	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,06	I-Premise	HighQuality
)	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
cuando	I-Premise	HighQuality
se	I-Premise	HighQuality
cambió	I-Premise	HighQuality
de	I-Premise	HighQuality
NPT	I-Premise	HighQuality
a	I-Premise	HighQuality
PT.	I-Premise	HighQuality

Tanto	B-Claim	HighQuality
el	I-Claim	HighQuality
conservante	I-Claim	HighQuality
como	I-Claim	HighQuality
el	I-Claim	HighQuality
que	I-Claim	HighQuality
no	I-Claim	HighQuality
contiene	I-Claim	HighQuality
conservantes	I-Claim	HighQuality
0,0015	I-Claim	HighQuality
%	I-Claim	HighQuality
de	I-Claim	HighQuality
tafluprost	I-Claim	HighQuality
redujeron	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
intraocular.	I-Claim	HighQuality

Además,	O	-
cambiar	B-Claim	HighQuality
la	I-Claim	HighQuality
medicación	I-Claim	HighQuality
de	I-Claim	HighQuality
PT	I-Claim	HighQuality
a	I-Claim	HighQuality
NPT	I-Claim	HighQuality
podría	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
la	I-Claim	HighQuality
satisfacción	I-Claim	HighQuality
subjetiva	I-Claim	HighQuality
y	I-Claim	HighQuality
romper	I-Claim	HighQuality
el	I-Claim	HighQuality
tiempo	I-Claim	HighQuality
de	I-Claim	HighQuality
ruptura.	I-Claim	HighQuality

Comparar	O	-
la	O	-
facoemulsificación	O	-
versus	O	-
la	O	-
trabeculectomía	O	-
con	O	-
la	O	-
mitomicina	O	-
C	O	-
concomitante	O	-
en	O	-
el	O	-
glaucoma	O	-
crónico	O	-
de	O	-
cierre	O	-
de	O	-
ángulos	O	-
(	O	-
CACG	O	-
)	O	-
sin	O	-
control	O	-
médico	O	-
sin	O	-
cataratas.	O	-

Ensayo	O	-
clínico	O	-
prospectivo,	O	-
aleatorizado.	O	-

Cincuenta	O	-
ojos	O	-
de	O	-
CACG	O	-
médicamente	O	-
incontrolados	O	-
sin	O	-
cataratas	O	-
de	O	-
50	O	-
pacientes.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
ser	O	-
sometidos	O	-
a	O	-
facoemulsificación	O	-
o	O	-
trabeculectomía	O	-
con	O	-
mitomicina	O	-
C	O	-
adyuvante.	O	-
Después	O	-
de	O	-
la	O	-
cirugía,	O	-
los	O	-
pacientes	O	-
fueron	O	-
seguidos	O	-
cada	O	-
3	O	-
meses	O	-
durante	O	-
2	O	-
años.	O	-

Presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
y	O	-
necesidad	O	-
de	O	-
medicamentos	O	-
contra	O	-
el	O	-
glaucoma.	O	-

Veintiséis	O	-
ojos	O	-
de	O	-
CACG	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
facoemulsificación,	O	-
y	O	-
24	O	-
ojos	O	-
fueron	O	-
sometidos	O	-
a	O	-
trabeculectomía	O	-
con	O	-
mitomicina	O	-
C.	O	-
La	B-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
y	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
dieron	I-Premise	HighQuality
lugar	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
significativa	I-Premise	HighQuality
y	I-Premise	HighQuality
comparable	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
24	I-Premise	HighQuality
meses	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
cirugía	I-Premise	HighQuality
(reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
8,4	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
o	I-Premise	HighQuality
34%	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
8,9	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
o	I-Premise	HighQuality
36%	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
;	I-Premise	HighQuality
P=0,76	I-Premise	HighQuality
).	I-Premise	HighQuality

Durante	B-Premise	HighQuality
los	I-Premise	HighQuality
primeros	I-Premise	HighQuality
24	I-Premise	HighQuality
meses,	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
requerían	I-Premise	HighQuality
en	I-Premise	HighQuality
promedio	I-Premise	HighQuality
1,1	I-Premise	HighQuality
menos	I-Premise	HighQuality
fármacos	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Sin	O	-
embargo,	O	-
la	B-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
quirúrgicas	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
(	I-Premise	HighQuality
46%	I-Premise	HighQuality
vs	I-Premise	HighQuality
4	I-Premise	HighQuality
%;	I-Premise	HighQuality
p=0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Ocho	B-Premise	HighQuality
(	I-Premise	HighQuality
33	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
24	I-Premise	HighQuality
ojos	I-Premise	HighQuality
de	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
demostraron	I-Premise	HighQuality
cataratas	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
seguimiento.	I-Premise	HighQuality

Tanto	B-Claim	HighQuality
la	I-Claim	HighQuality
facoemulsificación	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
son	I-Claim	HighQuality
eficaces	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
ojos	I-Claim	HighQuality
CACG	I-Claim	HighQuality
no	I-Claim	HighQuality
controlados	I-Claim	HighQuality
médicamente	I-Claim	HighQuality
sin	I-Claim	HighQuality
cataratas.	I-Claim	HighQuality

La	B-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
es	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
facoemulsificación	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
dependencia	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
fármacos	I-Claim	HighQuality
del	I-Claim	HighQuality
glaucoma,	I-Claim	HighQuality
pero	I-Claim	HighQuality
se	I-Claim	HighQuality
asocia	I-Claim	HighQuality
con	I-Claim	HighQuality
más	I-Claim	HighQuality
complicaciones.	I-Claim	HighQuality

La	O	-
hipertensión	O	-
no	O	-
controlada	O	-
es	O	-
un	O	-
problema	O	-
importante	O	-
entre	O	-
los	O	-
hombres	O	-
negros	O	-
no	O	-
hispanos,	O	-
que	O	-
están	O	-
insuficientemente	O	-
representados	O	-
en	O	-
los	O	-
ensayos	O	-
de	O	-
intervención	O	-
farmacéutica	O	-
en	O	-
entornos	O	-
tradicionales	O	-
de	O	-
atención	O	-
de	O	-
la	O	-
salud.	O	-

Se	O	-
inscribió	O	-
a	O	-
una	O	-
cohorte	O	-
de	O	-
319	O	-
clientes	O	-
varones	O	-
negros	O	-
con	O	-
presión	O	-
arterial	O	-
sistólica	O	-
de	O	-
140	O	-
mm	O	-
Hg	O	-
o	O	-
más	O	-
de	O	-
52	O	-
barberías	O	-
de	O	-
propiedad	O	-
negra	O	-
(establecimiento	O	-
de	O	-
atención	O	-
médica	O	-
no	O	-
tradicional)	O	-
en	O	-
un	O	-
ensayo	O	-
aleatorizado	O	-
en	O	-
el	O	-
que	O	-
se	O	-
asignaron	O	-
barberías	O	-
a	O	-
una	O	-
intervención	O	-
dirigida	O	-
por	O	-
farmacéuticos	O	-
(en	O	-
el	O	-
que	O	-
los	O	-
barberos	O	-
alentaron	O	-
reuniones	O	-
en	O	-
barberías	O	-
con	O	-
farmacéuticos	O	-
especializados	O	-
que	O	-
prescribían	O	-
terapia	O	-
de	O	-
drogas	O	-
bajo	O	-
un	O	-
acuerdo	O	-
de	O	-
práctica	O	-
colaborativa	O	-
con	O	-
los	O	-
médicos	O	-
de	O	-
los	O	-
participantes)	O	-
o	O	-
a	O	-
un	O	-
enfoque	O	-
de	O	-
control	O	-
activo	O	-
(en	O	-
el	O	-
que	O	-
los	O	-
barberos	O	-
alentaron	O	-
la	O	-
modificación	O	-
del	O	-
estilo	O	-
de	O	-
vida	O	-
y	O	-
las	O	-
citas	O	-
de	O	-
médicos	O	-
).	O	-

El	O	-
resultado	O	-
primario	O	-
fue	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
a	O	-
los	O	-
6	O	-
meses.	O	-

Al	O	-
inicio,	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
media	O	-
fue	O	-
de	O	-
152,8	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
intervención	O	-
y	O	-
de	O	-
154,6	O	-
mm	O	-
Hg	O	-
en	O	-
el	O	-
grupo	O	-
control.	O	-

A	B-Premise	HighQuality
los	I-Premise	HighQuality
6	I-Premise	HighQuality
meses,	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
media	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
en	I-Premise	HighQuality
27,0	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
a	I-Premise	HighQuality
125,8	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
9,3	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
a	I-Premise	HighQuality
145,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
;	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
media	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
21,6	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
mayor	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
intervención	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
14,7	I-Premise	HighQuality
a	I-Premise	HighQuality
28,4	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Se	B-Premise	HighQuality
alcanzó	I-Premise	HighQuality
un	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
inferior	I-Premise	HighQuality
a	I-Premise	HighQuality
130/80	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
63,6%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
11,7%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención,	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
retención	I-Premise	HighQuality
de	I-Premise	HighQuality
cohorte	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
hubo	I-Premise	HighQuality
pocos	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
(	I-Premise	HighQuality
tres	I-Premise	HighQuality
casos	I-Premise	HighQuality
de	I-Premise	HighQuality
lesión	I-Premise	HighQuality
renal	I-Premise	HighQuality
aguda	I-Premise	HighQuality
).	I-Premise	HighQuality

Entre	B-Claim	HighQuality
los	I-Claim	HighQuality
patrones	I-Claim	HighQuality
de	I-Claim	HighQuality
barbería	I-Claim	HighQuality
masculinos	I-Claim	HighQuality
negros	I-Claim	HighQuality
con	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
no	I-Claim	HighQuality
controlada,	I-Claim	HighQuality
la	I-Claim	HighQuality
promoción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
salud	I-Claim	HighQuality
por	I-Claim	HighQuality
los	I-Claim	HighQuality
barberos	I-Claim	HighQuality
resultó	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
mayor	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
cuando	I-Claim	HighQuality
se	I-Claim	HighQuality
combina	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
manejo	I-Claim	HighQuality
de	I-Claim	HighQuality
medicamentos	I-Claim	HighQuality
en	I-Claim	HighQuality
barberías	I-Claim	HighQuality
por	I-Claim	HighQuality
farmacéuticos	I-Claim	HighQuality
especializados.	I-Claim	HighQuality

La	B-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
(QOL	I-Claim	HighQuality
)	I-Claim	HighQuality
es	I-Claim	HighQuality
un	I-Claim	HighQuality
aspecto	I-Claim	HighQuality
importante	I-Claim	HighQuality
del	I-Claim	HighQuality
manejo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
diabetes.	I-Claim	HighQuality

Sin	O	-
embargo,	O	-
ningún	O	-
estudio	O	-
ha	O	-
comparado	O	-
la	O	-
influencia	O	-
de	O	-
los	O	-
inhibidores	O	-
de	O	-
la	O	-
dipeptidil	O	-
peptidasa-4	O	-
frente	O	-
a	O	-
los	O	-
inhibidores	O	-
de	O	-
la	O	-
alfa-glucosidasa	O	-
sobre	O	-
la	O	-
CV	O	-
relacionada	O	-
con	O	-
el	O	-
tratamiento.	O	-

Este	O	-
subanálisis	O	-
preespecificado	O	-
del	O	-
estudio	O	-
de	O	-
linagliptina	O	-
de	O	-
efectos	O	-
sobre	O	-
la	O	-
glucosa	O	-
en	O	-
sangre	O	-
postprandial	O	-
(	O	-
L-STEP	O	-
)	O	-
comparó	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
linagliptina	O	-
(	O	-
5	O	-
mg	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
)	O	-
y	O	-
la	O	-
voglibosa	O	-
(	O	-
0,2	O	-
mg/comida	O	-
tres	O	-
veces	O	-
al	O	-
día	O	-
)	O	-
sobre	O	-
la	O	-
CV	O	-
relacionada	O	-
con	O	-
el	O	-
tratamiento	O	-
en	O	-
pacientes	O	-
japoneses	O	-
con	O	-
diabetes	O	-
tipo	O	-
2	O	-
(	O	-
T2DM	O	-
)	O	-
controlados	O	-
de	O	-
forma	O	-
inadecuada	O	-
con	O	-
terapia	O	-
de	O	-
dieta	O	-
y	O	-
ejercicio.	O	-

Entre	O	-
366	O	-
sujetos	O	-
en	O	-
el	O	-
estudio	O	-
original,	O	-
182	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
linagliptina	O	-
y	O	-
173	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
voglibosa	O	-
fueron	O	-
incluidos	O	-
en	O	-
este	O	-
análisis.	O	-

El	O	-
resultado	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
un	O	-
cambio	O	-
en	O	-
la	O	-
CV	O	-
evaluado	O	-
por	O	-
el	O	-
cuestionario	O	-
de	O	-
Calidad	O	-
de	O	-
Vida	O	-
Relacionada	O	-
con	O	-
la	O	-
Terapia	O	-
Diabetes	O	-
17	O	-
(	O	-
DTR-QOL17	O	-
)	O	-
desde	O	-
el	O	-
inicio	O	-
hasta	O	-
la	O	-
semana	O	-
12.	O	-

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
datos	I-Premise	HighQuality
basales,	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
totales	I-Premise	HighQuality
de	I-Premise	HighQuality
DTR-QOL17	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
linagliptina	I-Premise	HighQuality
y	I-Premise	HighQuality
voglibosa.	I-Premise	HighQuality

El	B-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
total	I-Premise	HighQuality
de	I-Premise	HighQuality
DTR-QOL17	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
dominio,	I-Premise	HighQuality
carga	I-Premise	HighQuality
sobre	I-Premise	HighQuality
las	I-Premise	HighQuality
actividades	I-Premise	HighQuality
sociales	I-Premise	HighQuality
y	I-Premise	HighQuality
diarias,	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
linagliptina	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
voglibosa.	I-Premise	HighQuality

Además,	B-Premise	HighQuality
sólo	I-Premise	HighQuality
se	I-Premise	HighQuality
identificó	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
linagliptina	I-Premise	HighQuality
como	I-Premise	HighQuality
un	I-Premise	HighQuality
factor	I-Premise	HighQuality
asociado	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
total	I-Premise	HighQuality
de	I-Premise	HighQuality
DTR-QOL17.	I-Premise	HighQuality

La	B-Claim	HighQuality
linagliptina	I-Claim	HighQuality
es	I-Claim	HighQuality
superior	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
voglibosa	I-Claim	HighQuality
en	I-Claim	HighQuality
términos	I-Claim	HighQuality
de	I-Claim	HighQuality
mejora	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
CV	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
japoneses	I-Claim	HighQuality
con	I-Claim	HighQuality
T2DM.	I-Claim	HighQuality

El	O	-
tratamiento	O	-
a	O	-
largo	O	-
plazo	O	-
con	O	-
tenofovir	O	-
disoproxil	O	-
fumarato	O	-
(	O	-
TDF	O	-
)	O	-
solo	O	-
o	O	-
en	O	-
combinación	O	-
con	O	-
emtricitabina	O	-
(	O	-
FTC	O	-
)	O	-
se	O	-
asocia	O	-
con	O	-
supresión	O	-
viral	O	-
sostenida	O	-
en	O	-
pacientes	O	-
con	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
resistente	O	-
a	O	-
lamivudina	O	-
(	O	-
LAM-R	O	-
).	O	-

Los	O	-
pacientes	O	-
con	O	-
CHB	O	-
LAM-R	O	-
fueron	O	-
aleatorizados	O	-
1:1	O	-
para	O	-
recibir	O	-
TDF	O	-
300mg	O	-
o	O	-
FTC	O	-
200mg	O	-
y	O	-
TDF	O	-
300mg	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
en	O	-
un	O	-
estudio	O	-
prospectivo,	O	-
doble	O	-
ciego.	O	-

La	O	-
proporción	O	-
de	O	-
pacientes	O	-
con	O	-
el	O	-
ADN	O	-
del	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB	O	-
)	O	-
plasmático	O	-
<	O	-
69IU/ml	O	-
(	O	-
<	O	-
400copias/ml	O	-
)	O	-
en	O	-
la	O	-
semana	O	-
96	O	-
(	O	-
variable	O	-
principal	O	-
de	O	-
eficacia	O	-
)	O	-
se	O	-
notificó	O	-
previamente.	O	-

Aquí	O	-
presentamos	O	-
los	O	-
datos	O	-
de	O	-
seguimiento	O	-
de	O	-
la	O	-
semana	O	-
240.	O	-

En	O	-
total,	O	-
280	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
TDF	O	-
(	O	-
n=141	O	-
)	O	-
o	O	-
FTC/TDF	O	-
(	O	-
n=139	O	-
)	O	-
y	O	-
el	O	-
85,4%	O	-
completaron	O	-
240	O	-
semanas	O	-
de	O	-
tratamiento.	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240,	I-Premise	HighQuality
el	I-Premise	HighQuality
83,0	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
TDF	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
82,7	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
FTC/TDF	I-Premise	HighQuality
tenían	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
69IU/ml	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,96	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
normal	I-Premise	HighQuality
(	I-Premise	HighQuality
ALT	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
ALT	I-Premise	HighQuality
normalizada	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,41	I-Premise	HighQuality
y	I-Premise	HighQuality
p=0,97	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
pérdida	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos,	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,41	I-Premise	HighQuality
y	I-Premise	HighQuality
p=0,67	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
total,	I-Premise	HighQuality
seis	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
alcanzaron	I-Premise	HighQuality
la	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
del	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
paciente	I-Premise	HighQuality
(	I-Premise	HighQuality
brazo	I-Premise	HighQuality
FTC/TDF	I-Premise	HighQuality
)	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
a	I-Premise	HighQuality
TDF	I-Premise	HighQuality
hasta	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240.	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
fue	I-Premise	HighQuality
generalmente	I-Premise	HighQuality
bien	I-Premise	HighQuality
tolerado,	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
renales	I-Premise	HighQuality
fueron	I-Premise	HighQuality
leves	I-Premise	HighQuality
e	I-Premise	HighQuality
infrecuentes	I-Premise	HighQuality
(	I-Premise	HighQuality
8,6%).	I-Premise	HighQuality

El	B-Premise	HighQuality
cambio	I-Premise	HighQuality
medio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
densidad	I-Premise	HighQuality
mineral	I-Premise	HighQuality
ósea	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
240	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
-0,98	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
-2,54	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
columna	I-Premise	HighQuality
vertebral	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
cadera,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
TDF	I-Claim	HighQuality
fue	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerada	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB	I-Claim	HighQuality
LAM-R	I-Claim	HighQuality
hasta	I-Claim	HighQuality
240	I-Claim	HighQuality
semanas.	I-Claim	HighQuality

El	O	-
objetivo	O	-
del	O	-
tratamiento	O	-
antiviral	O	-
oral	O	-
para	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
es	O	-
alcanzar	O	-
y	O	-
mantener	O	-
niveles	O	-
indetectables	O	-
de	O	-
ADN	O	-
del	O	-
VHB.	O	-

Se	O	-
requieren	O	-
opciones	O	-
de	O	-
tratamiento	O	-
con	O	-
potencia	O	-
mejorada,	O	-
y	O	-
bajo	O	-
riesgo	O	-
de	O	-
desarrollo	O	-
de	O	-
resistencia	O	-
para	O	-
pacientes	O	-
infectados	O	-
con	O	-
VHB	O	-
resistente	O	-
a	O	-
lamivudina	O	-
(	O	-
LAM-R	O	-
).	O	-

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
tenofovir	I-Claim	HighQuality
disoproxil	I-Claim	HighQuality
fumarato	I-Claim	HighQuality
(	I-Claim	HighQuality
TDF	I-Claim	HighQuality
)	I-Claim	HighQuality
fue	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerada	I-Claim	HighQuality
sin	I-Claim	HighQuality
el	I-Claim	HighQuality
desarrollo	I-Claim	HighQuality
de	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
a	I-Claim	HighQuality
TDF	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB	I-Claim	HighQuality
con	I-Claim	HighQuality
LAM-R,	I-Claim	HighQuality
hasta	I-Claim	HighQuality
240	I-Claim	HighQuality
semanas.	I-Claim	HighQuality

Para	O	-
comparar	O	-
el	O	-
resultado	O	-
de	O	-
la	O	-
trabeculectomía	O	-
utilizando	O	-
bevacizumab	O	-
intracameral	O	-
concomitante	O	-
versus	O	-
mitomicina	O	-
C	O	-
(MCM	O	-
)	O	-
intraoperatoria.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
doble	O	-
ciego	O	-
aleatorizado	O	-
se	O	-
asignaron	O	-
87	O	-
ojos	O	-
de	O	-
87	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
o	O	-
pseudoexfoliación	O	-
a	O	-
cada	O	-
grupo	O	-
de	O	-
tratamiento	O	-
(44	O	-
casos	O	-
recibieron	O	-
1,25	O	-
mg	O	-
de	O	-
bevacizumab	O	-
intracameral	O	-
al	O	-
final	O	-
de	O	-
la	O	-
operación	O	-
y	O	-
en	O	-
43	O	-
casos	O	-
se	O	-
aplicó	O	-
MMC	O	-
durante	O	-
la	O	-
cirugía	O	-
).	O	-

El	O	-
éxito	O	-
se	O	-
definió	O	-
como	O	-
presión	O	-
intraocular	O	-
(PIO	O	-
)	O	-
entre	O	-
6	O	-
y	O	-
21	O	-
mm	O	-
Hg	O	-
y	O	-
al	O	-
menos	O	-
un	O	-
30	O	-
%	O	-
de	O	-
caída	O	-
de	O	-
la	O	-
PIO	O	-
con	O	-
(	O	-
cualificado	O	-
)	O	-
o	O	-
sin	O	-
(	O	-
completo	O	-
)	O	-
medicaciones	O	-
de	O	-
glaucoma	O	-
sin	O	-
cirugía	O	-
adicional	O	-
de	O	-
glaucoma.	O	-

El	O	-
tiempo	O	-
de	O	-
seguimiento	O	-
fue	O	-
de	O	-
17,12±2,58	O	-
meses	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
bevacizumab	O	-
y	O	-
de	O	-
17,23±2,42	O	-
meses	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
MMC	O	-
(p=0,845).	O	-

La	B-Premise	HighQuality
PIO	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
29,17±3,94	I-Premise	HighQuality
y	I-Premise	HighQuality
28,8±4,08	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
MMC,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,689	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
última	I-Premise	HighQuality
visita	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
17,41±3,11	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
15,34±3,62	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,009	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal,	I-Premise	HighQuality
la	I-Premise	HighQuality
caída	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
visita	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
11,76±5,51	I-Premise	HighQuality
y	I-Premise	HighQuality
13,43±5,92	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
MMC,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,207	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
visita,	I-Premise	HighQuality
se	I-Premise	HighQuality
logró	I-Premise	HighQuality
el	I-Premise	HighQuality
éxito	I-Premise	HighQuality
completo	I-Premise	HighQuality
en	I-Premise	HighQuality
25	I-Premise	HighQuality
casos	I-Premise	HighQuality
(	I-Premise	HighQuality
61	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
23	I-Premise	HighQuality
casos	I-Premise	HighQuality
(	I-Premise	HighQuality
66	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,669	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
filtración	I-Premise	HighQuality
temprana	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
fuga	I-Premise	HighQuality
de	I-Premise	HighQuality
bleb	I-Premise	HighQuality
fue	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuente	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
(	I-Premise	HighQuality
29	I-Premise	HighQuality
%	I-Premise	HighQuality
vs.	I-Premise	HighQuality
11	I-Premise	HighQuality
%	I-Premise	HighQuality
).	I-Premise	HighQuality

Una	B-Claim	HighQuality
dosis	I-Claim	HighQuality
única	I-Claim	HighQuality
de	I-Claim	HighQuality
1,25	I-Claim	HighQuality
mg	I-Claim	HighQuality
de	I-Claim	HighQuality
bevacizumab	I-Claim	HighQuality
intracameral	I-Claim	HighQuality
mejora	I-Claim	HighQuality
el	I-Claim	HighQuality
éxito	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
comparable	I-Claim	HighQuality
con	I-Claim	HighQuality
MMC	I-Claim	HighQuality
;	I-Claim	HighQuality
sin	B-Claim	HighQuality
embargo,	I-Claim	HighQuality
aumenta	I-Claim	HighQuality
el	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
filtración	I-Claim	HighQuality
temprana	I-Claim	HighQuality
de	I-Claim	HighQuality
fugas	I-Claim	HighQuality
de	I-Claim	HighQuality
bleb.	I-Claim	HighQuality

Evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
tolerabilidad	O	-
de	O	-
dos	O	-
dosis	O	-
de	O	-
gefitinib	O	-
(	O	-
Iressa	O	-
[	O	-
ZD1839	O	-
]	O	-
;	O	-
AstraZeneca,	O	-
Wilmington,	O	-
DE	O	-
),	O	-
un	O	-
nuevo	O	-
inhibidor	O	-
de	O	-
la	O	-
tirosina	O	-
cinasa	O	-
del	O	-
receptor	O	-
del	O	-
factor	O	-
de	O	-
crecimiento	O	-
epidérmico,	O	-
en	O	-
pacientes	O	-
con	O	-
cáncer	O	-
avanzado	O	-
de	O	-
pulmón	O	-
no	O	-
microcítico	O	-
pretratado	O	-
(	O	-
CPNM	O	-
).	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
ensayo	O	-
aleatorizado,	O	-
doble	O	-
ciego,	O	-
grupo	O	-
paralelo,	O	-
fase	O	-
II	O	-
multicéntrico.	O	-

Doscientos	O	-
diez	O	-
pacientes	O	-
con	O	-
CPNM	O	-
avanzado	O	-
que	O	-
fueron	O	-
tratados	O	-
previamente	O	-
con	O	-
uno	O	-
o	O	-
dos	O	-
regímenes	O	-
de	O	-
quimioterapia	O	-
(al	O	-
menos	O	-
uno	O	-
con	O	-
platino	O	-
)	O	-
fueron	O	-
asignados	O	-
al	O	-
azar	O	-
para	O	-
recibir	O	-
dosis	O	-
orales	O	-
de	O	-
250	O	-
mg	O	-
o	O	-
500	O	-
mg	O	-
de	O	-
gefitinib	O	-
una	O	-
vez	O	-
al	O	-
día.	O	-

La	B-Premise	HighQuality
eficacia	I-Premise	HighQuality
fue	I-Premise	HighQuality
similar	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
250	I-Premise	HighQuality
y	I-Premise	HighQuality
500	I-Premise	HighQuality
mg/d.	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
del	I-Premise	HighQuality
tumor	I-Premise	HighQuality
objetivo	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
18,4	I-Premise	HighQuality
%	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[IC	I-Premise	HighQuality
],	I-Premise	HighQuality
del	I-Premise	HighQuality
11,5	I-Premise	HighQuality
al	I-Premise	HighQuality
27,3	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
19,0	I-Premise	HighQuality
%	I-Premise	HighQuality
(IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
del	I-Premise	HighQuality
12,1	I-Premise	HighQuality
al	I-Premise	HighQuality
27,9	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
evaluables,	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
40,3	I-Premise	HighQuality
%	I-Premise	HighQuality
(IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
del	I-Premise	HighQuality
28,5	I-Premise	HighQuality
al	I-Premise	HighQuality
53,0	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
37,0	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
del	I-Premise	HighQuality
26,0	I-Premise	HighQuality
al	I-Premise	HighQuality
49,1	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
la	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
tiempos	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
sin	I-Premise	HighQuality
progresión	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
2,7	I-Premise	HighQuality
y	I-Premise	HighQuality
2,8	I-Premise	HighQuality
meses	I-Premise	HighQuality
;	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
tiempos	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
global	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
7,6	I-Premise	HighQuality
y	I-Premise	HighQuality
8,0	I-Premise	HighQuality
meses,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Se	B-Premise	HighQuality
registraron	I-Premise	HighQuality
mejorías	I-Premise	HighQuality
sintomáticas	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
69,2	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
250	I-Premise	HighQuality
mg/d	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
85,7	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
500	I-Premise	HighQuality
mg/d	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
tumoral.	I-Premise	HighQuality

Las	B-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
(EA)	I-Premise	HighQuality
a	I-Premise	HighQuality
ambos	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
fueron	I-Premise	HighQuality
generalmente	I-Premise	HighQuality
leves	I-Premise	HighQuality
(grado	I-Premise	HighQuality
1	I-Premise	HighQuality
ó	I-Premise	HighQuality
2)	I-Premise	HighQuality
y	I-Premise	HighQuality
consistieron	I-Premise	HighQuality
principalmente	I-Premise	HighQuality
en	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
cutáneas	I-Premise	HighQuality
y	I-Premise	HighQuality
diarrea.	I-Premise	HighQuality

Las	B-Premise	HighQuality
toxicidades	I-Premise	HighQuality
relacionadas	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
más	I-Premise	HighQuality
altas.	I-Premise	HighQuality

El	B-Premise	HighQuality
retiro	I-Premise	HighQuality
debido	I-Premise	HighQuality
a	I-Premise	HighQuality
las	I-Premise	HighQuality
EA	I-Premise	HighQuality
relacionadas	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
1,9	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
9,4	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
gefitinib	I-Premise	HighQuality
250	I-Premise	HighQuality
y	I-Premise	HighQuality
500	I-Premise	HighQuality
mg/d,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Gefitinib	B-Claim	HighQuality
mostró	I-Claim	HighQuality
actividad	I-Claim	HighQuality
antitumoral	I-Claim	HighQuality
clínicamente	I-Claim	HighQuality
significativa	I-Claim	HighQuality
y	I-Claim	HighQuality
proporcionó	I-Claim	HighQuality
alivio	I-Claim	HighQuality
sintomático	I-Claim	HighQuality
como	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
segunda	I-Claim	HighQuality
y	I-Claim	HighQuality
tercera	I-Claim	HighQuality
línea	I-Claim	HighQuality
en	I-Claim	HighQuality
estos	I-Claim	HighQuality
pacientes.	I-Claim	HighQuality

Con	B-Claim	HighQuality
250	I-Claim	HighQuality
mg/d,	I-Claim	HighQuality
gefitinib	I-Claim	HighQuality
tenía	I-Claim	HighQuality
un	I-Claim	HighQuality
perfil	I-Claim	HighQuality
favorable	I-Claim	HighQuality
de	I-Claim	HighQuality
EA.	I-Claim	HighQuality

Gefitinib	B-Claim	HighQuality
250	I-Claim	HighQuality
mg/d	I-Claim	HighQuality
es	I-Claim	HighQuality
una	I-Claim	HighQuality
nueva	I-Claim	HighQuality
opción	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
importante	I-Claim	HighQuality
para	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CPNM	I-Claim	HighQuality
avanzado	I-Claim	HighQuality
pretratado.	I-Claim	HighQuality

Múltiples	B-Claim	HighQuality
estudios	I-Claim	HighQuality
han	I-Claim	HighQuality
evaluado	I-Claim	HighQuality
el	I-Claim	HighQuality
efecto	I-Claim	HighQuality
hipoglucemiante	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
canela	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
mellitus	I-Claim	HighQuality
(	I-Claim	HighQuality
DM	I-Claim	HighQuality
)	I-Claim	HighQuality
tipo	I-Claim	HighQuality
II,	I-Claim	HighQuality
con	I-Claim	HighQuality
resultados	I-Claim	HighQuality
contradictorios.	I-Claim	HighQuality

Las	O	-
diferencias	O	-
en	O	-
el	O	-
Índice	O	-
de	O	-
Masa	O	-
Corporal	O	-
basal	O	-
(IMC)	O	-
de	O	-
los	O	-
pacientes	O	-
pueden	O	-
ser	O	-
capaces	O	-
de	O	-
explicar	O	-
las	O	-
diferencias	O	-
observadas	O	-
en	O	-
los	O	-
resultados.	O	-

Este	O	-
estudio	O	-
fue	O	-
diseñado	O	-
para	O	-
evaluar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
canela	O	-
en	O	-
los	O	-
resultados	O	-
antropométricos,	O	-
glucémicos	O	-
y	O	-
lipídicos	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
DM	O	-
tipo	O	-
II	O	-
en	O	-
base	O	-
a	O	-
su	O	-
IMC	O	-
basal.	O	-

El	O	-
estudio	O	-
fue	O	-
diseñado	O	-
como	O	-
un	O	-
ensayo	O	-
clínico	O	-
aleatorizado	O	-
controlado	O	-
con	O	-
placebo	O	-
triple	O	-
ciego,	O	-
utilizando	O	-
un	O	-
diseño	O	-
paralelo.	O	-

Ciento	O	-
cuarenta	O	-
pacientes	O	-
referidos	O	-
a	O	-
la	O	-
Clínica	O	-
de	O	-
Diabetes	O	-
de	O	-
la	O	-
Universidad	O	-
de	O	-
Ciencias	O	-
Médicas	O	-
de	O	-
Yazd	O	-
con	O	-
diagnóstico	O	-
de	O	-
DM	O	-
tipo	O	-
II	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
en	O	-
cuatro	O	-
grupos	O	-
:	O	-
canela	O	-
(	O	-
IMC	O	-
≥	O	-
27,	O	-
IMC	O	-
<	O	-
27	O	-
)	O	-
y	O	-
Placebo	O	-
(	O	-
IMC	O	-
≥	O	-
27,	O	-
IMC	O	-
<	O	-
27	O	-
).	O	-

Los	O	-
pacientes	O	-
recibieron	O	-
polvo	O	-
de	O	-
corteza	O	-
de	O	-
canela	O	-
o	O	-
placebo	O	-
en	O	-
cápsulas	O	-
de	O	-
500	O	-
mg	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
durante	O	-
3	O	-
meses.	O	-

Se	O	-
midieron	O	-
los	O	-
resultados	O	-
antropométricos,	O	-
glucémicos	O	-
y	O	-
lipídicos	O	-
antes	O	-
y	O	-
después	O	-
de	O	-
la	O	-
intervención.	O	-

La	B-Premise	HighQuality
suplementación	I-Premise	HighQuality
con	I-Premise	HighQuality
canela	I-Premise	HighQuality
llevó	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
mejora	I-Premise	HighQuality
de	I-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
resultados	I-Premise	HighQuality
antropométricos	I-Premise	HighQuality
(IMC,	I-Premise	HighQuality
grasa	I-Premise	HighQuality
corporal,	I-Premise	HighQuality
y	I-Premise	HighQuality
grasa	I-Premise	HighQuality
visceral	I-Premise	HighQuality
),	I-Premise	HighQuality
glucémicos	I-Premise	HighQuality
(	I-Premise	HighQuality
FPG,	I-Premise	HighQuality
2hpp,	I-Premise	HighQuality
HbA1C,	I-Premise	HighQuality
Insulina	I-Premise	HighQuality
de	I-Premise	HighQuality
ayuno,	I-Premise	HighQuality
y	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
lípidos	I-Premise	HighQuality
(	I-Premise	HighQuality
Colesterol	I-Premise	HighQuality
Total,	I-Premise	HighQuality
LDL-c	I-Premise	HighQuality
y	I-Premise	HighQuality
HDL-c	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
excepto	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
triglicéridos	I-Premise	HighQuality
).	I-Premise	HighQuality

Todos	B-Premise	HighQuality
los	I-Premise	HighQuality
cambios	I-Premise	HighQuality
observados	I-Premise	HighQuality
(excepto	I-Premise	HighQuality
Colesterol	I-Premise	HighQuality
Total	I-Premise	HighQuality
y	I-Premise	HighQuality
LDL-c	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
más	I-Premise	HighQuality
prominentes	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
mayor	I-Premise	HighQuality
IMC	I-Premise	HighQuality
basal	I-Premise	HighQuality
(	I-Premise	HighQuality
IMC	I-Premise	HighQuality
≥	I-Premise	HighQuality
27	I-Premise	HighQuality
).	I-Premise	HighQuality

Con	B-Claim	HighQuality
base	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
hallazgos	I-Claim	HighQuality
del	I-Claim	HighQuality
estudio,	I-Claim	HighQuality
la	I-Claim	HighQuality
canela	I-Claim	HighQuality
puede	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
los	I-Claim	HighQuality
parámetros	I-Claim	HighQuality
antropométricos,	I-Claim	HighQuality
los	I-Claim	HighQuality
índices	I-Claim	HighQuality
glucémicos	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
perfil	I-Claim	HighQuality
lipídico	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
tipo	I-Claim	HighQuality
II.	I-Claim	HighQuality

Estos	B-Claim	HighQuality
beneficios	I-Claim	HighQuality
son	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
más	I-Claim	HighQuality
prominentes	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
mayor	I-Claim	HighQuality
IMC	I-Claim	HighQuality
basal	I-Claim	HighQuality
(	I-Claim	HighQuality
IMC	I-Claim	HighQuality
≥	I-Claim	HighQuality
27	I-Claim	HighQuality
).	I-Claim	HighQuality

Aunque	O	-
las	B-Claim	HighQuality
antraciclinas	I-Claim	HighQuality
son	I-Claim	HighQuality
agentes	I-Claim	HighQuality
quimioterapéuticos	I-Claim	HighQuality
eficaces	I-Claim	HighQuality
para	I-Claim	HighQuality
tratar	I-Claim	HighQuality
el	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
B,	I-Claim	HighQuality
los	B-Claim	HighQuality
efectos	I-Claim	HighQuality
adversos,	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
supresión	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
médula	I-Claim	HighQuality
ósea	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
cardiotoxicidad,	I-Claim	HighQuality
limitan	I-Claim	HighQuality
su	I-Claim	HighQuality
aplicación	I-Claim	HighQuality
clínica.	I-Claim	HighQuality

Se	O	-
evaluó	O	-
si	O	-
el	O	-
tratamiento	O	-
con	O	-
antraciclina	O	-
también	O	-
aumenta	O	-
el	O	-
riesgo	O	-
de	O	-
diabetes	O	-
mellitus	O	-
en	O	-
pacientes	O	-
con	O	-
linfoma	O	-
de	O	-
células	O	-
B.	O	-

Utilizando	O	-
los	O	-
datos	O	-
obtenidos	O	-
de	O	-
la	O	-
base	O	-
de	O	-
datos	O	-
de	O	-
investigación	O	-
del	O	-
Seguro	O	-
Nacional	O	-
de	O	-
Salud	O	-
de	O	-
Taiwán	O	-
de	O	-
2004	O	-
a	O	-
2011,	O	-
comparamos	O	-
la	O	-
supervivencia	O	-
global	O	-
y	O	-
las	O	-
características	O	-
clínicas	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
linfoma	O	-
de	O	-
células	O	-
B	O	-
que	O	-
administraron	O	-
antraciclinas	O	-
(	O	-
n	O	-
=	O	-
3147	O	-
)	O	-
y	O	-
los	O	-
que	O	-
no	O	-
administraron	O	-
antraciclinas	O	-
(	O	-
n	O	-
=	O	-
837	O	-
).	O	-

El	O	-
impacto	O	-
del	O	-
tratamiento	O	-
con	O	-
antraciclinas	O	-
en	O	-
el	O	-
riesgo	O	-
de	O	-
diabetes	O	-
fue	O	-
investigado	O	-
más	O	-
a	O	-
fondo	O	-
utilizando	O	-
una	O	-
prueba	O	-
de	O	-
Gray	O	-
y	O	-
modelos	O	-
de	O	-
regresión	O	-
de	O	-
riesgo	O	-
multivariable	O	-
de	O	-
una	O	-
manera	O	-
dependiente	O	-
de	O	-
la	O	-
dosis.	O	-

La	B-Premise	HighQuality
administración	I-Premise	HighQuality
de	I-Premise	HighQuality
antraciclina	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
1,75	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,11-2,75	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0163	I-Premise	HighQuality
)	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
ajustes	I-Premise	HighQuality
por	I-Premise	HighQuality
edad,	I-Premise	HighQuality
sexo,	I-Premise	HighQuality
dosis	I-Premise	HighQuality
acumulada	I-Premise	HighQuality
de	I-Premise	HighQuality
prednisolona,	I-Premise	HighQuality
y	I-Premise	HighQuality
comorbilidades.	I-Premise	HighQuality

Dosis	B-Premise	HighQuality
acumuladas	I-Premise	HighQuality
de	I-Premise	HighQuality
antraciclina	I-Premise	HighQuality
de	I-Premise	HighQuality
253-400	I-Premise	HighQuality
mg	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
2,35	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,41-3,91	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0010	I-Premise	HighQuality
),	I-Premise	HighQuality
401-504	I-Premise	HighQuality
mg	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
2,26	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,26-4,05	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0063	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
>	I-Premise	HighQuality
504	I-Premise	HighQuality
mg	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
:	I-Premise	HighQuality
2,29	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,25-4,18	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0072	I-Premise	HighQuality
)	I-Premise	HighQuality
aumentaron	I-Premise	HighQuality
la	I-Premise	HighQuality
densidad	I-Premise	HighQuality
de	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
de	I-Premise	HighQuality
forma	I-Premise	HighQuality
dosis-dependiente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0006	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
alteración	I-Premise	HighQuality
anual	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
del	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
severidad	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
adaptada	I-Premise	HighQuality
no	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
diferente	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
linfoma	I-Premise	HighQuality
de	I-Premise	HighQuality
células	I-Premise	HighQuality
B	I-Premise	HighQuality
con	I-Premise	HighQuality
o	I-Premise	HighQuality
sin	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
antraciclina	I-Premise	HighQuality
(p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,4924	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
terapia	I-Claim	HighQuality
con	I-Claim	HighQuality
antraciclina	I-Claim	HighQuality
aumenta	I-Claim	HighQuality
el	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
de	I-Claim	HighQuality
forma	I-Claim	HighQuality
dosis-dependiente	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
B.	I-Claim	HighQuality

Debe	B-Claim	HighQuality
recomendarse	I-Claim	HighQuality
la	I-Claim	HighQuality
monitorización	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
intensivos	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
glucosa	I-Claim	HighQuality
en	I-Claim	HighQuality
sangre	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
B	I-Claim	HighQuality
que	I-Claim	HighQuality
reciban	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
antraciclina.	I-Claim	HighQuality

Se	O	-
ha	O	-
recomendado	O	-
la	O	-
terapia	O	-
combinada	O	-
para	O	-
el	O	-
tratamiento	O	-
de	O	-
pacientes	O	-
con	O	-
múltiples	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB)	O	-
resistentes	O	-
a	O	-
medicamentos.	O	-

Sin	O	-
embargo,	O	-
recientemente	O	-
se	O	-
demostró	O	-
que	O	-
la	O	-
monoterapia	O	-
con	O	-
tenofovir	O	-
disoproxil	O	-
fumarato	O	-
(	O	-
TDF	O	-
)	O	-
durante	O	-
48	O	-
semanas	O	-
mostró	O	-
eficacia	O	-
no	O	-
inferior	O	-
al	O	-
tratamiento	O	-
combinado	O	-
con	O	-
TDF	O	-
más	O	-
entecavir	O	-
(	O	-
ETV	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
VHB	O	-
resistentes	O	-
a	O	-
múltiples	O	-
fármacos,	O	-
incluyendo	O	-
ETV	O	-
y	O	-
adefovir.	O	-

No	O	-
obstante,	O	-
no	O	-
estaba	O	-
claro	O	-
si	O	-
la	O	-
monoterapia	O	-
prolongada	O	-
con	O	-
TDF	O	-
sería	O	-
segura	O	-
y	O	-
aumentaría	O	-
la	O	-
tasa	O	-
de	O	-
respuesta	O	-
virológica	O	-
en	O	-
estos	O	-
pacientes.	O	-

Entre	O	-
192	O	-
pacientes	O	-
con	O	-
mutaciones	O	-
de	O	-
resistencia	O	-
al	O	-
VHB	O	-
a	O	-
ETV	O	-
y/o	O	-
adefovir,	O	-
que	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
TDF	O	-
en	O	-
monoterapia	O	-
(	O	-
n	O	-
=	O	-
95	O	-
)	O	-
o	O	-
terapia	O	-
de	O	-
combinación	O	-
TDF/ETV	O	-
(	O	-
n	O	-
=	O	-
97	O	-
)	O	-
durante	O	-
48	O	-
semanas,	O	-
189	O	-
acordaron	O	-
continuar	O	-
con	O	-
TDF	O	-
en	O	-
monoterapia	O	-
(	O	-
grupo	O	-
TDF-TDF	O	-
)	O	-
o	O	-
cambiar	O	-
a	O	-
TDF	O	-
en	O	-
monoterapia	O	-
(	O	-
grupo	O	-
TDF/ETV-TDF	O	-
)	O	-
y	O	-
180	O	-
(	O	-
93,8	O	-
%	O	-
)	O	-
completaron	O	-
el	O	-
estudio	O	-
de	O	-
144	O	-
semanas.	O	-

El	B-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
sérico	I-Premise	HighQuality
<	I-Premise	HighQuality
15	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
48,	I-Premise	HighQuality
la	I-Premise	HighQuality
variable	I-Premise	HighQuality
principal	I-Premise	HighQuality
de	I-Premise	HighQuality
eficacia,	I-Premise	HighQuality
se	I-Premise	HighQuality
alcanzó	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
66,3	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF-TDF	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
68,0	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF/ETV-TDF	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,80	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
144,	I-Premise	HighQuality
la	I-Premise	HighQuality
proporción	I-Premise	HighQuality
de	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
15	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
al	I-Premise	HighQuality
74,5	I-Premise	HighQuality
%,	I-Premise	HighQuality
lo	I-Premise	HighQuality
que	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
48	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
),	I-Premise	HighQuality
sin	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
significativa	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,46	I-Premise	HighQuality
).	I-Premise	HighQuality

Mediante	B-Premise	HighQuality
análisis	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
un	I-Premise	HighQuality
total	I-Premise	HighQuality
del	I-Premise	HighQuality
79,4%	I-Premise	HighQuality
tenía	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
<	I-Premise	HighQuality
15	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
144.	I-Premise	HighQuality

Se	B-Premise	HighQuality
produjo	I-Premise	HighQuality
un	I-Premise	HighQuality
avance	I-Premise	HighQuality
virológico	I-Premise	HighQuality
transitorio	I-Premise	HighQuality
en	I-Premise	HighQuality
6	I-Premise	HighQuality
pacientes,	I-Premise	HighQuality
lo	I-Premise	HighQuality
que	I-Premise	HighQuality
se	I-Premise	HighQuality
debió	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
mala	I-Premise	HighQuality
adherencia	I-Premise	HighQuality
al	I-Premise	HighQuality
fármaco.	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
144,	I-Premise	HighQuality
19	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
>	I-Premise	HighQuality
60	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
calificados	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
genotípica,	I-Premise	HighQuality
y	I-Premise	HighQuality
6	I-Premise	HighQuality
mantuvieron	I-Premise	HighQuality
algunas	I-Premise	HighQuality
de	I-Premise	HighQuality
sus	I-Premise	HighQuality
mutaciones	I-Premise	HighQuality
basales	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB.	I-Premise	HighQuality

Ningún	B-Premise	HighQuality
paciente	I-Premise	HighQuality
desarrolló	I-Premise	HighQuality
mutaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
adicionales	I-Premise	HighQuality
a	I-Premise	HighQuality
lo	I-Premise	HighQuality
largo	I-Premise	HighQuality
del	I-Premise	HighQuality
período	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio.	I-Premise	HighQuality

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
TDF	I-Claim	HighQuality
fue	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
segura	I-Claim	HighQuality
durante	I-Claim	HighQuality
un	I-Claim	HighQuality
máximo	I-Claim	HighQuality
de	I-Claim	HighQuality
144	I-Claim	HighQuality
semanas,	I-Claim	HighQuality
proporcionando	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
creciente	I-Claim	HighQuality
de	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
virológica	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
fuertemente	I-Claim	HighQuality
pretratados	I-Claim	HighQuality
con	I-Claim	HighQuality
VHB	I-Claim	HighQuality
multirresistente.	I-Claim	HighQuality

Estimar	O	-
los	O	-
efectos	O	-
reales	O	-
de	O	-
ofrecer	O	-
una	O	-
intervención	O	-
de	O	-
estilo	O	-
de	O	-
vida	O	-
grupal	O	-
(GLI	O	-
)	O	-
a	O	-
adultos	O	-
con	O	-
diabetes.	O	-

Este	O	-
ensayo	O	-
de	O	-
estímulo	O	-
aleatorizado	O	-
incluyó	O	-
pacientes	O	-
adultos	O	-
de	O	-
atención	O	-
primaria	O	-
en	O	-
el	O	-
área	O	-
metropolitana	O	-
de	O	-
Chicago	O	-
con	O	-
diabetes	O	-
tipo	O	-
2	O	-
e	O	-
índice	O	-
de	O	-
masa	O	-
corporal	O	-
≥24	O	-
kg/m2.	O	-

Los	O	-
participantes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
atención	O	-
estándar	O	-
(consejería	O	-
dietética	O	-
y	O	-
de	O	-
estilo	O	-
de	O	-
vida	O	-
breve)	O	-
o	O	-
atención	O	-
estándar	O	-
más	O	-
ser	O	-
alentado,	O	-
pero	O	-
no	O	-
requerido,	O	-
para	O	-
participar	O	-
en	O	-
un	O	-
GLI	O	-
gratuito	O	-
ofrecido	O	-
por	O	-
el	O	-
YMCA.	O	-

El	O	-
GLI	O	-
fue	O	-
una	O	-
adaptación	O	-
grupal	O	-
de	O	-
la	O	-
intervención	O	-
de	O	-
estilo	O	-
de	O	-
vida	O	-
Look	O	-
AHEAD.	O	-

De	O	-
331	O	-
participantes,	O	-
167	O	-
fueron	O	-
aleatorizados	O	-
al	O	-
tratamiento	O	-
estándar	O	-
y	O	-
164	O	-
al	O	-
grupo	O	-
de	O	-
estímulo	O	-
del	O	-
GLI.	O	-

Alrededor	O	-
de	O	-
un	O	-
tercio	O	-
de	O	-
los	O	-
participantes	O	-
eran	O	-
blancos	O	-
no	O	-
hispanos	O	-
(	O	-
34,4%	O	-
).	O	-

En	O	-
el	O	-
brazo	O	-
del	O	-
GLI,	O	-
75	O	-
(	O	-
45,7%)	O	-
asistieron	O	-
a	O	-
≥1	O	-
visitas	O	-
del	O	-
GLI.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
primario	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
intención	I-Premise	HighQuality
de	I-Premise	HighQuality
tratar,	I-Premise	HighQuality
el	I-Premise	HighQuality
efecto	I-Premise	HighQuality
del	I-Premise	HighQuality
estímulo	I-Premise	HighQuality
del	I-Premise	HighQuality
GLI	I-Premise	HighQuality
fue	I-Premise	HighQuality
0,95	I-Premise	HighQuality
%	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
seis	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
],	I-Premise	HighQuality
0,13-1,77	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
1,20	I-Premise	HighQuality
%	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
0,05-2,36	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04	I-Premise	HighQuality
).	I-Premise	HighQuality

A	B-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses,	I-Premise	HighQuality
hubo	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
0,30%	I-Premise	HighQuality
(	I-Premise	HighQuality
3,3	I-Premise	HighQuality
mmol/mol	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
hemoglobina	I-Premise	HighQuality
A1c,	I-Premise	HighQuality
pero	B-Premise	HighQuality
este	I-Premise	HighQuality
resultado	I-Premise	HighQuality
no	I-Premise	HighQuality
alcanzó	I-Premise	HighQuality
significación	I-Premise	HighQuality
estadística	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,054	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
variables	I-Premise	HighQuality
instrumentales	I-Premise	HighQuality
estimando	I-Premise	HighQuality
los	I-Premise	HighQuality
efectos	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
subgrupos	I-Premise	HighQuality
de	I-Premise	HighQuality
participantes	I-Premise	HighQuality
que	I-Premise	HighQuality
asistieron	I-Premise	HighQuality
a	I-Premise	HighQuality
cualquier	I-Premise	HighQuality
visita	I-Premise	HighQuality
al	I-Premise	HighQuality
GLI,	I-Premise	HighQuality
el	I-Premise	HighQuality
efecto	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
asistencia	I-Premise	HighQuality
al	I-Premise	HighQuality
GLI	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
2,30	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
seis	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
0,30-4,30	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
2,07	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
0,25-3,88	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02	I-Premise	HighQuality
).	I-Premise	HighQuality

No	O	-
detectamos	O	-
ningún	O	-
efecto	O	-
significativo	O	-
sobre	O	-
la	O	-
presión	O	-
arterial	O	-
o	O	-
el	O	-
colesterol.	O	-

Entre	B-Claim	HighQuality
los	I-Claim	HighQuality
adultos	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
tipo	I-Claim	HighQuality
2,	I-Claim	HighQuality
una	I-Claim	HighQuality
intervención	I-Claim	HighQuality
de	I-Claim	HighQuality
estilo	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
en	I-Claim	HighQuality
grupo	I-Claim	HighQuality
en	I-Claim	HighQuality
un	I-Claim	HighQuality
entorno	I-Claim	HighQuality
comunitario	I-Claim	HighQuality
logró	I-Claim	HighQuality
una	I-Claim	HighQuality
modesta	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
de	I-Claim	HighQuality
peso	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
6	I-Claim	HighQuality
y	I-Claim	HighQuality
12	I-Claim	HighQuality
meses.	I-Claim	HighQuality

Para	O	-
determinar	O	-
la	O	-
seguridad	O	-
y	O	-
eficacia	O	-
del	O	-
bexaroteno	O	-
oral	O	-
(	O	-
cápsulas	O	-
de	O	-
Targretin	O	-
;	O	-
Ligand	O	-
Pharmaceuticals	O	-
Incorporated,	O	-
San	O	-
Diego,	O	-
Calif	O	-
).	O	-

Los	O	-
efectos	O	-
de	O	-
2	O	-
dosis	O	-
aleatorias	O	-
de	O	-
6,5	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
(	O	-
con	O	-
cruce	O	-
para	O	-
la	O	-
progresión	O	-
)	O	-
frente	O	-
a	O	-
650	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
(	O	-
posteriormente	O	-
modificadas	O	-
a	O	-
300	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
)	O	-
se	O	-
evaluaron	O	-
en	O	-
un	O	-
estudio	O	-
abierto,	O	-
multicéntrico,	O	-
fase	O	-
2	O	-
y	O	-
3	O	-
realizado	O	-
entre	O	-
febrero	O	-
de	O	-
1997	O	-
y	O	-
noviembre	O	-
de	O	-
1998.	O	-

Dieciocho	O	-
clínicas	O	-
internacionales	O	-
de	O	-
linfoma	O	-
cutáneo	O	-
de	O	-
células	O	-
T	O	-
en	O	-
centros	O	-
académicos	O	-
de	O	-
referencia.	O	-

58	O	-
pacientes	O	-
con	O	-
estadio	O	-
IA	O	-
probado	O	-
por	O	-
biopsia	O	-
a	O	-
través	O	-
de	O	-
linfoma	O	-
cutáneo	O	-
de	O	-
células	O	-
T	O	-
IIA	O	-
que	O	-
era	O	-
refractario	O	-
al	O	-
tratamiento	O	-
(o	O	-
los	O	-
pacientes	O	-
eran	O	-
intolerantes	O	-
al	O	-
tratamiento	O	-
)	O	-
o	O	-
habían	O	-
alcanzado	O	-
al	O	-
menos	O	-
una	O	-
meseta	O	-
de	O	-
respuesta	O	-
de	O	-
6	O	-
meses	O	-
bajo	O	-
al	O	-
menos	O	-
2	O	-
formas	O	-
de	O	-
tratamiento	O	-
previo	O	-
(	O	-
mediana	O	-
de	O	-
3,5	O	-
terapias	O	-
previas	O	-
).	O	-

Bexaroteno	O	-
(	O	-
cápsulas	O	-
de	O	-
Targretin	O	-
)	O	-
administrado	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
con	O	-
la	O	-
comida	O	-
durante	O	-
16	O	-
semanas	O	-
o	O	-
más.	O	-

Clasificación	O	-
del	O	-
punto	O	-
final	O	-
primario	O	-
de	O	-
la	O	-
tasa	O	-
de	O	-
respuesta	O	-
global	O	-
de	O	-
remisiones	O	-
completas	O	-
y	O	-
parciales	O	-
determinada	O	-
por	O	-
la	O	-
Evaluación	O	-
Global	O	-
de	O	-
la	O	-
Condición	O	-
Clínica	O	-
del	O	-
Médico	O	-
o	O	-
la	O	-
Evaluación	O	-
Compositiva	O	-
objetiva	O	-
de	O	-
la	O	-
Severidad	O	-
del	O	-
Índice	O	-
de	O	-
Lesión.	O	-

El	O	-
área	O	-
de	O	-
superficie	O	-
corporal,	O	-
el	O	-
tiempo	O	-
hasta	O	-
la	O	-
respuesta,	O	-
la	O	-
duración	O	-
del	O	-
control	O	-
de	O	-
la	O	-
enfermedad,	O	-
el	O	-
tiempo	O	-
hasta	O	-
la	O	-
progresión	O	-
de	O	-
la	O	-
enfermedad,	O	-
los	O	-
signos	O	-
y	O	-
síntomas	O	-
de	O	-
la	O	-
lesión	O	-
del	O	-
índice	O	-
individual	O	-
y	O	-
los	O	-
parámetros	O	-
de	O	-
calidad	O	-
de	O	-
vida	O	-
fueron	O	-
resultados	O	-
secundarios.	O	-

Se	B-Premise	HighQuality
observaron	I-Premise	HighQuality
respuestas	I-Premise	HighQuality
(	I-Premise	HighQuality
>	I-Premise	HighQuality
o	I-Premise	HighQuality
=	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
del	I-Premise	HighQuality
50	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
3	I-Premise	HighQuality
(	I-Premise	HighQuality
20	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
dosis	I-Premise	HighQuality
inicial	I-Premise	HighQuality
a	I-Premise	HighQuality
6,5	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
],	I-Premise	HighQuality
0	I-Premise	HighQuality
%	I-Premise	HighQuality
-40	I-Premise	HighQuality
%	I-Premise	HighQuality
),	I-Premise	HighQuality
15	I-Premise	HighQuality
(	I-Premise	HighQuality
54	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
28	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
a	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
35	I-Premise	HighQuality
%	I-Premise	HighQuality
-72	I-Premise	HighQuality
%	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
10	I-Premise	HighQuality
(	I-Premise	HighQuality
67	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
a	I-Premise	HighQuality
más	I-Premise	HighQuality
de	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
43	I-Premise	HighQuality
%	I-Premise	HighQuality
-91	I-Premise	HighQuality
%	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
progresiva	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
47	I-Premise	HighQuality
%,	I-Premise	HighQuality
21	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
13	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
mismos	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Ocho	B-Premise	HighQuality
(	I-Premise	HighQuality
73	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
11	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
pasaban	I-Premise	HighQuality
de	I-Premise	HighQuality
6,5	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
a	I-Premise	HighQuality
dosis	I-Premise	HighQuality
más	I-Premise	HighQuality
altas	I-Premise	HighQuality
respondieron	I-Premise	HighQuality
posteriormente.	I-Premise	HighQuality

La	B-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
duración	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
pudo	I-Premise	HighQuality
estimar	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
a	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
debido	I-Premise	HighQuality
a	I-Premise	HighQuality
las	I-Premise	HighQuality
bajas	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
recaída	I-Premise	HighQuality
en	I-Premise	HighQuality
2	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
13	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
a	I-Premise	HighQuality
dosis	I-Premise	HighQuality
más	I-Premise	HighQuality
altas	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
516	I-Premise	HighQuality
días.	I-Premise	HighQuality

Los	B-Premise	HighQuality
siguientes	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
fueron	I-Premise	HighQuality
reversibles	I-Premise	HighQuality
y	I-Premise	HighQuality
tratables:	I-Premise	HighQuality
hipertrigliceridemia	I-Premise	HighQuality
(	I-Premise	HighQuality
46	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
79	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
),	I-Premise	HighQuality
hipercolesterolemia	I-Premise	HighQuality
(	I-Premise	HighQuality
28	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
48	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
),	I-Premise	HighQuality
cefalea	I-Premise	HighQuality
(	I-Premise	HighQuality
27	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
47	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
),	I-Premise	HighQuality
hipotiroidismo	I-Premise	HighQuality
central	I-Premise	HighQuality
(	I-Premise	HighQuality
23	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
40	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
),	I-Premise	HighQuality
astenia	I-Premise	HighQuality
(	I-Premise	HighQuality
21	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
36	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
leucopenia	I-Premise	HighQuality
(	I-Premise	HighQuality
16	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
[	I-Premise	HighQuality
28	I-Premise	HighQuality
%	I-Premise	HighQuality
]	I-Premise	HighQuality
).	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
casos	I-Premise	HighQuality
de	I-Premise	HighQuality
fiebre	I-Premise	HighQuality
neutropénica	I-Premise	HighQuality
relacionada	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
fármaco,	I-Premise	HighQuality
sepsis	I-Premise	HighQuality
o	I-Premise	HighQuality
muerte.	I-Premise	HighQuality

Se	B-Premise	HighQuality
produjo	I-Premise	HighQuality
pancreatitis	I-Premise	HighQuality
en	I-Premise	HighQuality
3	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
triglicéridos	I-Premise	HighQuality
superiores	I-Premise	HighQuality
a	I-Premise	HighQuality
14,69	I-Premise	HighQuality
mmol/l	I-Premise	HighQuality
(	I-Premise	HighQuality
1300	I-Premise	HighQuality
mg/dl	I-Premise	HighQuality
),	I-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
cuales	I-Premise	HighQuality
estaban	I-Premise	HighQuality
tomando	I-Premise	HighQuality
300	I-Premise	HighQuality
mg/m	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
más	I-Premise	HighQuality
de	I-Premise	HighQuality
bexaroteno	I-Premise	HighQuality
oral	I-Premise	HighQuality
al	I-Premise	HighQuality
día.	I-Premise	HighQuality

El	B-Claim	HighQuality
bexaroteno	I-Claim	HighQuality
(	I-Claim	HighQuality
cápsulas	I-Claim	HighQuality
de	I-Claim	HighQuality
Targretin	I-Claim	HighQuality
)	I-Claim	HighQuality
(	I-Claim	HighQuality
el	I-Claim	HighQuality
primer	I-Claim	HighQuality
rexinoide	I-Claim	HighQuality
selectivo	I-Claim	HighQuality
del	I-Claim	HighQuality
receptor	I-Claim	HighQuality
X	I-Claim	HighQuality
retinoide	I-Claim	HighQuality
)	I-Claim	HighQuality
fue	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerado	I-Claim	HighQuality
y	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
como	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
oral	I-Claim	HighQuality
para	I-Claim	HighQuality
15	I-Claim	HighQuality
(	I-Claim	HighQuality
54%	I-Claim	HighQuality
)	I-Claim	HighQuality
de	I-Claim	HighQuality
28	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
linfoma	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
T	I-Claim	HighQuality
cutáneas	I-Claim	HighQuality
en	I-Claim	HighQuality
fase	I-Claim	HighQuality
temprana	I-Claim	HighQuality
refractario	I-Claim	HighQuality
o	I-Claim	HighQuality
persistente	I-Claim	HighQuality
a	I-Claim	HighQuality
dosis	I-Claim	HighQuality
de	I-Claim	HighQuality
300	I-Claim	HighQuality
mg/m	I-Claim	HighQuality
(	I-Claim	HighQuality
2	I-Claim	HighQuality
)	I-Claim	HighQuality
al	I-Claim	HighQuality
día.	I-Claim	HighQuality

La	B-Claim	HighQuality
hipertrigliceridemia	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
hipotiroidismo	I-Claim	HighQuality
requieren	I-Claim	HighQuality
monitorización,	I-Claim	HighQuality
pero	I-Claim	HighQuality
son	I-Claim	HighQuality
reversibles	I-Claim	HighQuality
y	I-Claim	HighQuality
manejables	I-Claim	HighQuality
con	I-Claim	HighQuality
medicación	I-Claim	HighQuality
concomitante.	I-Claim	HighQuality

Existen	O	-
pocos	O	-
ensayos	O	-
clínicos	O	-
controlados	O	-
para	O	-
apoyar	O	-
la	O	-
terapia	O	-
de	O	-
combinación	O	-
oral	O	-
en	O	-
hipertensión	O	-
arterial	O	-
pulmonar	O	-
(	O	-
HAP	O	-
).	O	-

Los	O	-
pacientes	O	-
con	O	-
HAP	O	-
(	O	-
idiopática	O	-
[	O	-
IPAH	O	-
]	O	-
o	O	-
asociada	O	-
a	O	-
enfermedad	O	-
del	O	-
tejido	O	-
conjuntivo	O	-
[	O	-
APAH-CTD	O	-
]	O	-
)	O	-
que	O	-
tomaban	O	-
bosentan	O	-
(	O	-
62,5	O	-
ó	O	-
125	O	-
mg	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
a	O	-
una	O	-
dosis	O	-
estable	O	-
durante	O	-
≥	O	-
3	O	-
meses	O	-
)	O	-
fueron	O	-
aleatorizados	O	-
(1:1	O	-
)	O	-
a	O	-
sildenafilo	O	-
(	O	-
20	O	-
mg,	O	-
3	O	-
veces	O	-
al	O	-
día	O	-
;	O	-
n	O	-
=	O	-
50	O	-
)	O	-
o	O	-
placebo	O	-
(	O	-
n	O	-
=	O	-
53	O	-
).	O	-

La	O	-
variable	O	-
principal	O	-
de	O	-
valoración	O	-
fue	O	-
el	O	-
cambio	O	-
respecto	O	-
al	O	-
valor	O	-
basal	O	-
en	O	-
la	O	-
distancia	O	-
a	O	-
pie	O	-
de	O	-
6	O	-
minutos	O	-
(	O	-
6MWD	O	-
)	O	-
en	O	-
la	O	-
semana	O	-
12,	O	-
evaluado	O	-
mediante	O	-
el	O	-
análisis	O	-
de	O	-
covarianza.	O	-

Los	O	-
pacientes	O	-
podrían	O	-
continuar	O	-
en	O	-
un	O	-
estudio	O	-
de	O	-
extensión	O	-
de	O	-
52	O	-
semanas.	O	-

Se	O	-
utilizó	O	-
un	O	-
análisis	O	-
del	O	-
modelo	O	-
de	O	-
efectos	O	-
principales	O	-
de	O	-
covarianza,	O	-
que	O	-
incluyó	O	-
términos	O	-
categóricos	O	-
para	O	-
el	O	-
tratamiento,	O	-
valor	O	-
basal	O	-
6MWD	O	-
(	O	-
<	O	-
325	O	-
m	O	-
;	O	-
≥	O	-
325	O	-
m	O	-
)	O	-
y	O	-
etiología	O	-
basal	O	-
;	O	-
posteriormente	O	-
se	O	-
realizaron	O	-
análisis	O	-
de	O	-
sensibilidad.	O	-

En	B-Premise	HighQuality
los	I-Premise	HighQuality
brazos	I-Premise	HighQuality
de	I-Premise	HighQuality
sildenafilo	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
los	I-Premise	HighQuality
aumentos	I-Premise	HighQuality
de	I-Premise	HighQuality
6MWD	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana-12	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
(	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
mínimos	I-Premise	HighQuality
cuadrados	I-Premise	HighQuality
[	I-Premise	HighQuality
sildenafilo-placebo	I-Premise	HighQuality
],	I-Premise	HighQuality
-2,4	I-Premise	HighQuality
m	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
90	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
-21,8	I-Premise	HighQuality
a	I-Premise	HighQuality
17,1	I-Premise	HighQuality
m	I-Premise	HighQuality
]	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,6	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
los	I-Premise	HighQuality
cambios	I-Premise	HighQuality
medios	I-Premise	HighQuality
±	I-Premise	HighQuality
DE	I-Premise	HighQuality
respecto	I-Premise	HighQuality
al	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
fueron	I-Premise	HighQuality
26,4	I-Premise	HighQuality
±	I-Premise	HighQuality
45,7	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
11,8	I-Premise	HighQuality
±	I-Premise	HighQuality
57,4	I-Premise	HighQuality
m,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
IPAH	I-Premise	HighQuality
(	I-Premise	HighQuality
65	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
población	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
-18,3	I-Premise	HighQuality
±	I-Premise	HighQuality
82,0	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
17,5	I-Premise	HighQuality
±	I-Premise	HighQuality
59,1	I-Premise	HighQuality
m	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
APAH-CTD	I-Premise	HighQuality
(	I-Premise	HighQuality
35	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
población	I-Premise	HighQuality
).	I-Premise	HighQuality

La	O	-
supervivencia	O	-
a	O	-
un	O	-
año	O	-
fue	O	-
del	O	-
96	O	-
%	O	-
;	O	-
los	O	-
pacientes	O	-
mantuvieron	O	-
modestas	O	-
mejorías	O	-
de	O	-
6MWD.	O	-

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
clase	I-Premise	HighQuality
funcional	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
OMS	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
disnea	I-Premise	HighQuality
Borg	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
empeoramiento	I-Premise	HighQuality
clínico	I-Premise	HighQuality
no	I-Premise	HighQuality
difirieron.	I-Premise	HighQuality

El	B-Premise	HighQuality
dolor	I-Premise	HighQuality
de	I-Premise	HighQuality
cabeza,	I-Premise	HighQuality
la	I-Premise	HighQuality
diarrea,	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
rubor	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
con	I-Premise	HighQuality
sildenafilo.	I-Premise	HighQuality

Sildenafilo,	B-Claim	HighQuality
además	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
bosentan	I-Claim	HighQuality
estable	I-Claim	HighQuality
(	I-Claim	HighQuality
≥	I-Claim	HighQuality
3	I-Claim	HighQuality
meses	I-Claim	HighQuality
),	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
ningún	I-Claim	HighQuality
beneficio	I-Claim	HighQuality
sobre	I-Claim	HighQuality
el	I-Claim	HighQuality
placebo	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
cambio	I-Claim	HighQuality
de	I-Claim	HighQuality
12	I-Claim	HighQuality
semanas	I-Claim	HighQuality
con	I-Claim	HighQuality
respecto	I-Claim	HighQuality
al	I-Claim	HighQuality
valor	I-Claim	HighQuality
basal	I-Claim	HighQuality
en	I-Claim	HighQuality
6MWD.	I-Claim	HighQuality

La	O	-
influencia	O	-
de	O	-
la	O	-
etiología	O	-
de	O	-
la	O	-
HAP	O	-
merece	O	-
estudio	O	-
futuro.	O	-

El	O	-
linfoma	O	-
extranodal	O	-
de	O	-
células	O	-
T	O	-
o	O	-
de	O	-
asesinos	O	-
naturales,	O	-
tipo	O	-
nasal	O	-
(	O	-
ENKTL	O	-
)	O	-
es	O	-
un	O	-
subtipo	O	-
raro	O	-
de	O	-
linfoma	O	-
que	O	-
a	O	-
menudo	O	-
se	O	-
asocia	O	-
con	O	-
un	O	-
pronóstico	O	-
clínico	O	-
deficiente.	O	-

Varios	O	-
estudios	O	-
han	O	-
demostrado	O	-
que	O	-
la	O	-
infección	O	-
por	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB	O	-
)	O	-
puede	O	-
estar	O	-
asociada	O	-
con	O	-
un	O	-
aumento	O	-
del	O	-
riesgo	O	-
de	O	-
linfoma	O	-
no	O	-
Hodgkin	O	-
de	O	-
células	O	-
B	O	-
;	O	-
sin	O	-
embargo,	O	-
debido	O	-
a	O	-
la	O	-
rareza	O	-
de	O	-
ENKTL,	O	-
poco	O	-
se	O	-
sabe	O	-
acerca	O	-
de	O	-
su	O	-
asociación	O	-
con	O	-
el	O	-
VHB.	O	-

Nuestro	O	-
estudio	O	-
tuvo	O	-
como	O	-
objetivo	O	-
evaluar	O	-
si	O	-
la	O	-
infección	O	-
por	O	-
VHB	O	-
se	O	-
asoció	O	-
con	O	-
mayores	O	-
probabilidades	O	-
de	O	-
ENKTL.	O	-

Se	O	-
realizó	O	-
un	O	-
estudio	O	-
de	O	-
casos	O	-
y	O	-
controles	O	-
hospitalarios	O	-
que	O	-
incluyó	O	-
417	O	-
casos	O	-
ENKTL	O	-
y	O	-
488	O	-
sujetos	O	-
de	O	-
edad	O	-
y	O	-
sexo	O	-
con	O	-
enfermedades	O	-
no	O	-
malignas	O	-
no	O	-
relacionadas	O	-
con	O	-
la	O	-
infección	O	-
por	O	-
VHB.	O	-

Se	O	-
realizaron	O	-
análisis	O	-
de	O	-
regresión	O	-
logística	O	-
incondicional	O	-
multivariable	O	-
para	O	-
estimar	O	-
las	O	-
odds	O	-
ratios	O	-
ajustadas	O	-
[	O	-
AOR	O	-
]	O	-
y	O	-
sus	O	-
correspondientes	O	-
intervalos	O	-
de	O	-
confianza	O	-
del	O	-
95	O	-
%	O	-
(	O	-
IC	O	-
).	O	-

Los	B-Premise	HighQuality
resultados	I-Premise	HighQuality
del	I-Premise	HighQuality
análisis	I-Premise	HighQuality
multivariable	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
tras	I-Premise	HighQuality
el	I-Premise	HighQuality
ajuste	I-Premise	HighQuality
para	I-Premise	HighQuality
un	I-Premise	HighQuality
conjunto	I-Premise	HighQuality
de	I-Premise	HighQuality
factores	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
conocidos,	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
previamente	I-Premise	HighQuality
infectados	I-Premise	HighQuality
con	I-Premise	HighQuality
VHB	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg-seronegativo/anti-HBc-seropositivo	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
naturalmente	I-Premise	HighQuality
inmunes	I-Premise	HighQuality
al	I-Premise	HighQuality
VHB	I-Premise	HighQuality
(	I-Premise	HighQuality
anti-HBs-seropositivo/anti-HBc-seropositivo	I-Premise	HighQuality
)	I-Premise	HighQuality
tenían	I-Premise	HighQuality
mayores	I-Premise	HighQuality
probabilidades	I-Premise	HighQuality
de	I-Premise	HighQuality
ser	I-Premise	HighQuality
diagnosticados	I-Premise	HighQuality
con	I-Premise	HighQuality
ENKTL	I-Premise	HighQuality
(	I-Premise	HighQuality
AOR,	I-Premise	HighQuality
1,497	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,098-2,042,	I-Premise	HighQuality
P=0,033	I-Premise	HighQuality
y	I-Premise	HighQuality
AOR,	I-Premise	HighQuality
1,871	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,302-2,689,	I-Premise	HighQuality
P=0,001,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
).	I-Premise	HighQuality

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
ajustar	I-Premise	HighQuality
por	I-Premise	HighQuality
otros	I-Premise	HighQuality
factores,	I-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
probabilidades	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
de	I-Premise	HighQuality
ser	I-Premise	HighQuality
diagnosticados	I-Premise	HighQuality
con	I-Premise	HighQuality
ENKTL	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
casos	I-Premise	HighQuality
que	I-Premise	HighQuality
notificaron	I-Premise	HighQuality
alguna	I-Premise	HighQuality
vez	I-Premise	HighQuality
consumo	I-Premise	HighQuality
de	I-Premise	HighQuality
alcohol	I-Premise	HighQuality
(	I-Premise	HighQuality
AOR,	I-Premise	HighQuality
1,675	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
1,054-2,660,	I-Premise	HighQuality
P=0,029	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
probabilidades	I-Premise	HighQuality
de	I-Premise	HighQuality
diagnóstico	I-Premise	HighQuality
de	I-Premise	HighQuality
ENKTL	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tipo	I-Premise	HighQuality
de	I-Premise	HighQuality
sangre	I-Premise	HighQuality
ABO,	I-Premise	HighQuality
estado	I-Premise	HighQuality
de	I-Premise	HighQuality
tabaquismo	I-Premise	HighQuality
o	I-Premise	HighQuality
antecedentes	I-Premise	HighQuality
familiares	I-Premise	HighQuality
de	I-Premise	HighQuality
cáncer.	I-Premise	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
de	I-Claim	HighQuality
nuestro	I-Claim	HighQuality
estudio	I-Claim	HighQuality
sugieren	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
previamente	I-Claim	HighQuality
infectados	I-Claim	HighQuality
con	I-Claim	HighQuality
VHB	I-Claim	HighQuality
y	I-Claim	HighQuality
naturalmente	I-Claim	HighQuality
inmunes	I-Claim	HighQuality
al	I-Claim	HighQuality
VHB	I-Claim	HighQuality
tenían	I-Claim	HighQuality
mayores	I-Claim	HighQuality
probabilidades	I-Claim	HighQuality
de	I-Claim	HighQuality
ser	I-Claim	HighQuality
diagnosticados	I-Claim	HighQuality
con	I-Claim	HighQuality
ENKTL.	I-Claim	HighQuality

Se	O	-
evaluó	O	-
la	O	-
morfología	O	-
del	O	-
bleb	O	-
y	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
-	O	-
efecto	O	-
reductor	O	-
de	O	-
la	O	-
trabeculectomía	O	-
con	O	-
ológeno	O	-
en	O	-
comparación	O	-
con	O	-
la	O	-
mitomicina	O	-
C	O	-
(MCM	O	-
)	O	-
en	O	-
el	O	-
glaucoma	O	-
de	O	-
ángulo	O	-
abierto	O	-
juvenil	O	-
(	O	-
JOAG	O	-
).	O	-
Se	O	-
trata	O	-
de	O	-
un	O	-
estudio	O	-
comparativo	O	-
intervencionista	O	-
prospectivo	O	-
realizado	O	-
en	O	-
40	O	-
ojos	O	-
(	O	-
20	O	-
pacientes	O	-
)	O	-
con	O	-
JOAG	O	-
no	O	-
controlado	O	-
médicamente,	O	-
operando	O	-
aleatoriamente	O	-
un	O	-
ojo	O	-
para	O	-
la	O	-
trabeculectomía	O	-
con	O	-
ológeno	O	-
(	O	-
grupo	O	-
A	O	-
:	O	-
20	O	-
ojos	O	-
)	O	-
y	O	-
el	O	-
otro	O	-
con	O	-
MC	O	-
(	O	-
grupo	O	-
B	O	-
:	O	-
20	O	-
ojos	O	-
).	O	-

La	O	-
medición	O	-
de	O	-
la	O	-
PIO,	O	-
la	O	-
perimetría	O	-
estándar	O	-
SITA,	O	-
y	O	-
la	O	-
tomografía	O	-
de	O	-
coherencia	O	-
óptica	O	-
de	O	-
dominio	O	-
espectral	O	-
(	O	-
OCT	O	-
)	O	-
para	O	-
el	O	-
espesor	O	-
de	O	-
la	O	-
capa	O	-
de	O	-
fibra	O	-
nerviosa	O	-
de	O	-
la	O	-
retina	O	-
(	O	-
NFL	O	-
)	O	-
se	O	-
realizaron	O	-
pre	O	-
y	O	-
postoperatoriamente.	O	-

Los	O	-
blebs	O	-
postoperatorios	O	-
se	O	-
evaluaron	O	-
clínicamente	O	-
utilizando	O	-
el	O	-
sistema	O	-
de	O	-
clasificación	O	-
de	O	-
blebs	O	-
de	O	-
Moorfields	O	-
(	O	-
MBGS	O	-
)	O	-
y	O	-
el	O	-
segmento	O	-
anterior	O	-
OCT	O	-
(	O	-
AS-OCT	O	-
).	O	-

Todos	O	-
los	O	-
pacientes	O	-
fueron	O	-
examinados	O	-
durante	O	-
un	O	-
máximo	O	-
de	O	-
1	O	-
año	O	-
en	O	-
el	O	-
postoperatorio.	O	-

La	B-Premise	HighQuality
PIO	I-Premise	HighQuality
media	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
fue	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
media	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
grupo.	I-Premise	HighQuality

A	B-Premise	HighQuality
1	I-Premise	HighQuality
año,	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
media	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
A.	I-Premise	HighQuality

Según	B-Premise	HighQuality
el	I-Premise	HighQuality
MBGS,	I-Premise	HighQuality
los	I-Premise	HighQuality
blebs	I-Premise	HighQuality
con	I-Premise	HighQuality
implante	I-Premise	HighQuality
ológeno	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
una	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mejor	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
con	I-Premise	HighQuality
MMC.	I-Premise	HighQuality

AS-OCT	B-Premise	HighQuality
mostró	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
blebs	I-Premise	HighQuality
inducidos	I-Premise	HighQuality
por	I-Premise	HighQuality
ológenos	I-Premise	HighQuality
tenían	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
más	I-Premise	HighQuality
espacios	I-Premise	HighQuality
llenos	I-Premise	HighQuality
de	I-Premise	HighQuality
líquido,	I-Premise	HighQuality
planos	I-Premise	HighQuality
de	I-Premise	HighQuality
escote	I-Premise	HighQuality
y	I-Premise	HighQuality
menos	I-Premise	HighQuality
fibrosis.	I-Premise	HighQuality

El	B-Claim	HighQuality
ológeno	I-Claim	HighQuality
resultó	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
menor	I-Claim	HighQuality
PIO	I-Claim	HighQuality
postoperatoria	I-Claim	HighQuality
a	I-Claim	HighQuality
largo	I-Claim	HighQuality
plazo,	I-Claim	HighQuality
una	I-Claim	HighQuality
mejor	I-Claim	HighQuality
morfología	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
blebs	I-Claim	HighQuality
y	I-Claim	HighQuality
menos	I-Claim	HighQuality
complicaciones.	I-Claim	HighQuality

Nuestros	B-Claim	HighQuality
resultados	I-Claim	HighQuality
sugieren	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
ológeno	I-Claim	HighQuality
puede	I-Claim	HighQuality
ser	I-Claim	HighQuality
una	I-Claim	HighQuality
alternativa	I-Claim	HighQuality
útil	I-Claim	HighQuality
a	I-Claim	HighQuality
MMC	I-Claim	HighQuality
en	I-Claim	HighQuality
JOAG.	I-Claim	HighQuality

KAMUT	B-Claim	HighQuality
khorasan	I-Claim	HighQuality
es	I-Claim	HighQuality
un	I-Claim	HighQuality
grano	I-Claim	HighQuality
antiguo	I-Claim	HighQuality
con	I-Claim	HighQuality
beneficios	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
salud	I-Claim	HighQuality
ampliamente	I-Claim	HighQuality
aclamados.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
investigar	O	-
los	O	-
efectos	O	-
de	O	-
una	O	-
dieta	O	-
de	O	-
reemplazo	O	-
con	O	-
productos	O	-
de	O	-
trigo	O	-
khorasan	O	-
antiguos	O	-
en	O	-
pacientes	O	-
con	O	-
NAFLD,	O	-
en	O	-
comparación	O	-
con	O	-
una	O	-
dieta	O	-
de	O	-
reemplazo	O	-
similar	O	-
con	O	-
productos	O	-
de	O	-
control	O	-
elaborados	O	-
a	O	-
partir	O	-
de	O	-
trigo	O	-
orgánico	O	-
semi-grano	O	-
integral	O	-
moderno.	O	-

Se	O	-
incluyeron	O	-
40	O	-
pacientes	O	-
con	O	-
NAFLD	O	-
(	O	-
12	O	-
M/28	O	-
F	O	-
;	O	-
edad	O	-
55,2	O	-
±	O	-
10,4	O	-
años	O	-
)	O	-
con	O	-
esteatosis	O	-
hepática	O	-
de	O	-
leve	O	-
a	O	-
moderada.	O	-

El	O	-
diseño	O	-
experimental	O	-
fue	O	-
un	O	-
estudio	O	-
aleatorizado,	O	-
doble	O	-
ciego,	O	-
de	O	-
brazo	O	-
paralelo	O	-
con	O	-
20	O	-
participantes	O	-
asignados	O	-
para	O	-
consumir	O	-
KAMUT	O	-
khorasan	O	-
o	O	-
controlar	O	-
productos	O	-
de	O	-
trigo	O	-
(pasta,	O	-
pan,	O	-
galletas,	O	-
galletas)	O	-
durante	O	-
un	O	-
período	O	-
de	O	-
3	O	-
meses.	O	-

Se	O	-
realizaron	O	-
mediciones	O	-
antropométricas,	O	-
análisis	O	-
de	O	-
sangre	O	-
y	O	-
ecografía	O	-
tanto	O	-
al	O	-
inicio	O	-
como	O	-
al	O	-
final	O	-
de	O	-
cada	O	-
intervención	O	-
dietética.	O	-

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
implementación	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
modelo	I-Premise	HighQuality
lineal	I-Premise	HighQuality
general	I-Premise	HighQuality
para	I-Premise	HighQuality
mediciones	I-Premise	HighQuality
repetidas	I-Premise	HighQuality
ajustado	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
detalles	I-Premise	HighQuality
demográficos	I-Premise	HighQuality
basales,	I-Premise	HighQuality
factores	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
y	I-Premise	HighQuality
medicación,	I-Premise	HighQuality
la	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
ALT	I-Premise	HighQuality
)	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
12	I-Premise	HighQuality
%,	I-Premise	HighQuality
la	I-Premise	HighQuality
aspartato	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
AST	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
14	I-Premise	HighQuality
%,	I-Premise	HighQuality
la	I-Premise	HighQuality
fosfatasa	I-Premise	HighQuality
alcalina	I-Premise	HighQuality
(	I-Premise	HighQuality
ALP	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
8	I-Premise	HighQuality
%,	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
6	I-Premise	HighQuality
%	I-Premise	HighQuality
sólo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
khorasan	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
para	I-Premise	HighQuality
todos	I-Premise	HighQuality
).	I-Premise	HighQuality

Del	O	-
mismo	O	-
modo,	O	-
las	B-Premise	HighQuality
reducciones	I-Premise	HighQuality
significativas	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
factor-alfa	I-Premise	HighQuality
circulante	I-Premise	HighQuality
de	I-Premise	HighQuality
necrosis	I-Premise	HighQuality
tumoral	I-Premise	HighQuality
proinflamatoria	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
50	I-Premise	HighQuality
%,	I-Premise	HighQuality
antagonista-alfa	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
receptores	I-Premise	HighQuality
de	I-Premise	HighQuality
l	I-Premise	HighQuality
de	I-Premise	HighQuality
interleucina	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
37	I-Premise	HighQuality
%,	I-Premise	HighQuality
interleucina-8	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
24	I-Premise	HighQuality
%,	I-Premise	HighQuality
e	I-Premise	HighQuality
interferón	I-Premise	HighQuality
gamma	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
24	I-Premise	HighQuality
%	I-Premise	HighQuality
fueron	I-Premise	HighQuality
evidentes	I-Premise	HighQuality
sólo	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
que	I-Premise	HighQuality
consumieron	I-Premise	HighQuality
los	I-Premise	HighQuality
productos	I-Premise	HighQuality
khorasan	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
para	I-Premise	HighQuality
todos	I-Premise	HighQuality
).	I-Premise	HighQuality

Finalmente,	O	-
se	B-Premise	HighQuality
evidenciaron	I-Premise	HighQuality
mejoras	I-Premise	HighQuality
significativas	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
clasificación	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
esteatosis	I-Premise	HighQuality
hepática,	I-Premise	HighQuality
los	I-Premise	HighQuality
valores	I-Premise	HighQuality
del	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
perfusión	I-Premise	HighQuality
Doppler	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
producción	I-Premise	HighQuality
de	I-Premise	HighQuality
especies	I-Premise	HighQuality
reactivas	I-Premise	HighQuality
de	I-Premise	HighQuality
oxígeno	I-Premise	HighQuality
(	I-Premise	HighQuality
ROS	I-Premise	HighQuality
)	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
consumo	I-Premise	HighQuality
tanto	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
productos	I-Premise	HighQuality
khorasan	I-Premise	HighQuality
como	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

Este	B-Claim	HighQuality
estudio	I-Claim	HighQuality
sugiere	I-Claim	HighQuality
que	I-Claim	HighQuality
una	I-Claim	HighQuality
dieta	I-Claim	HighQuality
de	I-Claim	HighQuality
reemplazo	I-Claim	HighQuality
a	I-Claim	HighQuality
corto	I-Claim	HighQuality
plazo	I-Claim	HighQuality
con	I-Claim	HighQuality
productos	I-Claim	HighQuality
KAMUT	I-Claim	HighQuality
khorasan	I-Claim	HighQuality
antiguos	I-Claim	HighQuality
es	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
para	I-Claim	HighQuality
reducir	I-Claim	HighQuality
los	I-Claim	HighQuality
factores	I-Claim	HighQuality
de	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
metabólico	I-Claim	HighQuality
y	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
el	I-Claim	HighQuality
perfil	I-Claim	HighQuality
hepático	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
NAFLD.	I-Claim	HighQuality

Se	O	-
muestra	O	-
el	O	-
papel	O	-
de	O	-
la	O	-
microbiota	O	-
intestinal	O	-
en	O	-
el	O	-
manejo	O	-
de	O	-
la	O	-
diabetes.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
aleatorizado	O	-
se	O	-
evaluaron	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
suplementación	O	-
sinbiótica	O	-
sobre	O	-
la	O	-
insulina,	O	-
el	O	-
perfil	O	-
lipídico	O	-
y	O	-
el	O	-
estado	O	-
antioxidante	O	-
en	O	-
mujeres	O	-
con	O	-
diabetes	O	-
mellitus	O	-
gestacional	O	-
(GDM	O	-
).	O	-

Noventa	O	-
mujeres	O	-
embarazadas	O	-
con	O	-
GDM	O	-
fueron	O	-
asignadas	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos	O	-
para	O	-
recibir	O	-
una	O	-
cápsula	O	-
sinbiótica	O	-
diaria	O	-
-	O	-
compuesta	O	-
de	O	-
L.	O	-
acidophilus,	O	-
L.	O	-
plantarum,	O	-
L.	O	-
fermentum,	O	-
L.	O	-
gasseri	O	-
(	O	-
1,5-7,0	O	-
×	O	-
109-10	O	-
CFU/g	O	-
)	O	-
-	O	-
con	O	-
fructooligosacárido	O	-
(	O	-
38,5	O	-
mg	O	-
)	O	-
o	O	-
placebo	O	-
durante	O	-
6	O	-
semanas.	O	-

La	O	-
glucosa	O	-
plasmática	O	-
en	O	-
ayunas	O	-
(	O	-
FPG	O	-
),	O	-
insulina,	O	-
modelo	O	-
homeostasis	O	-
de	O	-
evaluación	O	-
de	O	-
resistencia	O	-
a	O	-
la	O	-
insulina	O	-
(	O	-
HOMA-IR	O	-
),	O	-
índice	O	-
cuantitativo	O	-
de	O	-
comprobación	O	-
de	O	-
la	O	-
sensibilidad	O	-
a	O	-
la	O	-
insulina	O	-
(	O	-
QUICKI	O	-
),	O	-
colesterol	O	-
lipoproteína	O	-
de	O	-
alta	O	-
y	O	-
baja	O	-
densidad	O	-
(	O	-
HDL-C,	O	-
LDL-C	O	-
),	O	-
colesterol	O	-
total	O	-
(	O	-
TC	O	-
),	O	-
triglicéridos	O	-
(	O	-
TG	O	-
),	O	-
capacidad	O	-
antioxidante	O	-
total	O	-
(	O	-
TAC	O	-
),	O	-
y	O	-
presión	O	-
arterial	O	-
sistólica	O	-
y	O	-
diastólica	O	-
(	O	-
PAS,	O	-
DSP	O	-
)	O	-
se	O	-
evaluaron	O	-
antes	O	-
y	O	-
después	O	-
de	O	-
la	O	-
intervención.	O	-

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
cambios	I-Premise	HighQuality
significativos	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
de	I-Premise	HighQuality
FPG,	I-Premise	HighQuality
resistencia/sensibilidad	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina,	I-Premise	HighQuality
perfil	I-Premise	HighQuality
lipídico	I-Premise	HighQuality
y	I-Premise	HighQuality
TAC	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
sinbiótico	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
>	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

Se	B-Premise	HighQuality
observaron	I-Premise	HighQuality
aumentos	I-Premise	HighQuality
significativos	I-Premise	HighQuality
dentro	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
HDL-C	I-Premise	HighQuality
y	I-Premise	HighQuality
TAC	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
sinbiótico	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
LDL-C	I-Premise	HighQuality
mostró	I-Premise	HighQuality
un	I-Premise	HighQuality
incremento	I-Premise	HighQuality
significativo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
placebo	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
del	I-Premise	HighQuality
estudio	I-Premise	HighQuality
(	I-Premise	HighQuality
6,9	I-Premise	HighQuality
mg/dL,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
comparación	I-Premise	HighQuality
entre	I-Premise	HighQuality
grupos	I-Premise	HighQuality
mostró	I-Premise	HighQuality
una	I-Premise	HighQuality
disminución	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PAS	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
PAD	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
sinbiótico	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
-2,5	I-Premise	HighQuality
vs.	I-Premise	HighQuality
8,6	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
y	I-Premise	HighQuality
-1,8	I-Premise	HighQuality
vs.	I-Premise	HighQuality
2,1	I-Premise	HighQuality
mmHg,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05).	I-Premise	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
mostraron	I-Claim	HighQuality
que,	I-Claim	HighQuality
en	I-Claim	HighQuality
mujeres	I-Claim	HighQuality
con	I-Claim	HighQuality
GDM,	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
sinbiótica	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
ningún	I-Claim	HighQuality
efecto	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
índices	I-Claim	HighQuality
de	I-Claim	HighQuality
resistencia/sensibilidad	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
insulina	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
FPG.	I-Claim	HighQuality

El	B-Claim	HighQuality
perfil	I-Claim	HighQuality
lipídico	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
estado	I-Claim	HighQuality
del	I-Claim	HighQuality
TAC	I-Claim	HighQuality
pueden	I-Claim	HighQuality
verse	I-Claim	HighQuality
afectados	I-Claim	HighQuality
por	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
sinbiótica.	I-Claim	HighQuality

El	B-Claim	HighQuality
sinbiótico	I-Claim	HighQuality
es	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
en	I-Claim	HighQuality
mujeres	I-Claim	HighQuality
con	I-Claim	HighQuality
GDM.	I-Claim	HighQuality

La	O	-
hepatotoxicidad	O	-
asociada	O	-
con	O	-
la	O	-
terapia	O	-
preventiva	O	-
con	O	-
isoniazida	O	-
(	O	-
TPI	O	-
)	O	-
y	O	-
la	O	-
terapia	O	-
antirretroviral	O	-
(	O	-
ART	O	-
)	O	-
no	O	-
ha	O	-
sido	O	-
bien	O	-
estudiada	O	-
en	O	-
personas	O	-
gravemente	O	-
inmunosuprimidas	O	-
con	O	-
VIH.	O	-

Nuestro	O	-
objetivo	O	-
fue	O	-
determinar	O	-
los	O	-
factores	O	-
de	O	-
riesgo	O	-
de	O	-
hepatotoxicidad	O	-
en	O	-
individuos	O	-
gravemente	O	-
inmunosuprimidos	O	-
tratados	O	-
con	O	-
TPI	O	-
y	O	-
ART.	O	-

Estudio	O	-
multicéntrico	O	-
en	O	-
entornos	O	-
con	O	-
recursos	O	-
limitados	O	-
con	O	-
alta	O	-
carga	O	-
de	O	-
tuberculosis.	O	-

Se	O	-
realizó	O	-
un	O	-
análisis	O	-
secundario	O	-
de	O	-
los	O	-
datos	O	-
de	O	-
1	O	-
brazo	O	-
aleatorizado	O	-
del	O	-
ensayo	O	-
REMEMBER.	O	-

El	O	-
análisis	O	-
incluye	O	-
participantes	O	-
con	O	-
recuentos	O	-
de	O	-
células	O	-
CD4	O	-
pre-ART	O	-
de	O	-
<	O	-
50	O	-
células/μl	O	-
que	O	-
recibieron	O	-
TPI	O	-
y	O	-
ART	O	-
durante	O	-
24	O	-
semanas.	O	-

La	O	-
hepatotoxicidad	O	-
se	O	-
definió	O	-
como	O	-
aspartato	O	-
aminotransferasa	O	-
elevada	O	-
(	O	-
AST	O	-
)	O	-
o	O	-
alanina	O	-
aminotransferasa	O	-
(	O	-
ALT	O	-
)	O	-
>	O	-
5	O	-
×	O	-
límite	O	-
superior	O	-
de	O	-
la	O	-
hepatitis	O	-
normal	O	-
o	O	-
sintomática	O	-
durante	O	-
el	O	-
PTI	O	-
y	O	-
el	O	-
tratamiento	O	-
antirretroviral.	O	-

Se	O	-
utilizó	O	-
regresión	O	-
logística	O	-
para	O	-
identificar	O	-
los	O	-
factores	O	-
de	O	-
riesgo	O	-
basales	O	-
de	O	-
hepatotoxicidad.	O	-

El	O	-
tiempo	O	-
hasta	O	-
la	O	-
aparición	O	-
de	O	-
hepatotoxicidad	O	-
fue	O	-
estimado	O	-
por	O	-
el	O	-
método	O	-
de	O	-
Kaplan-Meier.	O	-

Entre	B-Premise	HighQuality
426	I-Premise	HighQuality
participantes	I-Premise	HighQuality
(	I-Premise	HighQuality
53	I-Premise	HighQuality
%	I-Premise	HighQuality
varones,	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
edad	I-Premise	HighQuality
35	I-Premise	HighQuality
años,	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
recuento	I-Premise	HighQuality
de	I-Premise	HighQuality
CD4	I-Premise	HighQuality
19	I-Premise	HighQuality
células/μl	I-Premise	HighQuality
),	I-Premise	HighQuality
31	I-Premise	HighQuality
desarrollaron	I-Premise	HighQuality
hepatotoxicidad	I-Premise	HighQuality
(	I-Premise	HighQuality
7,3	I-Premise	HighQuality
%	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
aumento	I-Premise	HighQuality
del	I-Premise	HighQuality
AST/ALT	I-Premise	HighQuality
pretratamiento	I-Premise	HighQuality
(	I-Premise	HighQuality
odds	I-Premise	HighQuality
ratio	I-Premise	HighQuality
[	I-Premise	HighQuality
OR	I-Premise	HighQuality
]	I-Premise	HighQuality
3,6,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
]	I-Premise	HighQuality
:	I-Premise	HighQuality
1,7	I-Premise	HighQuality
a	I-Premise	HighQuality
7,7	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
seropositividad	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
)	I-Premise	HighQuality
al	I-Premise	HighQuality
inicio	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
4,7,	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
1,7	I-Premise	HighQuality
a	I-Premise	HighQuality
12,9	I-Premise	HighQuality
)	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
del	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
desarrollar	I-Premise	HighQuality
hepatotoxicidad.	I-Premise	HighQuality

Los	B-Premise	HighQuality
participantes	I-Premise	HighQuality
con	I-Premise	HighQuality
AST/ALT	I-Premise	HighQuality
elevado	I-Premise	HighQuality
y	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
positivo	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
un	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
mayor	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
19,9,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
5,3	I-Premise	HighQuality
a	I-Premise	HighQuality
74,3	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
inicio	I-Premise	HighQuality
más	I-Premise	HighQuality
temprano	I-Premise	HighQuality
de	I-Premise	HighQuality
hepatotoxicidad	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
que	I-Premise	HighQuality
no	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
estas	I-Premise	HighQuality
condiciones	I-Premise	HighQuality
al	I-Premise	HighQuality
inicio.	I-Premise	HighQuality

La	B-Claim	HighQuality
incidencia	I-Claim	HighQuality
de	I-Claim	HighQuality
hepatotoxicidad	I-Claim	HighQuality
durante	I-Claim	HighQuality
el	I-Claim	HighQuality
TPI	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
TAR	I-Claim	HighQuality
fue	I-Claim	HighQuality
alta.	I-Claim	HighQuality

Los	B-Claim	HighQuality
individuos	I-Claim	HighQuality
gravemente	I-Claim	HighQuality
inmunosuprimidos	I-Claim	HighQuality
con	I-Claim	HighQuality
elevación	I-Claim	HighQuality
del	I-Claim	HighQuality
pretratamiento	I-Claim	HighQuality
AST/ALT	I-Claim	HighQuality
o	I-Claim	HighQuality
HBsAg	I-Claim	HighQuality
seropositividad	I-Claim	HighQuality
necesitan	I-Claim	HighQuality
una	I-Claim	HighQuality
monitorización	I-Claim	HighQuality
más	I-Claim	HighQuality
estrecha	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatotoxicidad.	I-Claim	HighQuality

Para	O	-
determinar	O	-
los	O	-
predictores	O	-
de	O	-
eventos	O	-
adversos	O	-
graves	O	-
(SAE	O	-
)	O	-
que	O	-
involucran	O	-
síncope,	O	-
hipotensión	O	-
y	O	-
caídas,	O	-
con	O	-
especial	O	-
atención	O	-
a	O	-
la	O	-
edad,	O	-
en	O	-
el	O	-
Ensayo	O	-
de	O	-
Intervención	O	-
de	O	-
Presión	O	-
Sanguínea	O	-
Sistólica.	O	-

Prácticas	O	-
académicas	O	-
y	O	-
privadas	O	-
en	O	-
los	O	-
Estados	O	-
Unidos	O	-
(	O	-
N	O	-
=	O	-
102	O	-
).	O	-

Adultos	O	-
de	O	-
50	O	-
años	O	-
y	O	-
más	O	-
con	O	-
una	O	-
presión	O	-
arterial	O	-
sistólica	O	-
(PAS	O	-
)	O	-
de	O	-
130	O	-
a	O	-
180	O	-
mmHg	O	-
con	O	-
alto	O	-
riesgo	O	-
de	O	-
eventos	O	-
de	O	-
enfermedad	O	-
cardiovascular,	O	-
pero	O	-
sin	O	-
diabetes,	O	-
antecedentes	O	-
de	O	-
accidente	O	-
cerebrovascular,	O	-
insuficiencia	O	-
cardiaca	O	-
sintomática	O	-
o	O	-
fracción	O	-
de	O	-
eyección	O	-
inferior	O	-
al	O	-
35	O	-
%,	O	-
demencia,	O	-
o	O	-
PAS	O	-
de	O	-
pie	O	-
inferior	O	-
a	O	-
110	O	-
mmHg	O	-
(	O	-
N	O	-
=	O	-
9.361	O	-
).	O	-

Tratamiento	O	-
de	O	-
la	O	-
PAS	O	-
a	O	-
una	O	-
meta	O	-
de	O	-
menos	O	-
de	O	-
120	O	-
mmHg	O	-
o	O	-
140	O	-
mmHg.	O	-

Los	O	-
resultados	O	-
fueron	O	-
EAE	O	-
que	O	-
involucraron	O	-
síncope,	O	-
hipotensión	O	-
y	O	-
caídas.	O	-

Los	O	-
predictores	O	-
fueron	O	-
asignación	O	-
de	O	-
tratamiento,	O	-
características	O	-
demográficas,	O	-
comorbilidades,	O	-
mediciones	O	-
basales,	O	-
y	O	-
uso	O	-
basal	O	-
de	O	-
medicamentos	O	-
cardiovasculares.	O	-

Ciento	O	-
setenta	O	-
y	O	-
dos	O	-
(	O	-
1,8	O	-
%	O	-
)	O	-
participantes	O	-
presentaron	O	-
SAE	O	-
con	O	-
síncope,	O	-
155	O	-
(	O	-
1,6	O	-
%	O	-
)	O	-
hipotensión	O	-
y	O	-
203	O	-
(	O	-
2,2	O	-
%	O	-
)	O	-
caídas.	O	-

La	B-Premise	HighQuality
aleatorización	I-Premise	HighQuality
al	I-Premise	HighQuality
control	I-Premise	HighQuality
intensivo	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PAS	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
mayor	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
una	I-Premise	HighQuality
EAE	I-Premise	HighQuality
con	I-Premise	HighQuality
hipotensión	I-Premise	HighQuality
(hazard	I-Premise	HighQuality
ratio	I-Premise	HighQuality
(HR	I-Premise	HighQuality
)	I-Premise	HighQuality
=	I-Premise	HighQuality
1,67,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
(IC	I-Premise	HighQuality
)	I-Premise	HighQuality
=	I-Premise	HighQuality
1,21-2,32,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,002	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
posiblemente	I-Premise	HighQuality
síncope	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
=	I-Premise	HighQuality
1,32,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,98-1,79,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,77	I-Premise	HighQuality
),	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
caídas	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
=	I-Premise	HighQuality
0,98,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,75-1,29,	I-Premise	HighQuality
P	I-Premise	HighQuality
=,90	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
tres	I-Premise	HighQuality
resultados	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
con	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
renal	I-Premise	HighQuality
crónica	I-Premise	HighQuality
o	I-Premise	HighQuality
fragilidad.	I-Premise	HighQuality

La	B-Premise	HighQuality
edad	I-Premise	HighQuality
avanzada	I-Premise	HighQuality
también	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
mayor	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
síncope,	I-Premise	HighQuality
hipotensión	I-Premise	HighQuality
y	I-Premise	HighQuality
caídas,	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
hubo	I-Premise	HighQuality
interacción	I-Premise	HighQuality
edad	I-Premise	HighQuality
por	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
para	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
resultados	I-Premise	HighQuality
del	I-Premise	HighQuality
SAE.	I-Premise	HighQuality

Los	B-Claim	HighQuality
participantes	I-Claim	HighQuality
aleatorizados	I-Claim	HighQuality
al	I-Claim	HighQuality
control	I-Claim	HighQuality
intensivo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PAS	I-Claim	HighQuality
presentaron	I-Claim	HighQuality
mayor	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
hipotensión	I-Claim	HighQuality
y	I-Claim	HighQuality
posiblemente	I-Claim	HighQuality
síncope,	I-Claim	HighQuality
pero	I-Claim	HighQuality
no	I-Claim	HighQuality
caídas.	I-Claim	HighQuality

El	O	-
mayor	O	-
riesgo	O	-
de	O	-
desarrollar	O	-
estos	O	-
acontecimientos	O	-
asociados	O	-
con	O	-
el	O	-
tratamiento	O	-
intensivo	O	-
no	O	-
varió	O	-
según	O	-
la	O	-
edad.	O	-

La	B-Claim	HighQuality
resección	I-Claim	HighQuality
anterior	I-Claim	HighQuality
baja	I-Claim	HighQuality
con	I-Claim	HighQuality
anastomosis	I-Claim	HighQuality
coloanal	I-Claim	HighQuality
previene	I-Claim	HighQuality
un	I-Claim	HighQuality
estoma	I-Claim	HighQuality
definitivo	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
rectal	I-Claim	HighQuality
distal.	I-Claim	HighQuality

Sin	B-Premise	HighQuality
embargo,	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
situación	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
se	I-Premise	HighQuality
observan	I-Premise	HighQuality
con	I-Premise	HighQuality
frecuencia	I-Premise	HighQuality
urgencias	I-Premise	HighQuality
de	I-Premise	HighQuality
heces	I-Premise	HighQuality
imperativas,	I-Premise	HighQuality
fragmentación	I-Premise	HighQuality
de	I-Premise	HighQuality
heces,	I-Premise	HighQuality
sesiones	I-Premise	HighQuality
prolongadas	I-Premise	HighQuality
de	I-Premise	HighQuality
heces,	I-Premise	HighQuality
y	I-Premise	HighQuality
problemas	I-Premise	HighQuality
menores	I-Premise	HighQuality
de	I-Premise	HighQuality
incontinencia,	I-Premise	HighQuality
que	I-Premise	HighQuality
afectan	I-Premise	HighQuality
negativamente	I-Premise	HighQuality
la	I-Premise	HighQuality
calidad	I-Premise	HighQuality
de	I-Premise	HighQuality
vida.	I-Premise	HighQuality

Por	O	-
lo	O	-
tanto,	O	-
el	O	-
colónico	O	-
J-pouch	O	-
fue	O	-
construido	O	-
originalmente	O	-
para	O	-
crear	O	-
un	O	-
depósito	O	-
de	O	-
heces.	O	-

En	O	-
un	O	-
estudio	O	-
prospectivo	O	-
aleatorizado,	O	-
el	O	-
corto	O	-
(	O	-
5	O	-
cm	O	-
)	O	-
colonico	O	-
J-pouch	O	-
fue	O	-
probado	O	-
para	O	-
función	O	-
y	O	-
continencia	O	-
vs.	O	-
anastomosis	O	-
coloanal	O	-
recta.	O	-

Durante	O	-
un	O	-
período	O	-
de	O	-
30	O	-
meses,	O	-
74	O	-
pacientes	O	-
consecutivos	O	-
(	O	-
55	O	-
hombres	O	-
)	O	-
con	O	-
cáncer	O	-
rectal	O	-
en	O	-
el	O	-
tercio	O	-
inferior	O	-
y	O	-
medio	O	-
del	O	-
recto	O	-
fueron	O	-
incluidos	O	-
y	O	-
aleatorizados	O	-
en	O	-
dos	O	-
grupos.	O	-

La	O	-
anastomosis	O	-
se	O	-
realizó	O	-
como	O	-
anastomosis	O	-
coloanal	O	-
o	O	-
anastomosis	O	-
anal-poco-colon.	O	-

El	O	-
procedimiento	O	-
quirúrgico	O	-
estandarizado	O	-
incluyó	O	-
movilización	O	-
del	O	-
hemicolón	O	-
izquierdo,	O	-
ligadura	O	-
central	O	-
de	O	-
la	O	-
arteria	O	-
y	O	-
vena	O	-
mesentérica	O	-
inferior,	O	-
disección	O	-
de	O	-
ganglios	O	-
linfáticos	O	-
preaortales,	O	-
preservación	O	-
del	O	-
nervio	O	-
autónomo,	O	-
y	O	-
escisión	O	-
mesorrectal	O	-
total.	O	-

La	O	-
anastomosis	O	-
se	O	-
realizó	O	-
en	O	-
el	O	-
canal	O	-
anal	O	-
superior	O	-
o	O	-
en	O	-
el	O	-
nivel	O	-
interesfinctérico.	O	-

Todos	O	-
los	O	-
pacientes	O	-
fueron	O	-
evaluados	O	-
preoperatoriamente	O	-
y	O	-
seis	O	-
meses	O	-
postoperatorio	O	-
para	O	-
la	O	-
continencia	O	-
fecal,	O	-
incluyendo	O	-
los	O	-
hábitos	O	-
de	O	-
manometría	O	-
y	O	-
defecación	O	-
del	O	-
esfínter.	O	-

Además,	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
se	O	-
determinó	O	-
mediante	O	-
el	O	-
uso	O	-
de	O	-
un	O	-
cuestionario	O	-
estandarizado	O	-
(	O	-
Organización	O	-
Europea	O	-
para	O	-
la	O	-
Investigación	O	-
y	O	-
el	O	-
Tratamiento	O	-
del	O	-
Cáncer,	O	-
EORTC-QLQ-C30	O	-
).	O	-

Treinta	O	-
y	O	-
siete	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
en	O	-
cada	O	-
grupo.	O	-

En	O	-
general,	O	-
los	B-Premise	HighQuality
problemas	I-Premise	HighQuality
de	I-Premise	HighQuality
continencia	I-Premise	HighQuality
para	I-Premise	HighQuality
líquidos	I-Premise	HighQuality
o	I-Premise	HighQuality
gases	I-Premise	HighQuality
ocurrieron	I-Premise	HighQuality
con	I-Premise	HighQuality
menos	I-Premise	HighQuality
frecuencia	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
J-pouch	I-Premise	HighQuality
colonico	I-Premise	HighQuality
6	I-Premise	HighQuality
meses	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
cirugía.	I-Premise	HighQuality

La	B-Premise	HighQuality
frecuencia	I-Premise	HighQuality
de	I-Premise	HighQuality
deposiciones	I-Premise	HighQuality
fue	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
J-pouch	I-Premise	HighQuality
(	I-Premise	HighQuality
2,5	I-Premise	HighQuality
por	I-Premise	HighQuality
día	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
coloanal	I-Premise	HighQuality
(	I-Premise	HighQuality
4,7	I-Premise	HighQuality
por	I-Premise	HighQuality
día	I-Premise	HighQuality
).	I-Premise	HighQuality

Es	O	-
importante	O	-
destacar	O	-
que	O	-
en	B-Premise	HighQuality
un	I-Premise	HighQuality
estudio	I-Premise	HighQuality
manométrico	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
mismo	I-Premise	HighQuality
punto	I-Premise	HighQuality
postoperatorio,	I-Premise	HighQuality
la	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
neorectal	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
a	I-Premise	HighQuality
un	I-Premise	HighQuality
grado	I-Premise	HighQuality
similar	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
volumen	I-Premise	HighQuality
rectal	I-Premise	HighQuality
preoperatorio.	I-Premise	HighQuality

Por	O	-
lo	O	-
tanto,	O	-
el	B-Premise	HighQuality
efecto	I-Premise	HighQuality
de	I-Premise	HighQuality
reservorio	I-Premise	HighQuality
esperado	I-Premise	HighQuality
y	I-Premise	HighQuality
postulado	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
pudo	I-Premise	HighQuality
lograr	I-Premise	HighQuality
mediante	I-Premise	HighQuality
la	I-Premise	HighQuality
formación	I-Premise	HighQuality
de	I-Premise	HighQuality
una	I-Premise	HighQuality
bolsa	I-Premise	HighQuality
colónica	I-Premise	HighQuality
J	I-Premise	HighQuality
de	I-Premise	HighQuality
5	I-Premise	HighQuality
cm.	I-Premise	HighQuality

El	B-Claim	HighQuality
colónico	I-Claim	HighQuality
J-pouch	I-Claim	HighQuality
fue	I-Claim	HighQuality
superior	I-Claim	HighQuality
con	I-Claim	HighQuality
respecto	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
continencia	I-Claim	HighQuality
de	I-Claim	HighQuality
gases	I-Claim	HighQuality
y	I-Claim	HighQuality
líquidos	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
anastomosis	I-Claim	HighQuality
coloanal	I-Claim	HighQuality
recta.	I-Claim	HighQuality

Además,	O	-
la	B-Claim	HighQuality
frecuencia	I-Claim	HighQuality
de	I-Claim	HighQuality
heces	I-Claim	HighQuality
fue	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
menor	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
J-pouch	I-Claim	HighQuality
que	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
de	I-Claim	HighQuality
reconstrucción	I-Claim	HighQuality
coloanal.	I-Claim	HighQuality

Sin	O	-
embargo,	O	-
debido	B-Premise	HighQuality
a	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
neorectal	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
por	I-Premise	HighQuality
igual	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos,	I-Premise	HighQuality
se	B-Claim	HighQuality
especula	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
ventaja	I-Claim	HighQuality
del	I-Claim	HighQuality
colónico	I-Claim	HighQuality
J-pouch	I-Claim	HighQuality
no	I-Claim	HighQuality
está	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
creación	I-Claim	HighQuality
de	I-Claim	HighQuality
un	I-Claim	HighQuality
reservorio	I-Claim	HighQuality
neorectal	I-Claim	HighQuality
más	I-Claim	HighQuality
grande,	I-Claim	HighQuality
sino	I-Claim	HighQuality
que	I-Claim	HighQuality
puede	I-Claim	HighQuality
estar	I-Claim	HighQuality
relacionado	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
disminución	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
motilidad.	I-Claim	HighQuality

Observar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
administración	O	-
combinada	O	-
de	O	-
entecavir	O	-
y	O	-
adefovir	O	-
dipivoxil	O	-
para	O	-
mejorar	O	-
la	O	-
fibrosis	O	-
hepática	O	-
en	O	-
pacientes	O	-
con	O	-
hepatitis	O	-
B	O	-
con	O	-
resistencia	O	-
al	O	-
interferón.	O	-

Este	O	-
estudio	O	-
incluyó	O	-
a	O	-
90	O	-
pacientes	O	-
con	O	-
hepatitis	O	-
B	O	-
con	O	-
fibrosis	O	-
hepática	O	-
y	O	-
resistencia	O	-
al	O	-
interferón	O	-
(	O	-
IFN	O	-
)	O	-
que	O	-
fueron	O	-
ingresados	O	-
en	O	-
el	O	-
departamento	O	-
de	O	-
enfermedad	O	-
infecciosa	O	-
del	O	-
hospital	O	-
para	O	-
diagnóstico	O	-
y	O	-
tratamiento	O	-
entre	O	-
enero	O	-
de	O	-
2013	O	-
y	O	-
septiembre	O	-
de	O	-
2015.	O	-

Se	O	-
dividieron	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos	O	-
de	O	-
acuerdo	O	-
con	O	-
la	O	-
tabla	O	-
de	O	-
números	O	-
aleatorios:	O	-
el	O	-
grupo	O	-
de	O	-
tratamiento	O	-
combinado	O	-
(	O	-
N.=45	O	-
)	O	-
y	O	-
el	O	-
grupo	O	-
de	O	-
entecavir	O	-
(	O	-
N.=45	O	-
).	O	-

Fueron	O	-
observados	O	-
para	O	-
cualquier	O	-
variación	O	-
en	O	-
los	O	-
índices	O	-
de	O	-
función	O	-
hepática	O	-
y	O	-
fibrosis,	O	-
así	O	-
como	O	-
el	O	-
Modelo	O	-
para	O	-
la	O	-
enfermedad	O	-
hepática	O	-
en	O	-
etapa	O	-
final	O	-
(	O	-
MELD	O	-
),	O	-
antes	O	-
y	O	-
después	O	-
del	O	-
tratamiento.	O	-

Después	B-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
combinado	I-Premise	HighQuality
vs.	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
entecavir	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
los	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
:	I-Premise	HighQuality
bilirrubina	I-Premise	HighQuality
(	I-Premise	HighQuality
67,5±7,7	I-Premise	HighQuality
vs.	I-Premise	HighQuality
82,4±13,5	I-Premise	HighQuality
μmol/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
Relación	I-Premise	HighQuality
Internacional	I-Premise	HighQuality
Normalizada	I-Premise	HighQuality
(	I-Premise	HighQuality
INR	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
1,21±0,8	I-Premise	HighQuality
vs.	I-Premise	HighQuality
1,14±0,7	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
creatinina	I-Premise	HighQuality
(	I-Premise	HighQuality
147,3±12,4	I-Premise	HighQuality
vs.	I-Premise	HighQuality
287,4±21,6	I-Premise	HighQuality
mg/dL	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
GGT	I-Premise	HighQuality
(	I-Premise	HighQuality
67,4±23,2	I-Premise	HighQuality
vs.	I-Premise	HighQuality
88,4±23,7	I-Premise	HighQuality
U/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
y	I-Premise	HighQuality
ALT	I-Premise	HighQuality
(	I-Premise	HighQuality
63,4±40,8	I-Premise	HighQuality
vs.	I-Premise	HighQuality
96,5±23,5	I-Premise	HighQuality
U/L	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
de	I-Premise	HighQuality
fibrosis	I-Premise	HighQuality
hepática	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos,	I-Premise	HighQuality
encontramos	I-Premise	HighQuality
las	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
diferencias:	I-Premise	HighQuality
PCIII	I-Premise	HighQuality
(	I-Premise	HighQuality
67,5±7,7	I-Premise	HighQuality
vs.	I-Premise	HighQuality
82,4±13,5	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
IV-C	I-Premise	HighQuality
(	I-Premise	HighQuality
61,3±18,7	I-Premise	HighQuality
vs.	I-Premise	HighQuality
74,5±17,9	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
HA	I-Premise	HighQuality
(	I-Premise	HighQuality
147,3±12,4	I-Premise	HighQuality
vs.	I-Premise	HighQuality
87,4±31,6	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
y	I-Premise	HighQuality
LN	I-Premise	HighQuality
(	I-Premise	HighQuality
88,7±13,2	I-Premise	HighQuality
vs.	I-Premise	HighQuality
102,5±23,4	I-Premise	HighQuality
μg/L	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Premise	HighQuality
resultados	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
comparación	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
índices	I-Premise	HighQuality
antes	I-Premise	HighQuality
y	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
fueron	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativas	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

Después	B-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
MELD	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
combinado	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
entecavir	I-Premise	HighQuality
(	I-Premise	HighQuality
18,7±3,2	I-Premise	HighQuality
vs.	I-Premise	HighQuality
22,5±3,4	I-Premise	HighQuality
),	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativa	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica	I-Claim	HighQuality
con	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
al	I-Claim	HighQuality
interferón,	I-Claim	HighQuality
la	I-Claim	HighQuality
administración	I-Claim	HighQuality
combinada	I-Claim	HighQuality
de	I-Claim	HighQuality
entecavir	I-Claim	HighQuality
y	I-Claim	HighQuality
adefovir	I-Claim	HighQuality
dipivoxil	I-Claim	HighQuality
puede	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
hepática,	I-Claim	HighQuality
la	I-Claim	HighQuality
fibrosis	I-Claim	HighQuality
hepática	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
puntuación	I-Claim	HighQuality
MELD.	I-Claim	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
destacan	I-Claim	HighQuality
la	I-Claim	HighQuality
necesidad	I-Claim	HighQuality
de	I-Claim	HighQuality
promover	I-Claim	HighQuality
los	I-Claim	HighQuality
beneficios	I-Claim	HighQuality
de	I-Claim	HighQuality
esta	I-Claim	HighQuality
combinación	I-Claim	HighQuality
farmacológica	I-Claim	HighQuality
para	I-Claim	HighQuality
ayudar	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica	I-Claim	HighQuality
con	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
al	I-Claim	HighQuality
interferón,	I-Claim	HighQuality
y	I-Claim	HighQuality
promover	I-Claim	HighQuality
su	I-Claim	HighQuality
aplicación	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
prácticas	I-Claim	HighQuality
clínicas.	I-Claim	HighQuality

En	O	-
China,	O	-
el	O	-
manejo	O	-
clínico	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
se	O	-
complica	O	-
por	O	-
el	O	-
uso	O	-
de	O	-
diversos	O	-
regímenes	O	-
análogos	O	-
de	O	-
nucleos	O	-
(	O	-
t	O	-
)	O	-
ide	O	-
(	O	-
NUC	O	-
)	O	-
en	O	-
pacientes	O	-
no	O	-
tratados	O	-
previamente,	O	-
incluyendo	O	-
NUCs	O	-
con	O	-
barreras	O	-
genéticas	O	-
bajas	O	-
a	O	-
la	O	-
resistencia,	O	-
con/sin	O	-
terapia	O	-
adicional	O	-
y	O	-
combinaciones	O	-
de	O	-
NUC	O	-
de	O	-
novo.	O	-

Por	O	-
lo	O	-
tanto,	O	-
este	O	-
estudio	O	-
observacional	O	-
longitudinal	O	-
investigó	O	-
el	O	-
manejo	O	-
clínico	O	-
en	O	-
el	O	-
mundo	O	-
real	O	-
y	O	-
la	O	-
eficacia	O	-
del	O	-
tratamiento	O	-
con	O	-
NUC	O	-
en	O	-
pacientes	O	-
con	O	-
CHB	O	-
no	O	-
tratados	O	-
previamente	O	-
en	O	-
China.	O	-

Los	O	-
pacientes	O	-
sin	O	-
tratamiento	O	-
previo	O	-
con	O	-
CHB	O	-
iniciados	O	-
en	O	-
terapia	O	-
con	O	-
NUC	O	-
fueron	O	-
incluidos	O	-
en	O	-
63	O	-
hospitales	O	-
de	O	-
las	O	-
ciudades	O	-
chinas	O	-
del	O	-
nivel	O	-
2.	O	-

Se	O	-
recogieron	O	-
datos	O	-
demográficos	O	-
y	O	-
específicos	O	-
del	O	-
tratamiento,	O	-
con	O	-
el	O	-
objetivo	O	-
de	O	-
notificar	O	-
los	O	-
patrones	O	-
de	O	-
tratamiento	O	-
en	O	-
el	O	-
mundo	O	-
real	O	-
y	O	-
comparar	O	-
la	O	-
eficacia	O	-
del	O	-
tratamiento	O	-
con	O	-
entecavir	O	-
(	O	-
ETV	O	-
)	O	-
y	O	-
el	O	-
tratamiento	O	-
basado	O	-
en	O	-
lamivudina	O	-
(	O	-
LAM	O	-
).	O	-

Aquí	O	-
presentamos	O	-
los	O	-
datos	O	-
del	O	-
primer	O	-
año.	O	-

3,408	O	-
pacientes	O	-
no	O	-
tratados	O	-
previamente	O	-
con	O	-
NUC	O	-
fueron	O	-
incluidos	O	-
y	O	-
tratados	O	-
con	O	-
NUC	O	-
(53%	O	-
ETV,	O	-
18	O	-
%	O	-
LAM,	O	-
29	O	-
%	O	-
otros	O	-
).	O	-

En	B-Premise	HighQuality
general,	I-Premise	HighQuality
el	I-Premise	HighQuality
6,6%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
modificaron	I-Premise	HighQuality
su	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
inicial,	I-Premise	HighQuality
con	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
modificación	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
TVC	I-Premise	HighQuality
más	I-Premise	HighQuality
bajas	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
demás	I-Premise	HighQuality
UCN	I-Premise	HighQuality
importantes	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
52,	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
virológica	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
con	I-Premise	HighQuality
ETV	I-Premise	HighQuality
que	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
basado	I-Premise	HighQuality
en	I-Premise	HighQuality
LAM	I-Premise	HighQuality
(	I-Premise	HighQuality
77,0	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
61,4	I-Premise	HighQuality
%,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
basado	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
LAM	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
probabilidad	I-Premise	HighQuality
de	I-Premise	HighQuality
avance	I-Premise	HighQuality
virológico	I-Premise	HighQuality
y	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
genotípica	I-Premise	HighQuality
(	I-Premise	HighQuality
21,4	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
19,6	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
ETV	I-Premise	HighQuality
(	I-Premise	HighQuality
1,6	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
0,1	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
relacionadas	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
o	I-Premise	HighQuality
las	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
graves	I-Premise	HighQuality
fueron	I-Premise	HighQuality
poco	I-Premise	HighQuality
frecuentes.	I-Premise	HighQuality

En	O	-
este	O	-
estudio	O	-
observacional	O	-
nacional,	O	-
más	O	-
del	O	-
50	O	-
%	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
CHB	O	-
en	O	-
hospitales	O	-
urbanos	O	-
de	O	-
nivel	O	-
2	O	-
en	O	-
China	O	-
recibieron	O	-
inicialmente	O	-
terapia	O	-
ETV.	O	-

De	B-Claim	HighQuality
acuerdo	I-Claim	HighQuality
con	I-Claim	HighQuality
los	I-Claim	HighQuality
resultados	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
ensayos	I-Claim	HighQuality
clínicos,	I-Claim	HighQuality
ETV	I-Claim	HighQuality
fue	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
tratamientos	I-Claim	HighQuality
basados	I-Claim	HighQuality
en	I-Claim	HighQuality
LAM	I-Claim	HighQuality
en	I-Claim	HighQuality
un	I-Claim	HighQuality
entorno	I-Claim	HighQuality
real,	I-Claim	HighQuality
siendo	I-Claim	HighQuality
la	I-Claim	HighQuality
modificación	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
relativamente	I-Claim	HighQuality
baja	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
ETV.	I-Claim	HighQuality

Comparar	O	-
la	O	-
presión	O	-
intraocular	O	-
postoperatoria	O	-
(PIO	O	-
)	O	-
y	O	-
la	O	-
incidencia	O	-
de	O	-
complicaciones	O	-
tempranas	O	-
después	O	-
de	O	-
la	O	-
trabeculectomía	O	-
con	O	-
sutura	O	-
releasable	O	-
a	O	-
trabeculectomía	O	-
estándar	O	-
en	O	-
pacientes	O	-
chinos	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
cierre	O	-
angular.	O	-

Ciento	O	-
setenta	O	-
y	O	-
cinco	O	-
pacientes	O	-
diagnosticados	O	-
como	O	-
glaucoma	O	-
primario	O	-
de	O	-
cierre	O	-
angular	O	-
con	O	-
6	O	-
horas	O	-
de	O	-
reloj	O	-
o	O	-
más	O	-
de	O	-
sinequia	O	-
anterior	O	-
periférica	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
2	O	-
grupos	O	-
de	O	-
tratamiento:	O	-
87	O	-
fueron	O	-
sometidos	O	-
a	O	-
trabeculectomía	O	-
estándar	O	-
(grupo	O	-
S:	O	-
2	O	-
suturas	O	-
permanentes	O	-
interrumpidas	O	-
al	O	-
colgajo	O	-
escleral	O	-
)	O	-
y	O	-
88	O	-
recibieron	O	-
trabeculectomía	O	-
con	O	-
2	O	-
suturas	O	-
permanentes	O	-
y	O	-
2	O	-
releasables	O	-
(grupo	O	-
R	O	-
).	O	-

Se	O	-
compararon	O	-
la	O	-
PIO	O	-
postoperatoria	O	-
y	O	-
las	O	-
complicaciones	O	-
durante	O	-
los	O	-
primeros	O	-
3	O	-
meses	O	-
después	O	-
de	O	-
la	O	-
cirugía.	O	-

Cien	O	-
setenta	O	-
y	O	-
un	O	-
pacientes	O	-
(	O	-
97,7%	O	-
)	O	-
asistieron	O	-
a	O	-
la	O	-
visita	O	-
de	O	-
tres	O	-
meses.	O	-

La	B-Premise	HighQuality
PIO	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
primera	I-Premise	HighQuality
semana	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
R:	I-Premise	HighQuality
día	I-Premise	HighQuality
1,	I-Premise	HighQuality
17,3	I-Premise	HighQuality
±	I-Premise	HighQuality
8,6	I-Premise	HighQuality
versus	I-Premise	HighQuality
12,7	I-Premise	HighQuality
±	I-Premise	HighQuality
6,0	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
día	I-Premise	HighQuality
3,	I-Premise	HighQuality
18,0	I-Premise	HighQuality
±	I-Premise	HighQuality
7,3	I-Premise	HighQuality
versus	I-Premise	HighQuality
12,9	I-Premise	HighQuality
±	I-Premise	HighQuality
6,3	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
día	O	-
7,	O	-
14,8	O	-
±	O	-
6,3	O	-
versus	O	-
12,0	O	-
±	O	-
4,9	O	-
mm	O	-
Hg	O	-
(	O	-
p	O	-
=	O	-
0,001	O	-
),	O	-
pero	O	-
no	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
segunda	I-Premise	HighQuality
semana	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,659	I-Premise	HighQuality
a	I-Premise	HighQuality
0,753	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
hipotonía	I-Premise	HighQuality
transitoria	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
S	I-Premise	HighQuality
(	I-Premise	HighQuality
20,4%	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
R	I-Premise	HighQuality
(9,1%	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,046	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
la	B-Premise	HighQuality
hipotonía	I-Premise	HighQuality
se	I-Premise	HighQuality
recuperó	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
80,8%	I-Premise	HighQuality
(	I-Premise	HighQuality
21/26	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
1	I-Premise	HighQuality
semana.	I-Premise	HighQuality

No	B-Premise	HighQuality
hubo	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
ocurrencia	I-Premise	HighQuality
de	I-Premise	HighQuality
cámara	I-Premise	HighQuality
superficial,	I-Premise	HighQuality
desprendimiento	I-Premise	HighQuality
coroidal,	I-Premise	HighQuality
edema	I-Premise	HighQuality
macular,	I-Premise	HighQuality
cirugía	I-Premise	HighQuality
adicional	I-Premise	HighQuality
o	I-Premise	HighQuality
hifema	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,56	I-Premise	HighQuality
a	I-Premise	HighQuality
1,0	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
técnica	I-Claim	HighQuality
de	I-Claim	HighQuality
suturas	I-Claim	HighQuality
releasables	I-Claim	HighQuality
para	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
utilizada	I-Claim	HighQuality
en	I-Claim	HighQuality
este	I-Claim	HighQuality
estudio	I-Claim	HighQuality
no	I-Claim	HighQuality
demostró	I-Claim	HighQuality
ventajas	I-Claim	HighQuality
significativas	I-Claim	HighQuality
sobre	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
estándar.	I-Claim	HighQuality

Las	B-Claim	HighQuality
suturas	I-Claim	HighQuality
liberables	I-Claim	HighQuality
se	I-Claim	HighQuality
asociaron	I-Claim	HighQuality
con	I-Claim	HighQuality
cierta	I-Claim	HighQuality
disminución	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
agudeza	I-Claim	HighQuality
visual	I-Claim	HighQuality
y	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
quejas	I-Claim	HighQuality
postoperatorias.	I-Claim	HighQuality

Este	O	-
estudio	O	-
tuvo	O	-
como	O	-
objetivo	O	-
observar	O	-
y	O	-
comparar	O	-
la	O	-
eficacia	O	-
y	O	-
seguridad	O	-
de	O	-
la	O	-
terapia	O	-
combinada	O	-
y	O	-
dos	O	-
terapias	O	-
optimizadas	O	-
diferentes	O	-
de	O	-
lamivudina	O	-
(	O	-
LAM	O	-
)	O	-
y	O	-
adefovir	O	-
dipivoxil	O	-
(	O	-
ADV	O	-
),	O	-
así	O	-
como	O	-
entecavir	O	-
(	O	-
ETV	O	-
)	O	-
en	O	-
monoterapia	O	-
en	O	-
pacientes	O	-
con	O	-
cirrosis	O	-
descompensada	O	-
inducida	O	-
por	O	-
hepatitis	O	-
B.	O	-

Un	O	-
total	O	-
de	O	-
127	O	-
pacientes	O	-
con	O	-
cirrosis	O	-
descompensada	O	-
fueron	O	-
divididos	O	-
en	O	-
cuatro	O	-
grupos,	O	-
y	O	-
cada	O	-
grupo	O	-
recibió	O	-
diferentes	O	-
dosis	O	-
de	O	-
regímenes	O	-
:	O	-
combinación	O	-
inicial	O	-
de	O	-
LAM	O	-
y	O	-
ADV,	O	-
terapias	O	-
adicionales	O	-
de	O	-
ADV	O	-
con	O	-
terapias	O	-
previas	O	-
de	O	-
LAM	O	-
de	O	-
12	O	-
semanas,	O	-
terapias	O	-
adicionales	O	-
de	O	-
ADV	O	-
con	O	-
LAM	O	-
de	O	-
24	O	-
semanas,	O	-
y	O	-
monoterapia	O	-
de	O	-
ETV.	O	-

Al	B-Premise	HighQuality
final	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
el	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
ALT	I-Premise	HighQuality
),	I-Premise	HighQuality
albúmina	I-Premise	HighQuality
(	I-Premise	HighQuality
ALB	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
bilirrubina	I-Premise	HighQuality
total	I-Premise	HighQuality
(	I-Premise	HighQuality
TBIL	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
de	I-Premise	HighQuality
combinación	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
optimizada	I-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
significativamente.	I-Premise	HighQuality

Para	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
optimizada	I-Premise	HighQuality
de	I-Premise	HighQuality
24	I-Premise	HighQuality
semanas,	I-Premise	HighQuality
sólo	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
ALT	I-Premise	HighQuality
revelaron	I-Premise	HighQuality
una	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
significativa.	I-Premise	HighQuality

No	B-Premise	HighQuality
hubo	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
obvias	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
normalización	I-Premise	HighQuality
de	I-Premise	HighQuality
ALT,	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
conversión	I-Premise	HighQuality
negativa	I-Premise	HighQuality
del	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
y	I-Premise	HighQuality
HBeAg,	I-Premise	HighQuality
así	I-Premise	HighQuality
como	I-Premise	HighQuality
la	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
puntajes	I-Premise	HighQuality
de	I-Premise	HighQuality
Child-Pugh	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
combinada,	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
optimizada	I-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
monoterapia	I-Premise	HighQuality
de	I-Premise	HighQuality
ETV.	I-Premise	HighQuality

Sin	B-Premise	HighQuality
embargo,	I-Premise	HighQuality
la	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
entre	I-Premise	HighQuality
estos	I-Premise	HighQuality
tres	I-Premise	HighQuality
grupos	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
optimizada	I-Premise	HighQuality
de	I-Premise	HighQuality
24	I-Premise	HighQuality
semanas	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativa.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
entre	I-Premise	HighQuality
cada	I-Premise	HighQuality
grupo.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
nitrógeno	I-Premise	HighQuality
de	I-Premise	HighQuality
urea	I-Premise	HighQuality
en	I-Premise	HighQuality
sangre,	I-Premise	HighQuality
creatinina	I-Premise	HighQuality
sérica,	I-Premise	HighQuality
creatina	I-Premise	HighQuality
cinasa	I-Premise	HighQuality
u	I-Premise	HighQuality
otros	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
graves	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
grupo	I-Premise	HighQuality
al	I-Premise	HighQuality
final	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
de	I-Premise	HighQuality
96	I-Premise	HighQuality
semanas.	I-Premise	HighQuality

La	B-Claim	HighQuality
terapia	I-Claim	HighQuality
combinada	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
adición	I-Claim	HighQuality
precoz	I-Claim	HighQuality
de	I-Claim	HighQuality
ADV	I-Claim	HighQuality
fueron	I-Claim	HighQuality
los	I-Claim	HighQuality
enfoques	I-Claim	HighQuality
preferidos	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
estrategia	I-Claim	HighQuality
antiviral	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
cirrosis	I-Claim	HighQuality
descompensada	I-Claim	HighQuality
inducida	I-Claim	HighQuality
por	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B.	I-Claim	HighQuality

Se	O	-
buscó	O	-
comparar	O	-
un	O	-
anticonceptivo	O	-
oral	O	-
combinado	O	-
(COC	O	-
)	O	-
más	O	-
la	O	-
espironolactona	O	-
antiandrógena	O	-
con	O	-
la	O	-
metformina	O	-
sensibilizadora	O	-
de	O	-
insulina	O	-
en	O	-
mujeres	O	-
con	O	-
síndrome	O	-
de	O	-
ovario	O	-
poliquístico	O	-
(SOP	O	-
).	O	-

Se	O	-
realizó	O	-
un	O	-
ensayo	O	-
clínico	O	-
aleatorizado,	O	-
paralelo,	O	-
abierto,	O	-
en	O	-
el	O	-
que	O	-
se	O	-
comparó	O	-
COC	O	-
(	O	-
30	O	-
μg	O	-
de	O	-
etinilestradiol	O	-
y	O	-
150	O	-
μg	O	-
de	O	-
desogestrel	O	-
)	O	-
más	O	-
espironolactona	O	-
(	O	-
100	O	-
mg/día	O	-
)	O	-
con	O	-
metformina	O	-
(850	O	-
mg	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
)	O	-

durante	O	-
un	O	-
año	O	-
en	O	-
mujeres	O	-
con	O	-
SOP	O	-
(	O	-
EudraCT2008-004531-38	O	-
).	O	-

El	O	-
resultado	O	-
primario	O	-
compuesto	O	-
incluyó	O	-
eficacia	O	-
(mejoración	O	-
del	O	-
hirsutismo,	O	-
exceso	O	-
de	O	-
andrógeno	O	-
y	O	-
disfunción	O	-
menstrual	O	-
)	O	-
y	O	-
seguridad	O	-
cardiometabólica	O	-
(cambios	O	-
en	O	-
las	O	-
frecuencias	O	-
de	O	-
los	O	-
trastornos	O	-
de	O	-
tolerancia	O	-
a	O	-
la	O	-
glucosa,	O	-
dislipemia	O	-
e	O	-
hipertensión	O	-
).	O	-

Se	O	-
realizó	O	-
una	O	-
evaluación	O	-
antropométrica,	O	-
bioquímica,	O	-
hormonal	O	-
y	O	-
metabólica	O	-
completa	O	-
cada	O	-
tres	O	-
meses	O	-
y	O	-
los	O	-
datos	O	-
fueron	O	-
sometidos	O	-
a	O	-
análisis	O	-
de	O	-
intención	O	-
de	O	-
tratamiento.	O	-

Veinticuatro	O	-
pacientes	O	-
fueron	O	-
asignados	O	-
a	O	-
COC	O	-
más	O	-
espironolactona	O	-
y	O	-
22	O	-
pacientes	O	-
a	O	-
metformina.	O	-

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
metformina,	I-Premise	HighQuality
el	I-Premise	HighQuality
COC	I-Premise	HighQuality
más	I-Premise	HighQuality
espironolactona	I-Premise	HighQuality
causó	I-Premise	HighQuality
mayores	I-Premise	HighQuality
disminuciones	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
del	I-Premise	HighQuality
hirsutismo	I-Premise	HighQuality
(	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
media	I-Premise	HighQuality
4,6	I-Premise	HighQuality
puntos,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
2,6-6,7	I-Premise	HighQuality
),	I-Premise	HighQuality
testosterona	I-Premise	HighQuality
total	I-Premise	HighQuality
(	I-Premise	HighQuality
1,1	I-Premise	HighQuality
nmol/L,	I-Premise	HighQuality
0,4-1,7	I-Premise	HighQuality
),	I-Premise	HighQuality
testosterona	I-Premise	HighQuality
libre	I-Premise	HighQuality
(	I-Premise	HighQuality
25	I-Premise	HighQuality
pmol/L,	I-Premise	HighQuality
12-39	I-Premise	HighQuality
),	I-Premise	HighQuality
androstenediona	I-Premise	HighQuality
(	I-Premise	HighQuality
5,5	I-Premise	HighQuality
nmol/L,	I-Premise	HighQuality
1,8-92	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
sulfato	I-Premise	HighQuality
de	I-Premise	HighQuality
dehidroepiandrosterona	I-Premise	HighQuality
(	I-Premise	HighQuality
2,7	I-Premise	HighQuality
μmol/L,	I-Premise	HighQuality
1,4-4,0	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
disfunción	I-Premise	HighQuality
menstrual	I-Premise	HighQuality
fue	I-Premise	HighQuality
menos	I-Premise	HighQuality
frecuente	I-Premise	HighQuality
con	I-Premise	HighQuality
COC	I-Premise	HighQuality
más	I-Premise	HighQuality
espironolactona	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
:	I-Premise	HighQuality
0,06,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
0,02-0,23	I-Premise	HighQuality
).	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
encontraron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
frecuencias	I-Premise	HighQuality
de	I-Premise	HighQuality
tolerancia	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
anormal	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
:	I-Premise	HighQuality
1,7,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
0,7-4,4	I-Premise	HighQuality
),	I-Premise	HighQuality
dislipemia	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
:	I-Premise	HighQuality
0,6,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
0,2-1,8	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
hipertensión	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
:	I-Premise	HighQuality
0,3,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
0,5-2,0	I-Premise	HighQuality
).	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
eventos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
mayores	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
marcadores	I-Premise	HighQuality
bioquímicos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
igualmente	I-Premise	HighQuality
seguros	I-Premise	HighQuality
con	I-Premise	HighQuality
ambos	I-Premise	HighQuality
tratamientos.	I-Premise	HighQuality

El	B-Claim	HighQuality
COC	I-Claim	HighQuality
más	I-Claim	HighQuality
la	I-Claim	HighQuality
espironolactona	I-Claim	HighQuality
fue	I-Claim	HighQuality
más	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
metformina	I-Claim	HighQuality
para	I-Claim	HighQuality
los	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
de	I-Claim	HighQuality
SOP	I-Claim	HighQuality
que	I-Claim	HighQuality
mostraron	I-Claim	HighQuality
efectos	I-Claim	HighQuality
neutros	I-Claim	HighQuality
similares	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
factores	I-Claim	HighQuality
de	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
cardiometabólicos.	I-Claim	HighQuality

Para	O	-
investigar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
eritropoyetina	O	-
humana	O	-
recombinante	O	-
(	O	-
epoetina	O	-
beta	O	-
)	O	-
sobre	O	-
la	O	-
anemia,	O	-
la	O	-
necesidad	O	-
de	O	-
transfusión,	O	-
y	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(	O	-
CV	O	-
)	O	-
en	O	-
pacientes	O	-
anémicos	O	-
graves	O	-
con	O	-
linfoma	O	-
no	O	-
Hodgkin	O	-
de	O	-
bajo	O	-
grado	O	-
(	O	-
LNH	O	-
),	O	-
leucemia	O	-
linfocítica	O	-
crónica	O	-
(	O	-
CLL	O	-
)	O	-
o	O	-
mieloma	O	-
múltiple	O	-
(	O	-
MM	O	-
).	O	-

Los	O	-
pacientes	O	-
dependientes	O	-
de	O	-
la	O	-
transfusión	O	-
con	O	-
LNH	O	-
(	O	-
n	O	-
=	O	-
106	O	-
),	O	-
CLL	O	-
(	O	-
n	O	-
=	O	-
126	O	-
),	O	-
o	O	-
MM	O	-
(	O	-
n	O	-
=	O	-
117	O	-
)	O	-
y	O	-
una	O	-
baja	O	-
concentración	O	-
sérica	O	-
de	O	-
eritropoyetina	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
epoyetina	O	-
beta	O	-
150	O	-
UI/	O	-
kg	O	-
o	O	-
placebo	O	-
por	O	-
vía	O	-
subcutánea	O	-
tres	O	-
veces	O	-
a	O	-
la	O	-
semana	O	-
durante	O	-
16	O	-
semanas.	O	-

Los	O	-
criterios	O	-
primarios	O	-
de	O	-
eficacia	O	-
fueron	O	-
la	O	-
supervivencia	O	-
libre	O	-
de	O	-
transfusiones	O	-
y	O	-
de	O	-
anemia	O	-
grave	O	-
(hemoglobina	O	-
[	O	-
Hb	O	-
]	O	-
>	O	-
8,5	O	-
g/dL	O	-
)	O	-
entre	O	-
las	O	-
semanas	O	-
5	O	-
a	O	-
16.	O	-

La	O	-
respuesta	O	-
se	O	-
definió	O	-
como	O	-
un	O	-
aumento	O	-
de	O	-
Hb	O	-
>	O	-
o	O	-
=	O	-
2	O	-
g/dL	O	-
con	O	-
la	O	-
eliminación	O	-
de	O	-
la	O	-
necesidad	O	-
de	O	-
transfusión.	O	-

La	O	-
CV	O	-
se	O	-
evaluó	O	-
mediante	O	-
la	O	-
escala	O	-
de	O	-
Evaluación	O	-
Funcional	O	-
del	O	-
Tratamiento	O	-
del	O	-
Cáncer.	O	-

La	B-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre	I-Premise	HighQuality
de	I-Premise	HighQuality
transfusiones	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0012	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre	I-Premise	HighQuality
de	I-Premise	HighQuality
transfusiones	I-Premise	HighQuality
y	I-Premise	HighQuality
anemia	I-Premise	HighQuality
grave	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayores	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
epoetina	I-Premise	HighQuality
beta	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
prueba	I-Premise	HighQuality
Wald	I-Premise	HighQuality
chi	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
),	I-Premise	HighQuality
lo	I-Premise	HighQuality
que	I-Premise	HighQuality
dio	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
relativa	I-Premise	HighQuality
del	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
del	I-Premise	HighQuality
43	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
51	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
67	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
27	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
tratado	I-Premise	HighQuality
con	I-Premise	HighQuality
epoetina	I-Premise	HighQuality
beta	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
grupo	I-Premise	HighQuality
tratado	I-Premise	HighQuality
con	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
).	I-Premise	HighQuality

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
y	I-Premise	HighQuality
16	I-Premise	HighQuality
semanas	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
la	I-Premise	HighQuality
CV	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
tratado	I-Premise	HighQuality
con	I-Premise	HighQuality
epoetina	I-Premise	HighQuality
beta	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
esta	B-Premise	HighQuality
mejoría	I-Premise	HighQuality
se	I-Premise	HighQuality
correlacionaba	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
concentración	I-Premise	HighQuality
de	I-Premise	HighQuality
Hb	I-Premise	HighQuality
(	I-Premise	HighQuality
>	I-Premise	HighQuality
o	I-Premise	HighQuality
=	I-Premise	HighQuality
2	I-Premise	HighQuality
g/dl	I-Premise	HighQuality
).	I-Premise	HighQuality

No	O	-
se	O	-
pudo	O	-
identificar	O	-
un	O	-
objetivo	O	-
Hb	O	-
que	O	-
pudiera	O	-
recomendarse	O	-
en	O	-
general.	O	-

Muchos	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
gravemente	I-Claim	HighQuality
anémicos	I-Claim	HighQuality
y	I-Claim	HighQuality
dependientes	I-Claim	HighQuality
de	I-Claim	HighQuality
transfusiones	I-Claim	HighQuality
con	I-Claim	HighQuality
MM	I-Claim	HighQuality
avanzado,	I-Claim	HighQuality
LNH	I-Claim	HighQuality
y	I-Claim	HighQuality
CLL	I-Claim	HighQuality
y	I-Claim	HighQuality
con	I-Claim	HighQuality
bajo	I-Claim	HighQuality
rendimiento	I-Claim	HighQuality
se	I-Claim	HighQuality
beneficiaron	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
epoyetina,	I-Claim	HighQuality
con	I-Claim	HighQuality
eliminación	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
anemia	I-Claim	HighQuality
grave	I-Claim	HighQuality
y	I-Claim	HighQuality
necesidad	I-Claim	HighQuality
de	I-Claim	HighQuality
transfusión,	I-Claim	HighQuality
y	I-Claim	HighQuality
mejoría	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
CV.	I-Claim	HighQuality

La	O	-
eficacia	O	-
del	O	-
tratamiento	O	-
secuencial	O	-
con	O	-
análogos	O	-
de	O	-
nucleos	O	-
(	O	-
t	O	-
)	O	-
ide	O	-
y	O	-
interferones	O	-
frente	O	-
a	O	-
la	O	-
monoterapia	O	-
en	O	-
pacientes	O	-
con	O	-
antígeno	O	-
de	O	-
hepatitis	O	-
B	O	-
e	O	-
(	O	-
HBeAg	O	-
)	O	-
-hepatitis	O	-
B	O	-
crónica	O	-
positiva	O	-
(	O	-
CHB	O	-
)	O	-
permanece	O	-
inexplorada.	O	-

Nuestro	O	-
objetivo	O	-
fue	O	-
evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
seguridad	O	-
del	O	-
tratamiento	O	-
secuencial	O	-
con	O	-
adefovir	O	-
(	O	-
ADV	O	-
)	O	-
o	O	-
entecavir	O	-
(	O	-
ETV	O	-
)	O	-
seguido	O	-
de	O	-
peginterferón	O	-
(	O	-
PEG-IFN	O	-
)	O	-
alfa-2a	O	-
en	O	-
pacientes	O	-
taiwaneses	O	-
con	O	-
HBeAg	O	-
positivo.	O	-

Este	O	-
ensayo	O	-
aleatorizado,	O	-
controlado	O	-
con	O	-
placebo,	O	-
doble	O	-
ciego	O	-
se	O	-
llevó	O	-
a	O	-
cabo	O	-
en	O	-
nueve	O	-
sitios	O	-
en	O	-
Taiwán	O	-
desde	O	-
abril	O	-
de	O	-
2010	O	-
hasta	O	-
octubre	O	-
de	O	-
2013.	O	-

Los	O	-
pacientes	O	-
(	O	-
N	O	-
=	O	-
280	O	-
)	O	-
fueron	O	-
aleatorizados	O	-
1:1:1	O	-
para	O	-
recibir	O	-
placebo,	O	-
ETV	O	-
o	O	-
ADV	O	-
solos	O	-
durante	O	-
cuatro	O	-
semanas,	O	-
combinados	O	-
con	O	-
PEG-IFN	O	-
alfa-2a	O	-
durante	O	-
dos	O	-
semanas,	O	-
luego	O	-
PEG-IFN	O	-
alfa-2a	O	-
solo	O	-
durante	O	-
46	O	-
semanas.	O	-

El	O	-
punto	O	-
final	O	-
de	O	-
eficacia	O	-
principal	O	-
fue	O	-
la	O	-
seroconversión	O	-
de	O	-
HBeAg	O	-
a	O	-
las	O	-
48	O	-
semanas	O	-
después	O	-
del	O	-
tratamiento.	O	-

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
significativas	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
(	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+placebo,	I-Premise	HighQuality
36,3	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+ETV,	I-Premise	HighQuality
29,5	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
y	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+ADV,	I-Premise	HighQuality
27,4	I-Premise	HighQuality
%	I-Premise	HighQuality
),	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
(	I-Premise	HighQuality
37,4	I-Premise	HighQuality
%,	I-Premise	HighQuality
32,2	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
28,6	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
)	I-Premise	HighQuality
con	I-Premise	HighQuality
respecto	I-Premise	HighQuality
al	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
(	I-Premise	HighQuality
-0,56	I-Premise	HighQuality
UI/ml,	I-Premise	HighQuality
-0,60	I-Premise	HighQuality
UI/ml	I-Premise	HighQuality
y	I-Premise	HighQuality
-0,41	I-Premise	HighQuality
UI/ml,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
).	I-Premise	HighQuality

Sin	B-Premise	HighQuality
embargo,	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
virus	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
fueron	I-Premise	HighQuality
mayores	I-Premise	HighQuality
con	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+placebo	I-Premise	HighQuality
que	I-Premise	HighQuality
con	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa+ETV	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
64	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0412	I-Premise	HighQuality
),	I-Premise	HighQuality
76	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0311	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
88	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0113	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
normalización	I-Premise	HighQuality
de	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
(	I-Premise	HighQuality
ALT	I-Premise	HighQuality
)	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
con	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+placebo	I-Premise	HighQuality
que	I-Premise	HighQuality
con	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+ADV	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0283	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
PEG-IFN	I-Premise	HighQuality
alfa-2a+ETV	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0369	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
88.	I-Premise	HighQuality

El	B-Premise	HighQuality
subanálisis	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
resultados	I-Premise	HighQuality
reveló	I-Premise	HighQuality
una	I-Premise	HighQuality
asociación	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
y	I-Premise	HighQuality
ALT	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
eficacia	I-Premise	HighQuality
48	I-Premise	HighQuality
semanas	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento.	I-Premise	HighQuality

La	B-Premise	HighQuality
seguridad	I-Premise	HighQuality
fue	I-Premise	HighQuality
comparable	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento.	I-Premise	HighQuality

El	B-Claim	HighQuality
tratamiento	I-Claim	HighQuality
previo	I-Claim	HighQuality
con	I-Claim	HighQuality
ADV	I-Claim	HighQuality
o	I-Claim	HighQuality
ETV	I-Claim	HighQuality
seguido	I-Claim	HighQuality
de	I-Claim	HighQuality
PEG-IFN	I-Claim	HighQuality
alfa-2a	I-Claim	HighQuality
no	I-Claim	HighQuality
es	I-Claim	HighQuality
superior	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
PEG-IFN	I-Claim	HighQuality
alfa-2a	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
taiwaneses	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB	I-Claim	HighQuality
HBeAg	I-Claim	HighQuality
positivo.	I-Claim	HighQuality

Para	O	-
evaluar	O	-
comparativamente,	O	-
en	O	-
términos	O	-
de	O	-
supervivencia	O	-
ajustada	O	-
a	O	-
la	O	-
calidad,	O	-
tres	O	-
tratamientos	O	-
de	O	-
primera	O	-
línea	O	-
en	O	-
pacientes	O	-
con	O	-
leucemia	O	-
linfocítica	O	-
crónica	O	-
en	O	-
estadio	O	-
B	O	-
o	O	-
C	O	-
(	O	-
CLL	O	-
).	O	-

Para	O	-
describir	O	-
mejor	O	-
y	O	-
comparar	O	-
la	O	-
supervivencia	O	-
después	O	-
de	O	-
la	O	-
aleatorización	O	-
de	O	-
pacientes	O	-
del	O	-
ensayo	O	-
CLL90	O	-
que	O	-
compararon	O	-
aleatoriamente	O	-
ChOP	O	-
(ciclofosfamida,	O	-
doxorubicina,	O	-
oncovina,	O	-
prednisona	O	-
),	O	-
CAP	O	-
(	O	-
ciclofosfamida,	O	-
doxorubicina,	O	-
prednisona	O	-
)	O	-
y	O	-
fludarabina	O	-
en	O	-
CLL	O	-
avanzado,	O	-
se	O	-
realizó	O	-
un	O	-
análisis	O	-
de	O	-
supervivencia	O	-
ajustado	O	-
a	O	-
la	O	-
calidad.	O	-

Esto	O	-
consistió	O	-
en	O	-
definir	O	-
cuatro	O	-
estados	O	-
clínicos	O	-
(	O	-
toxicidad,	O	-
tratamiento	O	-
libre	O	-
de	O	-
toxicidad,	O	-
sin	O	-
tratamiento	O	-
ni	O	-
síntomas,	O	-
recaída	O	-
),	O	-
y	O	-
luego	O	-
resumir	O	-
los	O	-
tiempos	O	-
promedio	O	-
pasados	O	-
en	O	-
cada	O	-
estado	O	-
ponderados	O	-
por	O	-
coeficientes	O	-
de	O	-
utilidad	O	-
que	O	-
reflejan	O	-
el	O	-
valor	O	-
relativo	O	-
según	O	-
la	O	-
calidad	O	-
de	O	-
vida.	O	-

El	O	-
tiempo	O	-
de	O	-
ajuste	O	-
de	O	-
calidad	O	-
resultante	O	-
sin	O	-
síntomas	O	-
ni	O	-
toxicidad	O	-
(	O	-
Q-TWIST	O	-
)	O	-
se	O	-
comparó	O	-
entre	O	-
los	O	-
grupos	O	-
aleatorizados,	O	-
y	O	-
se	O	-
realizaron	O	-
análisis	O	-
de	O	-
sensibilidad	O	-
(	O	-
umbral	O	-
)	O	-
a	O	-
la	O	-
elección	O	-
de	O	-
los	O	-
coeficientes	O	-
de	O	-
utilidad.	O	-

Más	B-Premise	HighQuality
de	I-Premise	HighQuality
73	I-Premise	HighQuality
meses	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
aleatorización,	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
fludarabina	I-Premise	HighQuality
obtuvo	I-Premise	HighQuality
una	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
45	I-Premise	HighQuality
días	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre	I-Premise	HighQuality
de	I-Premise	HighQuality
toxicidad	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
CAP,	I-Premise	HighQuality
y	I-Premise	HighQuality
61	I-Premise	HighQuality
días	I-Premise	HighQuality
durante	I-Premise	HighQuality
la	I-Premise	HighQuality
PCH.	I-Premise	HighQuality

La	B-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
TWIST	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
27,05	I-Premise	HighQuality
meses	I-Premise	HighQuality
con	I-Premise	HighQuality
CAP,	I-Premise	HighQuality
31,5	I-Premise	HighQuality
meses	I-Premise	HighQuality
con	I-Premise	HighQuality
ChOP	I-Premise	HighQuality
y	I-Premise	HighQuality
32,95	I-Premise	HighQuality
meses	I-Premise	HighQuality
con	I-Premise	HighQuality
fludarabina.	I-Premise	HighQuality

Los	B-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
umbral	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que,	I-Premise	HighQuality
independientemente	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pesos	I-Premise	HighQuality
de	I-Premise	HighQuality
utilidad,	I-Premise	HighQuality
la	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
Q-TWIST	I-Premise	HighQuality
fue	I-Premise	HighQuality
siempre	I-Premise	HighQuality
mayor	I-Premise	HighQuality
con	I-Premise	HighQuality
ChOP	I-Premise	HighQuality
o	I-Premise	HighQuality
fludarabina	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
CAP.	I-Premise	HighQuality

Fludarabina	B-Claim	HighQuality
fue	I-Claim	HighQuality
consistentemente	I-Claim	HighQuality
un	I-Claim	HighQuality
mejor	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
que	I-Claim	HighQuality
ChOP,	I-Claim	HighQuality
excepto	B-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
improbable	I-Premise	HighQuality
caso	I-Premise	HighQuality
de	I-Premise	HighQuality
pesos	I-Premise	HighQuality
altos	I-Premise	HighQuality
de	I-Premise	HighQuality
utilidad	I-Premise	HighQuality
atribuidos	I-Premise	HighQuality
a	I-Premise	HighQuality
toxicidad	I-Premise	HighQuality
y	I-Premise	HighQuality
pesos	I-Premise	HighQuality
bajos	I-Premise	HighQuality
de	I-Premise	HighQuality
utilidad	I-Premise	HighQuality
atribuidos	I-Premise	HighQuality
al	I-Premise	HighQuality
tratamiento.	I-Premise	HighQuality

Sin	O	-
embargo,	O	-
desde	B-Premise	HighQuality
el	I-Premise	HighQuality
punto	I-Premise	HighQuality
de	I-Premise	HighQuality
vista	I-Premise	HighQuality
clínico,	I-Premise	HighQuality
las	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
entre	I-Premise	HighQuality
la	I-Premise	HighQuality
PCH	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
fludarabina	I-Premise	HighQuality
fueron	I-Premise	HighQuality
moderadas	I-Premise	HighQuality
o	I-Premise	HighQuality
leves	I-Premise	HighQuality
(diferencia	I-Premise	HighQuality
media	I-Premise	HighQuality
en	I-Premise	HighQuality
TWIST	I-Premise	HighQuality
de	I-Premise	HighQuality
1,45	I-Premise	HighQuality
meses	I-Premise	HighQuality
).	I-Premise	HighQuality

Concluimos	O	-
que	O	-
los	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CLL	I-Claim	HighQuality
avanzado	I-Claim	HighQuality
tienen	I-Claim	HighQuality
un	I-Claim	HighQuality
beneficio	I-Claim	HighQuality
moderado	I-Claim	HighQuality
en	I-Claim	HighQuality
términos	I-Claim	HighQuality
de	I-Claim	HighQuality
Q-TWIST	I-Claim	HighQuality
cuando	I-Claim	HighQuality
se	I-Claim	HighQuality
tratan	I-Claim	HighQuality
con	I-Claim	HighQuality
fludarabina	I-Claim	HighQuality
sobre	I-Claim	HighQuality
ChOP.	I-Claim	HighQuality

Estos	B-Claim	HighQuality
dos	I-Claim	HighQuality
tratamientos	I-Claim	HighQuality
son	I-Claim	HighQuality
siempre	I-Claim	HighQuality
superiores	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
CAP.	I-Claim	HighQuality

Comparar	O	-
la	O	-
eficacia	O	-
de	O	-
las	O	-
combinaciones	O	-
fijas	O	-
bimatoprost/timolol	O	-
(	O	-
BTFC	O	-
)	O	-
o	O	-
travoprost/timolol	O	-
(	O	-
TTFC	O	-
)	O	-
sobre	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
en	O	-
una	O	-
población	O	-
egipcia.	O	-

Los	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
BTFC	O	-
o	O	-
TTFC.	O	-

Los	O	-
PIO	O	-
se	O	-
midieron	O	-
al	O	-
inicio,	O	-
2	O	-
semanas,	O	-
y	O	-
1,	O	-
2,	O	-
4	O	-
y	O	-
6	O	-
meses.	O	-

La	O	-
medida	O	-
de	O	-
resultado	O	-
principal	O	-
fue	O	-
el	O	-
cambio	O	-
medio	O	-
de	O	-
la	O	-
PIO	O	-
respecto	O	-
al	O	-
valor	O	-
basal	O	-
en	O	-
cada	O	-
visita.	O	-

Las	O	-
medidas	O	-
de	O	-
resultados	O	-
secundarios	O	-
incluyeron	O	-
la	O	-
incidencia	O	-
de	O	-
acontecimientos	O	-
adversos.	O	-

Finalmente	O	-
se	O	-
incluyeron	O	-
80	O	-
pacientes	O	-
(	O	-
80	O	-
ojos	O	-
)	O	-
:	O	-
40	O	-
ojos	O	-
en	O	-
cada	O	-
grupo.	O	-

La	O	-
media	O	-
basal	O	-
de	O	-
los	O	-
COP	O	-
fue	O	-
de	O	-
24,78±3,53	O	-
y	O	-
25,26±3,51	O	-
mm	O	-
Hg	O	-
para	O	-
BTFC	O	-
y	O	-
TTFC,	O	-
respectivamente	O	-
(	O	-
P=0,344).	O	-

Ambas	B-Premise	HighQuality
caídas	I-Premise	HighQuality
proporcionaron	I-Premise	HighQuality
reducciones	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativas	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
punto	I-Premise	HighQuality
de	I-Premise	HighQuality
vista	I-Premise	HighQuality
basal	I-Premise	HighQuality
en	I-Premise	HighQuality
todas	I-Premise	HighQuality
las	I-Premise	HighQuality
visitas	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
BTFC	I-Premise	HighQuality
proporcionó	I-Premise	HighQuality
mayores	I-Premise	HighQuality
reducciones	I-Premise	HighQuality
medias	I-Premise	HighQuality
significativas	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
con	I-Premise	HighQuality
respecto	I-Premise	HighQuality
al	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
que	I-Premise	HighQuality
el	I-Premise	HighQuality
TTFC	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
visita	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
reducciones	I-Premise	HighQuality
medias	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
fueron	I-Premise	HighQuality
de	I-Premise	HighQuality
11,34	I-Premise	HighQuality
y	I-Premise	HighQuality
6,42	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
a	I-Premise	HighQuality
las	I-Premise	HighQuality
2	I-Premise	HighQuality
semanas	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,000	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
11,17	I-Premise	HighQuality
y	I-Premise	HighQuality
7,89	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
6	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
para	I-Premise	HighQuality
BTFC	I-Premise	HighQuality
y	I-Premise	HighQuality
TTFC,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Los	B-Premise	HighQuality
PIO	I-Premise	HighQuality
a	I-Premise	HighQuality
las	I-Premise	HighQuality
2	I-Premise	HighQuality
semanas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
de	I-Premise	HighQuality
18	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
36	I-Premise	HighQuality
(	I-Premise	HighQuality
90,8%	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
22	I-Premise	HighQuality
(	I-Premise	HighQuality
55	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
ojos	I-Premise	HighQuality
y	I-Premise	HighQuality
16	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
28	I-Premise	HighQuality
(	I-Premise	HighQuality
70	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
16	I-Premise	HighQuality
(	I-Premise	HighQuality
40	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
ojos	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
6	I-Premise	HighQuality
meses,	I-Premise	HighQuality
18	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
38	I-Premise	HighQuality
(	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
28	I-Premise	HighQuality
(	I-Premise	HighQuality
70	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
ojos	I-Premise	HighQuality
y	I-Premise	HighQuality
16	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
30	I-Premise	HighQuality
(	I-Premise	HighQuality
75	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
18	I-Premise	HighQuality
(	I-Premise	HighQuality
45	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
ojos	I-Premise	HighQuality
para	I-Premise	HighQuality
BTCC	I-Premise	HighQuality
y	I-Premise	HighQuality
TTFC,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Ambas	B-Claim	HighQuality
gotas	I-Claim	HighQuality
proporcionaron	I-Claim	HighQuality
una	I-Claim	HighQuality
reducción	I-Claim	HighQuality
efectiva	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
que	I-Claim	HighQuality
fue	I-Claim	HighQuality
mayor	I-Claim	HighQuality
y	O	-
los	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
tuvieron	I-Claim	HighQuality
más	I-Claim	HighQuality
probabilidades	I-Claim	HighQuality
de	I-Claim	HighQuality
lograr	I-Claim	HighQuality
presiones	I-Claim	HighQuality
objetivo	I-Claim	HighQuality
más	I-Claim	HighQuality
bajas	I-Claim	HighQuality
con	I-Claim	HighQuality
BTFC	I-Claim	HighQuality
que	I-Claim	HighQuality
con	I-Claim	HighQuality
TTFC.	I-Claim	HighQuality

A	O	-
pesar	O	-
de	O	-
la	O	-
falta	O	-
de	O	-
evidencia,	O	-
un	O	-
número	O	-
creciente	O	-
de	O	-
personas	O	-
están	O	-
utilizando	O	-
la	O	-
medicina	O	-
herbal	O	-
para	O	-
atenuar	O	-
la	O	-
carga	O	-
de	O	-
la	O	-
diabetes.	O	-

Hay	O	-
una	O	-
necesidad	O	-
urgente	O	-
de	O	-
investigar	O	-
el	O	-
potencial	O	-
clínico	O	-
de	O	-
las	O	-
hierbas.	O	-

Las	O	-
observaciones	O	-
preliminares	O	-
sugieren	O	-
que	O	-
el	O	-
ginseng	O	-
americano	O	-
(	O	-
Panax	O	-
quinquefolius	O	-
[	O	-
AG	O	-
]	O	-
)	O	-
puede	O	-
reducir	O	-
la	O	-
glicemia	O	-
postprandial.	O	-

Así,	O	-
se	O	-
buscó	O	-
evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
seguridad	O	-
de	O	-
AG	O	-
como	O	-
terapia	O	-
adicional	O	-
en	O	-
individuos	O	-
con	O	-
diabetes	O	-
tipo	O	-
2	O	-
(	O	-
T2DM	O	-
)	O	-
controlada	O	-
por	O	-
tratamiento	O	-
convencional.	O	-

24	O	-
individuos	O	-
que	O	-
viven	O	-
con	O	-
T2DM	O	-
completaron	O	-
el	O	-
estudio	O	-
(	O	-
F	O	-
:	O	-
M	O	-
=	O	-
11:13	O	-
;	O	-
edad	O	-
=	O	-
64	O	-
±	O	-
7	O	-
años	O	-
;	O	-
IMC	O	-
=	O	-
27,8	O	-
±	O	-
4,6	O	-
kg/m2	O	-
;	O	-
HbA1c	O	-
=	O	-
7,1	O	-
±	O	-
1,2	O	-
%	O	-
).	O	-

Utilizando	O	-
un	O	-
diseño	O	-
cruzado	O	-
doble	O	-
ciego,	O	-
los	O	-
participantes	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
1	O	-
g/comida	O	-
(	O	-
3	O	-
g/día)	O	-
de	O	-
extracto	O	-
de	O	-
AG	O	-
o	O	-
placebo	O	-
durante	O	-
8	O	-
semanas	O	-
mientras	O	-
mantenían	O	-
su	O	-
tratamiento	O	-
original.	O	-

Después	O	-
de	O	-
un	O	-
período	O	-
de	O	-
lavado	O	-
≥	O	-
4	O	-
semanas,	O	-
los	O	-
participantes	O	-
fueron	O	-
cruzados	O	-
al	O	-
grupo	O	-
de	O	-
tratamiento	O	-
opuesto	O	-
de	O	-
8	O	-
semanas.	O	-

El	O	-
objetivo	O	-
principal	O	-
fue	O	-
HbA1c,	O	-
y	O	-
las	O	-
variables	O	-
secundarias	O	-
fueron	O	-
glucosa	O	-
en	O	-
sangre	O	-
en	O	-
ayunas	O	-
e	O	-
insulina,	O	-
presión	O	-
arterial,	O	-
lípidos	O	-
plasmáticos,	O	-
nitratos	O	-
séricos/nitritos	O	-
(	O	-
NOx	O	-
)	O	-
y	O	-
factor	O	-
activador	O	-
plasominógeno-1	O	-
(	O	-
PAI-1	O	-
).	O	-

Los	O	-
parámetros	O	-
de	O	-
seguridad	O	-
incluyeron	O	-
la	O	-
función	O	-
hepática	O	-
y	O	-
renal.	O	-

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
AG	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
la	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
0,29%;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,041	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
en	I-Premise	HighQuality
sangre	I-Premise	HighQuality
en	I-Premise	HighQuality
ayunas	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
0,71	I-Premise	HighQuality
mmol/l;	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,008	I-Premise	HighQuality
).	I-Premise	HighQuality

Además,	O	-
la	B-Premise	HighQuality
AG	I-Premise	HighQuality
redujo	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
5,6	I-Premise	HighQuality
±	I-Premise	HighQuality
2,7	I-Premise	HighQuality
mmHg;	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
los	I-Premise	HighQuality
NOx	I-Premise	HighQuality
(	I-Premise	HighQuality
+	I-Premise	HighQuality
1,85	I-Premise	HighQuality
±	I-Premise	HighQuality
2,13	I-Premise	HighQuality
μmol/L	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,03	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
produjo	I-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
media	I-Premise	HighQuality
porcentual	I-Premise	HighQuality
final	I-Premise	HighQuality
de	I-Premise	HighQuality
-	I-Premise	HighQuality
12,3	I-Premise	HighQuality
±	I-Premise	HighQuality
3,9	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
LDL-C	I-Premise	HighQuality
y	I-Premise	HighQuality
-	I-Premise	HighQuality
13,9	I-Premise	HighQuality
±	I-Premise	HighQuality
5,8	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
LDL-C/HDL.	I-Premise	HighQuality

Los	O	-
perfiles	O	-
de	O	-
seguridad	O	-
no	O	-
se	O	-
vieron	O	-
afectados.	O	-

El	B-Claim	HighQuality
extracto	I-Claim	HighQuality
de	I-Claim	HighQuality
AG	I-Claim	HighQuality
añadido	I-Claim	HighQuality
al	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
convencional	I-Claim	HighQuality
proporcionó	I-Claim	HighQuality
un	I-Claim	HighQuality
complemento	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
y	I-Claim	HighQuality
seguro	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
manejo	I-Claim	HighQuality
de	I-Claim	HighQuality
T2DM.	I-Claim	HighQuality

Los	B-Claim	HighQuality
estudios	I-Claim	HighQuality
más	I-Claim	HighQuality
grandes	I-Claim	HighQuality
que	I-Claim	HighQuality
utilizan	I-Claim	HighQuality
preparados	I-Claim	HighQuality
de	I-Claim	HighQuality
ginseng	I-Claim	HighQuality
fisiológicamente	I-Claim	HighQuality
estandarizados	I-Claim	HighQuality
están	I-Claim	HighQuality
justificados	I-Claim	HighQuality
para	I-Claim	HighQuality
fundamentar	I-Claim	HighQuality
los	I-Claim	HighQuality
hallazgos	I-Claim	HighQuality
actuales	I-Claim	HighQuality
y	I-Claim	HighQuality
para	I-Claim	HighQuality
demostrar	I-Claim	HighQuality
la	I-Claim	HighQuality
eficacia	I-Claim	HighQuality
terapéutica	I-Claim	HighQuality
de	I-Claim	HighQuality
AG.	I-Claim	HighQuality

Evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
seguridad	O	-
de	O	-
una	O	-
formulación	O	-
de	O	-
liberación	O	-
lenta	O	-
de	O	-
citarabina	O	-
(	O	-
DepoCyt	O	-
;	O	-
Chiron	O	-
Corp,	O	-
Emeryville,	O	-
CA,	O	-
y	O	-
Skye	O	-
Pharma,	O	-
Inc,	O	-
San	O	-
Diego,	O	-
CA	O	-
)	O	-
que	O	-
mantiene	O	-
concentraciones	O	-
citotóxicas	O	-
de	O	-
citarabina	O	-
(	O	-
ara-C	O	-
)	O	-
en	O	-
el	O	-
LCR	O	-
de	O	-
la	O	-
mayoría	O	-
de	O	-
los	O	-
pacientes	O	-
durante	O	-
más	O	-
de	O	-
14	O	-
días.	O	-

Veintiocho	O	-
pacientes	O	-
con	O	-
linfoma	O	-
y	O	-
citología	O	-
de	O	-
LCR	O	-
positiva	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
DepoCyt	O	-
50	O	-
mg	O	-
una	O	-
vez	O	-
cada	O	-
2	O	-
semanas	O	-
o	O	-
ara-C	O	-
50	O	-
mg	O	-
gratis	O	-
dos	O	-
veces	O	-
a	O	-
la	O	-
semana	O	-
durante	O	-
1	O	-
mes.	O	-

Los	O	-
pacientes	O	-
cuya	O	-
citología	O	-
de	O	-
LCR	O	-
se	O	-
convirtió	O	-
en	O	-
negativa	O	-
y	O	-
que	O	-
no	O	-
tuvieron	O	-
progresión	O	-
neurológica	O	-
recibieron	O	-
3	O	-
meses	O	-
adicionales	O	-
de	O	-
terapia	O	-
de	O	-
consolidación	O	-
y	O	-
luego	O	-
4	O	-
meses	O	-
de	O	-
terapia	O	-
de	O	-
mantenimiento.	O	-

Todos	O	-
los	O	-
pacientes	O	-
recibieron	O	-
4	O	-
mg	O	-
de	O	-
dexametasona	O	-
pujados	O	-
por	O	-
vía	O	-
oral	O	-
en	O	-
los	O	-
días	O	-
1	O	-
a	O	-
5	O	-
de	O	-
cada	O	-
ciclo	O	-
de	O	-
2	O	-
semanas.	O	-

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
71	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
DepoCyt	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
15	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
ara-C	I-Premise	HighQuality
sobre	I-Premise	HighQuality
la	I-Premise	HighQuality
base	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
intención	I-Premise	HighQuality
de	I-Premise	HighQuality
tratar	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,006	I-Premise	HighQuality
).	I-Premise	HighQuality

Todos	B-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
DepoCyt,	I-Premise	HighQuality
pero	I-Premise	HighQuality
sólo	I-Premise	HighQuality
el	I-Premise	HighQuality
53	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
ara-C,	I-Premise	HighQuality
pudieron	I-Premise	HighQuality
completar	I-Premise	HighQuality
el	I-Premise	HighQuality
régimen	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
de	I-Premise	HighQuality
inducción	I-Premise	HighQuality
de	I-Premise	HighQuality
1	I-Premise	HighQuality
mes	I-Premise	HighQuality
previsto.	I-Premise	HighQuality

Tiempo	B-Premise	HighQuality
hasta	I-Premise	HighQuality
progresión	I-Premise	HighQuality
neurológica	I-Premise	HighQuality
y	I-Premise	HighQuality
tendencia	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
a	I-Premise	HighQuality
favor	I-Premise	HighQuality
de	I-Premise	HighQuality
DepoCyt	I-Premise	HighQuality
(mediana,	I-Premise	HighQuality
78,5	I-Premise	HighQuality
v	I-Premise	HighQuality
42	I-Premise	HighQuality
días	I-Premise	HighQuality
y	I-Premise	HighQuality
99,5	I-Premise	HighQuality
v	I-Premise	HighQuality
63	I-Premise	HighQuality
días,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
>	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
DepoCyt	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
cambio	I-Premise	HighQuality
medio	I-Premise	HighQuality
mejorado	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
de	I-Premise	HighQuality
rendimiento	I-Premise	HighQuality
de	I-Premise	HighQuality
Karnofsky	I-Premise	HighQuality
al	I-Premise	HighQuality
final	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
inducción	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,041	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Premise	HighQuality
principales	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
brazos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
dolor	I-Premise	HighQuality
de	I-Premise	HighQuality
cabeza	I-Premise	HighQuality
y	I-Premise	HighQuality
aracnoiditis,	I-Premise	HighQuality
que	I-Premise	HighQuality
a	I-Premise	HighQuality
menudo	I-Premise	HighQuality
fueron	I-Premise	HighQuality
causados	I-Premise	HighQuality
por	I-Premise	HighQuality
la	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
subyacente.	I-Premise	HighQuality

DepoCyt	B-Claim	HighQuality
inyectado	I-Claim	HighQuality
una	I-Claim	HighQuality
vez	I-Claim	HighQuality
cada	I-Claim	HighQuality
2	I-Claim	HighQuality
semanas	I-Claim	HighQuality
produjo	I-Claim	HighQuality
una	I-Claim	HighQuality
alta	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
y	I-Claim	HighQuality
una	I-Claim	HighQuality
mejor	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
medida	I-Claim	HighQuality
por	I-Claim	HighQuality
la	I-Claim	HighQuality
puntuación	I-Claim	HighQuality
de	I-Claim	HighQuality
Karnofsky	I-Claim	HighQuality
en	I-Claim	HighQuality
relación	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
producida	I-Claim	HighQuality
por	I-Claim	HighQuality
ara-C	I-Claim	HighQuality
libre	I-Claim	HighQuality
inyectada	I-Claim	HighQuality
dos	I-Claim	HighQuality
veces	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
semana.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
grupo	O	-
2,	O	-
paralelo,	O	-
doble	O	-
ciego	O	-
de	O	-
un	O	-
solo	O	-
centro	O	-
de	O	-
TCR	O	-
fue	O	-
evaluar	O	-
los	O	-
impactos	O	-
agudos	O	-
y	O	-
crónicos	O	-
de	O	-
alto	O	-
consumo	O	-
de	O	-
flavanol	O	-
alto	O	-
teobromina	O	-
(	O	-
HFHT	O	-
)	O	-
chocolate	O	-
sobre	O	-
la	O	-
función	O	-
endotelial,	O	-
rigidez	O	-
arterial	O	-
y	O	-
presión	O	-
arterial	O	-
(	O	-
PA	O	-
)	O	-
en	O	-
mujeres	O	-
con	O	-
riesgo	O	-
de	O	-
preeclampsia.	O	-

131	O	-
mujeres	O	-
embarazadas	O	-
consideradas	O	-
en	O	-
riesgo	O	-
de	O	-
preeclampsia	O	-
en	O	-
base	O	-
al	O	-
ultrasonido	O	-
Doppler	O	-
de	O	-
arteria	O	-
uterina	O	-
fueron	O	-
divididas	O	-
en	O	-
dos	O	-
grupos	O	-
(	O	-
HFHT	O	-
o	O	-
bajo	O	-
flavanol	O	-
y	O	-
chocolate	O	-
teobromina	O	-
(	O	-
LFLT	O	-
).	O	-

Los	O	-
cambios	O	-
agudos	O	-
en	O	-
el	O	-
flavanol	O	-
plasmático	O	-
y	O	-
la	O	-
teobromina,	O	-
la	O	-
tonometría	O	-
arterial	O	-
periférica	O	-
y	O	-
la	O	-
PA	O	-
fueron	O	-
evaluados	O	-
al	O	-
azar	O	-
(	O	-
0,	O	-
60	O	-
y	O	-
120	O	-
min	O	-
después	O	-
de	O	-
una	O	-
dosis	O	-
única	O	-
de	O	-
40	O	-
g	O	-
de	O	-
chocolate	O	-
)	O	-
y	O	-
nuevamente	O	-
6	O	-
y	O	-
12	O	-
semanas	O	-
después	O	-
de	O	-
la	O	-
ingesta	O	-
diaria	O	-
de	O	-
30	O	-
g	O	-
de	O	-
chocolate.	O	-

El	O	-
EndoPAT	O	-
2000	O	-
proporcionó	O	-
índice	O	-
de	O	-
hiperemia	O	-
reactiva	O	-
(RHI	O	-
)	O	-
e	O	-
índice	O	-
de	O	-
aumento	O	-
ajustado	O	-
(	O	-
AIx	O	-
)	O	-
como	O	-
marcadores	O	-
de	O	-
la	O	-
función	O	-
endotelial	O	-
y	O	-
rigidez	O	-
arterial,	O	-
respectivamente.	O	-

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
LFLT,	I-Premise	HighQuality
la	I-Premise	HighQuality
ingesta	I-Premise	HighQuality
aguda	I-Premise	HighQuality
de	I-Premise	HighQuality
HFHT	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
la	I-Premise	HighQuality
epicatequina	I-Premise	HighQuality
plasmática	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
teobromina	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
),	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
la	I-Premise	HighQuality
AIx	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
la	I-Premise	HighQuality
PA	I-Premise	HighQuality
diastólica	I-Premise	HighQuality
(	I-Premise	HighQuality
3,49	I-Premise	HighQuality
±	I-Premise	HighQuality
3,40	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
aumento	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
HFHT	I-Premise	HighQuality
vs	I-Premise	HighQuality
1,55	I-Premise	HighQuality
±	I-Premise	HighQuality
2,59	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
aumento	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
LFLT,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0008	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
HFHT	I-Premise	HighQuality
crónica	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
ingesta	I-Premise	HighQuality
de	I-Premise	HighQuality
LFLT	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
la	I-Premise	HighQuality
teobromina	I-Premise	HighQuality
plasmática	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
).	I-Premise	HighQuality

No	O	-
se	O	-
observaron	O	-
otros	O	-
cambios	O	-
significativos	O	-
dentro	O	-
del	O	-
grupo	O	-
o	O	-
entre	O	-
el	O	-
grupo.	O	-

Consumo	B-Claim	HighQuality
agudo	I-Claim	HighQuality
de	I-Claim	HighQuality
HFHT,	I-Claim	HighQuality
comparado	I-Claim	HighQuality
con	I-Claim	HighQuality
LFLT,	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
concentraciones	I-Claim	HighQuality
plasmáticas	I-Claim	HighQuality
de	I-Claim	HighQuality
epicatequina	I-Claim	HighQuality
y	I-Claim	HighQuality
teobromina	I-Claim	HighQuality
y	I-Claim	HighQuality
disminución	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
rigidez	I-Claim	HighQuality
arterial,	I-Claim	HighQuality
sin	I-Claim	HighQuality
efecto	I-Claim	HighQuality
sobre	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
endotelial	I-Claim	HighQuality
y	I-Claim	HighQuality
aumento	I-Claim	HighQuality
marginal	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PA	I-Claim	HighQuality
diastólica.	I-Claim	HighQuality

La	B-Claim	HighQuality
ingesta	I-Claim	HighQuality
crónica	I-Claim	HighQuality
de	I-Claim	HighQuality
HFHT	I-Claim	HighQuality
aumentó	I-Claim	HighQuality
la	I-Claim	HighQuality
teobromina	I-Claim	HighQuality
plasmática,	I-Claim	HighQuality
aunque	I-Claim	HighQuality
no	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
impactos	I-Claim	HighQuality
positivos	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
endotelial,	I-Claim	HighQuality
rigidez	I-Claim	HighQuality
arterial	I-Claim	HighQuality
o	I-Claim	HighQuality
PA	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
LFLT	I-Claim	HighQuality
en	I-Claim	HighQuality
mujeres	I-Claim	HighQuality
embarazadas	I-Claim	HighQuality
con	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
PE.	I-Claim	HighQuality

Los	O	-
autores	O	-
probaron	O	-
la	O	-
hipótesis	O	-
de	O	-
que	O	-
una	B-Claim	HighQuality
combinación	I-Claim	HighQuality
valsartán/cilnidipina	I-Claim	HighQuality
suprimiría	I-Claim	HighQuality
el	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
matutina	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
hogar	I-Claim	HighQuality
(AP	I-Claim	HighQuality
)	I-Claim	HighQuality
más	I-Claim	HighQuality
eficazmente	I-Claim	HighQuality
que	I-Claim	HighQuality
una	I-Claim	HighQuality
combinación	I-Claim	HighQuality
valsartán/hidroclorotiazida	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
matutina,	I-Claim	HighQuality
definida	O	-
como	O	-
PA	O	-
sistólica	O	-
(	O	-
PAS	O	-
)	O	-
≥135	O	-
mm	O	-
Hg	O	-
o	O	-
PA	O	-
diastólica	O	-
≥85	O	-
mm	O	-
Hg	O	-
evaluada	O	-
por	O	-
un	O	-
dispositivo	O	-
de	O	-
monitorización	O	-
de	O	-
la	O	-
PA	O	-
domiciliaria	O	-
basado	O	-
en	O	-
la	O	-
tecnología	O	-
de	O	-
la	O	-
información	O	-
y	O	-
la	O	-
comunicación,	O	-
más	O	-
de	O	-
tres	O	-
veces	O	-
antes	O	-
de	O	-
la	O	-
administración	O	-
de	O	-
cada	O	-
combinación.	O	-

Se	O	-
trató	O	-
de	O	-
un	O	-
ensayo	O	-
clínico	O	-
prospectivo,	O	-
multicéntrico,	O	-
aleatorizado	O	-
y	O	-
abierto	O	-
de	O	-
8	O	-
semanas	O	-
de	O	-
duración.	O	-

El	O	-
HMBPS,	O	-
que	O	-
es	O	-
un	O	-
nuevo	O	-
índice,	O	-
fue	O	-
definido	O	-
como	O	-
el	O	-
promedio	O	-
de	O	-
PAS	O	-
matutino	O	-
menos	O	-
el	O	-
promedio	O	-
de	O	-
PAS	O	-
nocturno,	O	-
ambos	O	-
medidos	O	-
en	O	-
el	O	-
mismo	O	-
día.	O	-

Los	O	-
autores	O	-
asignaron	O	-
al	O	-
azar	O	-
129	O	-
pacientes	O	-
a	O	-
los	O	-
grupos	O	-
de	O	-
combinación	O	-
valsartán/cilnidipina	O	-
(	O	-
63	O	-
pacientes	O	-
;	O	-
media	O	-
68,4	O	-
años	O	-
)	O	-
o	O	-
valsartán/hidroclorotiazida	O	-
(	O	-
66	O	-
pacientes	O	-
;	O	-
media	O	-
67,3	O	-
años	O	-
)	O	-
y	O	-
los	O	-
valores	O	-
basales	O	-
del	O	-
HMBPS	O	-
fueron	O	-
de	O	-
17,4	O	-
mm	O	-
Hg	O	-
vs	O	-
16,9	O	-
mm	O	-
Hg,	O	-
respectivamente	O	-
(	O	-
P	O	-
=.820	O	-
).	O	-

Al	B-Premise	HighQuality
final	I-Premise	HighQuality
del	I-Premise	HighQuality
período	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
los	I-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
PAS	I-Premise	HighQuality
nocturna	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
PAS	I-Premise	HighQuality
matutina	I-Premise	HighQuality
respecto	I-Premise	HighQuality
al	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativos	I-Premise	HighQuality
tanto	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
valsartán/cilnidipina	I-Premise	HighQuality
como	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
valsartán/hidroclorotiazida	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
:	I-Premise	HighQuality
-5,0	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
-10,0	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,35	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
-10,7	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
-13,6	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
142	I-Premise	HighQuality
),	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

El	B-Premise	HighQuality
HMBPS	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
con	I-Premise	HighQuality
respecto	I-Premise	HighQuality
al	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
hubo	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
significativa	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
:	I-Premise	HighQuality
14,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
vs	I-Premise	HighQuality
14,0	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=.892	I-Premise	HighQuality
).	I-Premise	HighQuality

Valsartán/cilnidipina	B-Claim	HighQuality
no	I-Claim	HighQuality
pudo	I-Claim	HighQuality
suprimir	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
el	I-Claim	HighQuality
HMBPS	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
valsartán/hidroclorotiazida.	I-Claim	HighQuality

Se	O	-
necesitan	O	-
estudios	O	-
controlados	O	-
aleatorizados	O	-
a	O	-
gran	O	-
escala	O	-
para	O	-
evaluar	O	-
cómo	O	-
la	O	-
reducción	O	-
del	O	-
HMBPS	O	-
afectará	O	-
los	O	-
futuros	O	-
resultados	O	-
cardiovasculares.	O	-

El	O	-
dispositivo	O	-
de	O	-
monitorización	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
doméstica	O	-
basado	O	-
en	O	-
la	O	-
tecnología	O	-
de	O	-
la	O	-
información	O	-
y	O	-
la	O	-
comunicación	O	-
puede	O	-
convertirse	O	-
en	O	-
una	O	-
alternativa	O	-
al	O	-
monitoreo	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
ambulatoria,	O	-
que	O	-
ha	O	-
sido	O	-
una	O	-
norma	O	-
de	O	-
oro	O	-
para	O	-
medir	O	-
la	O	-
presión	O	-
arterial	O	-
nocturna	O	-
y	O	-
el	O	-
aumento	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
a	O	-
la	O	-
mañana.	O	-

Para	O	-
reportar	O	-
los	O	-
resultados	O	-
del	O	-
tratamiento	O	-
de	O	-
1	O	-
año	O	-
en	O	-
el	O	-
Estudio	O	-
de	O	-
Trabeculectomía	O	-
de	O	-
Tubo	O	-
Primario	O	-
Versus	O	-
(TVP	O	-
).	O	-

Doscientos	O	-
cuarenta	O	-
y	O	-
dos	O	-
ojos	O	-
de	O	-
242	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
no	O	-
controlado	O	-
médicamente	O	-
y	O	-
sin	O	-
cirugía	O	-
ocular	O	-
incisional	O	-
previa,	O	-
incluyendo	O	-
125	O	-
en	O	-
el	O	-
grupo	O	-
sonoro	O	-
y	O	-
117	O	-
en	O	-
el	O	-
grupo	O	-
trabeculectomía.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
incluidos	O	-
en	O	-
16	O	-
centros	O	-
clínicos	O	-
y	O	-
asignados	O	-
aleatoriamente	O	-
al	O	-
tratamiento	O	-
con	O	-
derivación	O	-
de	O	-
tubo	O	-
(implanto	O	-
de	O	-
glaucoma	O	-
Baerveldt	O	-
de	O	-
350	O	-
mm2)	O	-
o	O	-
trabeculectomía	O	-
con	O	-
mitomicina	O	-
C	O	-
(MMC	O	-
;	O	-
0,4	O	-
mg/ml	O	-
durante	O	-
2	O	-
minutos	O	-
).	O	-

Presión	O	-
intraocular	O	-
(OPI	O	-
),	O	-
terapia	O	-
médica	O	-
con	O	-
glaucoma,	O	-
agudeza	O	-
visual,	O	-
campos	O	-
visuales,	O	-
complicaciones	O	-
quirúrgicas	O	-
e	O	-
insuficiencia	O	-
(	O	-
PIO	O	-
de	O	-
más	O	-
de	O	-
21	O	-
mmHg	O	-
o	O	-
reducida	O	-
en	O	-
menos	O	-
del	O	-
20	O	-
%	O	-
desde	O	-
el	O	-
inicio,	O	-
PIO	O	-
de	O	-
5	O	-
mmHg	O	-
o	O	-
menos,	O	-
reoperación	O	-
para	O	-
el	O	-
glaucoma,	O	-
o	O	-
pérdida	O	-
de	O	-
la	O	-
visión	O	-
de	O	-
la	O	-
percepción	O	-
de	O	-
la	O	-
luz	O	-
).	O	-

La	B-Premise	HighQuality
probabilidad	I-Premise	HighQuality
acumulada	I-Premise	HighQuality
de	I-Premise	HighQuality
fracaso	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
primer	I-Premise	HighQuality
año	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
17,3	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tubos	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
7,9	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,01	I-Premise	HighQuality
;	I-Premise	HighQuality
hazard	I-Premise	HighQuality
ratio,	I-Premise	HighQuality
2,59	I-Premise	HighQuality
;	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
1,20-5,60	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
media	I-Premise	HighQuality
±	I-Premise	HighQuality
desviación	I-Premise	HighQuality
estándar	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
13,8±4,1	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
del	I-Premise	HighQuality
tubo	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
12,4±4,4	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
a	I-Premise	HighQuality
1	I-Premise	HighQuality
año	I-Premise	HighQuality
(P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,01	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
número	I-Premise	HighQuality
de	I-Premise	HighQuality
medicamentos	I-Premise	HighQuality
con	I-Premise	HighQuality
glaucoma	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
2,1±1,4	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
del	I-Premise	HighQuality
tubo	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
0,9±1,4	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
complicaciones	I-Premise	HighQuality
postoperatorias	I-Premise	HighQuality
se	I-Premise	HighQuality
desarrollaron	I-Premise	HighQuality
en	I-Premise	HighQuality
36	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
29	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tubos	I-Premise	HighQuality
y	I-Premise	HighQuality
48	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
41	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,06	I-Premise	HighQuality
).	I-Premise	HighQuality

Se	B-Premise	HighQuality
produjeron	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
graves	I-Premise	HighQuality
que	I-Premise	HighQuality
requirieron	I-Premise	HighQuality
cirugía	I-Premise	HighQuality
o	I-Premise	HighQuality
que	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
una	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
de	I-Premise	HighQuality
2	I-Premise	HighQuality
líneas	I-Premise	HighQuality
Snellen	I-Premise	HighQuality
o	I-Premise	HighQuality
más	I-Premise	HighQuality
en	I-Premise	HighQuality
1	I-Premise	HighQuality
paciente	I-Premise	HighQuality
(	I-Premise	HighQuality
1	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tubos	I-Premise	HighQuality
y	I-Premise	HighQuality
8	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
7	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
con	I-Claim	HighQuality
MMC	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
éxito	I-Claim	HighQuality
quirúrgico	I-Claim	HighQuality
más	I-Claim	HighQuality
alta	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
implantación	I-Claim	HighQuality
de	I-Claim	HighQuality
derivación	I-Claim	HighQuality
del	I-Claim	HighQuality
tubo	I-Claim	HighQuality
después	I-Claim	HighQuality
de	I-Claim	HighQuality
1	I-Claim	HighQuality
año	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
Estudio	I-Claim	HighQuality
PTVT.	I-Claim	HighQuality

Después	B-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
con	I-Claim	HighQuality
MMC	I-Claim	HighQuality
se	I-Claim	HighQuality
logró	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
uso	I-Claim	HighQuality
de	I-Claim	HighQuality
menos	I-Claim	HighQuality
medicamentos	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
glaucoma	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
derivación	I-Claim	HighQuality
del	I-Claim	HighQuality
tubo	I-Claim	HighQuality
durante	I-Claim	HighQuality
el	I-Claim	HighQuality
primer	I-Claim	HighQuality
año	I-Claim	HighQuality
de	I-Claim	HighQuality
seguimiento.	I-Claim	HighQuality

La	B-Claim	HighQuality
frecuencia	I-Claim	HighQuality
de	I-Claim	HighQuality
complicaciones	I-Claim	HighQuality
graves	I-Claim	HighQuality
que	I-Claim	HighQuality
producen	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
de	I-Claim	HighQuality
visión	I-Claim	HighQuality
o	I-Claim	HighQuality
requieren	I-Claim	HighQuality
reoperación	I-Claim	HighQuality
fue	I-Claim	HighQuality
menor	I-Claim	HighQuality
después	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
derivación	I-Claim	HighQuality
del	I-Claim	HighQuality
tubo	I-Claim	HighQuality
en	I-Claim	HighQuality
relación	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
con	I-Claim	HighQuality
MMC.	I-Claim	HighQuality

Durante	B-Claim	HighQuality
varias	I-Claim	HighQuality
décadas,	I-Claim	HighQuality
tanto	I-Claim	HighQuality
la	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
intraarterial	I-Claim	HighQuality
preoperatoria	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
irradiación	I-Claim	HighQuality
preoperatoria	I-Claim	HighQuality
han	I-Claim	HighQuality
sido	I-Claim	HighQuality
aceptados	I-Claim	HighQuality
tratamientos	I-Claim	HighQuality
para	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
tumores	I-Claim	HighQuality
de	I-Claim	HighQuality
cabeza	I-Claim	HighQuality
y	I-Claim	HighQuality
cuello.	I-Claim	HighQuality

Desafortunadamente,	O	-
a	O	-
menudo	O	-
se	O	-
han	O	-
presentado	O	-
argumentos	O	-
a	O	-
favor	O	-
de	O	-
uno	O	-
u	O	-
otro	O	-
de	O	-
los	O	-
dos	O	-
métodos,	O	-
pero	O	-
sin	O	-
la	O	-
realización	O	-
de	O	-
una	O	-
investigación	O	-
objetiva	O	-
y	O	-
aleatoria.	O	-

Para	O	-
resolver	O	-
esta	O	-
situación,	O	-
los	O	-
autores	O	-
han	O	-
realizado	O	-
un	O	-
estudio	O	-
prospectivo	O	-
multicéntrico	O	-
y	O	-
aleatorizado	O	-
de	O	-
pacientes	O	-
seleccionados	O	-
con	O	-
el	O	-
fin	O	-
de	O	-
determinar	O	-
qué	O	-
método	O	-
permite	O	-
mejores	O	-
resultados	O	-
en	O	-
la	O	-
terapia	O	-
tumoral	O	-
compleja	O	-
desde	O	-
los	O	-
aspectos	O	-
de	O	-
supervivencia	O	-
y	O	-
calidad	O	-
de	O	-
vida	O	-
postoperatoria.	O	-

Ciento	O	-
treinta	O	-
y	O	-
un	O	-
pacientes	O	-
con	O	-
carcinoma	O	-
de	O	-
células	O	-
escamosas	O	-
sublingual	O	-
o	O	-
lingual	O	-
operable	O	-
en	O	-
estadios	O	-
T2NXM0	O	-
a	O	-
T4MXM0	O	-
fueron	O	-
aleatorizados	O	-
en	O	-
dos	O	-
grupos:	O	-
1	O	-
grupo	O	-
participó	O	-
en	O	-
quimioterapia	O	-
preoperatoria	O	-
con	O	-
cisplatino	O	-
y	O	-
epirubicina	O	-
(dosis	O	-
totales:	O	-
200	O	-
mg	O	-
de	O	-
cisplatino,	O	-
120	O	-
mg	O	-
de	O	-
epirubicina	O	-
)	O	-
a	O	-
través	O	-
de	O	-
la	O	-
arteria	O	-
carótida	O	-
externa,	O	-
mientras	O	-
que	O	-
el	O	-
otro	O	-
grupo	O	-
recibió	O	-
radioterapia	O	-
preoperatoria	O	-
(	O	-
46	O	-
grises	O	-
).	O	-

Después	O	-
de	O	-
una	O	-
cirugía	O	-
radical	O	-
posterior,	O	-
los	O	-
pacientes	O	-
recibieron	O	-
seguimiento	O	-
regular	O	-
durante	O	-
5	O	-
años.	O	-

Al	O	-
final	O	-
de	O	-
los	O	-
5	O	-
años,	O	-
95	O	-
de	O	-
los	O	-
131	O	-
pacientes	O	-
se	O	-
habían	O	-
conformado	O	-
al	O	-
protocolo.	O	-

De	O	-
los	O	-
95,	O	-
47	O	-
habían	O	-
recibido	O	-
quimioterapia	O	-
preoperatoria	O	-
y	O	-
48	O	-
irradiación	O	-
preoperatoria.	O	-

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
5	I-Premise	HighQuality
años,	I-Premise	HighQuality
18	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
47	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
quimioterapia	I-Premise	HighQuality
y	I-Premise	HighQuality
15	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
48	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
irradiación	I-Premise	HighQuality
seguían	I-Premise	HighQuality
vivos	I-Premise	HighQuality
y	I-Premise	HighQuality
sin	I-Premise	HighQuality
tumores.	I-Premise	HighQuality

Unos	B-Premise	HighQuality
pocos	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
más	I-Premise	HighQuality
habían	I-Premise	HighQuality
muerto	I-Premise	HighQuality
de	I-Premise	HighQuality
recurrencia	I-Premise	HighQuality
o	I-Premise	HighQuality
metástasis	I-Premise	HighQuality
regional	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
quimioterapia	I-Premise	HighQuality
(	I-Premise	HighQuality
23	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
irradiación	I-Premise	HighQuality
(	I-Premise	HighQuality
20	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
aparición	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
segundo	I-Premise	HighQuality
carcinoma	I-Premise	HighQuality
fue	I-Premise	HighQuality
3	I-Premise	HighQuality
veces	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuente	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
irradiación	I-Premise	HighQuality
(9	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
quimioterapia	I-Premise	HighQuality
(3	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
).	I-Premise	HighQuality

En	O	-
general,	O	-
las	B-Claim	HighQuality
tasas	I-Claim	HighQuality
de	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
fueron	I-Claim	HighQuality
en	I-Claim	HighQuality
general	I-Claim	HighQuality
las	I-Claim	HighQuality
mismas	I-Claim	HighQuality
para	I-Claim	HighQuality
los	I-Claim	HighQuality
dos	I-Claim	HighQuality
grupos.	I-Claim	HighQuality

En	B-Claim	HighQuality
cuanto	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
postoperatoria,	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
quimioterapéutico	I-Claim	HighQuality
presentó	I-Claim	HighQuality
un	I-Claim	HighQuality
cuadro	I-Claim	HighQuality
más	I-Claim	HighQuality
favorable.	I-Claim	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
de	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
a	I-Claim	HighQuality
largo	I-Claim	HighQuality
plazo	I-Claim	HighQuality
posteriores	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
intraarterial	I-Claim	HighQuality
preoperatoria	I-Claim	HighQuality
o	I-Claim	HighQuality
la	I-Claim	HighQuality
radioterapia	I-Claim	HighQuality
preoperatoria	I-Claim	HighQuality
fueron	I-Claim	HighQuality
prácticamente	I-Claim	HighQuality
los	I-Claim	HighQuality
mismos.	I-Claim	HighQuality

En	B-Claim	HighQuality
cuanto	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
postoperatoria,	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
sometidos	I-Claim	HighQuality
a	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
intraarterial	I-Claim	HighQuality
parecían	I-Claim	HighQuality
encontrarse	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
situación	I-Claim	HighQuality
ligeramente	I-Claim	HighQuality
más	I-Claim	HighQuality
favorable.	I-Claim	HighQuality

Los	O	-
autores	O	-
consideran	O	-
importante	O	-
enfatizar	O	-
estos	O	-
hallazgos,	O	-
ya	O	-
que	O	-
no	O	-
son	O	-
conscientes	O	-
de	O	-
un	O	-
estudio	O	-
aleatorizado	O	-
similar	O	-
en	O	-
pacientes	O	-
con	O	-
tumores	O	-
de	O	-
la	O	-
cavidad	O	-
oral.	O	-

Vesatolimod	O	-
(	O	-
GS-9620	O	-
)	O	-
es	O	-
un	O	-
agonista	O	-
oral	O	-
del	O	-
receptor	O	-
7	O	-
tipo	O	-
peaje,	O	-
un	O	-
activador	O	-
de	O	-
las	O	-
respuestas	O	-
innatas	O	-
e	O	-
inmunitarias	O	-
adaptativas.	O	-

En	O	-
este	O	-
caso,	O	-
se	O	-
evalúa	O	-
la	O	-
seguridad	O	-
y	O	-
eficacia	O	-
de	O	-
vesatolimod	O	-
tras	O	-
un	O	-
tratamiento	O	-
una	O	-
vez	O	-
a	O	-
la	O	-
semana	O	-
en	O	-
pacientes	O	-
con	O	-
infección	O	-
crónica	O	-
por	O	-
hepatitis	O	-
B	O	-
(	O	-
CHB	O	-
)	O	-
suprimida	O	-
durante	O	-
el	O	-
tratamiento	O	-
antiviral	O	-
oral.	O	-

En	O	-
un	O	-
estudio	O	-
de	O	-
fase	O	-
II,	O	-
doble	O	-
ciego,	O	-
aleatorizado,	O	-
controlado	O	-
con	O	-
placebo	O	-
(	O	-
PBO	O	-
),	O	-
162	O	-
pacientes	O	-
estratificados	O	-
por	O	-
los	O	-
niveles	O	-
de	O	-
antígeno	O	-
de	O	-
superficie	O	-
de	O	-
hepatitis	O	-
B	O	-
(	O	-
HBsAg	O	-
)	O	-
y	O	-
el	O	-
estado	O	-
sérico	O	-
de	O	-
antígeno	O	-
de	O	-
hepatitis	O	-
B	O	-
e	O	-
(	O	-
HBeAg	O	-
)	O	-
fueron	O	-
aleatorizados	O	-
1:3:3:3	O	-
a	O	-
una	O	-
vez	O	-
por	O	-
semana	O	-
PBO	O	-
oral	O	-
o	O	-
vesatolimod	O	-
(	O	-
dosis	O	-
de	O	-
1-,	O	-
2-	O	-
ó	O	-
4	O	-
mg	O	-
)	O	-
durante	O	-
4,	O	-
8	O	-
ó	O	-
12	O	-
semanas	O	-
por	O	-
cohorte.	O	-

La	O	-
eficacia	O	-
se	O	-
evaluó	O	-
mediante	O	-
el	O	-
cambio	O	-
en	O	-
el	O	-
valor	O	-
basal	O	-
de	O	-
HBsAg	O	-
(	O	-
log10	O	-
UI/ml	O	-
)	O	-
en	O	-
la	O	-
variable	O	-
principal	O	-
de	O	-
valoración	O	-
(	O	-
semana	O	-
24	O	-
).	O	-

Las	O	-
evaluaciones	O	-
de	O	-
seguridad	O	-
incluyeron	O	-
acontecimientos	O	-
adversos	O	-
(	O	-
AE	O	-
)	O	-
y	O	-
control	O	-
de	O	-
anomalías	O	-
de	O	-
laboratorio.	O	-

Las	O	-
evaluaciones	O	-
farmacodinámicas	O	-
incluyeron	O	-
cuantificación	O	-
del	O	-
nivel	O	-
de	O	-
citocina	O	-
periférica	O	-
y	O	-
evaluación	O	-
de	O	-
la	O	-
expresión	O	-
del	O	-
ARNm	O	-
del	O	-
gen	O	-
estimulado	O	-
por	O	-
interferón	O	-
(	O	-
ISG	O	-
).	O	-

La	O	-
mayoría	O	-
de	O	-
los	O	-
pacientes	O	-
fueron	O	-
varones	O	-
(	O	-
76	O	-
%	O	-
)	O	-
y	O	-
HBeAg	O	-
negativo	O	-
(	O	-
79	O	-
%	O	-
)	O	-
al	O	-
inicio.	O	-

La	B-Premise	HighQuality
mayoría	I-Premise	HighQuality
(	I-Premise	HighQuality
41-80	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
experimentaron	I-Premise	HighQuality
≥1	I-Premise	HighQuality
EA	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
estudio	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
mayoría	I-Premise	HighQuality
de	I-Premise	HighQuality
EA	I-Premise	HighQuality
de	I-Premise	HighQuality
gravedad	I-Premise	HighQuality
leve	I-Premise	HighQuality
o	I-Premise	HighQuality
moderada.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
descensos	I-Premise	HighQuality
significativos	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
variables	I-Premise	HighQuality
primarias	I-Premise	HighQuality
(	I-Premise	HighQuality
semana	I-Premise	HighQuality
24	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
secundarias	I-Premise	HighQuality
(	I-Premise	HighQuality
semanas	I-Premise	HighQuality
4,	I-Premise	HighQuality
8,	I-Premise	HighQuality
12	I-Premise	HighQuality
y	I-Premise	HighQuality
48	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
inducción	I-Premise	HighQuality
ISG15	I-Premise	HighQuality
fue	I-Premise	HighQuality
dosis-dependiente	I-Premise	HighQuality
y	I-Premise	HighQuality
consistente	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
administración	I-Premise	HighQuality
repetida,	I-Premise	HighQuality
volviendo	I-Premise	HighQuality
a	I-Premise	HighQuality
acercarse	I-Premise	HighQuality
al	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
una	I-Premise	HighQuality
semana	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
a	I-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
;	I-Premise	HighQuality
ningún	B-Premise	HighQuality
paciente	I-Premise	HighQuality
demostró	I-Premise	HighQuality
una	I-Premise	HighQuality
expresión	I-Premise	HighQuality
sérica	I-Premise	HighQuality
significativa	I-Premise	HighQuality
del	I-Premise	HighQuality
interferón	I-Premise	HighQuality
alfa	I-Premise	HighQuality
(	I-Premise	HighQuality
IFNα	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
ningún	I-Premise	HighQuality
momento	I-Premise	HighQuality
evaluado.	I-Premise	HighQuality

Los	B-Premise	HighQuality
análisis	I-Premise	HighQuality
multivariables	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
inducción	I-Premise	HighQuality
≥2	I-Premise	HighQuality
veces	I-Premise	HighQuality
ISG15	I-Premise	HighQuality
se	I-Premise	HighQuality
asocia	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
dosis	I-Premise	HighQuality
de	I-Premise	HighQuality
2	I-Premise	HighQuality
ó	I-Premise	HighQuality
4	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
vesatolimod	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
sexo	I-Premise	HighQuality
femenino.	I-Premise	HighQuality

Vesatolimod	B-Claim	HighQuality
fue	I-Claim	HighQuality
seguro	I-Claim	HighQuality
y	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerado	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB,	I-Claim	HighQuality
demostrando	I-Claim	HighQuality
una	I-Claim	HighQuality
inducción	I-Claim	HighQuality
farmacodinámica	I-Claim	HighQuality
dosis-dependiente	I-Claim	HighQuality
consistente	I-Claim	HighQuality
de	I-Claim	HighQuality
ISG15	I-Claim	HighQuality
sin	I-Claim	HighQuality
inducción	I-Claim	HighQuality
sistémica	I-Claim	HighQuality
significativa	I-Claim	HighQuality
de	I-Claim	HighQuality
expresión	I-Claim	HighQuality
IFNα	I-Claim	HighQuality
o	I-Claim	HighQuality
síntomas	I-Claim	HighQuality
relacionados.	I-Claim	HighQuality

Sin	O	-
embargo,	O	-
no	O	-
se	O	-
observaron	O	-
descensos	O	-
significativos	O	-
de	O	-
HBsAg.	O	-

Quedan	O	-
por	O	-
definir	O	-
los	O	-
posibles	O	-
efectos	O	-
protectores	O	-
del	O	-
preacondicionado	O	-
isquémico	O	-
remoto	O	-
(RIPC	O	-
)	O	-
sobre	O	-
la	O	-
nefropatía	O	-
inducida	O	-
por	O	-
contraste	O	-
(	O	-
NIC	O	-
)	O	-
después	O	-
de	O	-
la	O	-
intervención	O	-
coronaria	O	-
percutánea	O	-
(	O	-
ICP	O	-
).	O	-

Se	O	-
realizó	O	-
un	O	-
estudio	O	-
multicéntrico	O	-
doble	O	-
ciego,	O	-
aleatorizado	O	-
y	O	-
controlado	O	-
con	O	-
placebo.	O	-

Los	O	-
pacientes	O	-
menores	O	-
de	O	-
85	O	-
años,	O	-
con	O	-
un	O	-
aclaramiento	O	-
renal	O	-
de	O	-
30-60ml/min/1,73m2,	O	-
que	O	-
eran	O	-
candidatos	O	-
a	O	-
ICP	O	-
para	O	-
todas	O	-
las	O	-
indicaciones	O	-
clínicas	O	-
excepto	O	-
para	O	-
ICP	O	-
primaria,	O	-
fueron	O	-
asignados	O	-
1:1	O	-
a	O	-
RIPC	O	-
o	O	-
al	O	-
tratamiento	O	-
estándar.	O	-

La	O	-
variable	O	-
principal	O	-
de	O	-
valoración	O	-
fue	O	-
la	O	-
incidencia	O	-
de	O	-
NIC.	O	-

La	O	-
variable	O	-
secundaria	O	-
fue	O	-
la	O	-
incidencia	O	-
de	O	-
infarto	O	-
de	O	-
miocardio	O	-
periprocedimiento	O	-
(IMP	O	-
).	O	-

De	O	-
febrero	O	-
de	O	-
2013	O	-
a	O	-
abril	O	-
de	O	-
2014,	O	-
3108	O	-
pacientes	O	-
programados	O	-
para	O	-
la	O	-
coronariografía	O	-
fueron	O	-
examinados	O	-
para	O	-
el	O	-
estudio.	O	-

442	O	-
cumplían	O	-
los	O	-
criterios	O	-
de	O	-
inclusión	O	-
y	O	-
223	O	-
recibieron	O	-
ICP.	O	-

Estos	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
simular	O	-
RIPC	O	-
(	O	-
n=107	O	-
)	O	-
o	O	-
grupo	O	-
de	O	-
tratamiento	O	-
(	O	-
n=116	O	-
).	O	-

El	O	-
único	O	-
subgrupo	O	-
pre-especificado	O	-
de	O	-
pacientes	O	-
diabéticos	O	-
incluyó	O	-
85	O	-
(	O	-
38	O	-
%	O	-
)	O	-
casos.	O	-

La	B-Premise	HighQuality
RIPC	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
la	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
NIC	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
población	I-Premise	HighQuality
total	I-Premise	HighQuality
(	I-Premise	HighQuality
12,1	I-Premise	HighQuality
%	I-Premise	HighQuality
vs.	I-Premise	HighQuality
26,1	I-Premise	HighQuality
%,	I-Premise	HighQuality
p=0,01,	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
NNT=9	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
no	I-Premise	HighQuality
diabéticos	I-Premise	HighQuality
(	I-Premise	HighQuality
9,2	I-Premise	HighQuality
%	I-Premise	HighQuality
vs.	I-Premise	HighQuality
25,0	I-Premise	HighQuality
%,	I-Premise	HighQuality
p=0,02	I-Premise	HighQuality
),	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
mostró	I-Premise	HighQuality
beneficio	I-Premise	HighQuality
en	I-Premise	HighQuality
diabéticos	I-Premise	HighQuality
(	I-Premise	HighQuality
16,7	I-Premise	HighQuality
%	I-Premise	HighQuality
vs.	I-Premise	HighQuality
28,2	I-Premise	HighQuality
%,	I-Premise	HighQuality
p=0,21	I-Premise	HighQuality
).	I-Premise	HighQuality

Se	B-Premise	HighQuality
observó	I-Premise	HighQuality
una	I-Premise	HighQuality
tendencia	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
IMP	I-Premise	HighQuality
inferior	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
(creatina	I-Premise	HighQuality
cinasa	I-Premise	HighQuality
-	I-Premise	HighQuality
cerebro	I-Premise	HighQuality
muscular	I-Premise	HighQuality
>	I-Premise	HighQuality
5	I-Premise	HighQuality
URL	I-Premise	HighQuality
;	I-Premise	HighQuality
8,4	I-Premise	HighQuality
%	I-Premise	HighQuality
vs.	I-Premise	HighQuality
16,4	I-Premise	HighQuality
%,	I-Premise	HighQuality
p=0,07	I-Premise	HighQuality
;	I-Premise	HighQuality
troponina	I-Premise	HighQuality
T	I-Premise	HighQuality
>	I-Premise	HighQuality
5	I-Premise	HighQuality
URL	I-Premise	HighQuality
;	I-Premise	HighQuality
27	I-Premise	HighQuality
%	I-Premise	HighQuality
vs.	I-Premise	HighQuality
38	I-Premise	HighQuality
%,	I-Premise	HighQuality
p=0,21	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Claim	HighQuality
preacondicionamiento	I-Claim	HighQuality
isquémico	I-Claim	HighQuality
remoto	I-Claim	HighQuality
reduce	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
incidencia	I-Claim	HighQuality
de	I-Claim	HighQuality
lesión	I-Claim	HighQuality
renal	I-Claim	HighQuality
aguda	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
no	I-Claim	HighQuality
diabéticos	I-Claim	HighQuality
sometidos	I-Claim	HighQuality
a	I-Claim	HighQuality
ICP.	I-Claim	HighQuality

Se	B-Claim	HighQuality
presume	I-Claim	HighQuality
que	I-Claim	HighQuality
se	I-Claim	HighQuality
necesita	I-Claim	HighQuality
un	I-Claim	HighQuality
mayor	I-Claim	HighQuality
tamaño	I-Claim	HighQuality
de	I-Claim	HighQuality
muestra	I-Claim	HighQuality
para	I-Claim	HighQuality
evaluar	I-Claim	HighQuality
el	I-Claim	HighQuality
efecto	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
RIPC	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
mellitus.	I-Claim	HighQuality

La	B-Claim	HighQuality
hipertensión	I-Claim	HighQuality
es	I-Claim	HighQuality
un	I-Claim	HighQuality
factor	I-Claim	HighQuality
de	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
aterogénico	I-Claim	HighQuality
generalmente	I-Claim	HighQuality
aceptado.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
longitudinal	O	-
prospectivo	O	-
fue	O	-
evaluar	O	-
los	O	-
cambios	O	-
en	O	-
el	O	-
espesor	O	-
de	O	-
la	O	-
carótida	O	-
íntima-media	O	-
(	O	-
C-IMT	O	-
)	O	-
y	O	-
explorar	O	-
la	O	-
asociación	O	-
de	O	-
los	O	-
factores	O	-
de	O	-
riesgo	O	-
cardiovascular	O	-
y	O	-
el	O	-
espesor	O	-
de	O	-
la	O	-
carótida	O	-
íntima	O	-
en	O	-
adultos	O	-
con	O	-
hipertensión	O	-
utilizando	O	-
métodos	O	-
estandarizados.	O	-

Se	O	-
utilizaron	O	-
datos	O	-
de	O	-
un	O	-
subgrupo	O	-
de	O	-
Beijing	O	-
Vascular	O	-
Disease	O	-
Pacients	O	-
Evaluation	O	-
Study	O	-
(	O	-
BEST	O	-
),	O	-
un	O	-
estudio	O	-
basado	O	-
en	O	-
la	O	-
población	O	-
de	O	-
adultos	O	-
residentes	O	-
en	O	-
la	O	-
comunidad.	O	-

El	O	-
C-IMT,	O	-
los	O	-
biomarcadores,	O	-
y	O	-
la	O	-
velocidad	O	-
de	O	-
onda	O	-
carótida-femoral-pulso	O	-
(	O	-
PWV	O	-
)	O	-
fueron	O	-
medidos	O	-
al	O	-
inicio,	O	-
y	O	-
los	O	-
estilos	O	-
de	O	-
vida	O	-
tales	O	-
como	O	-
el	O	-
estado	O	-
de	O	-
tabaquismo,	O	-
hábitos	O	-
de	O	-
sueño,	O	-
y	O	-
el	O	-
nivel	O	-
de	O	-
ingesta	O	-
de	O	-
aceite	O	-
o	O	-
sal	O	-
se	O	-
determinaron	O	-
con	O	-
el	O	-
uso	O	-
de	O	-
un	O	-
cuestionario	O	-
validado	O	-
en	O	-
el	O	-
seguimiento.	O	-

Se	O	-
reevaluó	O	-
la	O	-
C-IMT	O	-
en	O	-
todos	O	-
los	O	-
1284	O	-
pacientes	O	-
iniciales	O	-
(	O	-
540	O	-
mujeres	O	-
y	O	-
744	O	-
hombres	O	-
)	O	-
con	O	-
hipertensión	O	-
después	O	-
de	O	-
4	O	-
años.	O	-

En	O	-
la	O	-
reevaluación,	O	-
la	O	-
media	O	-
de	O	-
edad	O	-
(	O	-
±	O	-
DE)	O	-
fue	O	-
de	O	-
66	O	-
±	O	-
1,2	O	-
años,	O	-
la	O	-
presión	O	-
arterial	O	-
sistólica	O	-
fue	O	-
de	O	-
138	O	-
±	O	-
19	O	-
mmHg	O	-
y	O	-
la	O	-
presión	O	-
arterial	O	-
diastólica	O	-
fue	O	-
de	O	-
91	O	-
±	O	-
10	O	-
mmHg.	O	-

Los	B-Premise	HighQuality
resultados	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
medias	I-Premise	HighQuality
de	I-Premise	HighQuality
c-IMT	I-Premise	HighQuality
z	I-Premise	HighQuality
aumentaron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
durante	I-Premise	HighQuality
4	I-Premise	HighQuality
años	I-Premise	HighQuality
(	I-Premise	HighQuality
0,002	I-Premise	HighQuality
±	I-Premise	HighQuality
0,003,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
así	I-Premise	HighQuality
como	I-Premise	HighQuality
el	I-Premise	HighQuality
VPM	I-Premise	HighQuality
carotídeo-femoral	I-Premise	HighQuality
(	I-Premise	HighQuality
13,99	I-Premise	HighQuality
±	I-Premise	HighQuality
2,74,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,01	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
total	I-Premise	HighQuality
(	I-Premise	HighQuality
6,97	I-Premise	HighQuality
±	I-Premise	HighQuality
1,08,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
regresión	I-Premise	HighQuality
lineal	I-Premise	HighQuality
mostró	I-Premise	HighQuality
asociaciones	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativas	I-Premise	HighQuality
entre	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
sistólica,	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
diastólica,	I-Premise	HighQuality
la	I-Premise	HighQuality
proteína	I-Premise	HighQuality
C	I-Premise	HighQuality
reactiva,	I-Premise	HighQuality
la	I-Premise	HighQuality
línea	I-Premise	HighQuality
labial	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
frecuencia	I-Premise	HighQuality
cardíaca	I-Premise	HighQuality
con	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
z	I-Premise	HighQuality
de	I-Premise	HighQuality
C-IMT	I-Premise	HighQuality
de	I-Premise	HighQuality
>	I-Premise	HighQuality
1,5SD	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
modelos	I-Premise	HighQuality
totalmente	I-Premise	HighQuality
ajustados	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
valores	I-Premise	HighQuality
de	I-Premise	HighQuality
p	I-Premise	HighQuality
fueron	I-Premise	HighQuality
de	I-Premise	HighQuality
0,000,	I-Premise	HighQuality
0,000,	I-Premise	HighQuality
0,017,	I-Premise	HighQuality
0,001,	I-Premise	HighQuality
y	I-Premise	HighQuality
0,044,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Hubo	O	-
predictores	O	-
significativos	O	-
para	O	-
el	O	-
efecto	O	-
medio	O	-
sobre	O	-
la	O	-
puntuación	O	-
z	O	-
de	O	-
C-IMT.	O	-

En	B-Premise	HighQuality
una	I-Premise	HighQuality
regresión	I-Premise	HighQuality
logística	I-Premise	HighQuality
de	I-Premise	HighQuality
modelo	I-Premise	HighQuality
completo,	I-Premise	HighQuality
los	I-Premise	HighQuality
factores	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
significativos	I-Premise	HighQuality
para	I-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
TMI	I-Premise	HighQuality
de	I-Premise	HighQuality
≥1,5	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
z	I-Premise	HighQuality
fueron	I-Premise	HighQuality
la	I-Premise	HighQuality
VPM	I-Premise	HighQuality
carotídeo-femoral	I-Premise	HighQuality
(	I-Premise	HighQuality
odds	I-Premise	HighQuality
ratio	I-Premise	HighQuality
:	I-Premise	HighQuality
1,119,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
:	I-Premise	HighQuality
1,018,	I-Premise	HighQuality
1,230,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,010	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
primera	I-Premise	HighQuality
medición.	I-Premise	HighQuality

La	B-Claim	HighQuality
conclusión	I-Claim	HighQuality
del	I-Claim	HighQuality
estudio	I-Claim	HighQuality
fue	I-Claim	HighQuality
que	I-Claim	HighQuality
las	I-Claim	HighQuality
mediciones	I-Claim	HighQuality
longitudinales	I-Claim	HighQuality
de	I-Claim	HighQuality
C-IMT	I-Claim	HighQuality
revelaron	I-Claim	HighQuality
progresión	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
aterosclerosis	I-Claim	HighQuality
subclínica	I-Claim	HighQuality
durante	I-Claim	HighQuality
un	I-Claim	HighQuality
período	I-Claim	HighQuality
de	I-Claim	HighQuality
cuatro	I-Claim	HighQuality
años	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
cohorte	I-Claim	HighQuality
hipertensa	I-Claim	HighQuality
de	I-Claim	HighQuality
edad	I-Claim	HighQuality
avanzada.	I-Claim	HighQuality

La	B-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
sistólica	I-Claim	HighQuality
o	I-Claim	HighQuality
diastólica,	I-Claim	HighQuality
la	I-Claim	HighQuality
homocisteína,	I-Claim	HighQuality
el	I-Claim	HighQuality
VCP	I-Claim	HighQuality
carotídeo-femoral	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
cintura	I-Claim	HighQuality
estuvieron	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
relacionados	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
incremento	I-Claim	HighQuality
de	I-Claim	HighQuality
C-IMT.	I-Claim	HighQuality

Por	B-Claim	HighQuality
estilo	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
e	I-Claim	HighQuality
intervención	I-Claim	HighQuality
médica	I-Claim	HighQuality
para	I-Claim	HighQuality
controlar	I-Claim	HighQuality
estos	I-Claim	HighQuality
factores	I-Claim	HighQuality
de	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
puede	I-Claim	HighQuality
prevenir	I-Claim	HighQuality
la	I-Claim	HighQuality
progresión	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
C-IMT	I-Claim	HighQuality
en	I-Claim	HighQuality
cohorte	I-Claim	HighQuality
de	I-Claim	HighQuality
edad	I-Claim	HighQuality
avanzada	I-Claim	HighQuality
con	I-Claim	HighQuality
hipertensión.	I-Claim	HighQuality

El	B-Claim	HighQuality
fármaco	I-Claim	HighQuality
inmunosupresor	I-Claim	HighQuality
rapamicina	I-Claim	HighQuality
puede	I-Claim	HighQuality
influir	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
sensibilidad	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
insulina	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
tejidos	I-Claim	HighQuality
que	I-Claim	HighQuality
responden	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
insulina.	I-Claim	HighQuality

Este	O	-
estudio	O	-
tuvo	O	-
como	O	-
objetivo	O	-
evaluar	O	-
la	O	-
eficacia	O	-
del	O	-
tratamiento	O	-
previo	O	-
con	O	-
rapamicina	O	-
antes	O	-
de	O	-
la	O	-
alotrasplante	O	-
de	O	-
islotes	O	-
pancreáticos	O	-
(	O	-
ITx	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
diabetes	O	-
mellitus	O	-
tipo	O	-
1	O	-
(	O	-
T1DM	O	-
).	O	-

Cuarenta	O	-
y	O	-
un	O	-
pacientes	O	-
con	O	-
MDT1	O	-
fueron	O	-
estudiados.	O	-

Trece	O	-
pacientes	O	-
con	O	-
bajo	O	-
control	O	-
glucémico	O	-
se	O	-
sometieron	O	-
a	O	-
un	O	-
tratamiento	O	-
de	O	-
rapamicina	O	-
a	O	-
corto	O	-
plazo	O	-
antes	O	-
de	O	-
ITx	O	-
(	O	-
Grupo	O	-
1	O	-
)	O	-
y	O	-
se	O	-
compararon	O	-
con	O	-
28	O	-
pacientes	O	-
sometidos	O	-
a	O	-
ITx	O	-
sin	O	-
tratamiento	O	-
previo	O	-
con	O	-
rapamicina	O	-
(	O	-
Grupo	O	-
2	O	-
).	O	-

Los	O	-
resultados	O	-
fueron	O	-
requerimiento	O	-
diario	O	-
de	O	-
insulina	O	-
(DIR	O	-
),	O	-
glucosa	O	-
en	O	-
sangre	O	-
en	O	-
ayunas,	O	-
HbA1c,	O	-
péptido	O	-
C	O	-
y	O	-
el	O	-
índice	O	-
SUITO	O	-
de	O	-
la	O	-
función	O	-
de	O	-
las	O	-
células	O	-
beta.	O	-

Un	O	-
subgrupo	O	-
de	O	-
pacientes	O	-
pre-tratados	O	-
con	O	-
rapamicina	O	-
antes	O	-
de	O	-
que	O	-
ITx	O	-
se	O	-
sometiera	O	-
a	O	-
una	O	-
pinza	O	-
hiperinsulínica	O	-
euglicémica	O	-
con	O	-
[	O	-
6,6-2H2]	O	-
glucosa	O	-
antes	O	-
y	O	-
después	O	-
de	O	-
ITx	O	-
para	O	-
evaluar	O	-
la	O	-
sensibilidad	O	-
a	O	-
la	O	-
insulina.	O	-

Se	B-Premise	HighQuality
encontró	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
significativa	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
DIR	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
previo	I-Premise	HighQuality
con	I-Premise	HighQuality
rapamicina	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
8	I-Premise	HighQuality
±	I-Premise	HighQuality
6	I-Premise	HighQuality
U/día,	I-Premise	HighQuality
media	I-Premise	HighQuality
±	I-Premise	HighQuality
DE,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001)	I-Premise	HighQuality
y	I-Premise	HighQuality
1	I-Premise	HighQuality
año	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
ITx.	I-Premise	HighQuality

La	B-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
DIR	I-Premise	HighQuality
1	I-Premise	HighQuality
año	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
ITx	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
Grupo	I-Premise	HighQuality
1	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
Grupo	I-Premise	HighQuality
2	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
37	I-Premise	HighQuality
±	I-Premise	HighQuality
15	I-Premise	HighQuality
vs.	I-Premise	HighQuality
-	I-Premise	HighQuality
19	I-Premise	HighQuality
±	I-Premise	HighQuality
13	I-Premise	HighQuality
U/día,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,005	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
se	I-Premise	HighQuality
mantuvo	I-Premise	HighQuality
significativa	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
ajustar	I-Premise	HighQuality
para	I-Premise	HighQuality
sexo,	I-Premise	HighQuality
edad,	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
y	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
basal	I-Premise	HighQuality
(	I-Premise	HighQuality
beta	I-Premise	HighQuality
=	I-Premise	HighQuality
18,2	I-Premise	HighQuality
±	I-Premise	HighQuality
5,9,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,006	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
glucosa	I-Premise	HighQuality
en	I-Premise	HighQuality
ayunas	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
disminuyeron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
1	I-Premise	HighQuality
año	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
ITx	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
Grupo	I-Premise	HighQuality
1	I-Premise	HighQuality
(	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
:	I-Premise	HighQuality
-	I-Premise	HighQuality
2,1	I-Premise	HighQuality
±	I-Premise	HighQuality
1,4	I-Premise	HighQuality
%,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,002	I-Premise	HighQuality
),	I-Premise	HighQuality
mientras	O	-
que	O	-
el	B-Premise	HighQuality
péptido	I-Premise	HighQuality
C	I-Premise	HighQuality
en	I-Premise	HighQuality
ayunas	I-Premise	HighQuality
(	I-Premise	HighQuality
+	I-Premise	HighQuality
0,5	I-Premise	HighQuality
±	I-Premise	HighQuality
0,3	I-Premise	HighQuality
nmol/l,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,002	I-Premise	HighQuality
)	I-Premise	HighQuality
e	I-Premise	HighQuality
índice	I-Premise	HighQuality
SUITO	I-Premise	HighQuality
aumentaron	I-Premise	HighQuality
(	I-Premise	HighQuality
+	I-Premise	HighQuality
57,4	I-Premise	HighQuality
±	I-Premise	HighQuality
39,7,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,016	I-Premise	HighQuality
),	I-Premise	HighQuality
sin	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

La	B-Premise	HighQuality
producción	I-Premise	HighQuality
hepática	I-Premise	HighQuality
de	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
previo	I-Premise	HighQuality
con	I-Premise	HighQuality
rapamicina	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
1,1	I-Premise	HighQuality
±	I-Premise	HighQuality
1,1	I-Premise	HighQuality
mg/kg/min,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
ITx	I-Premise	HighQuality
(	I-Premise	HighQuality
-	I-Premise	HighQuality
1,6	I-Premise	HighQuality
±	I-Premise	HighQuality
0,6	I-Premise	HighQuality
mg/kg/min,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,015	I-Premise	HighQuality
),	I-Premise	HighQuality
mientras	O	-
que	O	-
no	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
eliminación	I-Premise	HighQuality
periférica	I-Premise	HighQuality
de	I-Premise	HighQuality
glucosa.	I-Premise	HighQuality

El	B-Claim	HighQuality
tratamiento	I-Claim	HighQuality
previo	I-Claim	HighQuality
con	I-Claim	HighQuality
rapamicina	I-Claim	HighQuality
antes	I-Claim	HighQuality
de	I-Claim	HighQuality
que	I-Claim	HighQuality
ITx	I-Claim	HighQuality
logre	I-Claim	HighQuality
reducir	I-Claim	HighQuality
los	I-Claim	HighQuality
requerimientos	I-Claim	HighQuality
de	I-Claim	HighQuality
insulina,	I-Claim	HighQuality
mejorando	I-Claim	HighQuality
la	I-Claim	HighQuality
sensibilidad	I-Claim	HighQuality
hepática	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
insulina.	I-Claim	HighQuality

Este	B-Claim	HighQuality
tratamiento	I-Claim	HighQuality
puede	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
los	I-Claim	HighQuality
resultados	I-Claim	HighQuality
de	I-Claim	HighQuality
ITx	I-Claim	HighQuality
a	I-Claim	HighQuality
corto	I-Claim	HighQuality
plazo,	I-Claim	HighQuality
posiblemente	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
seleccionados	I-Claim	HighQuality
con	I-Claim	HighQuality
T1DM	I-Claim	HighQuality
complicados	I-Claim	HighQuality
por	I-Claim	HighQuality
la	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
insulina.	I-Claim	HighQuality

La	O	-
hepatitis	O	-
B	O	-
es	O	-
la	O	-
enfermedad	O	-
más	O	-
prevalente	O	-
(junto	O	-
con	O	-
las	O	-
morbilidades	O	-
)	O	-
en	O	-
los	O	-
países	O	-
asiáticos.	O	-

Este	O	-
estudio	O	-
de	O	-
investigación	O	-
se	O	-
ha	O	-
llevado	O	-
a	O	-
cabo	O	-
para	O	-
proporcionar	O	-
un	O	-
tratamiento	O	-
alternativo	O	-
que	O	-
sea	O	-
seguro,	O	-
eficaz	O	-
y	O	-
rentable	O	-
para	O	-
comprender	O	-
las	O	-
relaciones	O	-
de	O	-
la	O	-
enfermedad,	O	-
los	O	-
síntomas,	O	-
la	O	-
respuesta	O	-
de	O	-
los	O	-
pacientes	O	-
y	O	-
la	O	-
respuesta	O	-
clínica	O	-
mediante	O	-
un	O	-
mejor	O	-
tratamiento	O	-
de	O	-
la	O	-
hepatitis	O	-
B.	O	-

El	O	-
objetivo	O	-
de	O	-
esta	O	-
investigación	O	-
es	O	-
evaluar	O	-
la	O	-
eficacia	O	-
y	O	-
la	O	-
seguridad	O	-
de	O	-
la	O	-
medicina	O	-
herbal	O	-
en	O	-
comparación	O	-
con	O	-
la	O	-
medicina	O	-
alopática	O	-
en	O	-
pacientes	O	-
con	O	-
hepatitis	O	-
B.	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
ensayo	O	-
clínico	O	-
controlado,	O	-
ciego	O	-
y	O	-
aleatorizado,	O	-
realizado	O	-
en	O	-
la	O	-
Universidad	O	-
Hamdard	O	-
del	O	-
Hospital	O	-
Memorial	O	-
Shifa-ul-Mulk,	O	-
Karachi	O	-
y	O	-
Dar	O	-
ul	O	-
Shifa	O	-
Unani	O	-
Dawakhana	O	-
Karachi,	O	-
Pakistán.	O	-

Fueron	O	-
registrados	O	-
los	O	-
pacientes	O	-
de	O	-
ambos	O	-
sexos	O	-
que	O	-
oscilaban	O	-
entre	O	-
25	O	-
y	O	-
50	O	-
años	O	-
con	O	-
síntomas	O	-
y	O	-
diagnosticados	O	-
de	O	-
hepatitis	O	-
B	O	-
que	O	-
cumplían	O	-
los	O	-
criterios	O	-
de	O	-
pertenencia,	O	-
y	O	-
consensuados	O	-
para	O	-
la	O	-
participación.	O	-

La	O	-
autorización	O	-
y	O	-
autorización	O	-
del	O	-
comité	O	-
ético	O	-
fue	O	-
obtenida	O	-
del	O	-
comité	O	-
en	O	-
cuestión	O	-
en	O	-
la	O	-
Facultad	O	-
de	O	-
Medicina	O	-
Oriental,	O	-
Universidad	O	-
de	O	-
Hamdard,	O	-
Karachi,	O	-
Pakistán.	O	-

No	B-Premise	HighQuality
se	I-Premise	HighQuality
identificó	I-Premise	HighQuality
ninguna	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
significativa	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
y	I-Premise	HighQuality
se	I-Premise	HighQuality
encontró	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
eficacia	I-Premise	HighQuality
de	I-Premise	HighQuality
Alpha	I-Premise	HighQuality
(fármaco	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
)	I-Premise	HighQuality
es	I-Premise	HighQuality
la	I-Premise	HighQuality
misma	I-Premise	HighQuality
que	I-Premise	HighQuality
Safoof	I-Premise	HighQuality
akseer	I-Premise	HighQuality
e	I-Premise	HighQuality
jigar	I-Premise	HighQuality
(fármaco	I-Premise	HighQuality
de	I-Premise	HighQuality
prueba	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Claim	HighQuality
datos	I-Claim	HighQuality
ofrecieron	I-Claim	HighQuality
apoyo	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
hipótesis	I-Claim	HighQuality
nula	I-Claim	HighQuality
y	I-Claim	HighQuality
por	I-Claim	HighQuality
lo	I-Claim	HighQuality
tanto	I-Claim	HighQuality
la	I-Claim	HighQuality
hipótesis	I-Claim	HighQuality
de	I-Claim	HighQuality
investigación	I-Claim	HighQuality
fue	I-Claim	HighQuality
rechazada.	I-Claim	HighQuality

De	B-Premise	HighQuality
acuerdo	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
estadístico	I-Premise	HighQuality
por	I-Premise	HighQuality
chi	I-Premise	HighQuality
cuadrado,	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
se	I-Premise	HighQuality
registró	I-Premise	HighQuality
como	I-Premise	HighQuality
negativa	I-Premise	HighQuality
en	I-Premise	HighQuality
26	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
57,77	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
45	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
mediante	I-Premise	HighQuality
el	I-Premise	HighQuality
uso	I-Premise	HighQuality
de	I-Premise	HighQuality
Interferón	I-Premise	HighQuality
Alpha	I-Premise	HighQuality
(	I-Premise	HighQuality
terapia	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
27	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
64,28	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
42	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
mediante	I-Premise	HighQuality
el	I-Premise	HighQuality
uso	I-Premise	HighQuality
de	I-Premise	HighQuality
Safoof	I-Premise	HighQuality
akseer	I-Premise	HighQuality
e	I-Premise	HighQuality
jigar	I-Premise	HighQuality
(	I-Premise	HighQuality
fármaco	I-Premise	HighQuality
de	I-Premise	HighQuality
prueba	I-Premise	HighQuality
).	I-Premise	HighQuality

Se	B-Premise	HighQuality
determinó	I-Premise	HighQuality
la	I-Premise	HighQuality
comparación	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
datos	I-Premise	HighQuality
registrados	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes,	I-Premise	HighQuality
ya	I-Premise	HighQuality
que	I-Premise	HighQuality
ambos	I-Premise	HighQuality
fármacos	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
significativa	I-Premise	HighQuality
y	I-Premise	HighQuality
valor	I-Premise	HighQuality
de	I-Premise	HighQuality
p	I-Premise	HighQuality
>	I-Premise	HighQuality
0,05.	I-Premise	HighQuality

La	B-Claim	HighQuality
respuesta	I-Claim	HighQuality
de	I-Claim	HighQuality
eficacia	I-Claim	HighQuality
es	I-Claim	HighQuality
igual	I-Claim	HighQuality
en	I-Claim	HighQuality
ambos	I-Claim	HighQuality
fármacos	I-Claim	HighQuality
mientras	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
fármaco	I-Claim	HighQuality
de	I-Claim	HighQuality
prueba	I-Claim	HighQuality
mostró	I-Claim	HighQuality
más	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
de	I-Claim	HighQuality
seguridad.	I-Claim	HighQuality

Se	B-Claim	HighQuality
concluye	I-Claim	HighQuality
que	I-Claim	HighQuality
Safoof	I-Claim	HighQuality
akseer	I-Claim	HighQuality
e	I-Claim	HighQuality
jigar	I-Claim	HighQuality
posee	I-Claim	HighQuality
un	I-Claim	HighQuality
valor	I-Claim	HighQuality
terapéutico	I-Claim	HighQuality
tan	I-Claim	HighQuality
efectivo	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
como	I-Claim	HighQuality
medicina	I-Claim	HighQuality
alopática.	I-Claim	HighQuality

Los	B-Claim	HighQuality
datos	I-Claim	HighQuality
observacionales	I-Claim	HighQuality
apoyan	I-Claim	HighQuality
un	I-Claim	HighQuality
papel	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
vitamina	I-Claim	HighQuality
D	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
tipo	I-Claim	HighQuality
2,	I-Claim	HighQuality
pero	B-Claim	HighQuality
la	I-Claim	HighQuality
evidencia	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
ensayos	I-Claim	HighQuality
no	I-Claim	HighQuality
es	I-Claim	HighQuality
concluyente.	I-Claim	HighQuality

Evaluar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
vitamina	O	-
D	O	-
en	O	-
la	O	-
función	O	-
β-células	O	-
y	O	-
hemoglobina	O	-
A1c	O	-
(	O	-
HbA1c	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
diabetes	O	-
tipo	O	-
2	O	-
bien	O	-
controlada.	O	-

Ensayo	O	-
clínico	O	-
doble	O	-
ciego,	O	-
aleatorizado,	O	-
controlado	O	-
con	O	-
placebo.	O	-

Tufts	O	-
Medical	O	-
Center,	O	-
Boston,	O	-
MA	O	-
;	O	-
VA	O	-
Medical	O	-
Center,	O	-
Cincinnati,	O	-
OH.	O	-

Un	O	-
total	O	-
de	O	-
127	O	-
pacientes	O	-
(edad	O	-
media,	O	-
60	O	-
años	O	-
)	O	-
con	O	-
diabetes	O	-
estable	O	-
(	O	-
HbA1c	O	-
≤7,5%	O	-
)	O	-
manejada	O	-
con	O	-
estilo	O	-
de	O	-
vida	O	-
o	O	-
estilo	O	-
de	O	-
vida	O	-
más	O	-
metformina.	O	-

Se	O	-
administraron	O	-
4000	O	-
unidades	O	-
diarias	O	-
de	O	-
vitamina	O	-
D3	O	-
(	O	-
colecalciferol	O	-
)	O	-
o	O	-
placebo	O	-
durante	O	-
48	O	-
semanas.	O	-

La	O	-
tasa	O	-
de	O	-
secreción	O	-
de	O	-
insulina	O	-
(	O	-
ISR	O	-
)	O	-
se	O	-
estimó	O	-
a	O	-
partir	O	-
de	O	-
los	O	-
niveles	O	-
plasmáticos	O	-
periféricos	O	-
de	O	-
péptido	O	-
C	O	-
después	O	-
de	O	-
una	O	-
prueba	O	-
de	O	-
tolerancia	O	-
oral	O	-
a	O	-
la	O	-
glucosa	O	-
de	O	-
3	O	-
horas	O	-
de	O	-
75	O	-
g	O	-
realizada	O	-
al	O	-
inicio	O	-
y	O	-
a	O	-
la	O	-
semana	O	-
24.	O	-

Los	O	-
cambios	O	-
en	O	-
la	O	-
HbA1c	O	-
se	O	-
evaluaron	O	-
a	O	-
las	O	-
16,	O	-
24,	O	-
36	O	-
y	O	-
48	O	-
semanas.	O	-

La	O	-
concentración	O	-
plasmática	O	-
media	O	-
basal	O	-
de	O	-
25-hidroxivitamina	O	-
D	O	-
[	O	-
25	O	-
(OH	O	-
)	O	-
D	O	-
]	O	-
fue	O	-
de	O	-
26,6	O	-
ng/ml,	O	-
la	O	-
media	O	-
de	O	-
HbA1c	O	-
fue	O	-
de	O	-
6,6	O	-
%	O	-
y	O	-
el	O	-
78	O	-
%	O	-
de	O	-
los	O	-
pacientes	O	-
estaban	O	-
tomando	O	-
metformina.	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
24,	I-Premise	HighQuality
la	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
25	I-Premise	HighQuality
(	I-Premise	HighQuality
OH	I-Premise	HighQuality
)	I-Premise	HighQuality
D	I-Premise	HighQuality
cambió	I-Premise	HighQuality
en	I-Premise	HighQuality
20,5	I-Premise	HighQuality
y	I-Premise	HighQuality
-1,6	I-Premise	HighQuality
ng/ml	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D	I-Premise	HighQuality
y	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D	I-Premise	HighQuality
y	I-Premise	HighQuality
placebo	I-Premise	HighQuality
no	I-Premise	HighQuality
difirieron	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
ISR	I-Premise	HighQuality
o	I-Premise	HighQuality
HbA1c.	I-Premise	HighQuality

Entre	B-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
estilo	I-Premise	HighQuality
de	I-Premise	HighQuality
vida	I-Premise	HighQuality
solamente	I-Premise	HighQuality
(n	I-Premise	HighQuality
=	I-Premise	HighQuality
28	I-Premise	HighQuality
),	I-Premise	HighQuality
la	I-Premise	HighQuality
suplementación	I-Premise	HighQuality
con	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D	I-Premise	HighQuality
redujo	I-Premise	HighQuality
la	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
-0,1	I-Premise	HighQuality
%	I-Premise	HighQuality
vs	I-Premise	HighQuality
0,3	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,034	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
24.	I-Premise	HighQuality

Este	O	-
resultado	O	-
no	O	-
se	O	-
observó	O	-
en	O	-
los	O	-
otros	O	-
momentos	O	-
y	O	-
podría	O	-
deberse	O	-
a	O	-
la	O	-
casualidad.	O	-

La	B-Premise	HighQuality
vitamina	I-Premise	HighQuality
D3	I-Premise	HighQuality
a	I-Premise	HighQuality
4000	I-Premise	HighQuality
UI/d	I-Premise	HighQuality
no	I-Premise	HighQuality
modificó	I-Premise	HighQuality
la	I-Premise	HighQuality
ISR	I-Premise	HighQuality
ni	I-Premise	HighQuality
la	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
diabetes	I-Premise	HighQuality
tipo	I-Premise	HighQuality
2	I-Premise	HighQuality
bien	I-Premise	HighQuality
controlada	I-Premise	HighQuality
con	I-Premise	HighQuality
metformina	I-Premise	HighQuality
no	I-Premise	HighQuality
seleccionados	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
deficiencia	I-Premise	HighQuality
de	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D.	I-Premise	HighQuality

Comparar	O	-
los	O	-
resultados	O	-
de	O	-
la	O	-
trabeculotomía	O	-
circunferencial	O	-
asistida	O	-
por	O	-
microcatéter	O	-
con	O	-
la	O	-
trabeculotomía	O	-
de	O	-
sonda	O	-
rígida	O	-
estándar	O	-
en	O	-
glaucomas	O	-
infantiles.	O	-

Los	O	-
ojos	O	-
de	O	-
los	O	-
niños	O	-
que	O	-
necesitaban	O	-
trabeculotomía	O	-
para	O	-
el	O	-
glaucoma	O	-
primario	O	-
congénito	O	-
o	O	-
pediátrico	O	-
secundario	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
someterse	O	-
a	O	-
una	O	-
trabeculotomía	O	-
utilizando	O	-
el	O	-
microcatéter	O	-
iluminado	O	-
por	O	-
Glaucolight	O	-
o	O	-
una	O	-
trabeculotomía	O	-
rígida	O	-
de	O	-
la	O	-
sonda.	O	-

El	O	-
éxito	O	-
completo	O	-
se	O	-
definió	O	-
como	O	-
una	O	-
presión	O	-
intraocular	O	-
(PIO)	O	-
de	O	-
<	O	-
18	O	-
mmHg	O	-
sin	O	-
medicamentos.	O	-

Se	O	-
incluyó	O	-
un	O	-
total	O	-
de	O	-
62	O	-
ojos	O	-
de	O	-
62	O	-
pacientes.	O	-

De	O	-
estos	O	-
30	O	-
ojos	O	-
de	O	-
30	O	-
pacientes	O	-
de	O	-
5,6	O	-
±	O	-
4,8	O	-
meses	O	-
de	O	-
edad	O	-
se	O	-
sometieron	O	-
a	O	-
trabeculotomía	O	-
asistida	O	-
por	O	-
microcatéteres,	O	-
con	O	-
15	O	-
ojos	O	-
(	O	-
50%	O	-
)	O	-
con	O	-
un	O	-
corte	O	-
completo	O	-
de	O	-
360°,	O	-
mientras	O	-
que	O	-
15	O	-
ojos	O	-
(	O	-
50%	O	-
)	O	-
tuvieron	O	-
un	O	-
corte	O	-
incompleto	O	-
de	O	-
250	O	-
a	O	-
350	O	-
grados.	O	-

El	O	-
grupo	O	-
de	O	-
trabeculotomía	O	-
de	O	-
sonda	O	-
rígida	O	-
incluyó	O	-
32	O	-
ojos	O	-
de	O	-
32	O	-
pacientes	O	-
de	O	-
4,4	O	-
±	O	-
3,8	O	-
meses	O	-
de	O	-
edad.	O	-

Al	B-Premise	HighQuality
final	I-Premise	HighQuality
del	I-Premise	HighQuality
período	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
de	I-Premise	HighQuality
2	I-Premise	HighQuality
años,	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
éxito	I-Premise	HighQuality
completo	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
fracaso	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
67	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
15	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
asistido	I-Premise	HighQuality
por	I-Premise	HighQuality
microcatéteres	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
47	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
50	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
trabeculotomía	I-Premise	HighQuality
de	I-Premise	HighQuality
sonda	I-Premise	HighQuality
rígida	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,006	I-Premise	HighQuality
).	I-Premise	HighQuality

Hubo	B-Premise	HighQuality
tendencia	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
menor	I-Premise	HighQuality
PIO	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
microcatéter	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
1,	I-Premise	HighQuality
3,	I-Premise	HighQuality
6,	I-Premise	HighQuality
12	I-Premise	HighQuality
y	I-Premise	HighQuality
24	I-Premise	HighQuality
meses	I-Premise	HighQuality
postoperatorio,	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
alcanzando	I-Premise	HighQuality
significación	I-Premise	HighQuality
estadística	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
6	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,004	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
tiempo	I-Premise	HighQuality
medio	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
microcatéter	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,01	I-Premise	HighQuality
).	I-Premise	HighQuality

A	B-Claim	HighQuality
los	I-Claim	HighQuality
2	I-Claim	HighQuality
años	I-Claim	HighQuality
del	I-Claim	HighQuality
postoperatorio,	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculotomía	I-Claim	HighQuality
asistida	I-Claim	HighQuality
por	I-Claim	HighQuality
microcatéter	I-Claim	HighQuality
aún	I-Claim	HighQuality
arrojaba	I-Claim	HighQuality
resultados	I-Claim	HighQuality
superiores	I-Claim	HighQuality
en	I-Claim	HighQuality
términos	I-Claim	HighQuality
de	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
y	I-Claim	HighQuality
tasas	I-Claim	HighQuality
de	I-Claim	HighQuality
éxito	I-Claim	HighQuality
en	I-Claim	HighQuality
niños	I-Claim	HighQuality
con	I-Claim	HighQuality
glaucoma	I-Claim	HighQuality
congénito	I-Claim	HighQuality
primario.	I-Claim	HighQuality

La	B-Premise	HighQuality
necesidad	I-Premise	HighQuality
de	I-Premise	HighQuality
reoperación	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
glaucoma	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
microcatéter.	I-Premise	HighQuality

Las	B-Claim	HighQuality
complicaciones	I-Claim	HighQuality
cardiovasculares	I-Claim	HighQuality
son	I-Claim	HighQuality
una	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
principales	I-Claim	HighQuality
causas	I-Claim	HighQuality
de	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
mortalidad	I-Claim	HighQuality
y	I-Claim	HighQuality
morbilidad	I-Claim	HighQuality
entre	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
Diabetes	I-Claim	HighQuality
Mellitus	I-Claim	HighQuality
(	I-Claim	HighQuality
DM	I-Claim	HighQuality
).	I-Claim	HighQuality

El	B-Claim	HighQuality
metabolismo	I-Claim	HighQuality
alterado	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
aminoácidos	I-Claim	HighQuality
sulfurosos	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
se	I-Claim	HighQuality
reflejó	I-Claim	HighQuality
como	I-Claim	HighQuality
incrementos	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
concentración	I-Claim	HighQuality
de	I-Claim	HighQuality
metionina	I-Claim	HighQuality
y	I-Claim	HighQuality
cisteína/cistina	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
sangre	I-Claim	HighQuality
que	I-Claim	HighQuality
se	I-Claim	HighQuality
conoce	I-Claim	HighQuality
como	I-Claim	HighQuality
marcadores	I-Claim	HighQuality
de	I-Claim	HighQuality
Enfermedades	I-Claim	HighQuality
Cardiovasculares	I-Claim	HighQuality
(CVD	I-Claim	HighQuality
).	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
determinar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
ácido	O	-
eicosapentaenoico	O	-
(EPA	O	-
)	O	-
sobre	O	-
los	O	-
aminoácidos	O	-
sulfidril	O	-
e	O	-
Índice	O	-
Aterogénico	O	-
de	O	-
Plasma	O	-
(	O	-
AIP	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
DM	O	-
tipo	O	-
2	O	-
(	O	-
T2DM	O	-
).	O	-

Se	O	-
realizó	O	-
un	O	-
ensayo	O	-
clínico	O	-
aleatorizado,	O	-
doble	O	-
ciego,	O	-
controlado	O	-
con	O	-
placebo	O	-
en	O	-
36	O	-
pacientes	O	-
con	O	-
control	O	-
y	O	-
DM.	O	-

Los	O	-
sujetos	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
para	O	-
obtener	O	-
2	O	-
g/d	O	-
EPA	O	-
(	O	-
n	O	-
=	O	-
18	O	-
)	O	-
o	O	-
placebo	O	-
(	O	-
n	O	-
=	O	-
18	O	-
)	O	-
durante	O	-
8	O	-
semanas.	O	-

El	O	-
nivel	O	-
sérico	O	-
de	O	-
ayuno	O	-
de	O	-
Cystein	O	-
y	O	-
Metionina	O	-
se	O	-
midió	O	-
utilizando	O	-
el	O	-
método	O	-
HPLC	O	-
y	O	-
se	O	-
calculó	O	-
el	O	-
índice	O	-
aterogénico	O	-
de	O	-
plasma	O	-
(	O	-
AIP	O	-
)	O	-
como	O	-
medida	O	-
proxy	O	-
de	O	-
la	O	-
aterosclerosis.	O	-

La	B-Premise	HighQuality
suplementación	I-Premise	HighQuality
de	I-Premise	HighQuality
ocho	I-Premise	HighQuality
semanas	I-Premise	HighQuality
con	I-Premise	HighQuality
EPA	I-Premise	HighQuality
llevó	I-Premise	HighQuality
a	I-Premise	HighQuality
reducciones	I-Premise	HighQuality
significativas	I-Premise	HighQuality
en	I-Premise	HighQuality
Met	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,002	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
Cys	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,06	I-Premise	HighQuality
).	I-Premise	HighQuality

Además,	O	-
en	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
placebo	I-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
AIP	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
tomar	I-Premise	HighQuality
EPA	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,04	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
suplementación	I-Claim	HighQuality
con	I-Claim	HighQuality
EPA	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
T2DM	I-Claim	HighQuality
durante	I-Claim	HighQuality
ocho	I-Claim	HighQuality
semanas	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
efectos	I-Claim	HighQuality
beneficiosos	I-Claim	HighQuality
en	I-Claim	HighQuality
Met,	I-Claim	HighQuality
Cys	I-Claim	HighQuality
y	I-Claim	HighQuality
AIP,	I-Claim	HighQuality
lo	I-Claim	HighQuality
que	I-Claim	HighQuality
puede	I-Claim	HighQuality
atribuir	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
prevención	I-Claim	HighQuality
de	I-Claim	HighQuality
complicaciones	I-Claim	HighQuality
vasculares	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
T2DM.	I-Claim	HighQuality

El	O	-
tratamiento	O	-
estándar	O	-
para	O	-
pacientes	O	-
con	O	-
cáncer	O	-
rectal	O	-
clínicamente	O	-
resecable	O	-
es	O	-
la	O	-
cirugía.	O	-

Se	B-Claim	HighQuality
recomienda	I-Claim	HighQuality
la	I-Claim	HighQuality
radioquimioterapia	I-Claim	HighQuality
postoperatoria	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
enfermedad	I-Claim	HighQuality
avanzada	I-Claim	HighQuality
(pT3/4	I-Claim	HighQuality
o	I-Claim	HighQuality
pN+	I-Claim	HighQuality
).	I-Claim	HighQuality

En	B-Claim	HighQuality
los	I-Claim	HighQuality
últimos	I-Claim	HighQuality
años,	I-Claim	HighQuality
se	I-Claim	HighQuality
han	I-Claim	HighQuality
reportado	I-Claim	HighQuality
resultados	I-Claim	HighQuality
alentadores	I-Claim	HighQuality
de	I-Claim	HighQuality
radioterapia	I-Claim	HighQuality
preoperatoria.	I-Claim	HighQuality

Este	O	-
ensayo	O	-
prospectivo	O	-
aleatorizado	O	-
de	O	-
fase	O	-
III	O	-
(CAO/ARO/AIO-94	O	-
)	O	-
compara	O	-
la	O	-
eficacia	O	-
de	O	-
la	O	-
radioquimioterapia	O	-
neoadyuvante	O	-
con	O	-
la	O	-
radioterapia	O	-
postoperatoria	O	-
estándar.	O	-

Se	O	-
reporta	O	-
el	O	-
diseño	O	-
del	O	-
estudio	O	-
y	O	-
los	O	-
primeros	O	-
resultados	O	-
con	O	-
respecto	O	-
a	O	-
la	O	-
toxicidad	O	-
de	O	-
la	O	-
radioquimioterapia	O	-
y	O	-
la	O	-
morbilidad	O	-
postoperatoria.	O	-

Los	O	-
pacientes	O	-
con	O	-
cáncer	O	-
rectal	O	-
operable	O	-
localmente	O	-
avanzado	O	-
(uT3/4	O	-
o	O	-
uN+,	O	-
Mason	O	-
CS	O	-
III/IV	O	-
)	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
la	O	-
radioquimioterapia	O	-
pre	O	-
o	O	-
postoperatoria	O	-
:	O	-
Se	O	-
aplicó	O	-
una	O	-
dosis	O	-
total	O	-
de	O	-
50,4	O	-
Gy	O	-
(dosis	O	-
única	O	-
1,8	O	-
Gy	O	-
)	O	-
al	O	-
tumor	O	-
y	O	-
a	O	-
los	O	-
ganglios	O	-
linfáticos	O	-
pélvicos.	O	-

El	O	-
5-FU	O	-
(	O	-
1.000	O	-
mg/m2/d	O	-
)	O	-
se	O	-
administró	O	-
concomitantemente	O	-
en	O	-
la	O	-
primera	O	-
y	O	-
quinta	O	-
semana	O	-
de	O	-
radiación	O	-
en	O	-
forma	O	-
de	O	-
perfusión	O	-
continua	O	-
de	O	-
120	O	-
h.	O	-

Cuatro	O	-
ciclos	O	-
adicionales	O	-
de	O	-
quimioterapia	O	-
con	O	-
5-FU	O	-
(500	O	-
mg/m2/d,	O	-
i.v.	O	-

bolus	O	-
)	O	-
se	O	-
aplicaron.	O	-

La	O	-
radioquimioterapia	O	-
fue	O	-
idéntica	O	-
en	O	-
ambos	O	-
brazos	O	-
a	O	-
excepción	O	-
de	O	-
un	O	-
impulso	O	-
de	O	-
pequeño	O	-
volumen	O	-
de	O	-
5,4	O	-
Gy	O	-
en	O	-
el	O	-
entorno	O	-
postoperatorio.	O	-

El	O	-
intervalo	O	-
de	O	-
tiempo	O	-
entre	O	-
la	O	-
radioquimioterapia	O	-
y	O	-
la	O	-
cirugía	O	-
fue	O	-
de	O	-
4-6	O	-
semanas	O	-
en	O	-
ambos	O	-
brazos.	O	-

Las	O	-
técnicas	O	-
de	O	-
cirugía	O	-
fueron	O	-
estandarizadas	O	-
e	O	-
incluyeron	O	-
la	O	-
escisión	O	-
mesorrectal	O	-
total.	O	-

Además,	O	-
la	O	-
estratificación	O	-
según	O	-
los	O	-
cirujanos	O	-
involucrados	O	-
se	O	-
ha	O	-
previsto	O	-
para.	O	-

Los	O	-
criterios	O	-
de	O	-
valoración	O	-
primarios	O	-
del	O	-
estudio	O	-
son	O	-
la	O	-
supervivencia	O	-
total	O	-
a	O	-
5	O	-
años,	O	-
el	O	-
control	O	-
local	O	-
y	O	-
distante,	O	-
los	O	-
criterios	O	-
de	O	-
valoración	O	-
secundarios	O	-
incluyen	O	-
la	O	-
tasa	O	-
de	O	-
resección	O	-
curativa	O	-
(	O	-
R0	O	-
)	O	-
y	O	-
procedimientos	O	-
de	O	-
ahorro	O	-
del	O	-
esfínter,	O	-
toxicidad	O	-
de	O	-
la	O	-
radioquimioterapia,	O	-
complicaciones	O	-
quirúrgicas	O	-
y	O	-
calidad	O	-
de	O	-
vida.	O	-

Al	O	-
15	O	-
de	O	-
noviembre	O	-
de	O	-
2000,	O	-
628	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
de	O	-
26	O	-
instituciones	O	-
participantes:	O	-
310	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
la	O	-
radioquimioterapia	O	-
postoperatoria,	O	-
318	O	-
pacientes	O	-
a	O	-
la	O	-
radioquimioterapia	O	-
preoperatoria.	O	-

La	B-Premise	HighQuality
toxicidad	I-Premise	HighQuality
aguda	I-Premise	HighQuality
(OMS	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
radioquimioterapia	I-Premise	HighQuality
fue	I-Premise	HighQuality
baja,	I-Premise	HighQuality
con	I-Premise	HighQuality
menos	I-Premise	HighQuality
del	I-Premise	HighQuality
15	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
experimentaron	I-Premise	HighQuality
toxicidad	I-Premise	HighQuality
de	I-Premise	HighQuality
grado	I-Premise	HighQuality
3	I-Premise	HighQuality
o	I-Premise	HighQuality
mayor:	I-Premise	HighQuality
la	B-Premise	HighQuality
principal	I-Premise	HighQuality
toxicidad	I-Premise	HighQuality
fue	I-Premise	HighQuality
la	I-Premise	HighQuality
diarrea,	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
12	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
de	I-Premise	HighQuality
radioquimioterapia	I-Premise	HighQuality
postoperatorio	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
10	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
de	I-Premise	HighQuality
radioquimioterapia	I-Premise	HighQuality
preoperatorio	I-Premise	HighQuality
con	I-Premise	HighQuality
grado	I-Premise	HighQuality
3	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
1	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
cada	I-Premise	HighQuality
brazo	I-Premise	HighQuality
con	I-Premise	HighQuality
diarrea	I-Premise	HighQuality
de	I-Premise	HighQuality
grado	I-Premise	HighQuality
4.	I-Premise	HighQuality

El	B-Premise	HighQuality
eritema,	I-Premise	HighQuality
las	I-Premise	HighQuality
náuseas	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
leucopenia	I-Premise	HighQuality
fueron	I-Premise	HighQuality
las	I-Premise	HighQuality
siguientes	I-Premise	HighQuality
toxicidades	I-Premise	HighQuality
comunes,	I-Premise	HighQuality
con	I-Premise	HighQuality
menos	I-Premise	HighQuality
del	I-Premise	HighQuality
3	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
brazos	I-Premise	HighQuality
que	I-Premise	HighQuality
sufrían	I-Premise	HighQuality
leucopenia	I-Premise	HighQuality
de	I-Premise	HighQuality
grado	I-Premise	HighQuality
3	I-Premise	HighQuality
o	I-Premise	HighQuality
mayor	I-Premise	HighQuality
o	I-Premise	HighQuality
náuseas.	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
postoperatorias	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
brazos,	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
12%	I-Premise	HighQuality
(radioquimioterapia	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
13%	I-Premise	HighQuality
(radioquimioterapia	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
que	I-Premise	HighQuality
sufrieron	I-Premise	HighQuality
fugas	I-Premise	HighQuality
anastomóticas,	I-Premise	HighQuality
un	I-Premise	HighQuality
4%	I-Premise	HighQuality
(radioquimioterapia	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
3%	I-Premise	HighQuality
(radioquimioterapia	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
hemorragias	I-Premise	HighQuality
postoperatorias,	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
6%	I-Premise	HighQuality
(radioquimioterapia	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
5%	I-Premise	HighQuality
(radioquimioterapia	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
cicatrización	I-Premise	HighQuality
tardía	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
heridas.	I-Premise	HighQuality

La	B-Claim	HighQuality
acumulación	I-Claim	HighQuality
de	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
en	I-Claim	HighQuality
nuestro	I-Claim	HighQuality
ensayo	I-Claim	HighQuality
es	I-Claim	HighQuality
satisfactoria,	I-Claim	HighQuality
la	I-Claim	HighQuality
radioquimioterapia	I-Claim	HighQuality
neoadyuvante	I-Claim	HighQuality
es	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerada	I-Claim	HighQuality
y	I-Claim	HighQuality
no	I-Claim	HighQuality
presenta	I-Claim	HighQuality
mayor	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
morbilidad	I-Claim	HighQuality
postoperatoria.	I-Claim	HighQuality

Imatinib	B-Claim	HighQuality
(	I-Claim	HighQuality
Gleevec	I-Claim	HighQuality
),	I-Claim	HighQuality
un	I-Claim	HighQuality
inhibidor	I-Claim	HighQuality
específico	I-Claim	HighQuality
altamente	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
tirosina	I-Claim	HighQuality
cinasa,	I-Claim	HighQuality
demuestra	I-Claim	HighQuality
un	I-Claim	HighQuality
mejor	I-Claim	HighQuality
perfil	I-Claim	HighQuality
de	I-Claim	HighQuality
efectos	I-Claim	HighQuality
secundarios	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
interferón-alfa	I-Claim	HighQuality
(	I-Claim	HighQuality
IFN	I-Claim	HighQuality
),	I-Claim	HighQuality
que	I-Claim	HighQuality
afecta	I-Claim	HighQuality
la	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
(	I-Claim	HighQuality
CV	I-Claim	HighQuality
).	I-Claim	HighQuality

Este	O	-
estudio	O	-
internacional	O	-
de	O	-
fase	O	-
III	O	-
evaluó	O	-
los	O	-
resultados	O	-
de	O	-
CV	O	-
en	O	-
1.106	O	-
pacientes	O	-
recién	O	-
diagnosticados	O	-
con	O	-
leucemia	O	-
mieloide	O	-
crónica	O	-
en	O	-
fase	O	-
crónica	O	-
(LMC	O	-
)	O	-
que	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
imatinib	O	-
400	O	-
mg	O	-
al	O	-
día	O	-
o	O	-
IFN	O	-
hasta	O	-
5	O	-
MU/m	O	-
(	O	-
2	O	-
)	O	-
/d	O	-
con	O	-
citarabina	O	-
(	O	-
Ara-C	O	-
)	O	-
20	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
/d	O	-
añadido	O	-
durante	O	-
10	O	-
días	O	-
al	O	-
mes	O	-
(	O	-
IFN	O	-
+	O	-
LDAC	O	-
).	O	-

Se	O	-
permitió	O	-
el	O	-
paso	O	-
al	O	-
otro	O	-
grupo	O	-
de	O	-
tratamiento	O	-
por	O	-
falta	O	-
de	O	-
eficacia	O	-
o	O	-
intolerancia	O	-
al	O	-
tratamiento.	O	-

La	O	-
CV	O	-
se	O	-
evaluó	O	-
con	O	-
la	O	-
Evaluación	O	-
Funcional	O	-
de	O	-
los	O	-
Modificadores	O	-
de	O	-
la	O	-
Respuesta	O	-
Terapia-Biológica	O	-
del	O	-
Cáncer	O	-
(	O	-
FACT-BRM	O	-
)	O	-
al	O	-
inicio,	O	-
mensualmente	O	-
durante	O	-
6	O	-
meses	O	-
y	O	-
luego	O	-
en	O	-
los	O	-
meses	O	-
9,	O	-
12	O	-
y	O	-
18.	O	-

El	O	-
Índice	O	-
de	O	-
Resultados	O	-
del	O	-
Ensayo	O	-
(	O	-
TOI	O	-
;	O	-
un	O	-
criterio	O	-
de	O	-
valoración	O	-
compuesto	O	-
de	O	-
subescalas	O	-
físicas/funcionales/específicas	O	-
del	O	-
tratamiento	O	-
)	O	-
fue	O	-
el	O	-
criterio	O	-
de	O	-
valoración	O	-
principal.	O	-

Los	O	-
criterios	O	-
de	O	-
valoración	O	-
secundarios	O	-
medidos	O	-
fueron	O	-
bienestar	O	-
social/familiar	O	-
(	O	-
SFWB	O	-
)	O	-
y	O	-
bienestar	O	-
emocional	O	-
(	O	-
EWB	O	-
).	O	-

La	O	-
CV	O	-
se	O	-
analizó	O	-
durante	O	-
los	O	-
primeros	O	-
18	O	-
meses	O	-
de	O	-
tratamiento	O	-
utilizando	O	-
modelos	O	-
de	O	-
curva	O	-
de	O	-
crecimiento	O	-
de	O	-
efectos	O	-
mixtos.	O	-

Los	O	-
análisis	O	-
primarios	O	-
fueron	O	-
la	O	-
intención	O	-
de	O	-
tratar	O	-
(	O	-
ITT	O	-
)	O	-
;	O	-
los	O	-
análisis	O	-
secundarios	O	-
incorporaron	O	-
el	O	-
crossover	O	-
como	O	-
covariable	O	-
dependiente	O	-
del	O	-
tiempo.	O	-

Un	O	-
total	O	-
de	O	-
1.049	O	-
pacientes	O	-
completaron	O	-
al	O	-
menos	O	-
una	O	-
evaluación	O	-
de	O	-
CV.	O	-

Doscientos	B-Premise	HighQuality
sesenta	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
(	I-Premise	HighQuality
50	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
cruzaron	I-Premise	HighQuality
de	I-Premise	HighQuality
IFN	I-Premise	HighQuality
a	I-Premise	HighQuality
imatinib	I-Premise	HighQuality
y	I-Premise	HighQuality
11	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
cruzaron	I-Premise	HighQuality
de	I-Premise	HighQuality
imatinib	I-Premise	HighQuality
a	I-Premise	HighQuality
IFN.	I-Premise	HighQuality

Hubo	B-Premise	HighQuality
una	I-Premise	HighQuality
disminución	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
IAT	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
IFN	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
preservación	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
basales	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
IAT	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
imatinib	I-Premise	HighQuality
(p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001,	I-Premise	HighQuality
ITT).	I-Premise	HighQuality

La	B-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
sociales/familia	I-Premise	HighQuality
y	I-Premise	HighQuality
EWB	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
22,8	I-Premise	HighQuality
y	I-Premise	HighQuality
19,5,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
para	I-Premise	HighQuality
imatinib	I-Premise	HighQuality
y	I-Premise	HighQuality
21,6	I-Premise	HighQuality
y	I-Premise	HighQuality
17,6,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
para	I-Premise	HighQuality
IFN	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001,	I-Premise	HighQuality
ITT	I-Premise	HighQuality
).	I-Premise	HighQuality

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
pasar	I-Premise	HighQuality
de	I-Premise	HighQuality
IFN	I-Premise	HighQuality
a	I-Premise	HighQuality
imatinib,	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
experimentaron	I-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
significativo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
TOI.	I-Premise	HighQuality

Imatinib	B-Claim	HighQuality
ofrece	I-Claim	HighQuality
claras	I-Claim	HighQuality
ventajas	I-Claim	HighQuality
de	I-Claim	HighQuality
CV	I-Claim	HighQuality
sobre	I-Claim	HighQuality
IFN	I-Claim	HighQuality
como	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
primera	I-Claim	HighQuality
línea	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
LMC	I-Claim	HighQuality
en	I-Claim	HighQuality
fase	I-Claim	HighQuality
crónica.	I-Claim	HighQuality

Además,	O	-
los	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
que	I-Claim	HighQuality
cruzaron	I-Claim	HighQuality
a	I-Claim	HighQuality
imatinib	I-Claim	HighQuality
notificaron	I-Claim	HighQuality
una	I-Claim	HighQuality
CV	I-Claim	HighQuality
más	I-Claim	HighQuality
alta	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
que	I-Claim	HighQuality
permanecieron	I-Claim	HighQuality
con	I-Claim	HighQuality
IFN.	I-Claim	HighQuality

Recientemente,	O	-
ha	B-Claim	HighQuality
habido	I-Claim	HighQuality
un	I-Claim	HighQuality
creciente	I-Claim	HighQuality
interés	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
influencia	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
vitaminas	I-Claim	HighQuality
antioxidantes	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
eficacia	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
terapia	I-Claim	HighQuality
hipoglucémica	I-Claim	HighQuality
oral	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
diabéticos	I-Claim	HighQuality
tipo	I-Claim	HighQuality
2	I-Claim	HighQuality
(	I-Claim	HighQuality
T2DM	I-Claim	HighQuality
).	I-Claim	HighQuality

Este	O	-
ensayo	O	-
clínico	O	-
controlado	O	-
aleatorizado	O	-
de	O	-
un	O	-
solo	O	-
ciego	O	-
tuvo	O	-
como	O	-
objetivo	O	-
investigar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
vitamina	O	-
C	O	-
y/o	O	-
E	O	-
en	O	-
la	O	-
eficacia	O	-
de	O	-
la	O	-
terapia	O	-
hipoglucémica	O	-
oral	O	-
en	O	-
pacientes	O	-
palestinos	O	-
T2DM	O	-
de	O	-
la	O	-
Franja	O	-
de	O	-
Gaza.	O	-

Cuarenta	O	-
pacientes	O	-
varones	O	-
T2DM	O	-
de	O	-
40-60	O	-
años	O	-
de	O	-
edad	O	-
con	O	-
tratamiento	O	-
con	O	-
metformina	O	-
fueron	O	-
divididos	O	-
aleatoriamente	O	-
en	O	-
cuatro	O	-
grupos,	O	-
cada	O	-
grupo	O	-
recibió	O	-
uno	O	-
adicional	O	-
de	O	-
los	O	-
siguientes	O	-
suplementos	O	-
orales	O	-
diarios	O	-
durante	O	-
90	O	-
días	O	-
:	O	-
placebo	O	-
;	O	-
vitamina	O	-
C	O	-
;	O	-
vitamina	O	-
E	O	-
y	O	-
vitamina	O	-
C	O	-
más	O	-
vitamina	O	-
E.	O	-
Después	O	-
del	O	-
ayuno	O	-
nocturno,	O	-
se	O	-
recolectaron	O	-
muestras	O	-
de	O	-
sangre	O	-
venosa	O	-
de	O	-
todos	O	-
los	O	-
individuos	O	-
en	O	-
tubos	O	-
K3-EDTA	O	-
y	O	-
tubos	O	-
séricos	O	-
para	O	-
medir	O	-
los	O	-
parámetros	O	-
bioquímicos	O	-
y	O	-
hematológicos	O	-
del	O	-
estudio	O	-
al	O	-
inicio	O	-
y	O	-
después	O	-
de	O	-
90	O	-
días	O	-
de	O	-
suplementación	O	-
con	O	-
vitaminas.	O	-

Los	O	-
resultados	O	-
revelaron	O	-
que	O	-
la	B-Premise	HighQuality
vitamina	I-Premise	HighQuality
C	I-Premise	HighQuality
y/o	I-Premise	HighQuality
E	I-Premise	HighQuality
mejoran	I-Premise	HighQuality
el	I-Premise	HighQuality
azúcar	I-Premise	HighQuality
en	I-Premise	HighQuality
sangre	I-Premise	HighQuality
en	I-Premise	HighQuality
ayunas	I-Premise	HighQuality
(	I-Premise	HighQuality
FBS	I-Premise	HighQuality
),	I-Premise	HighQuality
HbA1c,	I-Premise	HighQuality
el	I-Premise	HighQuality
perfil	I-Premise	HighQuality
lipídico,	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina,	I-Premise	HighQuality
la	I-Premise	HighQuality
evaluación	I-Premise	HighQuality
del	I-Premise	HighQuality
modelo	I-Premise	HighQuality
homeostasis	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina	I-Premise	HighQuality
(	I-Premise	HighQuality
HOMA-IR	I-Premise	HighQuality
),	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
glutatión	I-Premise	HighQuality
(	I-Premise	HighQuality
GSH	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
índice	I-Premise	HighQuality
cuantitativo	I-Premise	HighQuality
de	I-Premise	HighQuality
sensibilidad	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
insulina	I-Premise	HighQuality
(	I-Premise	HighQuality
QISCI	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
diabéticos	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
placebo.	I-Premise	HighQuality

Este	B-Claim	HighQuality
estudio	I-Claim	HighQuality
proporcionó	I-Claim	HighQuality
evidencia	I-Claim	HighQuality
adicional	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
efectos	I-Claim	HighQuality
beneficiosos	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
de	I-Claim	HighQuality
vitaminas	I-Claim	HighQuality
antioxidantes	I-Claim	HighQuality
en	I-Claim	HighQuality
T2DM	I-Claim	HighQuality
que	I-Claim	HighQuality
podrían	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
la	I-Claim	HighQuality
condición	I-Claim	HighQuality
clínica	I-Claim	HighQuality
y	I-Claim	HighQuality
atenuar	I-Claim	HighQuality
o	I-Claim	HighQuality
prevenir	I-Claim	HighQuality
la	I-Claim	HighQuality
patogénesis	I-Claim	HighQuality
diabética	I-Claim	HighQuality
y	I-Claim	HighQuality
las	I-Claim	HighQuality
complicaciones	I-Claim	HighQuality
que,	I-Claim	HighQuality
en	I-Claim	HighQuality
segundo	I-Claim	HighQuality
lugar,	I-Claim	HighQuality
al	I-Claim	HighQuality
control	I-Claim	HighQuality
glucémico	I-Claim	HighQuality
deficiente,	I-Claim	HighQuality
podrían	I-Claim	HighQuality
atribuir	I-Claim	HighQuality
al	I-Claim	HighQuality
desequilibrio	I-Claim	HighQuality
entre	I-Claim	HighQuality
la	I-Claim	HighQuality
disminución	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
antioxidantes	I-Claim	HighQuality
endógenos	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
producción	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
especies	I-Claim	HighQuality
reactivas	I-Claim	HighQuality
de	I-Claim	HighQuality
oxígeno	I-Claim	HighQuality
que	I-Claim	HighQuality
conducen	I-Claim	HighQuality
al	I-Claim	HighQuality
daño	I-Claim	HighQuality
mediado	I-Claim	HighQuality
por	I-Claim	HighQuality
oxidantes	I-Claim	HighQuality
presentes	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
contexto	I-Claim	HighQuality
diabético.	I-Claim	HighQuality

El	B-Claim	HighQuality
linfoma	I-Claim	HighQuality
cutáneo	I-Claim	HighQuality
de	I-Claim	HighQuality
células	I-Claim	HighQuality
T	I-Claim	HighQuality
(LTC	I-Claim	HighQuality
)	I-Claim	HighQuality
puede	I-Claim	HighQuality
estar	I-Claim	HighQuality
asociado	I-Claim	HighQuality
con	I-Claim	HighQuality
lesiones	I-Claim	HighQuality
dolorosas,	I-Claim	HighQuality
pruríticas,	I-Claim	HighQuality
desfigurantes.	I-Claim	HighQuality

Como	O	-
parte	O	-
de	O	-
un	O	-
ensayo	O	-
multicéntrico,	O	-
aleatorizado	O	-
en	O	-
fase	O	-
III	O	-
en	O	-
pacientes	O	-
con	O	-
CTCL	O	-
avanzado	O	-
y/o	O	-
recidivante	O	-
fuertemente	O	-
pretratados,	O	-
se	O	-
evaluaron	O	-
los	O	-
efectos	O	-
de	O	-
una	O	-
proteína	O	-
de	O	-
fusión	O	-
dirigida	O	-
a	O	-
receptores	O	-
de	O	-
interleucina	O	-
2,	O	-
denileukin	O	-
diftitox	O	-
(	O	-
DAB389IL-2,	O	-
ONTAK	O	-
)	O	-
sobre	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
global	O	-
(	O	-
CV	O	-
)	O	-
valorada	O	-
por	O	-
el	O	-
paciente,	O	-
la	O	-
apariencia	O	-
de	O	-
la	O	-
piel	O	-
y	O	-
la	O	-
gravedad	O	-
del	O	-
prurito.	O	-

Un	O	-
total	O	-
de	O	-
71	O	-
pacientes	O	-
con	O	-
LTC	O	-
IB-IVA	O	-
en	O	-
estadio	O	-
recibieron	O	-
diftitox	O	-
9	O	-
microg/kg/día	O	-
de	O	-
denileucina	O	-
intravenosa	O	-
o	O	-
18	O	-
microg/kg/día	O	-
durante	O	-
15-60	O	-
minutos	O	-
durante	O	-
5	O	-
días	O	-
consecutivos	O	-
ambulatoriamente	O	-
;	O	-
se	O	-
planificaron	O	-
ciclos	O	-
cada	O	-
21	O	-
días	O	-
para	O	-
un	O	-
total	O	-
de	O	-
8	O	-
ciclos	O	-
durante	O	-
6	O	-
meses.	O	-

Antes	O	-
de	O	-
cada	O	-
ciclo	O	-
de	O	-
tratamiento,	O	-
los	O	-
pacientes	O	-
fueron	O	-
evaluados	O	-
para	O	-
la	O	-
respuesta	O	-
a	O	-
la	O	-
enfermedad	O	-
y	O	-
se	O	-
les	O	-
pidió	O	-
que	O	-
autocalificaran	O	-
su	O	-
CV	O	-
global	O	-
a	O	-
través	O	-
del	O	-
cuestionario	O	-
de	O	-
Evaluación	O	-
Funcional	O	-
de	O	-
la	O	-
Terapia	O	-
del	O	-
Cáncer-General	O	-
(	O	-
FACT-G	O	-
),	O	-
la	O	-
apariencia	O	-
de	O	-
la	O	-
piel	O	-
(	O	-
escala	O	-
de	O	-
7	O	-
puntos	O	-
)	O	-
y	O	-
la	O	-
severidad	O	-
del	O	-
prurito	O	-
(	O	-
escala	O	-
analógica	O	-
visual	O	-
de	O	-
10	O	-
cm	O	-
).	O	-

El	B-Premise	HighQuality
FACT-G	I-Premise	HighQuality
compuesto	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
mayoría	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
puntajes	I-Premise	HighQuality
de	I-Premise	HighQuality
subescala	I-Premise	HighQuality
individuales	I-Premise	HighQuality
(fisico,	I-Premise	HighQuality
social/familia,	I-Premise	HighQuality
emocional	I-Premise	HighQuality
y	I-Premise	HighQuality
funcional	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
respondedores	I-Premise	HighQuality
documentados	I-Premise	HighQuality
(	I-Premise	HighQuality
n	I-Premise	HighQuality
=	I-Premise	HighQuality
21	I-Premise	HighQuality
)	I-Premise	HighQuality
aumentaron	I-Premise	HighQuality
gradualmente	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
período	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio,	I-Premise	HighQuality
alcanzando	I-Premise	HighQuality
generalmente	I-Premise	HighQuality
significación	I-Premise	HighQuality
estadística	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
por	I-Premise	HighQuality
ciclo	I-Premise	HighQuality
3,	I-Premise	HighQuality
y	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
o	I-Premise	HighQuality
=	I-Premise	HighQuality
0,041	I-Premise	HighQuality
)	I-Premise	HighQuality
más	I-Premise	HighQuality
altos	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
puntajes	I-Premise	HighQuality
de	I-Premise	HighQuality
no	I-Premise	HighQuality
respondedores	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
punto	I-Premise	HighQuality
final.	I-Premise	HighQuality

Además	B-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
respondedores,	I-Premise	HighQuality
las	I-Premise	HighQuality
evaluaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
severidad	I-Premise	HighQuality
cutánea	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
severidad	I-Premise	HighQuality
del	I-Premise	HighQuality
prurito	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
mejoras	I-Premise	HighQuality
significativas	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
o	I-Premise	HighQuality
=	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
variable	I-Premise	HighQuality
de	I-Premise	HighQuality
valoración	I-Premise	HighQuality
del	I-Premise	HighQuality
estudio	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
basal.	I-Premise	HighQuality

Los	B-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
transfusión	I-Premise	HighQuality
(	I-Premise	HighQuality
por	I-Premise	HighQuality
ejemplo,	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
de	I-Premise	HighQuality
hipersensibilidad,	I-Premise	HighQuality
síndrome	I-Premise	HighQuality
pseudogripal	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
durante	I-Premise	HighQuality
los	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
1	I-Premise	HighQuality
y	I-Premise	HighQuality
2,	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
síndrome	I-Premise	HighQuality
de	I-Premise	HighQuality
fuga	I-Premise	HighQuality
vascular	I-Premise	HighQuality
se	I-Premise	HighQuality
produjo	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
25%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes.	I-Premise	HighQuality

La	B-Claim	HighQuality
denileucina	I-Claim	HighQuality
diftitox	I-Claim	HighQuality
no	I-Claim	HighQuality
se	I-Claim	HighQuality
asoció	I-Claim	HighQuality
con	I-Claim	HighQuality
ninguna	I-Claim	HighQuality
mielosupresión	I-Claim	HighQuality
clínicamente	I-Claim	HighQuality
significativa.	I-Claim	HighQuality

Los	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
fuertemente	I-Claim	HighQuality
pretratados	I-Claim	HighQuality
con	I-Claim	HighQuality
LTC	I-Claim	HighQuality
avanzado	I-Claim	HighQuality
y/o	I-Claim	HighQuality
recidivante	I-Claim	HighQuality
que	I-Claim	HighQuality
respondieron	I-Claim	HighQuality
al	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
diftitox	I-Claim	HighQuality
de	I-Claim	HighQuality
denileucina	I-Claim	HighQuality
mostraron	I-Claim	HighQuality
mejoras	I-Claim	HighQuality
significativas	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
CV	I-Claim	HighQuality
global	I-Claim	HighQuality
auto-calificada,	I-Claim	HighQuality
la	I-Claim	HighQuality
apariencia	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
piel,	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
gravedad	I-Claim	HighQuality
del	I-Claim	HighQuality
prurito.	I-Claim	HighQuality

El	O	-
efecto	O	-
reductor	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
de	O	-
la	O	-
leche	O	-
fermentada	O	-
con	O	-
Lactococcus	O	-
lactis	O	-
NRRL	O	-
B-50571	O	-
se	O	-
evaluó	O	-
en	O	-
un	O	-
ensayo	O	-
clínico	O	-
controlado	O	-
aleatorizado	O	-
doble	O	-
ciego	O	-
con	O	-
sujetos	O	-
prehipertensivos.	O	-

Los	O	-
participantes	O	-
fueron	O	-
aleatorizados	O	-
en	O	-
2	O	-
grupos	O	-
(	O	-
n	O	-
=	O	-
18	O	-
cada	O	-
grupo	O	-
)	O	-
:	O	-
un	O	-
grupo	O	-
tratado	O	-
con	O	-
leche	O	-
fermentada	O	-
con	O	-
Lactococcus	O	-
lactis	O	-
NRRL	O	-
B-50571	O	-
y	O	-
un	O	-
grupo	O	-
control	O	-
tratado	O	-
con	O	-
leche	O	-
artificialmente	O	-
acidificada.	O	-

Los	B-Premise	HighQuality
resultados	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
consumo	I-Premise	HighQuality
diario	I-Premise	HighQuality
de	I-Premise	HighQuality
leche	I-Premise	HighQuality
fermentada	I-Premise	HighQuality
para	I-Premise	HighQuality
5	I-Premise	HighQuality
wk,	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
[	I-Premise	HighQuality
(	I-Premise	HighQuality
116,55	I-Premise	HighQuality
±	I-Premise	HighQuality
12,26	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
vs.	I-Premise	HighQuality
124,77	I-Premise	HighQuality
±	I-Premise	HighQuality
11,04	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
diastólica	I-Premise	HighQuality
(	I-Premise	HighQuality
80,7	I-Premise	HighQuality
±	I-Premise	HighQuality
9	I-Premise	HighQuality
vs.	I-Premise	HighQuality
84,5	I-Premise	HighQuality
±	I-Premise	HighQuality
8,5	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
)	I-Premise	HighQuality
]	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
lácteo	I-Premise	HighQuality
fermentado	I-Premise	HighQuality
fue	I-Premise	HighQuality
menor	I-Premise	HighQuality
que	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
control.	I-Premise	HighQuality

Además,	B-Premise	HighQuality
los	I-Premise	HighQuality
triglicéridos,	I-Premise	HighQuality
el	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
total,	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
lipoproteína	I-Premise	HighQuality
de	I-Premise	HighQuality
baja	I-Premise	HighQuality
densidad	I-Premise	HighQuality
en	I-Premise	HighQuality
suero	I-Premise	HighQuality
sanguíneo	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
bajos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
leche	I-Premise	HighQuality
fermentada	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
demostraron	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
consumo	I-Claim	HighQuality
diario	I-Claim	HighQuality
de	I-Claim	HighQuality
leche	I-Claim	HighQuality
fermentada	I-Claim	HighQuality
con	I-Claim	HighQuality
Lactococcus	I-Claim	HighQuality
lactis	I-Claim	HighQuality
(	I-Claim	HighQuality
NRRL	I-Claim	HighQuality
B-50571	I-Claim	HighQuality
)	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
un	I-Claim	HighQuality
efecto	I-Claim	HighQuality
reductor	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
en	I-Claim	HighQuality
sujetos	I-Claim	HighQuality
prehipertensivos.	I-Claim	HighQuality

El	B-Claim	HighQuality
consumo	I-Claim	HighQuality
regular	I-Claim	HighQuality
de	I-Claim	HighQuality
este	I-Claim	HighQuality
producto	I-Claim	HighQuality
puede	I-Claim	HighQuality
utilizarse	I-Claim	HighQuality
como	I-Claim	HighQuality
alimento	I-Claim	HighQuality
funcional	I-Claim	HighQuality
potencial.	I-Claim	HighQuality

Las	O	-
interrupciones	O	-
del	O	-
tratamiento	O	-
antirretroviral	O	-
aumentan	O	-
el	O	-
riesgo	O	-
de	O	-
morbilidad/mortalidad	O	-
grave	O	-
en	O	-
individuos	O	-
infectados	O	-
por	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
inmunodeficiencia	O	-
humana	O	-
(VIH)	O	-
procedentes	O	-
del	O	-
África	O	-
subsahariana.	O	-

Nuestro	O	-
objetivo	O	-
era	O	-
determinar	O	-
si	O	-
el	O	-
riesgo	O	-
aumenta	O	-
aún	O	-
más	O	-
entre	O	-
los	O	-
pacientes	O	-
coinfectados	O	-
con	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB	O	-
)	O	-
en	O	-
este	O	-
entorno.	O	-

En	O	-
este	O	-
subanálisis	O	-
de	O	-
un	O	-
ensayo	O	-
de	O	-
control	O	-
aleatorio,	O	-
se	O	-
analizaron	O	-
632	O	-
participantes	O	-
de	O	-
Côte	O	-
d'Ivoire	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
ART	O	-
continuo	O	-
(	O	-
ART-C	O	-
),	O	-
interrupciones	O	-
de	O	-
ART	O	-
estructuradas	O	-
de	O	-
2	O	-
meses	O	-
de	O	-
descanso,	O	-
4	O	-
meses	O	-
de	O	-
descanso	O	-
(	O	-
2/4-ART	O	-
),	O	-
e	O	-
interrupciones	O	-
de	O	-
ART	O	-
guiadas	O	-
por	O	-
CD4	O	-
(	O	-
CD4GT,	O	-
interrupción	O	-
a	O	-
350/mm3	O	-
y	O	-
reintroducción	O	-
a	O	-
250/mm3	O	-
).	O	-

Se	O	-
compararon	O	-
las	O	-
tasas	O	-
de	O	-
incidencia	O	-
(IR	O	-
)	O	-
de	O	-
morbilidad	O	-
grave	O	-
relacionada	O	-
con	O	-
el	O	-
VIH	O	-
y	O	-
no	O	-
relacionada	O	-
con	O	-
el	O	-
VIH	O	-
entre	O	-
los	O	-
pacientes	O	-
estratificados	O	-
con	O	-
el	O	-
antígeno	O	-
de	O	-
superficie	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(	O	-
HBsAg	O	-
).	O	-

En	O	-
total,	O	-
65	O	-
(	O	-
10,3%)	O	-
fueron	O	-
HBsAg	O	-
positivos,	O	-
29	O	-
(	O	-
44,6%)	O	-
de	O	-
los	O	-
cuales	O	-
tenían	O	-
niveles	O	-
de	O	-
HBV-DNA	O	-
>	O	-
10.000	O	-
copias/ml.	O	-

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
una	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
2,0	I-Premise	HighQuality
años	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
=	I-Premise	HighQuality
0,2-3,1	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento,	I-Premise	HighQuality
se	I-Premise	HighQuality
produjeron	I-Premise	HighQuality
≥	I-Premise	HighQuality
1	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
graves	I-Premise	HighQuality
relacionados	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
VIH	I-Premise	HighQuality
en	I-Premise	HighQuality
101	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
monoinfectados	I-Premise	HighQuality
con	I-Premise	HighQuality
VIH	I-Premise	HighQuality
y	I-Premise	HighQuality
15	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
coinfectados	I-Premise	HighQuality
con	I-Premise	HighQuality
VIH-VHB	I-Premise	HighQuality
(	I-Premise	HighQuality
IR	I-Premise	HighQuality
=	I-Premise	HighQuality
10,0	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
13,2/100	I-Premise	HighQuality
persona/año,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,3	I-Premise	HighQuality
),	I-Premise	HighQuality
mientras	O	-
que	O	-
se	O	-
observó	O	-
la	O	-
mayor	O	-
incidencia	O	-
en	O	-
pacientes	O	-
coinfectados	O	-
con	O	-
replicación	O	-
basal	O	-
del	O	-
VHB	O	-
>	O	-
10.000	O	-
copias/ml	O	-
(	O	-
IR	O	-
=	O	-
24,0/100	O	-
persona/año,	O	-
P	O	-
frente	O	-
a	O	-
VIH	O	-
monoinfectado	O	-
=	O	-
0,002	O	-
).	O	-

La	B-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
infecciones	I-Premise	HighQuality
bacterianas	I-Premise	HighQuality
también	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
coinfectado	I-Premise	HighQuality
con	I-Premise	HighQuality
replicación	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
>	I-Premise	HighQuality
10.000	I-Premise	HighQuality
copias/ml	I-Premise	HighQuality
(IR	I-Premise	HighQuality
=	I-Premise	HighQuality
12,9	I-Premise	HighQuality
versus	I-Premise	HighQuality
3,3/100	I-Premise	HighQuality
persona/año	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
monoinfectados	I-Premise	HighQuality
con	I-Premise	HighQuality
VIH,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
efecto	I-Premise	HighQuality
relativo	I-Premise	HighQuality
de	I-Premise	HighQuality
CD4GT	I-Premise	HighQuality
o	I-Premise	HighQuality
2/4-ART	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
C-ART	I-Premise	HighQuality
no	I-Premise	HighQuality
fue	I-Premise	HighQuality
diferente	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
infección	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
para	I-Premise	HighQuality
interacción	I-Premise	HighQuality
=	I-Premise	HighQuality
0,4	I-Premise	HighQuality
).	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
aumento	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
morbilidad	I-Premise	HighQuality
no	I-Premise	HighQuality
relacionada	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
VIH	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
coinfectados	I-Premise	HighQuality
(P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,5	I-Premise	HighQuality
),	I-Premise	HighQuality
ni	I-Premise	HighQuality
siquiera	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
replicación	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
>	I-Premise	HighQuality
10.000	I-Premise	HighQuality
copias/ml	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,7	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Claim	HighQuality
conclusión,	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
coinfectados	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
elevada	I-Claim	HighQuality
replicación	I-Claim	HighQuality
del	I-Claim	HighQuality
VHB	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
iniciación	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
antirretroviral	I-Claim	HighQuality
son	I-Claim	HighQuality
más	I-Claim	HighQuality
susceptibles	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
morbilidad	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
VIH,	I-Claim	HighQuality
especialmente	I-Claim	HighQuality
las	I-Claim	HighQuality
enfermedades	I-Claim	HighQuality
bacterianas	I-Claim	HighQuality
invasivas,	I-Claim	HighQuality
durante	I-Claim	HighQuality
la	I-Claim	HighQuality
interrupción	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento.	I-Claim	HighQuality

La	O	-
reactivación	O	-
del	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
infección	O	-
resuelta	O	-
por	O	-
el	O	-
VHB	O	-
(	O	-
HBsAg	O	-
negativo,	O	-
antiHBc	O	-
positivo	O	-
)	O	-
es	O	-
poco	O	-
frecuente,	O	-
pero	O	-
potencialmente	O	-
mortal.	O	-

El	O	-
papel	O	-
de	O	-
la	O	-
profilaxis	O	-
del	O	-
VHB	O	-
en	O	-
este	O	-
entorno	O	-
es	O	-
incierto.	O	-

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
comparar	O	-
la	O	-
eficacia	O	-
de	O	-
la	O	-
profilaxis	O	-
de	O	-
tenofovir	O	-
disoproxil	O	-
fumarato	O	-
(	O	-
TDF	O	-
)	O	-
frente	O	-
a	O	-
una	O	-
estrecha	O	-
monitorización	O	-
en	O	-
pacientes	O	-
anti-HBc	O	-
positivos,	O	-
HBsAg	O	-
negativos	O	-
bajo	O	-
tratamiento	O	-
con	O	-
regímenes	O	-
basados	O	-
en	O	-
rituximab	O	-
(	O	-
RTX	O	-
)	O	-
para	O	-
la	O	-
neoplasia	O	-
hematológica.	O	-

PREBLIN	O	-
es	O	-
un	O	-
ensayo	O	-
de	O	-
fase	O	-
IV,	O	-
aleatorizado,	O	-
prospectivo,	O	-
abierto,	O	-
multicéntrico,	O	-
en	O	-
grupos	O	-
paralelos	O	-
realizado	O	-
en	O	-
17	O	-
hospitales	O	-
de	O	-
toda	O	-
España.	O	-

Los	O	-
pacientes	O	-
anti-HBc	O	-
positivos,	O	-
HBsAg	O	-
negativos	O	-
con	O	-
ADN	O	-
indetectable	O	-
del	O	-
VHB	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
300	O	-
mg	O	-
de	O	-
TDF	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
(	O	-
Grupo	O	-
I	O	-
)	O	-
u	O	-
observación	O	-
(	O	-
Grupo	O	-
II	O	-
).	O	-

La	O	-
variable	O	-
principal	O	-
de	O	-
valoración	O	-
fue	O	-
el	O	-
porcentaje	O	-
de	O	-
pacientes	O	-
que	O	-
mostraron	O	-
reactivación	O	-
del	O	-
VHB	O	-
durante	O	-
los	O	-
18	O	-
meses	O	-
siguientes	O	-
al	O	-
inicio	O	-
del	O	-
tratamiento	O	-
con	O	-
RTX.	O	-

Los	O	-
pacientes	O	-
con	O	-
ADN	O	-
HBV	O	-
detectable	O	-
(	O	-
Grupo	O	-
III	O	-
)	O	-
recibieron	O	-
la	O	-
misma	O	-
dosis	O	-
de	O	-
TDF	O	-
y	O	-
fueron	O	-
analizados	O	-
junto	O	-
con	O	-
el	O	-
Grupo	O	-
I	O	-
para	O	-
investigar	O	-
la	O	-
seguridad	O	-
de	O	-
TDF.	O	-

Se	O	-
incluyeron	O	-
61	O	-
pacientes	O	-
en	O	-
el	O	-
estudio,	O	-
33	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
tratamiento	O	-
con	O	-
TDF	O	-
y	O	-
28	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
observación.	O	-

Mediante	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
ITT,	I-Premise	HighQuality
la	I-Premise	HighQuality
reactivación	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
0	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
0/33	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
10,7%	I-Premise	HighQuality
(	I-Premise	HighQuality
3/28	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
observación	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,091	I-Premise	HighQuality
).	I-Premise	HighQuality

Ninguno	B-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
de	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
mostró	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
significativas	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
parámetros	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
función	I-Premise	HighQuality
hepática	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
muestra	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento.	I-Premise	HighQuality

El	B-Claim	HighQuality
TDF	I-Claim	HighQuality
fue	I-Claim	HighQuality
generalmente	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerado	I-Claim	HighQuality
y	I-Claim	HighQuality
no	I-Claim	HighQuality
hubo	I-Claim	HighQuality
efectos	I-Claim	HighQuality
adversos	I-Claim	HighQuality
graves	I-Claim	HighQuality
relacionados	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento.	I-Claim	HighQuality

En	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
malignidad	I-Claim	HighQuality
hematológica	I-Claim	HighQuality
e	I-Claim	HighQuality
infección	I-Claim	HighQuality
por	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
resuelta	I-Claim	HighQuality
que	I-Claim	HighQuality
recibieron	I-Claim	HighQuality
regímenes	I-Claim	HighQuality
basados	I-Claim	HighQuality
en	I-Claim	HighQuality
RTX,	I-Claim	HighQuality
la	I-Claim	HighQuality
reactivación	I-Claim	HighQuality
del	I-Claim	HighQuality
VHB	I-Claim	HighQuality
no	I-Claim	HighQuality
se	I-Claim	HighQuality
produjo	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
profilaxis	I-Claim	HighQuality
de	I-Claim	HighQuality
TDF.	I-Claim	HighQuality

El	O	-
manejo	O	-
crónico	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
está	O	-
comúnmente	O	-
dirigido	O	-
a	O	-
reducir	O	-
la	O	-
replicación	O	-
viral.	O	-

Sin	O	-
embargo,	O	-
las	O	-
terapias	O	-
antivirales	O	-
actualmente	O	-
disponibles	O	-
están	O	-
asociadas	O	-
con	O	-
algunos	O	-
problemas,	O	-
incluyendo	O	-
resistencia	O	-
y	O	-
numerosos	O	-
efectos	O	-
adversos.	O	-

Se	O	-
ha	O	-
informado	O	-
de	O	-
que	O	-
el	O	-
ginseng	O	-
es	O	-
eficaz	O	-
para	O	-
tratar	O	-
infecciones	O	-
virales	O	-
como	O	-
la	O	-
gripe	O	-
y	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
inmunodeficiencia	O	-
humana.	O	-

Sin	O	-
embargo,	O	-
actualmente	O	-
hay	O	-
pocos	O	-
estudios	O	-
sobre	O	-
los	O	-
efectos	O	-
del	O	-
ginseng	O	-
en	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica.	O	-

Así,	O	-
este	O	-
estudio	O	-
investigó	O	-
los	O	-
efectos	O	-
del	O	-
ginseng	O	-
junto	O	-
con	O	-
agentes	O	-
antivirales	O	-
en	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica.	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
estudio	O	-
prospectivo,	O	-
un	O	-
solo	O	-
ciego,	O	-
aleatorizado	O	-
controlado,	O	-
y	O	-
un	O	-
solo	O	-
centro.	O	-

Se	O	-
incluyeron	O	-
38	O	-
pacientes.	O	-

El	O	-
grupo	O	-
control	O	-
(	O	-
n	O	-
=	O	-
19	O	-
)	O	-
se	O	-
administró	O	-
solo	O	-
agentes	O	-
antivirales.	O	-

El	O	-
grupo	O	-
experimental	O	-
(	O	-
n	O	-
=	O	-
19	O	-
)	O	-
se	O	-
administró	O	-
antivirales	O	-
junto	O	-
con	O	-
cápsulas	O	-
de	O	-
polvo	O	-
de	O	-
Ginseng	O	-
Rojo	O	-
Coreano	O	-
(cada	O	-
dosis	O	-
es	O	-
de	O	-
1	O	-
gramo	O	-
(	O	-
dos	O	-
cápsulas	O	-
),	O	-
una	O	-
dosis	O	-
de	O	-
un	O	-
día	O	-
es	O	-
de	O	-
3	O	-
gramos	O	-
).	O	-

Las	O	-
características	O	-
basales	O	-
no	O	-
difirieron	O	-
entre	O	-
los	O	-
dos	O	-
grupos.	O	-

Se	B-Premise	HighQuality
compararon	I-Premise	HighQuality
las	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
varios	I-Premise	HighQuality
marcadores	I-Premise	HighQuality
serológicos	I-Premise	HighQuality
de	I-Premise	HighQuality
fibrosis	I-Premise	HighQuality
no	I-Premise	HighQuality
invasiva	I-Premise	HighQuality
(	I-Premise	HighQuality
colágeno	I-Premise	HighQuality
tipo	I-Premise	HighQuality
IV,	I-Premise	HighQuality
ácido	I-Premise	HighQuality
hialurónico,	I-Premise	HighQuality
factor	I-Premise	HighQuality
de	I-Premise	HighQuality
crecimiento	I-Premise	HighQuality
transformador-β	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
virus	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

Los	B-Premise	HighQuality
marcadores	I-Premise	HighQuality
serológicos	I-Premise	HighQuality
de	I-Premise	HighQuality
fibrosis	I-Premise	HighQuality
no	I-Premise	HighQuality
invasiva	I-Premise	HighQuality
se	I-Premise	HighQuality
redujeron	I-Premise	HighQuality
aún	I-Premise	HighQuality
más	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
experimental,	I-Premise	HighQuality
con	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
significativas	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
observado	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
ácido	I-Premise	HighQuality
hialurónico	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,032	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
factor	I-Premise	HighQuality
de	I-Premise	HighQuality
crecimiento	I-Premise	HighQuality
transformador-β	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,008	I-Premise	HighQuality
),	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
colágeno	I-Premise	HighQuality
de	I-Premise	HighQuality
tipo	I-Premise	HighQuality
IV	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,174	I-Premise	HighQuality
).	I-Premise	HighQuality

Este	B-Claim	HighQuality
estudio	I-Claim	HighQuality
sugiere	I-Claim	HighQuality
la	I-Claim	HighQuality
posibilidad	I-Claim	HighQuality
de	I-Claim	HighQuality
ginseng	I-Claim	HighQuality
rojo	I-Claim	HighQuality
coreano	I-Claim	HighQuality
como	I-Claim	HighQuality
terapia	I-Claim	HighQuality
complementaria	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica.	I-Claim	HighQuality

Para	O	-
evaluar	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
-reducción	O	-
de	O	-
la	O	-
eficacia	O	-
y	O	-
seguridad	O	-
de	O	-
la	O	-
brimonidina	O	-
de	O	-
combinación	O	-
fija	O	-
0,2	O	-
%	O	-
-timolol	O	-
0,5	O	-
%	O	-
en	O	-
comparación	O	-
con	O	-
latanoprost	O	-
0,005	O	-
%	O	-
en	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
o	O	-
hipertensión	O	-
ocular.	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
ensayo	O	-
clínico	O	-
prospectivo,	O	-
aleatorizado,	O	-
multicéntrico,	O	-
enmascarado	O	-
por	O	-
investigador.	O	-

Después	O	-
del	O	-
lavado	O	-
de	O	-
cualquier	O	-
medicamento	O	-
previo	O	-
que	O	-
redujera	O	-
la	O	-
PIO,	O	-
los	O	-
pacientes	O	-
con	O	-
PIO	O	-
de	O	-
24	O	-
mmHg	O	-
o	O	-
superior	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
brimonidina	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
de	O	-
combinación	O	-
fija	O	-
0,2	O	-
%	O	-
-timolol	O	-
0,5%	O	-
(	O	-
n	O	-
=	O	-
73	O	-
)	O	-
o	O	-
latanoprost	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
0,005	O	-
%	O	-
(	O	-
n	O	-
=	O	-
75,	O	-
dosificado	O	-
por	O	-
la	O	-
noche,	O	-
con	O	-
control	O	-
del	O	-
vehículo	O	-
por	O	-
la	O	-
mañana	O	-
para	O	-
mantener	O	-
el	O	-
enmascaramiento	O	-
)	O	-
durante	O	-
12	O	-
semanas.	O	-

La	O	-
PIO	O	-
se	O	-
midió	O	-
a	O	-
las	O	-
8	O	-
a.m.	O	-
(	O	-
antes	O	-
de	O	-
la	O	-
administración	O	-
),	O	-
a	O	-
las	O	-
10	O	-
a.m.	O	-
y	O	-
a	O	-
las	O	-
3	O	-
p.m.	O	-
al	O	-
inicio,	O	-
a	O	-
la	O	-
semana	O	-
6	O	-
y	O	-
a	O	-
la	O	-
semana	O	-
12.	O	-

El	O	-
criterio	O	-
principal	O	-
de	O	-
valoración	O	-
de	O	-
la	O	-
eficacia	O	-
fue	O	-
la	O	-
PIO	O	-
diurna	O	-
(promedió	O	-
más	O	-
de	O	-
8	O	-
a.m.,	O	-
10	O	-
a.m.	O	-
y	O	-
3	O	-
p.m.)	O	-
en	O	-
la	O	-
semana	O	-
12.	O	-

Las	O	-
medidas	O	-
de	O	-
seguridad	O	-
incluyeron	O	-
la	O	-
biomicroscopía.	O	-

No	O	-
hubo	O	-
diferencia	O	-
estadísticamente	O	-
significativa	O	-
entre	O	-
los	O	-
grupos	O	-
de	O	-
tratamiento	O	-
en	O	-
la	O	-
PIO	O	-
diurna	O	-
media	O	-
al	O	-
inicio	O	-
(	O	-
p	O	-
=	O	-
0,118	O	-
).	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
12,	I-Premise	HighQuality
la	I-Premise	HighQuality
media	I-Premise	HighQuality
(	I-Premise	HighQuality
DE	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
diurna	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
17,8	I-Premise	HighQuality
(	I-Premise	HighQuality
2,9	I-Premise	HighQuality
)	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
con	I-Premise	HighQuality
brimonidina-timolol	I-Premise	HighQuality
y	I-Premise	HighQuality
17,9	I-Premise	HighQuality
(	I-Premise	HighQuality
3,9	I-Premise	HighQuality
)	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
con	I-Premise	HighQuality
latanoprost	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,794	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
porcentaje	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
alcanzaron	I-Premise	HighQuality
al	I-Premise	HighQuality
menos	I-Premise	HighQuality
una	I-Premise	HighQuality
disminución	I-Premise	HighQuality
del	I-Premise	HighQuality
20	I-Premise	HighQuality
%	I-Premise	HighQuality
con	I-Premise	HighQuality
respecto	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
diurna	I-Premise	HighQuality
basal	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
12	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
87,7%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
brimonidina-timolol	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
77,3%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
latanoprost	I-Premise	HighQuality
(p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,131	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
biomicroscópicos	I-Premise	HighQuality
medidos	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
hasta	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
12	I-Premise	HighQuality
fueron	I-Premise	HighQuality
poco	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

La	B-Claim	HighQuality
combinación	I-Claim	HighQuality
fija	I-Claim	HighQuality
de	I-Claim	HighQuality
brimonidina-timolol	I-Claim	HighQuality
fue	I-Claim	HighQuality
tan	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
como	I-Claim	HighQuality
latanoprost	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
glaucoma	I-Claim	HighQuality
o	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
ocular.	I-Claim	HighQuality

Ambos	B-Claim	HighQuality
tratamientos	I-Claim	HighQuality
demostraron	I-Claim	HighQuality
tolerancia	I-Claim	HighQuality
ocular	I-Claim	HighQuality
favorable.	I-Claim	HighQuality

La	O	-
duración	O	-
del	O	-
estudio	O	-
fue	O	-
de	O	-
12	O	-
semanas	O	-
y	O	-
se	O	-
necesitarán	O	-
estudios	O	-
adicionales	O	-
para	O	-
comparar	O	-
la	O	-
eficacia	O	-
y	O	-
seguridad	O	-
de	O	-
la	O	-
brimonidina-timolol	O	-
de	O	-
combinación	O	-
fija	O	-
y	O	-
latanoprost	O	-
durante	O	-
el	O	-
tratamiento	O	-
a	O	-
largo	O	-
plazo.	O	-

Se	O	-
compararon	O	-
los	O	-
efectos	O	-
clínicos	O	-
y	O	-
el	O	-
impacto	O	-
en	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(	O	-
CV	O	-
)	O	-
de	O	-
los	O	-
pacientes	O	-
que	O	-
recibieron	O	-
un	O	-
ciclo	O	-
de	O	-
3	O	-
meses	O	-
de	O	-
flutamida	O	-
en	O	-
monoterapia	O	-
antes	O	-
de	O	-
la	O	-
prostatectomía	O	-
radical	O	-
con	O	-
aquellos	O	-
que	O	-
recibieron	O	-
un	O	-
ciclo	O	-
de	O	-
3	O	-
meses	O	-
de	O	-
hormona	O	-
liberadora	O	-
de	O	-
hormonas	O	-
luteinizantes	O	-
(	O	-
LHRH	O	-
)	O	-
en	O	-
monoterapia.	O	-

En	O	-
este	O	-
estudio	O	-
se	O	-
incluyeron	O	-
37	O	-
pacientes	O	-
con	O	-
cáncer	O	-
de	O	-
próstata	O	-
no	O	-
metastásico	O	-
(	O	-
19,	O	-
flutamida	O	-
;	O	-
18,	O	-
agonista	O	-
de	O	-
LHRH	O	-
).	O	-

Se	O	-
analizaron	O	-
las	O	-
tasas	O	-
de	O	-
cambio	O	-
de	O	-
los	O	-
niveles	O	-
séricos	O	-
de	O	-
antígeno	O	-
prostático	O	-
específico	O	-
(	O	-
PSA	O	-
)	O	-
y	O	-
testosterona,	O	-
la	O	-
reducción	O	-
del	O	-
volumen	O	-
de	O	-
próstata,	O	-
la	O	-
tasa	O	-
de	O	-
enfermedad	O	-
confinada	O	-
de	O	-
órganos,	O	-
los	O	-
efectos	O	-
adversos	O	-
y	O	-
las	O	-
puntuaciones	O	-
perioperatorias	O	-
medidos	O	-
utilizando	O	-
el	O	-
Cuestionario	O	-
de	O	-
Calidad	O	-
de	O	-
Vida	O	-
del	O	-
Cáncer	O	-
de	O	-
Próstata	O	-
de	O	-
la	O	-
Organización	O	-
Europea	O	-
para	O	-
la	O	-
Investigación	O	-
y	O	-
el	O	-
Tratamiento	O	-
del	O	-
Cáncer	O	-
de	O	-
Próstata	O	-
(	O	-
EORTC-P	O	-
)	O	-
y	O	-
el	O	-
Cuestionario	O	-
de	O	-
Función	O	-
Sexual	O	-
de	O	-
la	O	-
Universidad	O	-
Médica	O	-
Sapporo	O	-
(	O	-
SMUF	O	-
).	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
prostatectomía	I-Premise	HighQuality
radical,	I-Premise	HighQuality
las	I-Premise	HighQuality
variables	I-Premise	HighQuality
patológicas	I-Premise	HighQuality
no	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
diferentes	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

El	B-Premise	HighQuality
nivel	I-Premise	HighQuality
sérico	I-Premise	HighQuality
de	I-Premise	HighQuality
testosterona	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
(media	I-Premise	HighQuality
359,2	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
10,5,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
la	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
completa	I-Premise	HighQuality
de	I-Premise	HighQuality
PSA	I-Premise	HighQuality
(	I-Premise	HighQuality
13	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
57	I-Premise	HighQuality
%,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,028	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
volumen	I-Premise	HighQuality
de	I-Premise	HighQuality
próstata	I-Premise	HighQuality
(	I-Premise	HighQuality
media,	I-Premise	HighQuality
-17,7	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
-35,4	I-Premise	HighQuality
%,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,038	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
más	I-Premise	HighQuality
bajas	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
flutamida	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
LHRH.	I-Premise	HighQuality

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
terapia	I-Premise	HighQuality
hormonal	I-Premise	HighQuality
neoadyuvante,	I-Premise	HighQuality
las	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
dominio	I-Premise	HighQuality
del	I-Premise	HighQuality
problema	I-Premise	HighQuality
sexual	I-Premise	HighQuality
de	I-Premise	HighQuality
EORTC-P	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,033	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
del	I-Premise	HighQuality
deseo	I-Premise	HighQuality
sexual	I-Premise	HighQuality
de	I-Premise	HighQuality
SMUF	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,021	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
más	I-Premise	HighQuality
altas	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
flutamida	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
LHRH.	I-Premise	HighQuality

A	B-Premise	HighQuality
una	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
de	I-Premise	HighQuality
34	I-Premise	HighQuality
meses	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
prostatectomía,	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre	I-Premise	HighQuality
de	I-Premise	HighQuality
fracasos	I-Premise	HighQuality
bioquímicos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
flutamida	I-Premise	HighQuality
no	I-Premise	HighQuality
difirió	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
LHRH.	I-Premise	HighQuality

Este	B-Claim	HighQuality
estudio	I-Claim	HighQuality
sugiere	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
flutamida	I-Claim	HighQuality
puede	I-Claim	HighQuality
ser	I-Claim	HighQuality
una	I-Claim	HighQuality
modalidad	I-Claim	HighQuality
aceptable	I-Claim	HighQuality
como	I-Claim	HighQuality
opción	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
terapia	I-Claim	HighQuality
hormonal	I-Claim	HighQuality
neoadyuvante.	I-Claim	HighQuality

Cada	O	-
vez	O	-
más	O	-
evidencia	O	-
sugiere	O	-
que	O	-
los	B-Claim	HighQuality
micronutrientes	I-Claim	HighQuality
múltiples	I-Claim	HighQuality
que	I-Claim	HighQuality
contienen	I-Claim	HighQuality
hierro	I-Claim	HighQuality
pueden	I-Claim	HighQuality
reducir	I-Claim	HighQuality
el	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
inducida	I-Claim	HighQuality
por	I-Claim	HighQuality
el	I-Claim	HighQuality
embarazo,	I-Claim	HighQuality
incluyendo	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
gestacional	I-Claim	HighQuality
o	I-Claim	HighQuality
preeclampsia.	I-Claim	HighQuality

Se	O	-
buscó	O	-
examinar	O	-
si	O	-
30	O	-
mg	O	-
de	O	-
hierro	O	-
más	O	-
ácido	O	-
fólico	O	-
o	O	-
múltiples	O	-
micronutrientes	O	-
durante	O	-
el	O	-
embarazo	O	-
reducen	O	-
el	O	-
riesgo	O	-
de	O	-
hipertensión	O	-
inducida	O	-
por	O	-
el	O	-
embarazo.	O	-

Se	O	-
realizó	O	-
un	O	-
análisis	O	-
secundario	O	-
de	O	-
datos	O	-
por	O	-
el	O	-
conjunto	O	-
de	O	-
datos	O	-
de	O	-
un	O	-
ensayo	O	-
controlado	O	-
aleatorizado	O	-
doble	O	-
ciego	O	-
en	O	-
China	O	-
de	O	-
2006	O	-
a	O	-
2009	O	-
que	O	-
se	O	-
llevó	O	-
a	O	-
cabo	O	-
para	O	-
investigar	O	-
los	O	-
efectos	O	-
de	O	-
suplementos	O	-
de	O	-
micronutrientes	O	-
múltiples	O	-
en	O	-
los	O	-
resultados	O	-
adversos	O	-
del	O	-
embarazo	O	-
cuando	O	-
se	O	-
proporcionó	O	-
a	O	-
mujeres	O	-
embarazadas	O	-
sin	O	-
anemia	O	-
leve.	O	-

Utilizamos	O	-
regresión	O	-
logística	O	-
para	O	-
estimar	O	-
la	O	-
odds	O	-
ratio	O	-
ajustada	O	-
y	O	-
el	O	-
intervalo	O	-
de	O	-
confianza	O	-
del	O	-
95	O	-
%	O	-
y	O	-
la	O	-
prueba	O	-
para	O	-
la	O	-
modificación	O	-
del	O	-
efecto.	O	-

La	B-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
hipertensión	I-Premise	HighQuality
inducida	I-Premise	HighQuality
por	I-Premise	HighQuality
el	I-Premise	HighQuality
embarazo	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
7,1	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
423/5923	I-Premise	HighQuality
),	I-Premise	HighQuality
6,3	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
374/5933	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
6,3	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
372/5914	I-Premise	HighQuality
)	I-Premise	HighQuality
entre	I-Premise	HighQuality
las	I-Premise	HighQuality
mujeres	I-Premise	HighQuality
embarazadas	I-Premise	HighQuality
que	I-Premise	HighQuality
tomaron	I-Premise	HighQuality
únicamente	I-Premise	HighQuality
ácido	I-Premise	HighQuality
fólico,	I-Premise	HighQuality
ácido	I-Premise	HighQuality
hierro-fólico	I-Premise	HighQuality
y	I-Premise	HighQuality
suplementos	I-Premise	HighQuality
múltiples	I-Premise	HighQuality
de	I-Premise	HighQuality
micronutrientes,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Las	B-Premise	HighQuality
odds	I-Premise	HighQuality
ratios	I-Premise	HighQuality
ajustadas	I-Premise	HighQuality
asociadas	I-Premise	HighQuality
con	I-Premise	HighQuality
suplementos	I-Premise	HighQuality
de	I-Premise	HighQuality
ácido	I-Premise	HighQuality
fólico	I-Premise	HighQuality
de	I-Premise	HighQuality
hierro	I-Premise	HighQuality
y	I-Premise	HighQuality
suplementos	I-Premise	HighQuality
múltiples	I-Premise	HighQuality
de	I-Premise	HighQuality
micronutrientes	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
hipertensión	I-Premise	HighQuality
inducida	I-Premise	HighQuality
por	I-Premise	HighQuality
el	I-Premise	HighQuality
embarazo	I-Premise	HighQuality
fueron	I-Premise	HighQuality
de	I-Premise	HighQuality
casi	I-Premise	HighQuality
0,88	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
0,76-1,02	I-Premise	HighQuality
),	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
suplementos	I-Premise	HighQuality
de	I-Premise	HighQuality
ácido	I-Premise	HighQuality
fólico	I-Premise	HighQuality
solamente.	I-Premise	HighQuality

Entre	B-Premise	HighQuality
las	I-Premise	HighQuality
mujeres	I-Premise	HighQuality
embarazadas	I-Premise	HighQuality
de	I-Premise	HighQuality
20	I-Premise	HighQuality
a	I-Premise	HighQuality
24	I-Premise	HighQuality
años,	I-Premise	HighQuality
el	I-Premise	HighQuality
ácido	I-Premise	HighQuality
hierro-fólico	I-Premise	HighQuality
(	I-Premise	HighQuality
odds	I-Premise	HighQuality
ratios	I-Premise	HighQuality
ajustados	I-Premise	HighQuality
:	I-Premise	HighQuality
0,81,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
0,67-0,96	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
la	I-Premise	HighQuality
suplementación	I-Premise	HighQuality
con	I-Premise	HighQuality
micronutrientes	I-Premise	HighQuality
múltiples	I-Premise	HighQuality
(	I-Premise	HighQuality
odds	I-Premise	HighQuality
ratios	I-Premise	HighQuality
ajustados	I-Premise	HighQuality
:	I-Premise	HighQuality
0,83,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
0,70-0,99	I-Premise	HighQuality
)	I-Premise	HighQuality
pueden	I-Premise	HighQuality
reducir	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
el	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
hipertensión	I-Premise	HighQuality
inducida	I-Premise	HighQuality
por	I-Premise	HighQuality
el	I-Premise	HighQuality
embarazo	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
suplementación	I-Premise	HighQuality
con	I-Premise	HighQuality
ácido	I-Premise	HighQuality
fólico.	I-Premise	HighQuality

En	O	-
general,	O	-
no	O	-
hubo	O	-
diferencias	O	-
significativas	O	-
en	O	-
la	O	-
hipertensión	O	-
inducida	O	-
por	O	-
el	O	-
embarazo	O	-
entre	O	-
los	O	-
grupos	O	-
de	O	-
suplementos.	O	-

Sin	O	-
embargo,	O	-
entre	B-Claim	HighQuality
las	I-Claim	HighQuality
mujeres	I-Claim	HighQuality
embarazadas	I-Claim	HighQuality
de	I-Claim	HighQuality
20	I-Claim	HighQuality
a	I-Claim	HighQuality
24	I-Claim	HighQuality
años	I-Claim	HighQuality
de	I-Claim	HighQuality
edad,	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
de	I-Claim	HighQuality
micronutrientes	I-Claim	HighQuality
múltiples	I-Claim	HighQuality
con	I-Claim	HighQuality
hierro	I-Claim	HighQuality
se	I-Claim	HighQuality
asoció	I-Claim	HighQuality
con	I-Claim	HighQuality
un	I-Claim	HighQuality
menor	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
inducida	I-Claim	HighQuality
por	I-Claim	HighQuality
el	I-Claim	HighQuality
embarazo	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
únicamente	I-Claim	HighQuality
con	I-Claim	HighQuality
suplementos	I-Claim	HighQuality
de	I-Claim	HighQuality
ácido	I-Claim	HighQuality
fólico.	I-Claim	HighQuality

Para	O	-
investigar	O	-
si	O	-
los	O	-
regímenes	O	-
de	O	-
docetaxel	O	-
más	O	-
platino	O	-
mejoran	O	-
la	O	-
supervivencia	O	-
y	O	-
afectan	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(QoL	O	-
)	O	-
en	O	-
cáncer	O	-
de	O	-
pulmón	O	-
avanzado	O	-
de	O	-
células	O	-
no	O	-
pequeñas	O	-
(NSCLC	O	-
)	O	-
en	O	-
comparación	O	-
con	O	-
vinorelbina	O	-
más	O	-
cisplatino	O	-
como	O	-
quimioterapia	O	-
de	O	-
primera	O	-
línea.	O	-

Los	O	-
pacientes	O	-
(	O	-
n	O	-
=	O	-
1.218	O	-
)	O	-
con	O	-
CPNM	O	-
en	O	-
estadio	O	-
IIIB	O	-
a	O	-
IV	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
para	O	-
recibir	O	-
docetaxel	O	-
75	O	-
mg/m2	O	-
y	O	-
cisplatino	O	-
75	O	-
mg/m2	O	-
cada	O	-
3	O	-
semanas	O	-
(	O	-
DC	O	-
)	O	-
;	O	-
docetaxel	O	-
75	O	-
mg/m2	O	-
y	O	-
área	O	-
de	O	-
carboplatino	O	-
bajo	O	-
la	O	-
curva	O	-
de	O	-
6	O	-
mg/mL	O	-
*	O	-
min	O	-
cada	O	-
3	O	-
semanas	O	-
(	O	-
DCb	O	-
)	O	-
;	O	-
o	O	-
vinorelbina	O	-
25	O	-
mg/m2/wk	O	-
y	O	-
cisplatino	O	-
100	O	-
mg/m2	O	-
cada	O	-
4	O	-
semanas	O	-
(	O	-
CV	O	-
).	O	-

Los	B-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
DC	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
una	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
de	I-Premise	HighQuality
11,3	I-Premise	HighQuality
v	I-Premise	HighQuality
10,1	I-Premise	HighQuality
meses	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
CV	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,044	I-Premise	HighQuality
;	I-Premise	HighQuality
hazard	I-Premise	HighQuality
ratio,	I-Premise	HighQuality
1,183	I-Premise	HighQuality
[	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
97,2	I-Premise	HighQuality
%,	I-Premise	HighQuality
0,989	I-Premise	HighQuality
a	I-Premise	HighQuality
1,416	I-Premise	HighQuality
]	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
a	I-Premise	HighQuality
2	I-Premise	HighQuality
años	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
21%	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
DC	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
14%	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
CV.	I-Premise	HighQuality

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
global	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
31,6%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
DC	I-Premise	HighQuality
v	I-Premise	HighQuality
24,5%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
CV	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
029	I-Premise	HighQuality
).	I-Premise	HighQuality

Mediana	B-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
(	I-Premise	HighQuality
9,4	I-Premise	HighQuality
v	I-Premise	HighQuality
9,9	I-Premise	HighQuality
meses	I-Premise	HighQuality
[	I-Premise	HighQuality
para	I-Premise	HighQuality
CV	I-Premise	HighQuality
]	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
657	I-Premise	HighQuality
;	I-Premise	HighQuality
hazard	I-Premise	HighQuality
ratio,	I-Premise	HighQuality
1,048	I-Premise	HighQuality
[	I-Premise	HighQuality
97,2	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza,	I-Premise	HighQuality
0,877	I-Premise	HighQuality
a	I-Premise	HighQuality
1,253	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
(	I-Premise	HighQuality
23,9	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
con	I-Premise	HighQuality
DCb	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
resultados	I-Premise	HighQuality
para	I-Premise	HighQuality
CV.	I-Premise	HighQuality

Neutropenia,	B-Premise	HighQuality
trombocitopenia,	I-Premise	HighQuality
infección	I-Premise	HighQuality
y	I-Premise	HighQuality
neutropenia	I-Premise	HighQuality
febril	I-Premise	HighQuality
fueron	I-Premise	HighQuality
similares	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
tres	I-Premise	HighQuality
regímenes.	I-Premise	HighQuality

La	B-Premise	HighQuality
anemia	I-Premise	HighQuality
de	I-Premise	HighQuality
grado	I-Premise	HighQuality
3	I-Premise	HighQuality
a	I-Premise	HighQuality
4,	I-Premise	HighQuality
las	I-Premise	HighQuality
náuseas	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
vómitos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,01	I-Premise	HighQuality
)	I-Premise	HighQuality
con	I-Premise	HighQuality
CV	I-Premise	HighQuality
que	I-Premise	HighQuality
con	I-Premise	HighQuality
DC	I-Premise	HighQuality
o	I-Premise	HighQuality
DCb.	I-Premise	HighQuality

Los	B-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
cualquiera	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
regímenes	I-Premise	HighQuality
de	I-Premise	HighQuality
docetaxel	I-Premise	HighQuality
habían	I-Premise	HighQuality
mejorado	I-Premise	HighQuality
constantemente	I-Premise	HighQuality
la	I-Premise	HighQuality
CV	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
CV,	I-Premise	HighQuality
que	I-Premise	HighQuality
experimentaron	I-Premise	HighQuality
deterioro	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
CV.	I-Premise	HighQuality

La	B-Claim	HighQuality
DC	I-Claim	HighQuality
resultó	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
global	I-Claim	HighQuality
y	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
más	I-Claim	HighQuality
favorable	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
CV.	I-Claim	HighQuality

Tanto	B-Claim	HighQuality
la	I-Claim	HighQuality
DC	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
DCb	I-Claim	HighQuality
fueron	I-Claim	HighQuality
mejor	I-Claim	HighQuality
toleradas	I-Claim	HighQuality
y	I-Claim	HighQuality
proporcionaron	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
una	I-Claim	HighQuality
CV	I-Claim	HighQuality
constantemente	I-Claim	HighQuality
mejorada	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
CV.	I-Claim	HighQuality

Estos	B-Claim	HighQuality
hallazgos	I-Claim	HighQuality
demuestran	I-Claim	HighQuality
que	I-Claim	HighQuality
una	I-Claim	HighQuality
combinación	I-Claim	HighQuality
de	I-Claim	HighQuality
docetaxel	I-Claim	HighQuality
más	I-Claim	HighQuality
platino	I-Claim	HighQuality
es	I-Claim	HighQuality
una	I-Claim	HighQuality
opción	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
con	I-Claim	HighQuality
un	I-Claim	HighQuality
índice	I-Claim	HighQuality
terapéutico	I-Claim	HighQuality
favorable	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
primera	I-Claim	HighQuality
línea	I-Claim	HighQuality
de	I-Claim	HighQuality
CPNM	I-Claim	HighQuality
avanzado	I-Claim	HighQuality
o	I-Claim	HighQuality
metastásico.	I-Claim	HighQuality

La	O	-
hipertensión	O	-
arterial	O	-
pulmonar	O	-
(HAP	O	-
)	O	-
es	O	-
una	O	-
enfermedad	O	-
rara	O	-
y	O	-
potencialmente	O	-
mortal	O	-
bien	O	-
marcada	O	-
por	O	-
el	O	-
diagnóstico,	O	-
el	O	-
diagnóstico	O	-
tardío	O	-
y	O	-
los	O	-
tratamientos	O	-
atípicos.	O	-

Se	O	-
dispone	O	-
de	O	-
pocos	O	-
datos	O	-
sobre	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(	O	-
CV	O	-
)	O	-
y	O	-
las	O	-
características	O	-
psicosociales	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
HAP.	O	-

Nuestro	O	-
objetivo	O	-
es	O	-
describir	O	-
el	O	-
impacto	O	-
de	O	-
los	O	-
factores	O	-
psicológicos	O	-
en	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
relacionada	O	-
con	O	-
la	O	-
salud	O	-
(	O	-
CVRS	O	-
)	O	-
de	O	-
los	O	-
pacientes	O	-
tratados	O	-
con	O	-
HAP	O	-
en	O	-
un	O	-
estudio	O	-
transversal.	O	-

Se	O	-
reclutaron	O	-
pacientes	O	-
consecutivos	O	-
que	O	-
se	O	-
presentaban	O	-
en	O	-
nuestro	O	-
Centro	O	-
de	O	-
Competencia	O	-
para	O	-
HAP.	O	-

La	O	-
etiología,	O	-
estadio	O	-
de	O	-
la	O	-
New	O	-
York	O	-
Heart	O	-
Association	O	-
(	O	-
NYHA	O	-
),	O	-
hemodinámica,	O	-
distancia	O	-
a	O	-
pie	O	-
de	O	-
6	O	-
minutos	O	-
(	O	-
6MWD	O	-
),	O	-
delta	O	-
SPO2	O	-
(	O	-
saturación	O	-
de	O	-
oxígeno	O	-
del	O	-
oxímetro	O	-
de	O	-
pulso	O	-
;	O	-
valor	O	-
basal	O	-
más	O	-
bajo	O	-
durante	O	-
la	O	-
prueba	O	-
de	O	-
caminata	O	-
de	O	-
6	O	-
minutos	O	-
(	O	-
6MWT	O	-
),	O	-
tratamientos	O	-
actuales	O	-
y	O	-
antecedentes	O	-
psicológicos	O	-
fueron	O	-
registrados.	O	-

La	O	-
CVRS,	O	-
la	O	-
ansiedad,	O	-
la	O	-
depresión	O	-
y	O	-
las	O	-
estrategias	O	-
de	O	-
afrontamiento	O	-
fueron	O	-
exploradas	O	-
mediante	O	-
cuestionarios	O	-
autoadministrados	O	-
(	O	-
SF-36,	O	-
HADS,	O	-
STAI-Y,	O	-
CHIP	O	-
y	O	-
WCC	O	-
).	O	-

Se	O	-
incluyó	O	-
un	O	-
total	O	-
de	O	-
55	O	-
pacientes.	O	-

La	O	-
CVRS	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
HAP	O	-
fue	O	-
pobre	O	-
con	O	-
resultados	O	-
alterados	O	-
en	O	-
varias	O	-
escalas.	O	-

La	O	-
ansiedad	O	-
y	O	-
la	O	-
depresión	O	-
fueron	O	-
altas	O	-
y	O	-
el	O	-
enfrentamiento	O	-
se	O	-
centró	O	-
en	O	-
las	O	-
estrategias	O	-
de	O	-
información	O	-
médica.	O	-

El	B-Premise	HighQuality
análisis	I-Premise	HighQuality
multivariado	I-Premise	HighQuality
indicó	I-Premise	HighQuality
una	I-Premise	HighQuality
relación	I-Premise	HighQuality
positiva	I-Premise	HighQuality
entre	I-Premise	HighQuality
6MWD	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
Score	I-Premise	HighQuality
de	I-Premise	HighQuality
Composite	I-Premise	HighQuality
Físico	I-Premise	HighQuality
para	I-Premise	HighQuality
CV	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,004	I-Premise	HighQuality
),	I-Premise	HighQuality
así	O	-
como	O	-
una	B-Premise	HighQuality
relación	I-Premise	HighQuality
negativa	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
SPO2	I-Premise	HighQuality
delta	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
Score	I-Premise	HighQuality
de	I-Premise	HighQuality
Composite	I-Premise	HighQuality
Mental	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,02	I-Premise	HighQuality
),	I-Premise	HighQuality
independientemente	I-Premise	HighQuality
de	I-Premise	HighQuality
otros	I-Premise	HighQuality
factores	I-Premise	HighQuality
pronósticos	I-Premise	HighQuality
conocidos	I-Premise	HighQuality
(como	I-Premise	HighQuality
la	I-Premise	HighQuality
hemodinámica	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
cateterismo	I-Premise	HighQuality
del	I-Premise	HighQuality
corazón	I-Premise	HighQuality
derecho	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
depresión	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
ansiedad	I-Premise	HighQuality
por	I-Premise	HighQuality
el	I-Premise	HighQuality
rasgo	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
CV	I-Premise	HighQuality
más	I-Premise	HighQuality
baja	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
mental	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Los	B-Claim	HighQuality
factores	I-Claim	HighQuality
psicológicos	I-Claim	HighQuality
impactan	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
CVRS	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados.	I-Claim	HighQuality

Un	B-Claim	HighQuality
estudio	I-Claim	HighQuality
longitudinal	I-Claim	HighQuality
y	I-Claim	HighQuality
cualitativo	I-Claim	HighQuality
debe	I-Claim	HighQuality
refinar	I-Claim	HighQuality
estos	I-Claim	HighQuality
resultados.	I-Claim	HighQuality

Los	O	-
datos	O	-
son	O	-
insuficientes	O	-
en	O	-
cuanto	O	-
al	O	-
beneficio	O	-
de	O	-
supervivencia	O	-
de	O	-
la	O	-
vigilancia	O	-
del	O	-
carcinoma	O	-
hepatocelular	O	-
(	O	-
HCC	O	-
).	O	-

Investigar	O	-
la	O	-
eficacia	O	-
de	O	-
la	O	-
vigilancia	O	-
del	O	-
HCC	O	-
en	O	-
una	O	-
población	O	-
endémica	O	-
de	O	-
hepatitis	O	-
B.	O	-

Este	O	-
estudio	O	-
retrospectivo	O	-
de	O	-
cohorte	O	-
incluyó	O	-
a	O	-
1.402	O	-
pacientes	O	-
consecutivos	O	-
que	O	-
fueron	O	-
diagnosticados	O	-
recientemente	O	-
con	O	-
HCC	O	-
entre	O	-
2005	O	-
y	O	-
2012	O	-
en	O	-
un	O	-
único	O	-
hospital	O	-
terciario	O	-
en	O	-
Corea.	O	-

La	O	-
variable	O	-
principal	O	-
de	O	-
valoración	O	-
fue	O	-
la	O	-
supervivencia	O	-
global.	O	-

Se	O	-
ajustaron	O	-
los	O	-
sesgos	O	-
de	O	-
tiempo	O	-
de	O	-
espera	O	-
y	O	-
de	O	-
duración	O	-
(	O	-
tiempo	O	-
de	O	-
estancia	O	-
=	O	-
140	O	-
días	O	-
)	O	-
y	O	-
se	O	-
realizaron	O	-
análisis	O	-
de	O	-
sensibilidad.	O	-

La	O	-
etiología	O	-
más	O	-
frecuente	O	-
fue	O	-
la	O	-
hepatitis	O	-
B	O	-
(	O	-
80,4%	O	-
).	O	-

La	O	-
cirrosis	O	-
estuvo	O	-
presente	O	-
en	O	-
el	O	-
78,2%.	O	-

El	O	-
HCC	O	-
fue	O	-
diagnosticado	O	-
durante	O	-
la	O	-
vigilancia	O	-
regular	O	-
(definido	O	-
como	O	-
intervalo	O	-
medio	O	-
de	O	-
ecografía	O	-
<	O	-
8	O	-
meses,	O	-
n	O	-
=	O	-
834	O	-
),	O	-
vigilancia	O	-
irregular	O	-
(	O	-
n	O	-
=	O	-
104	O	-
)	O	-
o	O	-
no	O	-
vigilancia	O	-
(	O	-
n	O	-
=	O	-
464	O	-
).	O	-

Los	B-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
regular	I-Premise	HighQuality
fueron	I-Premise	HighQuality
diagnosticados	I-Premise	HighQuality
en	I-Premise	HighQuality
etapas	I-Premise	HighQuality
anteriores	I-Premise	HighQuality
(	I-Premise	HighQuality
[	I-Premise	HighQuality
muy	I-Premise	HighQuality
]	I-Premise	HighQuality
tempranas,	I-Premise	HighQuality
64,4%	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
irregular	I-Premise	HighQuality
(	I-Premise	HighQuality
40,4%	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
no	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
(	I-Premise	HighQuality
26,9%	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
más	I-Premise	HighQuality
posibilidades	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamientos	I-Premise	HighQuality
curativos	I-Premise	HighQuality
(	I-Premise	HighQuality
52,4%	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
irregular	I-Premise	HighQuality
(	I-Premise	HighQuality
39,4%	I-Premise	HighQuality
)	I-Premise	HighQuality
o	I-Premise	HighQuality
no	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
(	I-Premise	HighQuality
23,3%	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
todos	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
mortalidad	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
regular	I-Premise	HighQuality
(hazard	I-Premise	HighQuality
ratio	I-Premise	HighQuality
ajustado	I-Premise	HighQuality
[	I-Premise	HighQuality
aHR	I-Premise	HighQuality
],	I-Premise	HighQuality
0,69	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
],	I-Premise	HighQuality
0,57-0,83	I-Premise	HighQuality
)	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
irregular	I-Premise	HighQuality
(	I-Premise	HighQuality
aHR,	I-Premise	HighQuality
0,94	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
IC,	I-Premise	HighQuality
0,69-1,28	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
no	I-Premise	HighQuality
vigilancia	I-Premise	HighQuality
tras	I-Premise	HighQuality
ajustar	I-Premise	HighQuality
los	I-Premise	HighQuality
factores	I-Premise	HighQuality
de	I-Premise	HighQuality
confusión	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
tiempo	I-Premise	HighQuality
de	I-Premise	HighQuality
plomo.	I-Premise	HighQuality

Cuando	B-Premise	HighQuality
los	I-Premise	HighQuality
sujetos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
restringidos	I-Premise	HighQuality
a	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
cirróticos	I-Premise	HighQuality
o	I-Premise	HighQuality
a	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
de	I-Premise	HighQuality
clase	I-Premise	HighQuality
A/B	I-Premise	HighQuality
de	I-Premise	HighQuality
Child-Pugh,	I-Premise	HighQuality
se	I-Premise	HighQuality
obtuvieron	I-Premise	HighQuality
resultados	I-Premise	HighQuality
similares	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
mortalidad	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

La	B-Claim	HighQuality
vigilancia	I-Claim	HighQuality
del	I-Claim	HighQuality
CHC	I-Claim	HighQuality
se	I-Claim	HighQuality
asoció	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
mayor	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
debido	I-Claim	HighQuality
a	I-Claim	HighQuality
un	I-Claim	HighQuality
diagnóstico	I-Claim	HighQuality
y	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
curativo	I-Claim	HighQuality
más	I-Claim	HighQuality
tempranos.	I-Claim	HighQuality

La	B-Claim	HighQuality
ventaja	I-Claim	HighQuality
de	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
fue	I-Claim	HighQuality
significativa	I-Claim	HighQuality
con	I-Claim	HighQuality
vigilancia	I-Claim	HighQuality
regular	I-Claim	HighQuality
pero	I-Claim	HighQuality
no	I-Claim	HighQuality
con	I-Claim	HighQuality
vigilancia	I-Claim	HighQuality
irregular.	I-Claim	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
es	O	-
comparar	O	-
la	O	-
espironolactona	O	-
frente	O	-
a	O	-
la	O	-
clonidina	O	-
como	O	-
el	O	-
cuarto	O	-
fármaco	O	-
en	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
resistente	O	-
en	O	-
un	O	-
ensayo	O	-
multicéntrico	O	-
aleatorizado.	O	-

La	O	-
adhesión	O	-
a	O	-
la	O	-
terapia	O	-
médica	O	-
se	O	-
verificó	O	-
con	O	-
el	O	-
recuento	O	-
de	O	-
píldoras.	O	-

Los	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
resistente	O	-
(sin	O	-
control	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
ambulatoria	O	-
y	O	-
del	O	-
consultorio	O	-
[PA],	O	-
a	O	-
pesar	O	-
del	O	-
tratamiento	O	-
con	O	-
3	O	-
fármacos,	O	-
incluyendo	O	-
un	O	-
diurético,	O	-
durante	O	-
12	O	-
semanas	O	-
)	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
un	O	-
tratamiento	O	-
adicional	O	-
de	O	-
12	O	-
semanas	O	-
con	O	-
espironolactona	O	-
(	O	-
12,5-50	O	-
mg	O	-
QD	O	-
)	O	-
o	O	-
clonidina	O	-
(	O	-
0,1-0,3	O	-
mg	O	-
BID	O	-
).	O	-

El	O	-
punto	O	-
final	O	-
primario	O	-
fue	O	-
el	O	-
control	O	-
de	O	-
la	O	-
PA	O	-
durante	O	-
el	O	-
consultorio	O	-
(	O	-
<	O	-
140/90	O	-
mm	O	-
Hg	O	-
)	O	-
y	O	-
la	O	-
monitorización	O	-
de	O	-
la	O	-
PA	O	-
ambulatoria	O	-
24h	O	-
(	O	-
<	O	-
130/80	O	-
mm	O	-
Hg	O	-
).	O	-

Los	O	-
puntos	O	-
finales	O	-
secundarios	O	-
incluyeron	O	-
el	O	-
control	O	-
de	O	-
la	O	-
PA	O	-
de	O	-
cada	O	-
método	O	-
y	O	-
la	O	-
reducción	O	-
absoluta	O	-
de	O	-
la	O	-
PA.	O	-

De	O	-
1597	O	-
pacientes	O	-
reclutados,	O	-
el	O	-
11,7%	O	-
(	O	-
187	O	-
pacientes	O	-
)	O	-
cumplieron	O	-
los	O	-
criterios	O	-
de	O	-
resistencia	O	-
a	O	-
la	O	-
hipertensión.	O	-

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
espironolactona	I-Premise	HighQuality
(	I-Premise	HighQuality
n=95	I-Premise	HighQuality
),	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
clonidina	I-Premise	HighQuality
(	I-Premise	HighQuality
n=92	I-Premise	HighQuality
)	I-Premise	HighQuality
presentó	I-Premise	HighQuality
tasas	I-Premise	HighQuality
similares	I-Premise	HighQuality
de	I-Premise	HighQuality
alcanzar	I-Premise	HighQuality
el	I-Premise	HighQuality
punto	I-Premise	HighQuality
final	I-Premise	HighQuality
primario	I-Premise	HighQuality
(	I-Premise	HighQuality
20,5	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
20,8	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
;	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
relativo,	I-Premise	HighQuality
1,01	I-Premise	HighQuality
[	I-Premise	HighQuality
0,55-1,88	I-Premise	HighQuality
]	I-Premise	HighQuality
;	I-Premise	HighQuality
P=1,00	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
análisis	I-Premise	HighQuality
secundario	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
puntos	I-Premise	HighQuality
finales	I-Premise	HighQuality
mostró	I-Premise	HighQuality
una	I-Premise	HighQuality
PA	I-Premise	HighQuality
similar	I-Premise	HighQuality
(	I-Premise	HighQuality
33,3	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
29,3	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
control	I-Premise	HighQuality
ambulatorio	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PA	I-Premise	HighQuality
(	I-Premise	HighQuality
44	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
46,2	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
espironolactona	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
clonidina,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

Sin	O	-
embargo,	O	-
la	B-Premise	HighQuality
espironolactona	I-Premise	HighQuality
promovió	I-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
disminución	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PA	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
y	I-Premise	HighQuality
diastólica	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PA	I-Premise	HighQuality
ambulatoria	I-Premise	HighQuality
diurna	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
clonidina.	I-Premise	HighQuality

El	O	-
análisis	O	-
por	O	-
protocolo	O	-
(limitado	O	-
a	O	-
pacientes	O	-
con	O	-
adhesión	O	-
≥80	O	-
%	O	-
al	O	-
tratamiento	O	-
con	O	-
espironolactona/clonidina	O	-
)	O	-
mostró	O	-
resultados	O	-
similares	O	-
con	O	-
respecto	O	-
al	O	-
punto	O	-
final	O	-
primario.	O	-

En	O	-
conclusión,	O	-
la	B-Claim	HighQuality
clonidina	I-Claim	HighQuality
no	I-Claim	HighQuality
fue	I-Claim	HighQuality
superior	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
espironolactona	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
hipertensos	I-Claim	HighQuality
resistentes	I-Claim	HighQuality
reales,	I-Claim	HighQuality
pero	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
global	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PA	I-Claim	HighQuality
fue	I-Claim	HighQuality
bajo	I-Claim	HighQuality
(	I-Claim	HighQuality
+21	I-Claim	HighQuality
%	I-Claim	HighQuality
).	I-Claim	HighQuality

Teniendo	O	-
en	O	-
cuenta	O	-
una	O	-
posología	O	-
más	O	-
fácil	O	-
y	O	-
una	O	-
mayor	O	-
disminución	O	-
en	O	-
los	O	-
puntos	O	-
finales	O	-
secundarios,	O	-
la	B-Claim	HighQuality
espironolactona	I-Claim	HighQuality
es	I-Claim	HighQuality
preferible	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
cuarto	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
farmacológico.	I-Claim	HighQuality

La	B-Claim	HighQuality
vitamina	I-Claim	HighQuality
D	I-Claim	HighQuality
sérica	I-Claim	HighQuality
baja	I-Claim	HighQuality
se	I-Claim	HighQuality
ha	I-Claim	HighQuality
asociado	I-Claim	HighQuality
con	I-Claim	HighQuality
síndrome	I-Claim	HighQuality
metabólico	I-Claim	HighQuality
y	I-Claim	HighQuality
enfermedad	I-Claim	HighQuality
del	I-Claim	HighQuality
hígado	I-Claim	HighQuality
graso	I-Claim	HighQuality
no	I-Claim	HighQuality
alcohólico	I-Claim	HighQuality
(	I-Claim	HighQuality
NAFLD	I-Claim	HighQuality
).	I-Claim	HighQuality

Este	O	-
estudio	O	-
tuvo	O	-
como	O	-
objetivo	O	-
investigar	O	-
el	O	-
impacto	O	-
de	O	-
la	O	-
suplementación	O	-
con	O	-
vitamina	O	-
D	O	-
en	O	-
el	O	-
tratamiento	O	-
de	O	-
pacientes	O	-
con	O	-
NAFLD.	O	-

En	O	-
un	O	-
ensayo	O	-
doble	O	-
ciego,	O	-
aleatorizado,	O	-
los	O	-
pacientes	O	-
controlados	O	-
con	O	-
placebo	O	-
con	O	-
NAFLD	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
una	O	-
perla	O	-
semanal	O	-
de	O	-
placebo,	O	-
50.000	O	-
U	O	-
de	O	-
vitamina	O	-
D3	O	-
(	O	-
colecalciferol	O	-
)	O	-
perla	O	-
por	O	-
semana	O	-
y	O	-
0,25	O	-
mg	O	-
de	O	-
calcitriol	O	-
(	O	-
1,25	O	-
dihidroxicolecalciferol	O	-
)	O	-
perla	O	-
por	O	-
día	O	-
durante	O	-
3	O	-
meses.	O	-

106	O	-
pacientes	O	-
con	O	-
NAFLD	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
perlas	O	-
de	O	-
calcitriol,	O	-
vitamina	O	-
D3	O	-
y	O	-
placebo	O	-
durante	O	-
12	O	-
semanas	O	-
y	O	-
se	O	-
analizaron	O	-
los	O	-
datos	O	-
de	O	-
91	O	-
pacientes.	O	-

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
séricos	I-Premise	HighQuality
de	I-Premise	HighQuality
fosfatasa	I-Premise	HighQuality
alcalina	I-Premise	HighQuality
disminuyeron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
desde	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
basales	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D	I-Premise	HighQuality
y	I-Premise	HighQuality
calcitriol	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
nivel	I-Premise	HighQuality
sérico	I-Premise	HighQuality
y	I-Premise	HighQuality
gamma	I-Premise	HighQuality
glutamil	I-Premise	HighQuality
transferasa	I-Premise	HighQuality
(GGT	I-Premise	HighQuality
)	I-Premise	HighQuality
también	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
basales	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D.	I-Premise	HighQuality
No	B-Premise	HighQuality
hubo	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativa	I-Premise	HighQuality
entre	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
calcitriol,	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
vitamina	I-Premise	HighQuality
D	I-Premise	HighQuality
en	I-Premise	HighQuality
términos	I-Premise	HighQuality
de	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
sérica,	I-Premise	HighQuality
fosfatasa	I-Premise	HighQuality
alcalina,	I-Premise	HighQuality
GGT	I-Premise	HighQuality
sérica	I-Premise	HighQuality
y	I-Premise	HighQuality
perfil	I-Premise	HighQuality
lipídico	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
>	I-Premise	HighQuality
0,05	I-Premise	HighQuality
).	I-Premise	HighQuality

Si	O	-
bien	O	-
se	B-Claim	HighQuality
observó	I-Claim	HighQuality
una	I-Claim	HighQuality
reducción	I-Claim	HighQuality
significativa	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
fosfatasa	I-Claim	HighQuality
alcalina	I-Claim	HighQuality
sérica	I-Claim	HighQuality
y	I-Claim	HighQuality
GGT	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
suplementación	I-Claim	HighQuality
con	I-Claim	HighQuality
vitamina	I-Claim	HighQuality
D	I-Claim	HighQuality
y	I-Claim	HighQuality
calcitriol	I-Claim	HighQuality
a	I-Claim	HighQuality
partir	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
niveles	I-Claim	HighQuality
basales,	I-Claim	HighQuality
no	O	-
se	O	-
observaron	O	-
efectos	O	-
beneficiosos	O	-
al	O	-
comparar	O	-
los	O	-
grupos	O	-
de	O	-
vitamina	O	-
D,	O	-
calcitriol	O	-
y	O	-
placebo	O	-
al	O	-
final	O	-
del	O	-
ensayo.	O	-

Evidencia	O	-
genética	O	-
emergente,	O	-
ex-vivo,	O	-
y	O	-
ensayos	O	-
clínicos	O	-
indican	O	-
que	O	-
los	O	-
bloqueadores	O	-
de	O	-
los	O	-
canales	O	-
de	O	-
calcio	O	-
(	O	-
CCB	O	-
)	O	-
pueden	O	-
mejorar	O	-
el	O	-
estado	O	-
de	O	-
ánimo	O	-
y	O	-
la	O	-
función	O	-
cognitiva.	O	-

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
examinar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
terapia	O	-
selectiva	O	-
con	O	-
inhibidor	O	-
de	O	-
la	O	-
recaptación	O	-
de	O	-
serotonina	O	-
(ISRS	O	-
)	O	-
aumentada	O	-
con	O	-
CCB	O	-
sobre	O	-
depresión	O	-
y	O	-
deterioro	O	-
cognitivo	O	-
en	O	-
una	O	-
población	O	-
anciana	O	-
con	O	-
hipertensión.	O	-

Estudio	O	-
prospectivo	O	-
de	O	-
296	O	-
personas	O	-
tratadas	O	-
con	O	-
ISRS	O	-
y	O	-
medicamentos	O	-
antihipertensivos.	O	-

Se	O	-
utilizaron	O	-
evaluaciones	O	-
clínicas	O	-
basales	O	-
y	O	-
de	O	-
dos	O	-
años	O	-
para	O	-
clasificar	O	-
a	O	-
los	O	-
participantes	O	-
como	O	-
usuarios	O	-
de	O	-
ISRS	O	-
+	O	-
CCB	O	-
(	O	-
n	O	-
=	O	-
53	O	-
)	O	-
o	O	-
usuarios	O	-
de	O	-
ISRS	O	-
+	O	-
otros	O	-
antihipertensivos	O	-
(	O	-
n	O	-
=	O	-
243	O	-
).	O	-

Las	O	-
visitas	O	-
clínicas	O	-
se	O	-
realizaron	O	-
hasta	O	-
cuatro	O	-
veces	O	-
en	O	-
un	O	-
período	O	-
de	O	-
diez	O	-
años	O	-
para	O	-
evaluar	O	-
la	O	-
depresión	O	-
y	O	-
la	O	-
función	O	-
cognitiva.	O	-

La	O	-
edad	O	-
media	O	-
de	O	-
la	O	-
muestra	O	-
fue	O	-
de	O	-
75,2	O	-
±	O	-
5,47	O	-
años	O	-
y	O	-
el	O	-
78	O	-
%	O	-
de	O	-
los	O	-
participantes	O	-
fueron	O	-
mujeres.	O	-

A	B-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
años	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
hubo	I-Premise	HighQuality
un	I-Premise	HighQuality
grupo	I-Premise	HighQuality
significativo	I-Premise	HighQuality
por	I-Premise	HighQuality
interacción	I-Premise	HighQuality
temporal	I-Premise	HighQuality
que	I-Premise	HighQuality
mostró	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
más	I-Premise	HighQuality
bajas	I-Premise	HighQuality
del	I-Premise	HighQuality
Centro	I-Premise	HighQuality
de	I-Premise	HighQuality
Estudios	I-Premise	HighQuality
Epidemiológicos-Depresión	I-Premise	HighQuality
(CESD	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
SSRI	I-Premise	HighQuality
+	I-Premise	HighQuality
CCB,	I-Premise	HighQuality
F	I-Premise	HighQuality
(	I-Premise	HighQuality
1.291	I-Premise	HighQuality
)	I-Premise	HighQuality
=	I-Premise	HighQuality
4,13,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,043,	I-Premise	HighQuality
η2	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,014.	I-Premise	HighQuality

A	B-Premise	HighQuality
lo	I-Premise	HighQuality
largo	I-Premise	HighQuality
de	I-Premise	HighQuality
diez	I-Premise	HighQuality
años	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento,	I-Premise	HighQuality
el	I-Premise	HighQuality
uso	I-Premise	HighQuality
de	I-Premise	HighQuality
ISRS	I-Premise	HighQuality
+	I-Premise	HighQuality
CCB	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
mejor	I-Premise	HighQuality
función	I-Premise	HighQuality
cognitiva	I-Premise	HighQuality
general	I-Premise	HighQuality
(	I-Premise	HighQuality
Mini-Mental	I-Premise	HighQuality
State	I-Premise	HighQuality
Examination	I-Premise	HighQuality
:	I-Premise	HighQuality
β	I-Premise	HighQuality
=	I-Premise	HighQuality
0,97	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
0,14	I-Premise	HighQuality
a	I-Premise	HighQuality
1,81,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,023	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
memoria	I-Premise	HighQuality
visual	I-Premise	HighQuality
inmediata	I-Premise	HighQuality
(	I-Premise	HighQuality
Boston	I-Premise	HighQuality
Visual	I-Premise	HighQuality
Retention	I-Premise	HighQuality
Test	I-Premise	HighQuality
:	I-Premise	HighQuality
β	I-Premise	HighQuality
=	I-Premise	HighQuality
0,69	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
0,06	I-Premise	HighQuality
a	I-Premise	HighQuality
1,32,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,033	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Claim	HighQuality
hallazgos	I-Claim	HighQuality
proporcionan	I-Claim	HighQuality
evidencia	I-Claim	HighQuality
poblacional	I-Claim	HighQuality
general	I-Claim	HighQuality
de	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
aumento	I-Claim	HighQuality
del	I-Claim	HighQuality
ISRS	I-Claim	HighQuality
con	I-Claim	HighQuality
CCB	I-Claim	HighQuality
puede	I-Claim	HighQuality
mejorar	I-Claim	HighQuality
la	I-Claim	HighQuality
depresión	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
cognitiva.	I-Claim	HighQuality

En	O	-
este	O	-
ensayo	O	-
aleatorizado	O	-
se	O	-
compararon	O	-
tres	O	-
regímenes	O	-
de	O	-
quimioterapia	O	-
en	O	-
el	O	-
tratamiento	O	-
de	O	-
primera	O	-
línea	O	-
del	O	-
cáncer	O	-
colorrectal	O	-
avanzado,	O	-
en	O	-
términos	O	-
de	O	-
su	O	-
efecto	O	-
sobre	O	-
la	O	-
supervivencia	O	-
global	O	-
y	O	-
sin	O	-
progresión	O	-
;	O	-
otras	O	-
variables	O	-
incluyeron	O	-
toxicidad,	O	-
paliación	O	-
de	O	-
los	O	-
síntomas	O	-
y	O	-
calidad	O	-
de	O	-
vida.	O	-

A	O	-
905	O	-
pacientes	O	-
se	O	-
les	O	-
asignó	O	-
aleatoriamente	O	-
el	O	-
régimen	O	-
de	O	-
Gramont	O	-
(	O	-
n=303	O	-
;	O	-
ácido	O	-
folínico	O	-
200	O	-
mg/m	O	-
(	O	-
2	O	-
),	O	-
fluorouracilo	O	-
bolus	O	-
400	O	-
mg/m	O	-
(	O	-
2	O	-
),	O	-
y	O	-
perfusión	O	-
600	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
en	O	-
los	O	-
días	O	-
1	O	-
y	O	-
2,	O	-
repetido	O	-
cada	O	-
14	O	-
días	O	-
),	O	-
el	O	-
régimen	O	-
de	O	-
Lokich	O	-
(	O	-
n=301	O	-
;	O	-
perfusión	O	-
venosa	O	-
prolongada	O	-
de	O	-
fluorouracilo	O	-
300	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
al	O	-
día	O	-
),	O	-
o	O	-
raltitrexed	O	-
(	O	-
n=301	O	-
;	O	-
3	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
por	O	-
vía	O	-
intravenosa	O	-
cada	O	-
21	O	-
días	O	-
).	O	-

Los	O	-
análisis	O	-
fueron	O	-
por	O	-
intención	O	-
de	O	-
tratar.	O	-

La	O	-
mediana	O	-
de	O	-
seguimiento	O	-
de	O	-
los	O	-
sobrevivientes	O	-
fue	O	-
de	O	-
67	O	-
semanas.	O	-

Para	B-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
Gramont,	I-Premise	HighQuality
Lokich,	I-Premise	HighQuality
y	I-Premise	HighQuality
raltitrexed,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
la	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
294,	I-Premise	HighQuality
302,	I-Premise	HighQuality
y	I-Premise	HighQuality
266	I-Premise	HighQuality
días.	I-Premise	HighQuality

Las	B-Premise	HighQuality
razones	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
global	I-Premise	HighQuality
fueron	I-Premise	HighQuality
0,88	I-Premise	HighQuality
(IC	I-Premise	HighQuality
95%	I-Premise	HighQuality
0,70-1,12,	I-Premise	HighQuality
p=0,17	I-Premise	HighQuality
)	I-Premise	HighQuality
para	I-Premise	HighQuality
de	I-Premise	HighQuality
Gramont	I-Premise	HighQuality
versus	I-Premise	HighQuality
Lokich,	I-Premise	HighQuality
y	I-Premise	HighQuality
0,99	I-Premise	HighQuality
(	I-Premise	HighQuality
0,79-1,25,	I-Premise	HighQuality
p=0,94	I-Premise	HighQuality
)	I-Premise	HighQuality
para	I-Premise	HighQuality
de	I-Premise	HighQuality
Gramont	I-Premise	HighQuality
versus	I-Premise	HighQuality
raltitrexed.	I-Premise	HighQuality

Se	B-Premise	HighQuality
observó	I-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
muertes	I-Premise	HighQuality
relacionadas	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
por	I-Premise	HighQuality
raltitrexed	I-Premise	HighQuality
(	I-Premise	HighQuality
de	I-Premise	HighQuality
Gramont	I-Premise	HighQuality
uno,	I-Premise	HighQuality
Lokich	I-Premise	HighQuality
dos,	I-Premise	HighQuality
raltitrexed	I-Premise	HighQuality
18	I-Premise	HighQuality
)	I-Premise	HighQuality
debido	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
toxicidad	I-Premise	HighQuality
gastrointestinal	I-Premise	HighQuality
y	I-Premise	HighQuality
hematológica	I-Premise	HighQuality
combinada.	I-Premise	HighQuality

La	B-Premise	HighQuality
evaluación	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
calidad	I-Premise	HighQuality
de	I-Premise	HighQuality
vida	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
mostró	I-Premise	HighQuality
que	I-Premise	HighQuality
raltitrexed	I-Premise	HighQuality
era	I-Premise	HighQuality
inferior	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
regímenes	I-Premise	HighQuality
basados	I-Premise	HighQuality
en	I-Premise	HighQuality
fluorouracilo,	I-Premise	HighQuality
especialmente	I-Premise	HighQuality
en	I-Premise	HighQuality
términos	I-Premise	HighQuality
de	I-Premise	HighQuality
paliación	I-Premise	HighQuality
y	I-Premise	HighQuality
funcionamiento.	I-Premise	HighQuality

Los	B-Claim	HighQuality
regímenes	I-Claim	HighQuality
deGramont	I-Claim	HighQuality
y	I-Claim	HighQuality
Lokich	I-Claim	HighQuality
fueron	I-Claim	HighQuality
similares	I-Claim	HighQuality
en	I-Claim	HighQuality
términos	I-Claim	HighQuality
de	I-Claim	HighQuality
supervivencia,	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
y	I-Claim	HighQuality
tasas	I-Claim	HighQuality
de	I-Claim	HighQuality
respuesta.	I-Claim	HighQuality

El	B-Claim	HighQuality
régimen	I-Claim	HighQuality
de	I-Claim	HighQuality
Lokich	I-Claim	HighQuality
se	I-Claim	HighQuality
asoció	I-Claim	HighQuality
con	I-Claim	HighQuality
complicaciones	I-Claim	HighQuality
de	I-Claim	HighQuality
línea	I-Claim	HighQuality
más	I-Claim	HighQuality
central	I-Claim	HighQuality
y	I-Claim	HighQuality
síndrome	I-Claim	HighQuality
mano-pie.	I-Claim	HighQuality

Raltitrexed	B-Claim	HighQuality
mostró	I-Claim	HighQuality
tasas	I-Claim	HighQuality
de	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
similares	I-Claim	HighQuality
y	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
global	I-Claim	HighQuality
al	I-Claim	HighQuality
régimen	I-Claim	HighQuality
de	I-Claim	HighQuality
Gramont	I-Claim	HighQuality
y	I-Claim	HighQuality
fue	I-Claim	HighQuality
más	I-Claim	HighQuality
fácil	I-Claim	HighQuality
de	I-Claim	HighQuality
administrar,	I-Claim	HighQuality
pero	B-Claim	HighQuality
resultó	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
mayor	I-Claim	HighQuality
toxicidad	I-Claim	HighQuality
y	I-Claim	HighQuality
una	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
inferior.	I-Claim	HighQuality

La	O	-
disminución	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
(PA	O	-
)	O	-
se	O	-
considera	O	-
neuroprotectora	O	-
en	O	-
pacientes	O	-
con	O	-
enfermedad	O	-
de	O	-
los	O	-
vasos	O	-
pequeños	O	-
cerebrales	O	-
;	O	-
sin	O	-
embargo,	O	-
regímenes	O	-
más	O	-
intensivos	O	-
pueden	O	-
aumentar	O	-
la	O	-
hipoperfusión	O	-
cerebral.	O	-

En	O	-
este	O	-
estudio	O	-
se	O	-
examinó	O	-
el	O	-
efecto	O	-
del	O	-
tratamiento	O	-
BP	O	-
estándar	O	-
vs.	O	-
intensivo	O	-
sobre	O	-
la	O	-
perfusión	O	-
cerebral	O	-
en	O	-
pacientes	O	-
con	O	-
enfermedad	O	-
vascular	O	-
grave.	O	-

Investigar	O	-
si	O	-
la	O	-
disminución	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
estándar	O	-
vs.	O	-
intensiva	O	-
durante	O	-
3	O	-
meses	O	-
causa	O	-
una	O	-
disminución	O	-
de	O	-
la	O	-
perfusión	O	-
cerebral	O	-
en	O	-
la	O	-
enfermedad	O	-
de	O	-
los	O	-
vasos	O	-
pequeños.	O	-

Este	O	-
ensayo	O	-
clínico	O	-
aleatorizado	O	-
tuvo	O	-
lugar	O	-
en	O	-
2	O	-
centros	O	-
médicos	O	-
universitarios	O	-
ingleses.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
través	O	-
de	O	-
un	O	-
sistema	O	-
central	O	-
en	O	-
línea	O	-
(en	O	-
una	O	-
proporción	O	-
1:1	O	-
).	O	-

Entre	O	-
el	O	-
29	O	-
de	O	-
febrero	O	-
de	O	-
2012	O	-
y	O	-
el	O	-
21	O	-
de	O	-
octubre	O	-
de	O	-
2015	O	-
se	O	-
reclutaron	O	-
70	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
y	O	-
con	O	-
hiperintensidad	O	-
de	O	-
materia	O	-
blanca	O	-
sintomática	O	-
confirmada	O	-
por	O	-
resonancia	O	-
magnética,	O	-
y	O	-
aleatoriamente	O	-
(36	O	-
en	O	-
el	O	-
grupo	O	-
estándar	O	-
y	O	-
34	O	-
en	O	-
el	O	-
grupo	O	-
intensivo).	O	-

Se	O	-
dispone	O	-
de	O	-
datos	O	-
analizables	O	-
en	O	-
62	O	-
pacientes,	O	-
33	O	-
en	O	-
el	O	-
grupo	O	-
estándar	O	-
y	O	-
29	O	-
en	O	-
el	O	-
grupo	O	-
intensivo,	O	-
para	O	-
el	O	-
análisis	O	-
de	O	-
la	O	-
intención	O	-
de	O	-
tratar.	O	-

Este	O	-
experimento	O	-
examina	O	-
el	O	-
período	O	-
de	O	-
seguimiento	O	-
de	O	-
3	O	-
meses.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
objetivos	O	-
estándar	O	-
(sistólicos,	O	-
130-140	O	-
mm	O	-
Hg	O	-
)	O	-
o	O	-
intensivos	O	-
(	O	-
sistólicos,	O	-
<	O	-
125	O	-
mm	O	-
Hg	O	-
)	O	-
de	O	-
PA,	O	-
que	O	-
se	O	-
lograrían	O	-
mediante	O	-
cambios	O	-
en	O	-
la	O	-
medicación.	O	-

La	O	-
perfusión	O	-
cerebral	O	-
se	O	-
midió	O	-
mediante	O	-
el	O	-
etiquetado	O	-
de	O	-
giros	O	-
arteriales	O	-
;	O	-
el	O	-
punto	O	-
final	O	-
primario	O	-
fue	O	-
el	O	-
cambio	O	-
en	O	-
la	O	-
perfusión	O	-
global	O	-
entre	O	-
el	O	-
inicio	O	-
y	O	-
3	O	-
meses,	O	-
comparado	O	-
entre	O	-
los	O	-
grupos	O	-
de	O	-
tratamiento	O	-
por	O	-
análisis	O	-
de	O	-
varianza.	O	-

La	O	-
regresión	O	-
lineal	O	-
comparó	O	-
el	O	-
cambio	O	-
en	O	-
la	O	-
perfusión	O	-
frente	O	-
al	O	-
cambio	O	-
en	O	-
la	O	-
PA.	O	-

El	O	-
análisis	O	-
por	O	-
resonancia	O	-
magnética	O	-
fue	O	-
enmascarado	O	-
al	O	-
grupo	O	-
de	O	-
tratamiento.	O	-

Entre	O	-
62	O	-
pacientes	O	-
analizables,	O	-
la	O	-
edad	O	-
media	O	-
fue	O	-
de	O	-
69,3	O	-
años	O	-
y	O	-
el	O	-
60	O	-
%	O	-
(n	O	-
=	O	-
37)	O	-
fueron	O	-
varones.	O	-

La	B-Premise	HighQuality
PA	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
media	I-Premise	HighQuality
(	I-Premise	HighQuality
DE	I-Premise	HighQuality
)	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
en	I-Premise	HighQuality
8	I-Premise	HighQuality
(	I-Premise	HighQuality
12	I-Premise	HighQuality
)	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
estándar	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
27	I-Premise	HighQuality
(	I-Premise	HighQuality
17	I-Premise	HighQuality
)	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
intensivo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
media	I-Premise	HighQuality
(	I-Premise	HighQuality
DE	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
presiones	I-Premise	HighQuality
de	I-Premise	HighQuality
141	I-Premise	HighQuality
(	I-Premise	HighQuality
13	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
126	I-Premise	HighQuality
(	I-Premise	HighQuality
10	I-Premise	HighQuality
)	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg,	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

El	B-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
perfusión	I-Premise	HighQuality
global	I-Premise	HighQuality
no	I-Premise	HighQuality
difirió	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
:	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
medio	I-Premise	HighQuality
(	I-Premise	HighQuality
DE	I-Premise	HighQuality
)	I-Premise	HighQuality
fue	I-Premise	HighQuality
-0,5	I-Premise	HighQuality
(	I-Premise	HighQuality
9,4	I-Premise	HighQuality
)	I-Premise	HighQuality
mL/min/100	I-Premise	HighQuality
g	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
estándar	I-Premise	HighQuality
vs	I-Premise	HighQuality
0,7	I-Premise	HighQuality
(	I-Premise	HighQuality
8,6	I-Premise	HighQuality
)	I-Premise	HighQuality
mL/min/100	I-Premise	HighQuality
g	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
intensivo	I-Premise	HighQuality
(	I-Premise	HighQuality
parcial	I-Premise	HighQuality
η2,	I-Premise	HighQuality
0,004	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
IC,	I-Premise	HighQuality
-3,551	I-Premise	HighQuality
a	I-Premise	HighQuality
5,818	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=,63	I-Premise	HighQuality
).	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
cuando	I-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
examinó	I-Premise	HighQuality
la	I-Premise	HighQuality
materia	I-Premise	HighQuality
gris	I-Premise	HighQuality
o	I-Premise	HighQuality
blanca	I-Premise	HighQuality
únicamente	I-Premise	HighQuality
o	I-Premise	HighQuality
se	I-Premise	HighQuality
limitó	I-Premise	HighQuality
a	I-Premise	HighQuality
aquellos	I-Premise	HighQuality
que	I-Premise	HighQuality
alcanzaron	I-Premise	HighQuality
el	I-Premise	HighQuality
objetivo	I-Premise	HighQuality
de	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial.	I-Premise	HighQuality

El	B-Premise	HighQuality
número	I-Premise	HighQuality
de	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
no	I-Premise	HighQuality
difirió	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
media	I-Premise	HighQuality
(	I-Premise	HighQuality
DE	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
0,21	I-Premise	HighQuality
(	I-Premise	HighQuality
0,65	I-Premise	HighQuality
)	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
estándar	I-Premise	HighQuality
y	I-Premise	HighQuality
0,32	I-Premise	HighQuality
(	I-Premise	HighQuality
0,75	I-Premise	HighQuality
)	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
intensivo	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,44	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
disminución	I-Claim	HighQuality
intensiva	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PA	I-Claim	HighQuality
no	I-Claim	HighQuality
redujo	I-Claim	HighQuality
la	I-Claim	HighQuality
perfusión	I-Claim	HighQuality
cerebral	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
enfermedad	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
vasos	I-Claim	HighQuality
pequeños	I-Claim	HighQuality
graves.	I-Claim	HighQuality

La	O	-
disregulación	O	-
del	O	-
flujo	O	-
sanguíneo	O	-
ocular	O	-
se	O	-
ha	O	-
implicado	O	-
en	O	-
la	O	-
patogénesis	O	-
del	O	-
glaucoma.	O	-

Mientras	O	-
que	O	-
el	O	-
efecto	O	-
de	O	-
una	O	-
sola	O	-
sustancia	O	-
antiglaucoma	O	-
sobre	O	-
el	O	-
flujo	O	-
sanguíneo	O	-
ocular	O	-
se	O	-
ha	O	-
abordado	O	-
en	O	-
varios	O	-
experimentos,	O	-
la	O	-
evidencia	O	-
de	O	-
combinaciones	O	-
fijas	O	-
es	O	-
escasa.	O	-

En	O	-
el	O	-
presente	O	-
estudio,	O	-
nos	O	-
propusimos	O	-
comparar	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
combinación	O	-
fija	O	-
latanoprost	O	-
0,005	O	-
%	O	-
/timolol	O	-
0,5%	O	-
(	O	-
LT	O	-
)	O	-
y	O	-
la	O	-
combinación	O	-
fija	O	-
brimonidina	O	-
0,2	O	-
%	O	-
/timolol	O	-
0,5%	O	-
(	O	-
BT	O	-
)	O	-
sobre	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
y	O	-
el	O	-
flujo	O	-
sanguíneo	O	-
ocular.	O	-

En	O	-
el	O	-
presente	O	-
estudio,	O	-
que	O	-
siguió	O	-
un	O	-
diseño	O	-
cruzado	O	-
de	O	-
dos	O	-
vías	O	-
aleatorizado	O	-
y	O	-
doble	O	-
enmascarado,	O	-
se	O	-
incluyeron	O	-
16	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
y	O	-
2	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
ocular.	O	-

Los	O	-
pacientes	O	-
se	O	-
sometieron	O	-
a	O	-
un	O	-
tratamiento	O	-
de	O	-
6	O	-
semanas	O	-
con	O	-
LT	O	-
y	O	-
a	O	-
un	O	-
tratamiento	O	-
de	O	-
6	O	-
semanas	O	-
con	O	-
BT	O	-
después	O	-
de	O	-
un	O	-
lavado	O	-
para	O	-
medicación	O	-
antiglaucoma	O	-
previa.	O	-

El	O	-
flujo	O	-
sanguíneo	O	-
óptico	O	-
de	O	-
la	O	-
cabeza	O	-
nerviosa	O	-
(ONHBF	O	-
)	O	-
se	O	-
midió	O	-
mediante	O	-
flujometría	O	-
Doppler	O	-
láser	O	-
;	O	-
las	O	-
velocidades	O	-
de	O	-
flujo	O	-
retrobulbar	O	-
se	O	-
midieron	O	-
mediante	O	-
imágenes	O	-
Doppler	O	-
de	O	-
color	O	-
en	O	-
la	O	-
arteria	O	-
oftalmológica,	O	-
la	O	-
arteria	O	-
retinal	O	-
central,	O	-
y	O	-
las	O	-
arterias	O	-
ciliares	O	-
posteriores.	O	-

La	O	-
PIO	O	-
se	O	-
midió	O	-
a	O	-
las	O	-
8	O	-
AM,	O	-
12	O	-
PM,	O	-
y	O	-
4	O	-
PM.	O	-

La	O	-
PIO	O	-
basal	O	-
media	O	-
fue	O	-
de	O	-
25,3	O	-
±2,8	O	-
mmHg.	O	-

Ambos	B-Premise	HighQuality
fármacos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
igualmente	I-Premise	HighQuality
eficaces	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
(	I-Premise	HighQuality
LT	I-Premise	HighQuality
:	I-Premise	HighQuality
-35,0	I-Premise	HighQuality
%	I-Premise	HighQuality
±10,0	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
BT	I-Premise	HighQuality
:	I-Premise	HighQuality
-33,6	I-Premise	HighQuality
%	I-Premise	HighQuality
±8,8	I-Premise	HighQuality
%,	I-Premise	HighQuality
P=0,463	I-Premise	HighQuality
entre	I-Premise	HighQuality
grupos	I-Premise	HighQuality
).	I-Premise	HighQuality

Además,	O	-
no	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
de	I-Premise	HighQuality
perfusión	I-Premise	HighQuality
ocular	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
2	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,1,	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
).	I-Premise	HighQuality

Ni	B-Premise	HighQuality
LT	I-Premise	HighQuality
ni	I-Premise	HighQuality
BT	I-Premise	HighQuality
alteraron	I-Premise	HighQuality
el	I-Premise	HighQuality
ONHBF	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,4,	I-Premise	HighQuality
basal	I-Premise	HighQuality
vs.	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
)	I-Premise	HighQuality
y	O	-
no	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
ningún	I-Premise	HighQuality
efecto	I-Premise	HighQuality
sobre	I-Premise	HighQuality
las	I-Premise	HighQuality
velocidades	I-Premise	HighQuality
de	I-Premise	HighQuality
flujo	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
vasos	I-Premise	HighQuality
retrobulbares	I-Premise	HighQuality
con	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
tratamientos.	I-Premise	HighQuality

En	O	-
el	O	-
presente	O	-
estudio,	O	-
un	B-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
6	I-Claim	HighQuality
semanas	I-Claim	HighQuality
con	I-Claim	HighQuality
LT	I-Claim	HighQuality
o	I-Claim	HighQuality
BT	I-Claim	HighQuality
fue	I-Claim	HighQuality
igualmente	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO.	I-Claim	HighQuality

Además,	O	-
ninguno	B-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
fármacos	I-Claim	HighQuality
administrados	I-Claim	HighQuality
indujo	I-Claim	HighQuality
un	I-Claim	HighQuality
efecto	I-Claim	HighQuality
significativo	I-Claim	HighQuality
sobre	I-Claim	HighQuality
los	I-Claim	HighQuality
parámetros	I-Claim	HighQuality
de	I-Claim	HighQuality
flujo	I-Claim	HighQuality
sanguíneo	I-Claim	HighQuality
ocular.	I-Claim	HighQuality

La	O	-
puntuación	O	-
de	O	-
riesgo	O	-
REVEAL	O	-
(RRS	O	-
)	O	-
fue	O	-
desarrollada	O	-
para	O	-
predecir	O	-
la	O	-
supervivencia	O	-
en	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
arterial	O	-
pulmonar	O	-
(	O	-
HAP	O	-
),	O	-
en	O	-
base	O	-
a	O	-
múltiples	O	-
características	O	-
de	O	-
los	O	-
pacientes.	O	-

Aquí	O	-
se	O	-
calculó	O	-
el	O	-
RRS	O	-
para	O	-
pacientes	O	-
en	O	-
el	O	-
estudio	O	-
aleatorizado	O	-
CHEST-1	O	-
y	O	-
en	O	-
el	O	-
estudio	O	-
abierto	O	-
CHEST-2	O	-
de	O	-
extensión	O	-
de	O	-
riociguat	O	-
en	O	-
hipertensión	O	-
pulmonar	O	-
tromboembólica	O	-
crónica	O	-
inoperable	O	-
o	O	-
persistente/periódica	O	-
(TEPH	O	-
).	O	-

Se	O	-
investigó	O	-
el	O	-
efecto	O	-
de	O	-
riociguat	O	-
vs	O	-
placebo	O	-
sobre	O	-
el	O	-
RRS	O	-
en	O	-
el	O	-
estudio	O	-
CHEST-1,	O	-
y	O	-
la	O	-
relación	O	-
entre	O	-
el	O	-
RRS	O	-
y	O	-
los	O	-
resultados	O	-
a	O	-
largo	O	-
plazo	O	-
en	O	-
el	O	-
estudio	O	-
CHEST-2.	O	-

El	O	-
RRS	O	-
se	O	-
calculó	O	-
post	O	-
hoc	O	-
para	O	-
el	O	-
valor	O	-
basal	O	-
y	O	-
la	O	-
semana	O	-
16	O	-
del	O	-
CHEST-1	O	-
y	O	-
la	O	-
semana	O	-
12	O	-
del	O	-
CHEST-2,	O	-
sobre	O	-
la	O	-
base	O	-
de	O	-
9	O	-
elementos	O	-
evaluables.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
agrupados	O	-
en	O	-
estratos	O	-
de	O	-
riesgo	O	-
por	O	-
RRS.	O	-

Las	O	-
relaciones	O	-
entre	O	-
el	O	-
RRS	O	-
y	O	-
la	O	-
supervivencia	O	-
y	O	-
la	O	-
supervivencia	O	-
libre	O	-
de	O	-
empeoramiento	O	-
clínico	O	-
fueron	O	-
examinadas	O	-
por	O	-
los	O	-
análisis	O	-
de	O	-
riesgos	O	-
proporcionales	O	-
de	O	-
Kaplan-Meier	O	-
y	O	-
Cox.	O	-

En	O	-
total,	O	-
237	O	-
pacientes	O	-
completaron	O	-
el	O	-
CHEST-1	O	-
y	O	-
entraron	O	-
en	O	-
el	O	-
CHEST-2.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
CHEST-1,	I-Premise	HighQuality
riociguat	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
el	I-Premise	HighQuality
RRS	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,0001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
estrato	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
placebo	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
hasta	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
16.	I-Premise	HighQuality

El	B-Premise	HighQuality
RRS	I-Premise	HighQuality
basal,	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
16,	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
RRS	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
CHEST-1	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
(	I-Premise	HighQuality
cocientes	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
para	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
1	I-Premise	HighQuality
punto	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
RRS	I-Premise	HighQuality
:	I-Premise	HighQuality
0,702,	I-Premise	HighQuality
0,692,	I-Premise	HighQuality
y	I-Premise	HighQuality
0,682,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre	I-Premise	HighQuality
de	I-Premise	HighQuality
empeoramiento	I-Premise	HighQuality
clínico	I-Premise	HighQuality
(	I-Premise	HighQuality
cocientes	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
:	I-Premise	HighQuality
0,697,	I-Premise	HighQuality
0,719,	I-Premise	HighQuality
y	I-Premise	HighQuality
0,754,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
a	I-Premise	HighQuality
lo	I-Premise	HighQuality
largo	I-Premise	HighQuality
de	I-Premise	HighQuality
2	I-Premise	HighQuality
años	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
CHEST-2.	I-Premise	HighQuality

Riociguat	B-Premise	HighQuality
mejoró	I-Premise	HighQuality
el	I-Premise	HighQuality
RRS	I-Premise	HighQuality
en	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
TEPH	I-Premise	HighQuality
inoperable	I-Premise	HighQuality
y	I-Premise	HighQuality
persistente/periódica.	I-Premise	HighQuality

RRS	B-Premise	HighQuality
al	I-Premise	HighQuality
inicio	I-Premise	HighQuality
y	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
16,	I-Premise	HighQuality
y	I-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
RRS	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio,	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
predicha	I-Premise	HighQuality
y	I-Premise	HighQuality
empeoramiento	I-Premise	HighQuality
clínico	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre.	I-Premise	HighQuality

Este	B-Claim	HighQuality
análisis	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
RRS	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
TEPH	I-Claim	HighQuality
inoperable	I-Claim	HighQuality
o	I-Claim	HighQuality
persistente/periódica	I-Claim	HighQuality
sugiere	I-Claim	HighQuality
utilidad	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
RRS	I-Claim	HighQuality
en	I-Claim	HighQuality
indicaciones	I-Claim	HighQuality
más	I-Claim	HighQuality
allá	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
HAP.	I-Claim	HighQuality

La	O	-
presión	O	-
arterial	O	-
alta	O	-
(PA	O	-
)	O	-
es	O	-
una	O	-
enfermedad	O	-
crónica	O	-
común	O	-
que	O	-
necesita	O	-
el	O	-
consumo	O	-
de	O	-
drogas	O	-
de	O	-
larga	O	-
vida	O	-
para	O	-
controlar.	O	-

La	B-Claim	HighQuality
espironolactona	I-Claim	HighQuality
puede	I-Claim	HighQuality
utilizarse	I-Claim	HighQuality
como	I-Claim	HighQuality
terapia	I-Claim	HighQuality
de	I-Claim	HighQuality
cuarta	I-Claim	HighQuality
línea	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
resistente.	I-Claim	HighQuality

Sin	O	-
embargo,	O	-
no	O	-
existe	O	-
ningún	O	-
estudio	O	-
para	O	-
determinar	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
espironolactona	O	-
a	O	-
dosis	O	-
bajas	O	-
como	O	-
terapia	O	-
de	O	-
primera	O	-
línea	O	-
en	O	-
el	O	-
tratamiento	O	-
de	O	-
la	O	-
hipertensión	O	-
esencial.	O	-

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
es	O	-
investigar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
monoterapia	O	-
con	O	-
espironolactona	O	-
a	O	-
dosis	O	-
bajas	O	-
en	O	-
el	O	-
manejo	O	-
de	O	-
la	O	-
hipertensión	O	-
esencial.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
aleatorizado	O	-
doble	O	-
ciego,	O	-
40	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
esencial	O	-
en	O	-
estadio	O	-
I	O	-
fueron	O	-
divididos	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos	O	-
:	O	-
el	O	-
grupo	O	-
de	O	-
intervención	O	-
recibió	O	-
espironolactona	O	-
25	O	-
miligramos	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
durante	O	-
un	O	-
mes	O	-
y	O	-
el	O	-
grupo	O	-
de	O	-
control	O	-
recibió	O	-
placebo	O	-
una	O	-
vez	O	-
al	O	-
día.	O	-

En	O	-
el	O	-
momento	O	-
basal	O	-
y	O	-
después	O	-
de	O	-
un	O	-
mes,	O	-
se	O	-
realizó	O	-
el	O	-
seguimiento	O	-
de	O	-
la	O	-
PA	O	-
de	O	-
24	O	-
horas	O	-
y	O	-
el	O	-
ensayo	O	-
sérico	O	-
de	O	-
potasio.	O	-

La	B-Premise	HighQuality
PA	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
de	I-Premise	HighQuality
143,5	I-Premise	HighQuality
±	I-Premise	HighQuality
8,2	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
a	I-Premise	HighQuality
137,10	I-Premise	HighQuality
±	I-Premise	HighQuality
7,57	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención,	I-Premise	HighQuality
mientras	I-Premise	HighQuality
que	I-Premise	HighQuality
no	I-Premise	HighQuality
cambió	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
control	I-Premise	HighQuality
(diferencia	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
=	I-Premise	HighQuality
-4,5	I-Premise	HighQuality
mmHg,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,004).	I-Premise	HighQuality

No	B-Premise	HighQuality
hubo	I-Premise	HighQuality
reducción	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PA	I-Premise	HighQuality
diastólica	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(diferencia	I-Premise	HighQuality
entre	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
=	I-Premise	HighQuality
-1,3	I-Premise	HighQuality
mmHg,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,099	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
monoterapia	I-Claim	HighQuality
de	I-Claim	HighQuality
ciclo	I-Claim	HighQuality
corto	I-Claim	HighQuality
con	I-Claim	HighQuality
dosis	I-Claim	HighQuality
bajas	I-Claim	HighQuality
de	I-Claim	HighQuality
espironolactona	I-Claim	HighQuality
es	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PA	I-Claim	HighQuality
sistólica	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
esencial	I-Claim	HighQuality
en	I-Claim	HighQuality
estadio	I-Claim	HighQuality
I.	I-Claim	HighQuality

La	O	-
infección	O	-
crónica	O	-
por	O	-
el	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB	O	-
)	O	-
en	O	-
niños	O	-
es	O	-
un	O	-
problema	O	-
de	O	-
salud	O	-
grave	O	-
en	O	-
todo	O	-
el	O	-
mundo.	O	-

Cómo	O	-
tratar	O	-
a	O	-
los	O	-
niños	O	-
con	O	-
infección	O	-
crónica	O	-
por	O	-
hepatitis	O	-
B	O	-
inmuno-tolerante,	O	-
comúnmente	O	-
caracterizada	O	-
por	O	-
el	O	-
antígeno	O	-
de	O	-
hepatitis	O	-
B	O	-
(	O	-
HBeAg	O	-
)	O	-
positividad,	O	-
alta	O	-
carga	O	-
viral,	O	-
alanina	O	-
aminotransferasa	O	-
normal	O	-
o	O	-
levemente	O	-
elevada	O	-
y	O	-
ninguna	O	-
o	O	-
mínima	O	-
inflamación	O	-
en	O	-
la	O	-
histología	O	-
hepática,	O	-
sigue	O	-
sin	O	-
resolverse.	O	-

Este	O	-
ensayo	O	-
tiene	O	-
como	O	-
objetivo	O	-
estudiar	O	-
los	O	-
beneficios	O	-
de	O	-
la	O	-
terapia	O	-
antiviral	O	-
en	O	-
niños	O	-
con	O	-
estas	O	-
características.	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
estudio	O	-
piloto	O	-
abierto	O	-
y	O	-
aleatorizado	O	-
controlado.	O	-

De	O	-
mayo	O	-
de	O	-
2014	O	-
a	O	-
abril	O	-
de	O	-
2015,	O	-
69	O	-
niños	O	-
infectados	O	-
crónicamente	O	-
por	O	-
el	O	-
VHB,	O	-
de	O	-
1	O	-
a	O	-
16	O	-
años	O	-
de	O	-
edad,	O	-
que	O	-
tenían	O	-
características	O	-
inmunotolerantes	O	-
fueron	O	-
reclutados	O	-
para	O	-
este	O	-
ensayo	O	-
y	O	-
asignados	O	-
aleatoriamente,	O	-
en	O	-
una	O	-
proporción	O	-
de	O	-
2:1,	O	-
al	O	-
grupo	O	-
de	O	-
tratamiento	O	-
y	O	-
grupo	O	-
control.	O	-

Los	O	-
pacientes	O	-
del	O	-
grupo	O	-
de	O	-
tratamiento	O	-
recibieron	O	-
interferón-α	O	-
(	O	-
IFN	O	-
)	O	-
en	O	-
monoterapia	O	-
o	O	-
recibieron	O	-
consecutivamente	O	-
IFN	O	-
en	O	-
monoterapia,	O	-
terapia	O	-
de	O	-
combinación	O	-
de	O	-
IFN	O	-
y	O	-
lamivudina	O	-
(	O	-
LAM	O	-
)	O	-
y	O	-
tratamiento	O	-
con	O	-
LAM	O	-
solo.	O	-

Todos	O	-
los	O	-
pacientes	O	-
fueron	O	-
observados	O	-
hasta	O	-
la	O	-
semana	O	-
96.	O	-

Al	O	-
inicio,	O	-
los	O	-
índices	O	-
epidemiológicos,	O	-
bioquímicos,	O	-
serológicos,	O	-
virológicos	O	-
e	O	-
histológicos	O	-
fueron	O	-
consistentes	O	-
entre	O	-
los	O	-
grupos	O	-
de	O	-
tratamiento	O	-
y	O	-
control.	O	-

De	B-Premise	HighQuality
los	I-Premise	HighQuality
46	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
el	I-Premise	HighQuality
73,91	I-Premise	HighQuality
%	I-Premise	HighQuality
tenía	I-Premise	HighQuality
ADN	I-Premise	HighQuality
sérico	I-Premise	HighQuality
indetectable	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB,	I-Premise	HighQuality
el	I-Premise	HighQuality
32,61	I-Premise	HighQuality
%	I-Premise	HighQuality
alcanzó	I-Premise	HighQuality
la	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
21,74	I-Premise	HighQuality
%	I-Premise	HighQuality
perdió	I-Premise	HighQuality
el	I-Premise	HighQuality
antígeno	I-Premise	HighQuality
de	I-Premise	HighQuality
superficie	I-Premise	HighQuality
de	I-Premise	HighQuality
hepatitis	I-Premise	HighQuality
B	I-Premise	HighQuality
(	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
variable	I-Premise	HighQuality
de	I-Premise	HighQuality
valoración.	I-Premise	HighQuality

No	B-Premise	HighQuality
surgió	I-Premise	HighQuality
ninguna	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
LAM	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
96.	I-Premise	HighQuality

En	B-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
control,	I-Premise	HighQuality
sólo	I-Premise	HighQuality
un	I-Premise	HighQuality
paciente	I-Premise	HighQuality
(	I-Premise	HighQuality
4,35	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
sufrió	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
espontánea	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
y	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
ADN	I-Premise	HighQuality
sérico	I-Premise	HighQuality
indetectable	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
durante	I-Premise	HighQuality
la	I-Premise	HighQuality
observación,	I-Premise	HighQuality
y	I-Premise	HighQuality
además,	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
desarrolló	I-Premise	HighQuality
aclaramiento	I-Premise	HighQuality
de	I-Premise	HighQuality
HBsAg.	I-Premise	HighQuality

En	B-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes,	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
graves.	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
antiviral	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
combinación	I-Premise	HighQuality
secuencial	I-Premise	HighQuality
de	I-Premise	HighQuality
IFN	I-Premise	HighQuality
y	I-Premise	HighQuality
LAM	I-Premise	HighQuality
produjo	I-Premise	HighQuality
una	I-Premise	HighQuality
mejora	I-Premise	HighQuality
significativa	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
ADN	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
sérico	I-Premise	HighQuality
indetectable,	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
del	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
y	I-Premise	HighQuality
pérdida	I-Premise	HighQuality
del	I-Premise	HighQuality
HBsAg	I-Premise	HighQuality
en	I-Premise	HighQuality
niños	I-Premise	HighQuality
con	I-Premise	HighQuality
infección	I-Premise	HighQuality
crónica	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
y	I-Premise	HighQuality
características	I-Premise	HighQuality
inmunotolerantes.	I-Premise	HighQuality

No	O	-
se	O	-
dispone	O	-
de	O	-
datos	O	-
sobre	O	-
el	O	-
tratamiento	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
crónica	O	-
(	O	-
CHB	O	-
)	O	-
tolerada	O	-
por	O	-
el	O	-
sistema	O	-
inmunitario.	O	-

Sigue	B-Claim	HighQuality
sin	I-Claim	HighQuality
resolverse	I-Claim	HighQuality
cómo	I-Claim	HighQuality
se	I-Claim	HighQuality
debe	I-Claim	HighQuality
tratar	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
niños	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
BCH	I-Claim	HighQuality
inmunotolerante.	I-Claim	HighQuality

En	O	-
este	O	-
trabajo	O	-
se	O	-
reportan	O	-
los	O	-
resultados	O	-
de	O	-
un	O	-
ensayo	O	-
piloto	O	-
abierto	O	-
y	O	-
aleatorizado	O	-
controlado	O	-
sobre	O	-
terapia	O	-
antiviral	O	-
en	O	-
niños	O	-
con	O	-
características	O	-
inmuno-tolerantes.	O	-

Muestra	B-Claim	HighQuality
que	I-Claim	HighQuality
una	I-Claim	HighQuality
combinación	I-Claim	HighQuality
secuencial	I-Claim	HighQuality
de	I-Claim	HighQuality
interferón-α	I-Claim	HighQuality
y	I-Claim	HighQuality
lamivudina	I-Claim	HighQuality
fue	I-Claim	HighQuality
beneficiosa.	I-Claim	HighQuality

El	O	-
inhibidor	O	-
de	O	-
la	O	-
acetazolamida	O	-
carbónica	O	-
(	O	-
AZT	O	-
)	O	-
modula	O	-
la	O	-
presión	O	-
arterial	O	-
a	O	-
gran	O	-
altitud	O	-
y	O	-
reduce	O	-
la	O	-
respiración	O	-
desordenada	O	-
del	O	-
sueño	O	-
en	O	-
pacientes	O	-
con	O	-
apnea	O	-
obstructiva	O	-
del	O	-
sueño	O	-
(	O	-
OSA	O	-
).	O	-

Se	O	-
buscó	O	-
investigar	O	-
el	O	-
efecto	O	-
del	O	-
tratamiento	O	-
de	O	-
AZT	O	-
y	O	-
en	O	-
combinación	O	-
con	O	-
presión	O	-
positiva	O	-
continua	O	-
de	O	-
las	O	-
vías	O	-
respiratorias	O	-
(CPAP	O	-
)	O	-
sobre	O	-
la	O	-
presión	O	-
arterial	O	-
en	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
y	O	-
AOS.	O	-

En	O	-
un	O	-
estudio	O	-
prospectivo,	O	-
aleatorizado,	O	-
de	O	-
tres	O	-
vías	O	-
crossover,	O	-
13	O	-
pacientes	O	-
varones	O	-
con	O	-
hipertensión	O	-
e	O	-
AOS	O	-
de	O	-
moderada	O	-
a	O	-
grave	O	-
(	O	-
64	O	-
±	O	-
7	O	-
años	O	-
de	O	-
edad,	O	-
índice	O	-
de	O	-
masa	O	-
corporal	O	-
29	O	-
±	O	-
4	O	-
kg/m2,	O	-
e	O	-
índice	O	-
medio	O	-
de	O	-
apnea-hipopnea	O	-
37	O	-
±	O	-
23	O	-
eventos/h	O	-
)	O	-
recibieron	O	-
AZT,	O	-
CPAP,	O	-
o	O	-
AZT	O	-
más	O	-
CPAP	O	-
durante	O	-
períodos	O	-
de	O	-
2	O	-
semanas.	O	-

Se	O	-
lavó	O	-
la	O	-
medicación	O	-
antihipertensiva.	O	-

Se	O	-
compararon	O	-
la	O	-
presión	O	-
arterial	O	-
de	O	-
oficina	O	-
y	O	-
24	O	-
horas,	O	-
la	O	-
rigidez	O	-
arterial,	O	-
los	O	-
datos	O	-
del	O	-
estudio	O	-
poligráfico	O	-
del	O	-
sueño	O	-
y	O	-
la	O	-
química	O	-
de	O	-
la	O	-
sangre.	O	-

El	O	-
AZT	O	-
solo	O	-
y	O	-
el	O	-
AZT	O	-
más	O	-
el	O	-
CPAP,	O	-
pero	O	-
no	O	-
el	O	-
CPAP	O	-
solo,	O	-
redujeron	O	-
la	O	-
presión	O	-
arterial	O	-
media	O	-
de	O	-
oficina	O	-
en	O	-
comparación	O	-
con	O	-
el	O	-
valor	O	-
basal	O	-
(	O	-
-7	O	-
[	O	-
IC	O	-
95	O	-
%	O	-
-11	O	-
a	O	-
-4	O	-
],	O	-
-7	O	-
[	O	-
IC	O	-
95	O	-
%	O	-
-11	O	-
a	O	-
-4	O	-
]	O	-
y	O	-
-1	O	-
[	O	-
IC	O	-
95	O	-
%	O	-
-5	O	-
a	O	-
4	O	-
]	O	-
mmHg,	O	-
respectivamente	O	-
;	O	-
el	O	-
análisis	O	-
de	O	-
mediciones	O	-
repetidas	O	-
de	O	-
la	O	-
varianza	O	-
(	O	-
RM-ANOVA	O	-
;	O	-
P	O	-
=	O	-
0,015	O	-
).	O	-

La	B-Premise	HighQuality
presión	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
aórtica	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
aumento,	I-Premise	HighQuality
evaluados	I-Premise	HighQuality
por	I-Premise	HighQuality
la	I-Premise	HighQuality
tonometría	I-Premise	HighQuality
oscilatoria	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
arteria	I-Premise	HighQuality
radial,	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
vieron	I-Premise	HighQuality
afectados	I-Premise	HighQuality
por	I-Premise	HighQuality
la	I-Premise	HighQuality
CPAP	I-Premise	HighQuality
pero	I-Premise	HighQuality
disminuyeron	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
AZT	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
AZT	I-Premise	HighQuality
más	I-Premise	HighQuality
CPAP	I-Premise	HighQuality
(	I-Premise	HighQuality
RM-ANOVA	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,030	I-Premise	HighQuality
y,031,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
apnea-hipopnea	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
tres	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
sobre	I-Premise	HighQuality
todo	I-Premise	HighQuality
por	I-Premise	HighQuality
AZT	I-Premise	HighQuality
más	I-Premise	HighQuality
CPAP	I-Premise	HighQuality
(	I-Premise	HighQuality
RM-ANOVA	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,003	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
concentración	I-Premise	HighQuality
venosa	I-Premise	HighQuality
de	I-Premise	HighQuality
bicarbonato	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
AZT	I-Premise	HighQuality
se	I-Premise	HighQuality
correlacionó	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
del	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
apnea-hipopnea	I-Premise	HighQuality
(	I-Premise	HighQuality
r	I-Premise	HighQuality
=	I-Premise	HighQuality
0,66,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,013	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Claim	HighQuality
AZT	I-Claim	HighQuality
redujo	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial,	I-Claim	HighQuality
la	I-Claim	HighQuality
rigidez	I-Claim	HighQuality
vascular,	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
respiración	I-Claim	HighQuality
desordenada	I-Claim	HighQuality
del	I-Claim	HighQuality
sueño	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
AOS	I-Claim	HighQuality
e	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
comorbida.	I-Claim	HighQuality

La	B-Claim	HighQuality
inhibición	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
anhidrasa	I-Claim	HighQuality
carbónica	I-Claim	HighQuality
puede	I-Claim	HighQuality
constituir	I-Claim	HighQuality
un	I-Claim	HighQuality
posible	I-Claim	HighQuality
objetivo	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
terapia	I-Claim	HighQuality
farmacológica	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
apnea	I-Claim	HighQuality
del	I-Claim	HighQuality
sueño	I-Claim	HighQuality
e	I-Claim	HighQuality
hipertensión	I-Claim	HighQuality
comorbida.	I-Claim	HighQuality

El	O	-
propósito	O	-
de	O	-
esta	O	-
revisión	O	-
es	O	-
correlacionar	O	-
las	O	-
predicciones	O	-
basadas	O	-
en	O	-
datos	O	-
preclínicos	O	-
con	O	-
los	O	-
resultados	O	-
de	O	-
ensayos	O	-
clínicos	O	-
que	O	-
examinan	O	-
los	O	-
efectos	O	-
de	O	-
los	O	-
tratamientos	O	-
de	O	-
diabetes	O	-
basados	O	-
en	O	-
la	O	-
incretina	O	-
sobre	O	-
el	O	-
riñón.	O	-

Los	O	-
tratamientos	O	-
basados	O	-
en	O	-
la	O	-
incretina	O	-
incluyen	O	-
agonistas	O	-
del	O	-
receptor	O	-
del	O	-
péptido	O	-
1	O	-
similar	O	-
al	O	-
glucagón	O	-
(	O	-
GLP-1R	O	-
)	O	-
e	O	-
inhibidores	O	-
de	O	-
la	O	-
enzima,	O	-
dipeptidil	O	-
peptidasa-4	O	-
(	O	-
DPP-4	O	-
).	O	-

Además,	O	-
lo	O	-
que	O	-
se	O	-
sabe	O	-
sobre	O	-
las	O	-
terapias	O	-
basadas	O	-
en	O	-
la	O	-
incretina	O	-
se	O	-
comparará	O	-
con	O	-
lo	O	-
que	O	-
se	O	-
sabe	O	-
sobre	O	-
los	O	-
efectos	O	-
renales	O	-
de	O	-
los	O	-
inhibidores	O	-
del	O	-
SGLT2.	O	-

Los	O	-
ensayos	O	-
clínicos	O	-
a	O	-
gran	O	-
escala	O	-
han	O	-
demostrado	O	-
que	O	-
los	O	-
inhibidores	O	-
de	O	-
SGLT2	O	-
reducen	O	-
la	O	-
albuminuria	O	-
y	O	-
preservan	O	-
la	O	-
tasa	O	-
estimada	O	-
de	O	-
filtración	O	-
glomerular	O	-
(TFG)	O	-
en	O	-
pacientes	O	-
con	O	-
nefropatía	O	-
diabética.	O	-

Un	O	-
mecanismo	O	-
hemodinámico	O	-
conciso	O	-
y	O	-
plausible	O	-
está	O	-
respaldado	O	-
por	O	-
la	O	-
investigación	O	-
preclínica	O	-
sobre	O	-
la	O	-
fisiología	O	-
y	O	-
farmacología	O	-
del	O	-
SGLT2.	O	-

Los	B-Premise	HighQuality
ensayos	I-Premise	HighQuality
clínicos	I-Premise	HighQuality
a	I-Premise	HighQuality
gran	I-Premise	HighQuality
escala	I-Premise	HighQuality
han	I-Premise	HighQuality
demostrado	I-Premise	HighQuality
que	I-Premise	HighQuality
las	I-Premise	HighQuality
terapias	I-Premise	HighQuality
basadas	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
incretina	I-Premise	HighQuality
mitigan	I-Premise	HighQuality
la	I-Premise	HighQuality
albuminuria,	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
han	I-Premise	HighQuality
mostrado	I-Premise	HighQuality
efectos	I-Premise	HighQuality
beneficiosos	I-Premise	HighQuality
sobre	I-Premise	HighQuality
la	I-Premise	HighQuality
TFG	I-Premise	HighQuality
e.	I-Premise	HighQuality

La	B-Premise	HighQuality
investigación	I-Premise	HighQuality
sobre	I-Premise	HighQuality
las	I-Premise	HighQuality
terapias	I-Premise	HighQuality
basadas	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
incretina	I-Premise	HighQuality
ha	I-Premise	HighQuality
producido	I-Premise	HighQuality
una	I-Premise	HighQuality
diversidad	I-Premise	HighQuality
de	I-Premise	HighQuality
efectos	I-Premise	HighQuality
directos	I-Premise	HighQuality
en	I-Premise	HighQuality
todo	I-Premise	HighQuality
el	I-Premise	HighQuality
cuerpo,	I-Premise	HighQuality
que	I-Premise	HighQuality
alimenta	I-Premise	HighQuality
la	I-Premise	HighQuality
especulación	I-Premise	HighQuality
sobre	I-Premise	HighQuality
cómo	I-Premise	HighQuality
estos	I-Premise	HighQuality
fármacos	I-Premise	HighQuality
podrían	I-Premise	HighQuality
beneficiar	I-Premise	HighQuality
al	I-Premise	HighQuality
riñón	I-Premise	HighQuality
diabético	I-Premise	HighQuality
y	I-Premise	HighQuality
afectar	I-Premise	HighQuality
su	I-Premise	HighQuality
función	I-Premise	HighQuality
(	I-Premise	HighQuality
s	I-Premise	HighQuality
).	I-Premise	HighQuality

Pero	B-Premise	HighQuality
los	I-Premise	HighQuality
experimentos	I-Premise	HighQuality
in	I-Premise	HighQuality
vivo	I-Premise	HighQuality
aún	I-Premise	HighQuality
no	I-Premise	HighQuality
han	I-Premise	HighQuality
confirmado	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
mecanismos	I-Premise	HighQuality
propuestos	I-Premise	HighQuality
que	I-Premise	HighQuality
subyacen	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
fenómenos	I-Premise	HighQuality
emergentes,	I-Premise	HighQuality
como	I-Premise	HighQuality
la	I-Premise	HighQuality
reabsorción	I-Premise	HighQuality
de	I-Premise	HighQuality
fluido	I-Premise	HighQuality
tubular	I-Premise	HighQuality
proximal,	I-Premise	HighQuality
son	I-Premise	HighQuality
los	I-Premise	HighQuality
predichos	I-Premise	HighQuality
por	I-Premise	HighQuality
los	I-Premise	HighQuality
experimentos	I-Premise	HighQuality
celulares	I-Premise	HighQuality
y	I-Premise	HighQuality
moleculares.	I-Premise	HighQuality

Puede	B-Claim	HighQuality
haber	I-Claim	HighQuality
efectos	I-Claim	HighQuality
saludables	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
tratamientos	I-Claim	HighQuality
a	I-Claim	HighQuality
base	I-Claim	HighQuality
de	I-Claim	HighQuality
incretina	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
riñón	I-Claim	HighQuality
diabético,	I-Claim	HighQuality
pero	B-Claim	HighQuality
el	I-Claim	HighQuality
sistema	I-Claim	HighQuality
es	I-Claim	HighQuality
complejo	I-Claim	HighQuality
y	I-Claim	HighQuality
no	I-Claim	HighQuality
es	I-Claim	HighQuality
susceptible	I-Claim	HighQuality
de	I-Claim	HighQuality
una	I-Claim	HighQuality
explicación	I-Claim	HighQuality
simple	I-Claim	HighQuality
o	I-Claim	HighQuality
predicción	I-Claim	HighQuality
previa.	I-Claim	HighQuality

Esto	B-Claim	HighQuality
contrasta	I-Claim	HighQuality
con	I-Claim	HighQuality
los	I-Claim	HighQuality
efectos	I-Claim	HighQuality
renales	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
inhibidores	I-Claim	HighQuality
de	I-Claim	HighQuality
SGLT2,	I-Claim	HighQuality
que	I-Claim	HighQuality
se	I-Claim	HighQuality
pueden	I-Claim	HighQuality
explicar	I-Claim	HighQuality
de	I-Claim	HighQuality
forma	I-Claim	HighQuality
concisa.	I-Claim	HighQuality

Comparar	O	-
la	O	-
eficacia	O	-
(	O	-
reducción	O	-
de	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
y	O	-
la	O	-
seguridad	O	-
de	O	-
latanoprost	O	-
(	O	-
T2345	O	-
)	O	-
sin	O	-
conservantes	O	-
con	O	-
cloruro	O	-
de	O	-
benzalconio	O	-
(	O	-
BAK	O	-
)	O	-
-latanoprost	O	-
conservada	O	-
(	O	-
BPL	O	-
;	O	-
Xalatan	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
ocular	O	-
(	O	-
OHT	O	-
)	O	-
o	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
(	O	-
POAG	O	-
).	O	-

Ensayo	O	-
prospectivo,	O	-
internacional,	O	-
multicéntrico,	O	-
aleatorizado,	O	-
enmascarado-investigado,	O	-
en	O	-
grupo	O	-
paralelo.	O	-

Después	O	-
de	O	-
un	O	-
período	O	-
de	O	-
lavado,	O	-
los	O	-
pacientes	O	-
con	O	-
POAG	O	-
u	O	-
OHT,	O	-
tratados	O	-
previamente	O	-
con	O	-
BPL	O	-
en	O	-
monoterapia,	O	-
recibieron	O	-
al	O	-
azar	O	-
T2345	O	-
o	O	-
BPL	O	-
(	O	-
una	O	-
gota	O	-
en	O	-
el	O	-
ojo	O	-
afectado	O	-
(	O	-
s	O	-
)	O	-
)	O	-
una	O	-
vez	O	-
al	O	-
día	O	-
de	O	-
D0	O	-
a	O	-
D84.	O	-

El	O	-
cambio	O	-
en	O	-
la	O	-
PIO	O	-
se	O	-
midió	O	-
a	O	-
las	O	-
09:00	O	-
(	O	-
±1	O	-
h	O	-
)	O	-
de	O	-
D0	O	-
a	O	-
D84	O	-
en	O	-
el	O	-
ojo	O	-
peor.	O	-

La	B-Premise	HighQuality
reducción	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
(	I-Premise	HighQuality
D0-D84	I-Premise	HighQuality
)	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
-8,6	I-Premise	HighQuality
±2,6	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
-36	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
T2345	I-Premise	HighQuality
y	I-Premise	HighQuality
-	I-Premise	HighQuality
9,0	I-Premise	HighQuality
±	I-Premise	HighQuality
2,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
-38	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
BPL,	I-Premise	HighQuality
confirmando	I-Premise	HighQuality
la	I-Premise	HighQuality
no	I-Premise	HighQuality
inferioridad	I-Premise	HighQuality
de	I-Premise	HighQuality
T2345	I-Premise	HighQuality
a	I-Premise	HighQuality
BPL.	I-Premise	HighQuality

La	O	-
no	O	-
inferioridad	O	-
de	O	-
T2345	O	-
se	O	-
observó	O	-
a	O	-
partir	O	-
de	O	-
D15.	O	-

El	B-Premise	HighQuality
acontecimiento	I-Premise	HighQuality
adverso	I-Premise	HighQuality
ocular	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuente,	I-Premise	HighQuality
intolerancia	I-Premise	HighQuality
al	I-Premise	HighQuality
fármaco,	I-Premise	HighQuality
se	I-Premise	HighQuality
notificó	I-Premise	HighQuality
en	I-Premise	HighQuality
1	I-Premise	HighQuality
(	I-Premise	HighQuality
0,5%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
T2345	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
4	I-Premise	HighQuality
(	I-Premise	HighQuality
2,1	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
BPL.	I-Premise	HighQuality

La	B-Premise	HighQuality
hiperemia	I-Premise	HighQuality
conjuntival	I-Premise	HighQuality
moderada	I-Premise	HighQuality
a	I-Premise	HighQuality
grave	I-Premise	HighQuality
fue	I-Premise	HighQuality
menos	I-Premise	HighQuality
frecuente	I-Premise	HighQuality
en	I-Premise	HighQuality
T2345	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
BPL	I-Premise	HighQuality
en	I-Premise	HighQuality
D42	I-Premise	HighQuality
(	I-Premise	HighQuality
20,2	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
30,6	I-Premise	HighQuality
%;	I-Premise	HighQuality
p=0,003	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
D84	I-Premise	HighQuality
(	I-Premise	HighQuality
21,4	I-Premise	HighQuality
%	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
29,1	I-Premise	HighQuality
%;	I-Premise	HighQuality
p=0,02	I-Premise	HighQuality
).	I-Premise	HighQuality

Tras	B-Premise	HighQuality
la	I-Premise	HighQuality
instilación,	I-Premise	HighQuality
la	I-Premise	HighQuality
puntuación	I-Premise	HighQuality
global	I-Premise	HighQuality
subjetiva	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
síntomas	I-Premise	HighQuality
oculares	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
T2345	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
BPL	I-Premise	HighQuality
en	I-Premise	HighQuality
D42	I-Premise	HighQuality
(	I-Premise	HighQuality
0,15	I-Premise	HighQuality
vs	I-Premise	HighQuality
0,41	I-Premise	HighQuality
;	I-Premise	HighQuality
p=0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
D84	I-Premise	HighQuality
(	I-Premise	HighQuality
0,18	I-Premise	HighQuality
vs	I-Premise	HighQuality
0,46	I-Premise	HighQuality
;	I-Premise	HighQuality
p=0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Claim	HighQuality
latanoprost	I-Claim	HighQuality
libre	I-Claim	HighQuality
de	I-Claim	HighQuality
conservantes	I-Claim	HighQuality
tiene	I-Claim	HighQuality
la	I-Claim	HighQuality
misma	I-Claim	HighQuality
eficacia	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
BPL,	I-Claim	HighQuality
con	I-Claim	HighQuality
tolerancia	I-Claim	HighQuality
local	I-Claim	HighQuality
mejorada.	I-Claim	HighQuality

La	O	-
hipotensión	O	-
intradialítica	O	-
(	O	-
IDH	O	-
)	O	-
es	O	-
una	O	-
causa	O	-
importante	O	-
de	O	-
morbilidad	O	-
y	O	-
mortalidad	O	-
entre	O	-
los	O	-
pacientes	O	-
en	O	-
hemodiálisis.	O	-

Utilizamos	O	-
un	O	-
modelo	O	-
de	O	-
inmersión	O	-
para	O	-
evaluar	O	-
el	O	-
papel	O	-
de	O	-
la	O	-
reducción	O	-
del	O	-
volumen	O	-
circulante	O	-
efectivo,	O	-
y	O	-
para	O	-
examinar	O	-
si	O	-
la	O	-
recarga	O	-
facilitada	O	-
puede	O	-
prevenir	O	-
la	O	-
IDH.	O	-

Diez	O	-
pacientes	O	-
en	O	-
hemodiálisis	O	-
masculina	O	-
con	O	-
episodios	O	-
frecuentes	O	-
de	O	-
IDH	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
una	O	-
sesión	O	-
de	O	-
hemodiálisis	O	-
"	O	-
húmeda	O	-
"	O	-
o	O	-
"	O	-
seca	O	-
"	O	-
de	O	-
media	O	-
semana,	O	-
y	O	-
posteriormente	O	-
se	O	-
sometieron	O	-
a	O	-
la	O	-
otra	O	-
sesión	O	-
de	O	-
manera	O	-
cruzada.	O	-

Las	O	-
sesiones	O	-
húmedas	O	-
se	O	-
realizaron	O	-
mientras	O	-
se	O	-
sumergía	O	-
hasta	O	-
el	O	-
cuello	O	-
en	O	-
un	O	-
baño	O	-
de	O	-
34	O	-
a	O	-
35°C,	O	-
y	O	-
la	O	-
sesión	O	-
seca	O	-
fue	O	-
hemodiálisis	O	-
estándar.	O	-

Los	O	-
objetivos	O	-
de	O	-
ultrafiltración	O	-
se	O	-
determinaron	O	-
como	O	-
la	O	-
media	O	-
de	O	-
ultrafiltración	O	-
durante	O	-
las	O	-
10	O	-
sesiones	O	-
anteriores	O	-
a	O	-
la	O	-
primera	O	-
sesión	O	-
de	O	-
estudio	O	-
±	O	-
10	O	-
%.	O	-

La	O	-
ultrafiltración	O	-
media	O	-
fue	O	-
similar	O	-
en	O	-
las	O	-
sesiones	O	-
húmeda	O	-
y	O	-
seca	O	-
(	O	-
2,99	O	-
±	O	-
0,64	O	-
kg	O	-
vs.	O	-
2,96	O	-
±	O	-
0,74	O	-
kg	O	-
).	O	-

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
hipotensión	I-Premise	HighQuality
sintomática	I-Premise	HighQuality
en	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
durante	I-Premise	HighQuality
la	I-Premise	HighQuality
sesión	I-Premise	HighQuality
húmeda,	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
4	I-Premise	HighQuality
(	I-Premise	HighQuality
40%	I-Premise	HighQuality
)	I-Premise	HighQuality
durante	I-Premise	HighQuality
la	I-Premise	HighQuality
sesión	I-Premise	HighQuality
seca.	I-Premise	HighQuality

La	B-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
ajustada	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
ultrafiltración	I-Premise	HighQuality
se	I-Premise	HighQuality
mantuvo	I-Premise	HighQuality
estable	I-Premise	HighQuality
durante	I-Premise	HighQuality
la	I-Premise	HighQuality
sesión	I-Premise	HighQuality
húmeda,	I-Premise	HighQuality
0,22	I-Premise	HighQuality
mmHg/15	I-Premise	HighQuality
min	I-Premise	HighQuality
(IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
-0,27	I-Premise	HighQuality
a	I-Premise	HighQuality
0,70	I-Premise	HighQuality
),	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,38,	I-Premise	HighQuality
y	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
durante	I-Premise	HighQuality
la	I-Premise	HighQuality
sesión	I-Premise	HighQuality
seca,	I-Premise	HighQuality
-0,68	I-Premise	HighQuality
mmHg/15	I-Premise	HighQuality
min	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
-1,24	I-Premise	HighQuality
a	I-Premise	HighQuality
-0,11	I-Premise	HighQuality
),	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,02.	I-Premise	HighQuality

La	B-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
diastólica	I-Premise	HighQuality
no	I-Premise	HighQuality
cambió	I-Premise	HighQuality
durante	I-Premise	HighQuality
las	I-Premise	HighQuality
sesiones.	I-Premise	HighQuality

El	B-Premise	HighQuality
péptido	I-Premise	HighQuality
natriurético	I-Premise	HighQuality
atrial	I-Premise	HighQuality
medio	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
sesión	I-Premise	HighQuality
húmeda,	I-Premise	HighQuality
31,36	I-Premise	HighQuality
pgr/ml	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
8,73-53,99	I-Premise	HighQuality
),	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,007,	I-Premise	HighQuality
y	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
leve	I-Premise	HighQuality
e	I-Premise	HighQuality
insignificantemente	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
sesión	I-Premise	HighQuality
seca,	I-Premise	HighQuality
21,66	I-Premise	HighQuality
pgr/ml	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
-52,59	I-Premise	HighQuality
a	I-Premise	HighQuality
9,25	I-Premise	HighQuality
),	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,167.	I-Premise	HighQuality

Los	B-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
aldosterona	I-Premise	HighQuality
en	I-Premise	HighQuality
sangre	I-Premise	HighQuality
no	I-Premise	HighQuality
cambiaron.	I-Premise	HighQuality

La	B-Claim	HighQuality
reducción	I-Claim	HighQuality
del	I-Claim	HighQuality
volumen	I-Claim	HighQuality
circulante	I-Claim	HighQuality
efectivo	I-Claim	HighQuality
es	I-Claim	HighQuality
una	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
principales	I-Claim	HighQuality
causas	I-Claim	HighQuality
de	I-Claim	HighQuality
IDH,	I-Claim	HighQuality
que	I-Claim	HighQuality
puede	I-Claim	HighQuality
prevenirse	I-Claim	HighQuality
mediante	I-Claim	HighQuality
una	I-Claim	HighQuality
redistribución	I-Claim	HighQuality
facilitada	I-Claim	HighQuality
por	I-Claim	HighQuality
inmersión	I-Claim	HighQuality
en	I-Claim	HighQuality
agua	I-Claim	HighQuality
de	I-Claim	HighQuality
salida.	I-Claim	HighQuality

Comparar	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
a	O	-
lo	O	-
largo	O	-
del	O	-
tiempo	O	-
después	O	-
de	O	-
la	O	-
trabeculectomía	O	-
estándar	O	-
frente	O	-
a	O	-
la	O	-
implantación	O	-
de	O	-
Ex-PRESS	O	-
en	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
primario	O	-
bilateral	O	-
de	O	-
ángulo	O	-
abierto	O	-
(	O	-
POAG	O	-
).	O	-

Estudio	O	-
prospectivo,	O	-
aleatorizado.	O	-

Este	O	-
estudio	O	-
incluyó	O	-
pacientes	O	-
adultos	O	-
con	O	-
POAG	O	-
bilateral	O	-
que	O	-
requerían	O	-
cirugía.	O	-

Cada	O	-
paciente	O	-
se	O	-
sometió	O	-
a	O	-
trabeculectomía	O	-
en	O	-
un	O	-
ojo	O	-
y	O	-
a	O	-
implante	O	-
de	O	-
Ex-PRESS	O	-
bajo	O	-
colgajo	O	-
escleral	O	-
en	O	-
el	O	-
otro	O	-
ojo	O	-
según	O	-
asignaciones	O	-
contralaterales	O	-
aleatorias.	O	-

La	O	-
eficacia	O	-
fue	O	-
evaluada	O	-
por	O	-
los	O	-
valores	O	-
de	O	-
la	O	-
PIO	O	-
y	O	-
las	O	-
tasas	O	-
de	O	-
éxito	O	-
(umbral	O	-
de	O	-
la	O	-
PIO	O	-
y/o	O	-
necesidad	O	-
de	O	-
glaucoma	O	-
tópico	O	-
)	O	-
durante	O	-
30	O	-
meses.	O	-

El	O	-
análisis	O	-
estadístico	O	-
incluyó	O	-
modelos	O	-
de	O	-
Ecuación	O	-
de	O	-
Estimación	O	-
Generalizada	O	-
y	O	-
Supervivencia	O	-
de	O	-
Cox,	O	-
y	O	-
pruebas	O	-
t	O	-
emparejadas.	O	-

Se	O	-
estudiaron	O	-
30	O	-
ojos	O	-
de	O	-
15	O	-
pacientes	O	-
durante	O	-
una	O	-
media	O	-
de	O	-
23,6	O	-
meses	O	-
(DE,	O	-
±	O	-
6,9	O	-
).	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
última	I-Premise	HighQuality
visita	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento,	I-Premise	HighQuality
la	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
de	I-Premise	HighQuality
31,1	I-Premise	HighQuality
(	I-Premise	HighQuality
±	I-Premise	HighQuality
14,2	I-Premise	HighQuality
)	I-Premise	HighQuality
a	I-Premise	HighQuality
16,2	I-Premise	HighQuality
(	I-Premise	HighQuality
±	I-Premise	HighQuality
1,5	I-Premise	HighQuality
)	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía,	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
28,1	I-Premise	HighQuality
(	I-Premise	HighQuality
±	I-Premise	HighQuality
9,0	I-Premise	HighQuality
)	I-Premise	HighQuality
a	I-Premise	HighQuality
15,7	I-Premise	HighQuality
(	I-Premise	HighQuality
±	I-Premise	HighQuality
1,8	I-Premise	HighQuality
)	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
implantación	I-Premise	HighQuality
Ex-PRESS	I-Premise	HighQuality
(	I-Premise	HighQuality
P=0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
número	I-Premise	HighQuality
medio	I-Premise	HighQuality
de	I-Premise	HighQuality
medicamentos	I-Premise	HighQuality
anti-glaucoma	I-Premise	HighQuality
prescritos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
último	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
de	I-Premise	HighQuality
3,7	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
preoperatorio	I-Premise	HighQuality
(ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
)	I-Premise	HighQuality
a	I-Premise	HighQuality
0,9	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
0,3	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
implantación	I-Premise	HighQuality
de	I-Premise	HighQuality
Ex-PRESS	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
éxito	I-Premise	HighQuality
completo	I-Premise	HighQuality
(	I-Premise	HighQuality
5	I-Premise	HighQuality
<	I-Premise	HighQuality
PIO	I-Premise	HighQuality
<	I-Premise	HighQuality
18	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
sin	I-Premise	HighQuality
medicamentos	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
mayores	I-Premise	HighQuality
con	I-Premise	HighQuality
Ex-PRESS	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0024	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
complicaciones	I-Premise	HighQuality
postoperatorias	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(	I-Premise	HighQuality
33	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
Ex-PRESS	I-Premise	HighQuality
(	I-Premise	HighQuality
20	I-Premise	HighQuality
%	I-Premise	HighQuality
),	I-Premise	HighQuality
con	I-Premise	HighQuality
cuatro	I-Premise	HighQuality
ojos	I-Premise	HighQuality
de	I-Premise	HighQuality
trabeculectomía	I-Premise	HighQuality
(	I-Premise	HighQuality
27	I-Premise	HighQuality
%	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
necesitaban	I-Premise	HighQuality
intervenciones	I-Premise	HighQuality
postoperatorias,	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
con	I-Premise	HighQuality
Ex-PRESS.	I-Premise	HighQuality

La	B-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
implantación	I-Claim	HighQuality
de	I-Claim	HighQuality
Ex-PRESS	I-Claim	HighQuality
proporcionaron	I-Claim	HighQuality
un	I-Claim	HighQuality
control	I-Claim	HighQuality
similar	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO,	I-Claim	HighQuality
pero	O	-
el	B-Claim	HighQuality
grupo	I-Claim	HighQuality
de	I-Claim	HighQuality
Ex-PRESS	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
una	I-Claim	HighQuality
menor	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
complicaciones,	I-Claim	HighQuality
menos	I-Claim	HighQuality
intervenciones	I-Claim	HighQuality
postoperatorias,	I-Claim	HighQuality
y	I-Claim	HighQuality
necesitó	I-Claim	HighQuality
menos	I-Claim	HighQuality
medicamentos	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
glaucoma.	I-Claim	HighQuality

Se	B-Claim	HighQuality
ha	I-Claim	HighQuality
informado	I-Claim	HighQuality
de	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
nitrito	I-Claim	HighQuality
de	I-Claim	HighQuality
sodio	I-Claim	HighQuality
es	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
para	I-Claim	HighQuality
reducir	I-Claim	HighQuality
el	I-Claim	HighQuality
dolor	I-Claim	HighQuality
periférico	I-Claim	HighQuality
crónico.	I-Claim	HighQuality

Evaluar	O	-
la	O	-
seguridad	O	-
y	O	-
eficacia	O	-
de	O	-
40	O	-
y	O	-
80	O	-
mg,	O	-
BID,	O	-
de	O	-
una	O	-
formulación	O	-
oral	O	-
de	O	-
liberación	O	-
sostenida	O	-
de	O	-
nitrito	O	-
sódico	O	-
(	O	-
SR-nitrita	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
neuropatía	O	-
diabética,	O	-
y	O	-
determinar	O	-
si	O	-
la	O	-
SR-nitrita	O	-
reduciría	O	-
la	O	-
frecuencia	O	-
de	O	-
cefaleas	O	-
notificadas	O	-
previamente	O	-
por	O	-
sujetos	O	-
que	O	-
recibían	O	-
las	O	-
mismas	O	-
dosis	O	-
de	O	-
una	O	-
formulación	O	-
de	O	-
liberación	O	-
inmediata.	O	-

Fase	O	-
II,	O	-
un	O	-
solo	O	-
centro,	O	-
aleatorizado,	O	-
doble	O	-
ciego,	O	-
ensayo	O	-
clínico	O	-
controlado	O	-
con	O	-
placebo.	O	-

Veinticuatro	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
40	O	-
mg	O	-
u	O	-
80	O	-
mg	O	-
de	O	-
SR-nitrita	O	-
o	O	-
placebo	O	-
dos	O	-
veces	O	-
al	O	-
día	O	-
durante	O	-
12	O	-
semanas.	O	-

El	O	-
objetivo	O	-
principal	O	-
era	O	-
determinar	O	-
si	O	-
los	O	-
dolores	O	-
de	O	-
cabeza	O	-
se	O	-
reducirían	O	-
utilizando	O	-
SR-nitrita.	O	-

La	O	-
variable	O	-
principal	O	-
de	O	-
eficacia	O	-
fue	O	-
la	O	-
diferencia	O	-
media	O	-
en	O	-
el	O	-
cambio	O	-
de	O	-
la	O	-
puntuación	O	-
del	O	-
Inventario	O	-
Neuropático	O	-
de	O	-
Dolor	O	-
Síntoma	O	-
(NPSI)	O	-
desde	O	-
el	O	-
valor	O	-
basal	O	-
hasta	O	-
el	O	-
notificado	O	-
después	O	-
de	O	-
12	O	-
semanas	O	-
de	O	-
tratamiento.	O	-

Las	O	-
variables	O	-
secundarias	O	-
incluyeron	O	-
cambios	O	-
desde	O	-
el	O	-
inicio	O	-
para	O	-
la	O	-
Escala	O	-
Breve	O	-
Inventario	O	-
de	O	-
Dolor	O	-
(BPI	O	-
),	O	-
el	O	-
cuestionario	O	-
RAND	O	-
36,	O	-
el	O	-
Cuestionario	O	-
McGill	O	-
de	O	-
Forma	O	-
Corta,	O	-
el	O	-
puntaje	O	-
diario	O	-
del	O	-
paciente	O	-
reportado	O	-
para	O	-
dolor	O	-
neuropático,	O	-
cambios	O	-
en	O	-
HbA1c,	O	-
PulseOx	O	-
y	O	-
pruebas	O	-
sensoriales	O	-
cuantitativas.	O	-

El	B-Premise	HighQuality
número	I-Premise	HighQuality
de	I-Premise	HighQuality
sujetos	I-Premise	HighQuality
que	I-Premise	HighQuality
notificaron	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
número	I-Premise	HighQuality
de	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
no	I-Premise	HighQuality
cambiaron	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
dosis.	I-Premise	HighQuality

No	B-Premise	HighQuality
hubo	I-Premise	HighQuality
informes	I-Premise	HighQuality
de	I-Premise	HighQuality
cefaleas	I-Premise	HighQuality
relacionadas	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento.	I-Premise	HighQuality

Aunque	O	-
no	O	-
se	O	-
identificaron	O	-
diferencias	O	-
significativas	O	-
en	O	-
las	O	-
respuestas	O	-
de	O	-
los	O	-
pacientes	O	-
a	O	-
los	O	-
cuestionarios,	O	-
se	O	-
observó	O	-
una	O	-
tendencia.	O	-

En	B-Premise	HighQuality
la	I-Premise	HighQuality
evaluación	I-Premise	HighQuality
del	I-Premise	HighQuality
NPSI,	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
de	I-Premise	HighQuality
40	I-Premise	HighQuality
mg	I-Premise	HighQuality
y	I-Premise	HighQuality
80	I-Premise	HighQuality
mg	I-Premise	HighQuality
notificaron	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
dolor	I-Premise	HighQuality
del	I-Premise	HighQuality
12,7	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
22,0	I-Premise	HighQuality
%,	I-Premise	HighQuality
respectivamente,	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
8,4	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
placebo.	I-Premise	HighQuality

También	O	-
se	O	-
observó	O	-
una	O	-
tendencia	O	-
con	O	-
la	O	-
puntuación	O	-
de	O	-
gravedad	O	-
total	O	-
del	O	-
BPI.	O	-

Sin	O	-
embargo,	O	-
el	B-Premise	HighQuality
grupo	I-Premise	HighQuality
posológico	I-Premise	HighQuality
de	I-Premise	HighQuality
40	I-Premise	HighQuality
mg	I-Premise	HighQuality
notificó	I-Premise	HighQuality
la	I-Premise	HighQuality
mayor	I-Premise	HighQuality
reducción	I-Premise	HighQuality
del	I-Premise	HighQuality
dolor	I-Premise	HighQuality
utilizando	I-Premise	HighQuality
el	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
dolor	I-Premise	HighQuality
de	I-Premise	HighQuality
McGill	I-Premise	HighQuality
y	I-Premise	HighQuality
a	I-Premise	HighQuality
través	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
registros	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
puntajes	I-Premise	HighQuality
diarios	I-Premise	HighQuality
de	I-Premise	HighQuality
dolor,	I-Premise	HighQuality
donde	O	-
la	B-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
puntajes	I-Premise	HighQuality
de	I-Premise	HighQuality
dolor	I-Premise	HighQuality
reportados	I-Premise	HighQuality
por	I-Premise	HighQuality
los	I-Premise	HighQuality
sujetos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
40	I-Premise	HighQuality
mg	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
al	I-Premise	HighQuality
día	I-Premise	HighQuality
41	I-Premise	HighQuality
y	I-Premise	HighQuality
generalmente	I-Premise	HighQuality
se	I-Premise	HighQuality
mantuvo	I-Premise	HighQuality
inferior	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
puntajes	I-Premise	HighQuality
reportados	I-Premise	HighQuality
por	I-Premise	HighQuality
los	I-Premise	HighQuality
sujetos	I-Premise	HighQuality
en	I-Premise	HighQuality
cualquiera	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
otros	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

Los	B-Premise	HighQuality
pacientes	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
80	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
SR-nitrita	I-Premise	HighQuality
presentaron	I-Premise	HighQuality
una	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
tanto	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
conducción	I-Premise	HighQuality
sensorial	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
nervios	I-Premise	HighQuality
como	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
velocidad	I-Premise	HighQuality
sensorial	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
nervios.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
HbA1c	I-Premise	HighQuality
ni	I-Premise	HighQuality
en	I-Premise	HighQuality
PulseOx.	I-Premise	HighQuality

El	B-Claim	HighQuality
nitrito	I-Claim	HighQuality
sódico	I-Claim	HighQuality
de	I-Claim	HighQuality
liberación	I-Claim	HighQuality
sostenida	I-Claim	HighQuality
impide	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
formulación	I-Claim	HighQuality
de	I-Claim	HighQuality
liberación	I-Claim	HighQuality
inmediata	I-Claim	HighQuality
de	I-Claim	HighQuality
nitrito	I-Claim	HighQuality
sódico	I-Claim	HighQuality
presenten	I-Claim	HighQuality
cefalea.	I-Claim	HighQuality

En	B-Premise	HighQuality
un	I-Premise	HighQuality
estudio	I-Premise	HighQuality
previo	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
enfermedad	I-Premise	HighQuality
arterial	I-Premise	HighQuality
periférica	I-Premise	HighQuality
(PAD	I-Premise	HighQuality
),	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
40	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
BID	I-Premise	HighQuality
produjo	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativa	I-Premise	HighQuality
del	I-Premise	HighQuality
dolor	I-Premise	HighQuality
notificado,	I-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
tendencias	I-Premise	HighQuality
similares	I-Premise	HighQuality
al	I-Premise	HighQuality
final	I-Premise	HighQuality
del	I-Premise	HighQuality
período	I-Premise	HighQuality
de	I-Premise	HighQuality
ensayo	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
mayoría	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
cuestionarios	I-Premise	HighQuality
de	I-Premise	HighQuality
dolor	I-Premise	HighQuality
utilizados	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
estudio.	I-Premise	HighQuality

El	B-Premise	HighQuality
tratamiento	I-Premise	HighQuality
de	I-Premise	HighQuality
80	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
BID	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
el	I-Premise	HighQuality
efecto	I-Premise	HighQuality
más	I-Premise	HighQuality
pronunciado	I-Premise	HighQuality
sobre	I-Premise	HighQuality
la	I-Premise	HighQuality
bioactividad	I-Premise	HighQuality
(pruebas	I-Premise	HighQuality
sensoriales	I-Premise	HighQuality
cuantitativas	I-Premise	HighQuality
),	I-Premise	HighQuality
que	I-Premise	HighQuality
fue	I-Premise	HighQuality
similar	I-Premise	HighQuality
al	I-Premise	HighQuality
estudio	I-Premise	HighQuality
PAD,	I-Premise	HighQuality
donde	I-Premise	HighQuality
este	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
la	I-Premise	HighQuality
mayor	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
DMF	I-Premise	HighQuality
{	I-Premise	HighQuality
UA	I-Premise	HighQuality
:	I-Premise	HighQuality
deletree	I-Premise	HighQuality
la	I-Premise	HighQuality
DMF	I-Premise	HighQuality
}.	I-Premise	HighQuality

La	B-Claim	HighQuality
capacidad	I-Claim	HighQuality
de	I-Claim	HighQuality
aliviar	I-Claim	HighQuality
el	I-Claim	HighQuality
dolor	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
BID	I-Claim	HighQuality
de	I-Claim	HighQuality
SR-nitrita	I-Claim	HighQuality
ofrece	I-Claim	HighQuality
la	I-Claim	HighQuality
promesa	I-Claim	HighQuality
de	I-Claim	HighQuality
un	I-Claim	HighQuality
nuevo	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
no	I-Claim	HighQuality
addictivo,	I-Claim	HighQuality
no	I-Claim	HighQuality
sedante	I-Claim	HighQuality
del	I-Claim	HighQuality
dolor	I-Claim	HighQuality
crónico	I-Claim	HighQuality
y	I-Claim	HighQuality
justifica	I-Claim	HighQuality
un	I-Claim	HighQuality
estudio	I-Claim	HighQuality
más	I-Claim	HighQuality
a	I-Claim	HighQuality
fondo.	I-Claim	HighQuality

Se	O	-
investigaron	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
fase	O	-
láctea	O	-
sin	O	-
grasa	O	-
de	O	-
Ca	O	-
alta	O	-
(MD	O	-
)	O	-
(	O	-
prescripción	O	-
de	O	-
aproximadamente	O	-
1500	O	-
mg	O	-
de	O	-
Ca/d	O	-
)	O	-
v.	O	-
fase	O	-
baja	O	-
de	O	-
Ca	O	-
(	O	-
CD	O	-
)	O	-
(	O	-
prescripción	O	-
de	O	-
aproximadamente	O	-
800	O	-
mg	O	-
de	O	-
Ca/d	O	-
)	O	-
en	O	-
una	O	-
dieta	O	-
restringida	O	-
energéticamente	O	-
sobre	O	-
el	O	-
síndrome	O	-
metabólico	O	-
(	O	-
SM	O	-
)	O	-
y	O	-
medidas	O	-
cardiometabólicas	O	-
en	O	-
individuos	O	-
con	O	-
diabetes	O	-
mellitus	O	-
tipo	O	-
2	O	-
(	O	-
T2DM	O	-
)	O	-
y	O	-
bajo	O	-
consumo	O	-
habitual	O	-
de	O	-
Ca	O	-
(	O	-
<	O	-
600	O	-
mg/d	O	-
).	O	-

En	O	-
este	O	-
diseño	O	-
cruzado	O	-
aleatorizado,	O	-
catorce	O	-
adultos	O	-
con	O	-
T2DM	O	-
(	O	-
49·5	O	-
(	O	-
sd	O	-
8·6	O	-
)	O	-
años,	O	-
IMC	O	-
29·4	O	-
(	O	-
sd	O	-
4·5	O	-
)	O	-
kg/m2	O	-
)	O	-
consumieron	O	-
MD	O	-
o	O	-
CD	O	-
durante	O	-
12	O	-
semanas,	O	-
con	O	-
un	O	-
lavado	O	-
de	O	-
18	O	-
semanas	O	-
entre	O	-
fases.	O	-

Un	O	-
batido	O	-
de	O	-
desayuno	O	-
conteniendo	O	-
700	O	-
mg	O	-
(	O	-
MD	O	-
)	O	-
o	O	-
6·4	O	-
mg	O	-
(	O	-
CD	O	-
)	O	-
de	O	-
Ca	O	-
fue	O	-
consumido	O	-
en	O	-
el	O	-
laboratorio.	O	-

Además,	O	-
se	O	-
prescribieron	O	-
dietas	O	-
restringidas	O	-
de	O	-
energía	O	-
(	O	-
800	O	-
mg	O	-
de	O	-
Ca/d	O	-
dietética	O	-
).	O	-

Circunferencia	O	-
de	O	-
cintura	O	-
(	O	-
WC	O	-
),	O	-
glucosa	O	-
en	O	-
ayunas,	O	-
TAG	O	-
en	O	-
ayunas,	O	-
sistólica	O	-
(	O	-
PAS	O	-
)	O	-
y	O	-
presión	O	-
arterial	O	-
diastólica	O	-
(	O	-
PAD	O	-
),	O	-
colesterol	O	-
total	O	-
en	O	-
ayunas,	O	-
colesterol	O	-
en	O	-
ayunas	O	-
LDL,	O	-
colesterol	O	-
HDL	O	-
en	O	-
ayunas,	O	-
HDL	O	-
:	O	-
relación	O	-
LDL,	O	-
HDL	O	-
:	O	-
relación	O	-
TAG	O	-
y	O	-
producto	O	-
de	O	-
acumulación	O	-
lipídica	O	-
(	O	-
LAP	O	-
)	O	-
índice	O	-
se	O	-
evaluaron	O	-
al	O	-
inicio	O	-
y	O	-
después	O	-
de	O	-
cada	O	-
fase.	O	-

El	B-Premise	HighQuality
consumo	I-Premise	HighQuality
de	I-Premise	HighQuality
ca	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
estudio	I-Premise	HighQuality
fue	I-Premise	HighQuality
equivalente	I-Premise	HighQuality
a	I-Premise	HighQuality
1200	I-Premise	HighQuality
mg/d	I-Premise	HighQuality
durante	I-Premise	HighQuality
MD	I-Premise	HighQuality
y	I-Premise	HighQuality
525	I-Premise	HighQuality
mg/d	I-Premise	HighQuality
durante	I-Premise	HighQuality
CD.	I-Premise	HighQuality

Hubo	B-Premise	HighQuality
una	I-Premise	HighQuality
mayor	I-Premise	HighQuality
reducción	I-Premise	HighQuality
en	I-Premise	HighQuality
CC,	I-Premise	HighQuality
PAS,	I-Premise	HighQuality
PAD	I-Premise	HighQuality
e	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
PLA	I-Premise	HighQuality
después	I-Premise	HighQuality
de	I-Premise	HighQuality
MD	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
CD.	I-Premise	HighQuality

HDL	B-Premise	HighQuality
:	I-Premise	HighQuality
LDL	I-Premise	HighQuality
razón	I-Premise	HighQuality
aumentada	I-Premise	HighQuality
y	I-Premise	HighQuality
colesterol	I-Premise	HighQuality
total,	I-Premise	HighQuality
LDL-colesterol,	I-Premise	HighQuality
PAS,	I-Premise	HighQuality
DBP	I-Premise	HighQuality
y	I-Premise	HighQuality
índice	I-Premise	HighQuality
LAP	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
sólo	I-Premise	HighQuality
en	I-Premise	HighQuality
MD.	I-Premise	HighQuality

El	B-Premise	HighQuality
consumo	I-Premise	HighQuality
de	I-Premise	HighQuality
aproximadamente	I-Premise	HighQuality
1200	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
Ca/d	I-Premise	HighQuality
(700	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
leche	I-Premise	HighQuality
sin	I-Premise	HighQuality
grasa	I-Premise	HighQuality
+	I-Premise	HighQuality
500	I-Premise	HighQuality
mg	I-Premise	HighQuality
de	I-Premise	HighQuality
otras	I-Premise	HighQuality
fuentes	I-Premise	HighQuality
dietéticas	I-Premise	HighQuality
)	I-Premise	HighQuality
asociado	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
dieta	I-Premise	HighQuality
restringida	I-Premise	HighQuality
energéticamente	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
algunos	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
componentes	I-Premise	HighQuality
de	I-Premise	HighQuality
MetS	I-Premise	HighQuality
y	I-Premise	HighQuality
medidas	I-Premise	HighQuality
cardiometabólicas	I-Premise	HighQuality
en	I-Premise	HighQuality
adultos	I-Premise	HighQuality
con	I-Premise	HighQuality
T2DM.	I-Premise	HighQuality

El	O	-
objetivo	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
proponer	O	-
el	O	-
papel	O	-
del	O	-
trasplante	O	-
de	O	-
membrana	O	-
amniótica	O	-
(AMT	O	-
)	O	-
como	O	-
modulador	O	-
adicional	O	-
en	O	-
la	O	-
trabeculectomía	O	-
aumentada	O	-
de	O	-
la	O	-
Mitomicina	O	-
C	O	-
(MCM	O	-
)	O	-
primaria.	O	-

Se	O	-
trata	O	-
de	O	-
un	O	-
estudio	O	-
prospectivo	O	-
aleatorizado	O	-
de	O	-
intervención.	O	-

Cuarenta	O	-
ojos	O	-
de	O	-
39	O	-
pacientes	O	-
adultos	O	-
con	O	-
glaucoma	O	-
primario	O	-
no	O	-
controlado	O	-
fueron	O	-
divididos	O	-
aleatoriamente	O	-
en	O	-
dos	O	-
grupos	O	-
iguales.	O	-

El	O	-
grupo	O	-
control	O	-
se	O	-
sometió	O	-
a	O	-
trabeculectomía	O	-
aumentada	O	-
con	O	-
MMC	O	-
mientras	O	-
que	O	-
el	O	-
grupo	O	-
de	O	-
estudio	O	-
se	O	-
sometió	O	-
a	O	-
AMT	O	-
adicional.	O	-

Los	O	-
pacientes	O	-
fueron	O	-
objeto	O	-
de	O	-
seguimiento	O	-
durante	O	-
12	O	-
meses	O	-
y	O	-
los	O	-
resultados	O	-
medidos	O	-
fueron	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
),	O	-
necesidad	O	-
de	O	-
intervención	O	-
adicional	O	-
y	O	-
morfología	O	-
bleb.	O	-

El	B-Premise	HighQuality
éxito	I-Premise	HighQuality
completo	I-Premise	HighQuality
(definido	I-Premise	HighQuality
como	I-Premise	HighQuality
PIO	I-Premise	HighQuality
<	I-Premise	HighQuality
16	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
sin	I-Premise	HighQuality
medicación	I-Premise	HighQuality
)	I-Premise	HighQuality
se	I-Premise	HighQuality
pudo	I-Premise	HighQuality
lograr	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
85%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio,	I-Premise	HighQuality
mientras	I-Premise	HighQuality
que	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
60%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
PIO	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
un	I-Premise	HighQuality
71,1	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio	I-Premise	HighQuality
de	I-Premise	HighQuality
41,9	I-Premise	HighQuality
±	I-Premise	HighQuality
10,6	I-Premise	HighQuality
a	I-Premise	HighQuality
12,1	I-Premise	HighQuality
±	I-Premise	HighQuality
2,7	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
40,5	I-Premise	HighQuality
±	I-Premise	HighQuality
8,5	I-Premise	HighQuality
a	I-Premise	HighQuality
12,8	I-Premise	HighQuality
±	I-Premise	HighQuality
4,5	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control,	I-Premise	HighQuality
una	I-Premise	HighQuality
disminución	I-Premise	HighQuality
del	I-Premise	HighQuality
68,29	I-Premise	HighQuality
%.	I-Premise	HighQuality

Los	B-Premise	HighQuality
Blebs	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
AMT	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
una	I-Premise	HighQuality
mejor	I-Premise	HighQuality
morfología	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
blebs	I-Premise	HighQuality
en	I-Premise	HighQuality
términos	I-Premise	HighQuality
de	I-Premise	HighQuality
extensión	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mejor	I-Premise	HighQuality
(	I-Premise	HighQuality
E3	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
día	I-Premise	HighQuality
1	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
mejor	I-Premise	HighQuality
altura	I-Premise	HighQuality
(	I-Premise	HighQuality
H2	I-Premise	HighQuality
y	I-Premise	HighQuality
H3	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04	I-Premise	HighQuality
),	I-Premise	HighQuality
de	I-Premise	HighQuality
acuerdo	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
Escala	I-Premise	HighQuality
de	I-Premise	HighQuality
Clasificación	I-Premise	HighQuality
de	I-Premise	HighQuality
Apariencia	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
Blebs	I-Premise	HighQuality
de	I-Premise	HighQuality
Indiana,	I-Premise	HighQuality
en	I-Premise	HighQuality
todas	I-Premise	HighQuality
las	I-Premise	HighQuality
visitas	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
junto	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
vascularidad	I-Premise	HighQuality
normal.	I-Premise	HighQuality

El	B-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
estudio	I-Premise	HighQuality
requirió	I-Premise	HighQuality
una	I-Premise	HighQuality
cantidad	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,03	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
babosas	I-Premise	HighQuality
bleb	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

Amnion	B-Claim	HighQuality
mejoró	I-Claim	HighQuality
la	I-Claim	HighQuality
eficacia	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
trabeculectomía	I-Claim	HighQuality
modulada	I-Claim	HighQuality
por	I-Claim	HighQuality
MMC	I-Claim	HighQuality
en	I-Claim	HighQuality
términos	I-Claim	HighQuality
de	I-Claim	HighQuality
ojos	I-Claim	HighQuality
con	I-Claim	HighQuality
éxito	I-Claim	HighQuality
completo	I-Claim	HighQuality
y	I-Claim	HighQuality
intervenciones	I-Claim	HighQuality
menores	I-Claim	HighQuality
como	I-Claim	HighQuality
la	I-Claim	HighQuality
necesidad	I-Claim	HighQuality
de	I-Claim	HighQuality
bleb.	I-Claim	HighQuality

Esto	B-Claim	HighQuality
reitera	I-Claim	HighQuality
el	I-Claim	HighQuality
papel	I-Claim	HighQuality
de	I-Claim	HighQuality
amnion	I-Claim	HighQuality
como	I-Claim	HighQuality
un	I-Claim	HighQuality
modulador	I-Claim	HighQuality
de	I-Claim	HighQuality
bleb	I-Claim	HighQuality
seguro	I-Claim	HighQuality
y	I-Claim	HighQuality
eficaz.	I-Claim	HighQuality

Un	O	-
bleb	O	-
difusamente	O	-
elevado	O	-
con	O	-
conjuntiva	O	-
más	O	-
saludable	O	-
puede	O	-
ir	O	-
un	O	-
largo	O	-
camino	O	-
en	O	-
la	O	-
predicción	O	-
de	O	-
una	O	-
mejor	O	-
salud	O	-
y	O	-
longevidad	O	-
del	O	-
bleb.	O	-

Se	B-Claim	HighQuality
ha	I-Claim	HighQuality
demostrado	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
inhibición	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
metionina	I-Claim	HighQuality
aminopeptidasa	I-Claim	HighQuality
2	I-Claim	HighQuality
(	I-Claim	HighQuality
MetAP2	I-Claim	HighQuality
)	I-Claim	HighQuality
produce	I-Claim	HighQuality
una	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
de	I-Claim	HighQuality
peso	I-Claim	HighQuality
significativa	I-Claim	HighQuality
y	I-Claim	HighQuality
un	I-Claim	HighQuality
mejor	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
glucosa.	I-Claim	HighQuality

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
de	O	-
fase	O	-
1	O	-
se	O	-
evaluaron	O	-
la	O	-
seguridad	O	-
y	O	-
tolerabilidad,	O	-
la	O	-
farmacocinética	O	-
y	O	-
la	O	-
eficacia	O	-
preliminar	O	-
de	O	-
un	O	-
nuevo	O	-
inhibidor	O	-
de	O	-
MetAP2,	O	-
ZGN-1061.	O	-

Este	O	-
ensayo	O	-
clínico	O	-
incluyó	O	-
una	O	-
fase	O	-
de	O	-
dosis	O	-
ascendente	O	-
única	O	-
(SAD	O	-
)	O	-
en	O	-
sujetos	O	-
sanos	O	-
(	O	-
IMC	O	-
23	O	-
a	O	-
<	O	-
30	O	-
kg/m2	O	-
)	O	-
y	O	-
una	O	-
fase	O	-
de	O	-
dosis	O	-
ascendente	O	-
múltiple	O	-
(	O	-
MAD	O	-
)	O	-
en	O	-
sujetos	O	-
sanos	O	-
con	O	-
IMC	O	-
27	O	-
a	O	-
40	O	-
kg/m2.	O	-

Las	O	-
dosis	O	-
de	O	-
fase	O	-
DAE	O	-
administradas	O	-
por	O	-
vía	O	-
subcutánea	O	-
(CC)	O	-
fueron	O	-
de	O	-
0,2,	O	-
0,6,	O	-
1,2,	O	-
2,4,	O	-
3,6	O	-
y	O	-
4,8	O	-
mg,	O	-
y	O	-
la	O	-
fase	O	-
DAM	O	-
evaluada	O	-
por	O	-
vía	O	-
subcutánea	O	-
fue	O	-
de	O	-
0,2,	O	-
0,6	O	-
y	O	-
1,8	O	-
mg	O	-
dos	O	-
veces	O	-
a	O	-
la	O	-
semana	O	-
durante	O	-
4	O	-
semanas.	O	-

La	O	-
fase	O	-
de	O	-
TAE	O	-
incluyó	O	-
39	O	-
sujetos	O	-
(	O	-
ZGN-1061	O	-
N=28,	O	-
placebo	O	-
N=11	O	-
),	O	-
90	O	-
%	O	-
hombres	O	-
e	O	-
IMC	O	-
26,4	O	-
kg/m2.	O	-

ZGN-1061	B-Premise	HighQuality
fue	I-Premise	HighQuality
bien	I-Premise	HighQuality
tolerado	I-Premise	HighQuality
en	I-Premise	HighQuality
todas	I-Premise	HighQuality
las	I-Premise	HighQuality
dosis	I-Premise	HighQuality
con	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
más	I-Premise	HighQuality
frecuentes	I-Premise	HighQuality
de	I-Premise	HighQuality
dolor	I-Premise	HighQuality
de	I-Premise	HighQuality
cabeza	I-Premise	HighQuality
leve	I-Premise	HighQuality
e	I-Premise	HighQuality
irritación	I-Premise	HighQuality
relacionada	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
procedimiento.	I-Premise	HighQuality

No	O	-
hubo	O	-
efectos	O	-
adversos	O	-
graves	O	-
o	O	-
graves.	O	-

Todas	B-Premise	HighQuality
las	I-Premise	HighQuality
dosis	I-Premise	HighQuality
de	I-Premise	HighQuality
ZGN-1061	I-Premise	HighQuality
se	I-Premise	HighQuality
absorbieron	I-Premise	HighQuality
y	I-Premise	HighQuality
eliminaron	I-Premise	HighQuality
rápidamente,	I-Premise	HighQuality
lo	I-Premise	HighQuality
que	I-Premise	HighQuality
dio	I-Premise	HighQuality
lugar	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
exposición	I-Premise	HighQuality
de	I-Premise	HighQuality
corta	I-Premise	HighQuality
duración	I-Premise	HighQuality
que	I-Premise	HighQuality
se	I-Premise	HighQuality
prevé	I-Premise	HighQuality
reducir	I-Premise	HighQuality
al	I-Premise	HighQuality
mínimo	I-Premise	HighQuality
los	I-Premise	HighQuality
posibles	I-Premise	HighQuality
riesgos	I-Premise	HighQuality
fuera	I-Premise	HighQuality
del	I-Premise	HighQuality
objetivo	I-Premise	HighQuality
del	I-Premise	HighQuality
medicamento.	I-Premise	HighQuality

La	O	-
fase	O	-
MAD	O	-
incluyó	O	-
29	O	-
sujetos	O	-
(	O	-
ZGN-1061	O	-
N=22,	O	-
placebo	O	-
N=7	O	-
),	O	-
76%	O	-
varones	O	-
e	O	-
IMC	O	-
33,5	O	-
kg/m2.	O	-

Las	B-Premise	HighQuality
observaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
seguridad	I-Premise	HighQuality
fueron	I-Premise	HighQuality
consistentes	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
hallazgos	I-Premise	HighQuality
del	I-Premise	HighQuality
TAE.	I-Premise	HighQuality

Las	B-Premise	HighQuality
medidas	I-Premise	HighQuality
de	I-Premise	HighQuality
eficacia	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
fase	I-Premise	HighQuality
MAD	I-Premise	HighQuality
indicaron	I-Premise	HighQuality
tendencias	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
de	I-Premise	HighQuality
peso	I-Premise	HighQuality
(	I-Premise	HighQuality
-1,5	I-Premise	HighQuality
kg	I-Premise	HighQuality
total	I-Premise	HighQuality
ZGN-1061	I-Premise	HighQuality
vs	I-Premise	HighQuality
-0,2	I-Premise	HighQuality
kg	I-Premise	HighQuality
placebo	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
otros	I-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
biomarcador.	I-Premise	HighQuality

ZGN-1061	B-Claim	HighQuality
fue	I-Claim	HighQuality
bien	I-Claim	HighQuality
tolerado	I-Claim	HighQuality
sin	I-Claim	HighQuality
señales	I-Claim	HighQuality
de	I-Claim	HighQuality
seguridad	I-Claim	HighQuality
en	I-Claim	HighQuality
todas	I-Claim	HighQuality
las	I-Claim	HighQuality
dosis	I-Claim	HighQuality
probadas.	I-Claim	HighQuality

Además,	O	-
el	B-Claim	HighQuality
perfil	I-Claim	HighQuality
farmacocinético	I-Claim	HighQuality
deseado	I-Claim	HighQuality
y	I-Claim	HighQuality
las	I-Claim	HighQuality
observaciones	I-Claim	HighQuality
preliminares	I-Claim	HighQuality
de	I-Claim	HighQuality
eficacia	I-Claim	HighQuality
con	I-Claim	HighQuality
ZGN-1061	I-Claim	HighQuality
apoyan	I-Claim	HighQuality
la	I-Claim	HighQuality
evaluación	I-Claim	HighQuality
en	I-Claim	HighQuality
ensayos	I-Claim	HighQuality
clínicos	I-Claim	HighQuality
mayores	I-Claim	HighQuality
y	I-Claim	HighQuality
más	I-Claim	HighQuality
largos.	I-Claim	HighQuality

Comparar	O	-
el	O	-
efecto	O	-
de	O	-
la	O	-
trabeculoplastia	O	-
selectiva	O	-
por	O	-
láser	O	-
(	O	-
SLT	O	-
)	O	-
y	O	-
travoprost	O	-
en	O	-
las	O	-
fluctuaciones	O	-
de	O	-
24	O	-
horas	O	-
de	O	-
la	O	-
PIO	O	-
en	O	-
el	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto	O	-
(	O	-
POAG	O	-
)	O	-
y	O	-
glaucoma	O	-
de	O	-
tensión	O	-
normal	O	-
(	O	-
NTG	O	-
).	O	-

Se	O	-
incluyeron	O	-
60	O	-
ojos.	O	-

Dieciséis	O	-
y	O	-
14	O	-
ojos	O	-
de	O	-
los	O	-
pacientes	O	-
con	O	-
POAG	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
un	O	-
SLT	O	-
de	O	-
360°	O	-
o	O	-
un	O	-
travoprost	O	-
de	O	-
0,004	O	-
%,	O	-
respectivamente.	O	-

Catorce	O	-
y	O	-
16	O	-
ojos	O	-
de	O	-
pacientes	O	-
con	O	-
GNT	O	-
fueron	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
SLT	O	-
o	O	-
travoprost,	O	-
respectivamente.	O	-

Los	O	-
datos	O	-
de	O	-
la	O	-
PIO	O	-
de	O	-
24	O	-
horas	O	-
se	O	-
recogieron	O	-
antes	O	-
del	O	-
tratamiento	O	-
y	O	-
de	O	-
6	O	-
a	O	-
8	O	-
semanas	O	-
después	O	-
del	O	-
tratamiento.	O	-

La	O	-
PIO	O	-
se	O	-
midió	O	-
a	O	-
intervalos	O	-
de	O	-
2	O	-
horas	O	-
en	O	-
posición	O	-
sentada	O	-
durante	O	-
el	O	-
día	O	-
(	O	-
9	O	-
AM	O	-
a	O	-
7	O	-
PM	O	-
)	O	-
y	O	-
en	O	-
posición	O	-
supina	O	-
durante	O	-
la	O	-
noche	O	-
(	O	-
9	O	-
PM	O	-
a	O	-
7	O	-
AM	O	-
).	O	-

La	O	-
principal	O	-
medida	O	-
del	O	-
resultado	O	-
fue	O	-
el	O	-
porcentaje	O	-
de	O	-
ojos	O	-
que	O	-
alcanzaron	O	-
fluctuaciones	O	-
de	O	-
la	O	-
PIO	O	-
después	O	-
del	O	-
tratamiento	O	-
de	O	-
24	O	-
horas	O	-
<	O	-
3	O	-
mm	O	-
Hg.	O	-

El	O	-
éxito	O	-
en	O	-
la	O	-
reducción	O	-
de	O	-
las	O	-
fluctuaciones	O	-
se	O	-
definió	O	-
como	O	-
al	O	-
menos	O	-
una	O	-
reducción	O	-
del	O	-
50	O	-
%	O	-
en	O	-
estas	O	-
fluctuaciones.	O	-

Se	O	-
analizaron	O	-
58	O	-
ojos.	O	-

En	O	-
general,	O	-
los	B-Premise	HighQuality
ojos	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
SLT	I-Premise	HighQuality
y	I-Premise	HighQuality
travoprost	I-Premise	HighQuality
lograron	I-Premise	HighQuality
una	I-Premise	HighQuality
reducción	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
valores	I-Premise	HighQuality
basales	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
(	I-Premise	HighQuality
-3,7	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
[	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,002	I-Premise	HighQuality
]	I-Premise	HighQuality
vs	I-Premise	HighQuality
-4,1	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
[	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
],	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
).	I-Premise	HighQuality

No	O	-
hubo	O	-
diferencia	O	-
significativa	O	-
en	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
PIO	O	-
en	O	-
ambos	O	-
grupos	O	-
según	O	-
el	O	-
tipo	O	-
de	O	-
glaucoma.	O	-

Durante	O	-
el	O	-
periodo	O	-
diurno,	O	-
el	O	-
100	O	-
%	O	-
de	O	-
los	O	-
ojos	O	-
POAG	O	-
en	O	-
el	O	-
grupo	O	-
travoprost	O	-
alcanzaron	O	-
fluctuaciones	O	-
de	O	-
la	O	-
PIO	O	-
después	O	-
del	O	-
tratamiento	O	-
<	O	-
3	O	-
mm	O	-
Hg,	O	-
y	O	-
el	O	-
87	O	-
%	O	-
de	O	-
los	O	-
ojos	O	-
en	O	-
el	O	-
grupo	O	-
SLT	O	-
alcanzaron	O	-
el	O	-
mismo	O	-
nivel	O	-
de	O	-
fluctuaciones	O	-
(	O	-
p	O	-
<	O	-
0,001	O	-
).	O	-

El	B-Premise	HighQuality
96%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
de	I-Premise	HighQuality
GNT	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
travoprost,	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
82%	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
SLT	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
fluctuaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
<	I-Premise	HighQuality
3	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,01	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
éxito	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
fluctuaciones	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
75	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
92	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
SLT	I-Premise	HighQuality
y	I-Premise	HighQuality
travoprost,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,005	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Claim	HighQuality
efecto	I-Claim	HighQuality
de	I-Claim	HighQuality
travoprost	I-Claim	HighQuality
sobre	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
POAG	I-Claim	HighQuality
y	I-Claim	HighQuality
NTG	I-Claim	HighQuality
fue	I-Claim	HighQuality
significativo	I-Claim	HighQuality
tanto	I-Claim	HighQuality
durante	I-Claim	HighQuality
el	I-Claim	HighQuality
día	I-Claim	HighQuality
como	I-Claim	HighQuality
durante	I-Claim	HighQuality
la	I-Claim	HighQuality
noche,	I-Claim	HighQuality
mientras	O	-
que	O	-
el	B-Claim	HighQuality
efecto	I-Claim	HighQuality
del	I-Claim	HighQuality
SLT	I-Claim	HighQuality
fue	I-Claim	HighQuality
significativo	I-Claim	HighQuality
sólo	I-Claim	HighQuality
durante	I-Claim	HighQuality
la	I-Claim	HighQuality
noche.	I-Claim	HighQuality

Tanto	B-Claim	HighQuality
travoprost	I-Claim	HighQuality
como	I-Claim	HighQuality
SLT	I-Claim	HighQuality
pueden	I-Claim	HighQuality
reducir	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
POAG	I-Claim	HighQuality
y	I-Claim	HighQuality
NTG.	I-Claim	HighQuality

Sobre	O	-
la	O	-
base	O	-
de	O	-
las	O	-
posiciones	O	-
habituales,	O	-
travoprost	B-Claim	LowQuality
controla	I-Claim	LowQuality
mejor	I-Claim	LowQuality
las	I-Claim	LowQuality
fluctuaciones	I-Claim	LowQuality
de	I-Claim	LowQuality
la	I-Claim	LowQuality
PIO	I-Claim	LowQuality
que	I-Claim	LowQuality
el	I-Claim	LowQuality
SLT,	I-Claim	LowQuality
especialmente	I-Claim	LowQuality
durante	I-Claim	LowQuality
el	I-Claim	LowQuality
día.	I-Claim	LowQuality

Comparar	O	-
los	O	-
efectos	O	-
aditivos	O	-
y	O	-
la	O	-
seguridad	O	-
del	O	-
1	O	-
%	O	-
de	O	-
brinzolamida/0,5	O	-
%	O	-
de	O	-
combinación	O	-
fija	O	-
de	O	-
timolol	O	-
(	O	-
BTFC	O	-
)	O	-
frente	O	-
al	O	-
régimen	O	-
de	O	-
dosis	O	-
bajas	O	-
del	O	-
1	O	-
%	O	-
de	O	-
dorzolamida/0,5	O	-
%	O	-
de	O	-
combinación	O	-
fija	O	-
de	O	-
timolol	O	-
(	O	-
DTFC	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
glaucoma	O	-
de	O	-
ángulo	O	-
abierto	O	-
e	O	-
hipertensión	O	-
ocular	O	-
(	O	-
OAG/OH	O	-
)	O	-
tras	O	-
el	O	-
tratamiento	O	-
con	O	-
análogos	O	-
de	O	-
prostaglandina	O	-
(	O	-
PGA	O	-
).	O	-

Un	O	-
estudio	O	-
prospectivo,	O	-
aleatorizado,	O	-
doble	O	-
enmascarado,	O	-
multicéntrico,	O	-
de	O	-
grupo	O	-
paralelo	O	-
y	O	-
controlado	O	-
con	O	-
actividad	O	-
incluyó	O	-
a	O	-
201	O	-
pacientes	O	-
japoneses	O	-
con	O	-
OAG/OH	O	-
que	O	-
habían	O	-
sido	O	-
tratados	O	-
con	O	-
PGA.	O	-

La	O	-
eficacia	O	-
se	O	-
evaluó	O	-
como	O	-
el	O	-
cambio	O	-
en	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
con	O	-
respecto	O	-
al	O	-
valor	O	-
basal	O	-
después	O	-
de	O	-
las	O	-
semanas	O	-
4	O	-
y	O	-
8.	O	-

Se	O	-
evaluó	O	-
la	O	-
seguridad	O	-
con	O	-
tasas	O	-
de	O	-
eventos	O	-
adversos,	O	-
puntuación	O	-
de	O	-
molestias	O	-
oculares,	O	-
escala	O	-
de	O	-
desenfoque,	O	-
presión	O	-
arterial	O	-
y	O	-
frecuencia	O	-
cardíaca,	O	-
agudeza	O	-
visual	O	-
mejor	O	-
corregida	O	-
(	O	-
BCVA	O	-
)	O	-
y	O	-
exámenes	O	-
con	O	-
lámpara	O	-
de	O	-
corte.	O	-

La	B-Premise	HighQuality
variación	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
intraocular	I-Premise	HighQuality
(	I-Premise	HighQuality
PIO	I-Premise	HighQuality
)	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
valor	I-Premise	HighQuality
basal	I-Premise	HighQuality
a	I-Premise	HighQuality
las	I-Premise	HighQuality
9	I-Premise	HighQuality
AM/11	I-Premise	HighQuality
AM	I-Premise	HighQuality
agrupada	I-Premise	HighQuality
a	I-Premise	HighQuality
lo	I-Premise	HighQuality
largo	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
8	I-Premise	HighQuality
semanas	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
-3,3/-3,3	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
BTFC	I-Premise	HighQuality
y	I-Premise	HighQuality
-2,9/-3,4	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
DTFC,	I-Premise	HighQuality
demostrando	O	-
no	O	-
inferioridad	O	-
de	O	-
BTFC	O	-
a	O	-
DTFC.	O	-

Se	B-Premise	HighQuality
observó	I-Premise	HighQuality
con	I-Premise	HighQuality
frecuencia	I-Premise	HighQuality
irritación	I-Premise	HighQuality
ocular	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
DTFC.	I-Premise	HighQuality

Aunque	O	-
la	B-Premise	HighQuality
visión	I-Premise	HighQuality
borrosa	I-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
con	I-Premise	HighQuality
frecuencia	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
BTFC,	I-Premise	HighQuality
fue	O	-
transitoria	O	-
y	O	-
la	O	-
desenfoque	O	-
se	O	-
convirtió	O	-
en	O	-
el	O	-
equivalente	O	-
a	O	-
3	O	-
minutos	O	-
después	O	-
de	O	-
la	O	-
instilación	O	-
entre	O	-
dos	O	-
grupos.	O	-

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
ningún	I-Premise	HighQuality
problema	I-Premise	HighQuality
digno	I-Premise	HighQuality
de	I-Premise	HighQuality
mención	I-Premise	HighQuality
en	I-Premise	HighQuality
otros	I-Premise	HighQuality
resultados	I-Premise	HighQuality
de	I-Premise	HighQuality
seguridad.	I-Premise	HighQuality

La	B-Claim	HighQuality
no	I-Claim	HighQuality
inferioridad	I-Claim	HighQuality
de	I-Claim	HighQuality
BTFC	I-Claim	HighQuality
a	I-Claim	HighQuality
DTFC	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
se	I-Claim	HighQuality
demostró	I-Claim	HighQuality
después	I-Claim	HighQuality
de	I-Claim	HighQuality
añadir	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
terapia	I-Claim	HighQuality
con	I-Claim	HighQuality
PGA	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
japoneses	I-Claim	HighQuality
con	I-Claim	HighQuality
OAG/OH.	I-Claim	HighQuality

Aunque	O	-
la	B-Claim	HighQuality
puntuación	I-Claim	HighQuality
de	I-Claim	HighQuality
visión	I-Claim	HighQuality
borrosa	I-Claim	HighQuality
fue	I-Claim	HighQuality
transitoriamente	I-Claim	HighQuality
mayor	I-Claim	HighQuality
en	I-Claim	HighQuality
BTFC	I-Claim	HighQuality
que	I-Claim	HighQuality
en	I-Claim	HighQuality
DTFC,	I-Claim	HighQuality
la	B-Claim	HighQuality
diferencia	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
disminuyó	I-Claim	HighQuality
y	I-Claim	HighQuality
desapareció	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tiempo.	I-Claim	HighQuality

Por	O	-
lo	O	-
tanto,	O	-
BTFC	B-Claim	HighQuality
puede	I-Claim	HighQuality
ser	I-Claim	HighQuality
considerado	I-Claim	HighQuality
como	I-Claim	HighQuality
un	I-Claim	HighQuality
agente	I-Claim	HighQuality
seguro	I-Claim	HighQuality
y	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
para	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
del	I-Claim	HighQuality
glaucoma.	I-Claim	HighQuality

La	B-Claim	HighQuality
eficacia	I-Claim	HighQuality
del	I-Claim	HighQuality
cambio	I-Claim	HighQuality
a	I-Claim	HighQuality
tenofovir	I-Claim	HighQuality
disoproxil	I-Claim	HighQuality
fumarato	I-Claim	HighQuality
(	I-Claim	HighQuality
TDF	I-Claim	HighQuality
)	I-Claim	HighQuality
en	I-Claim	HighQuality
monoterapia	I-Claim	HighQuality
a	I-Claim	HighQuality
partir	I-Claim	HighQuality
de	I-Claim	HighQuality
lamivudina	I-Claim	HighQuality
(	I-Claim	HighQuality
LAM	I-Claim	HighQuality
)	I-Claim	HighQuality
más	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
de	I-Claim	HighQuality
combinación	I-Claim	HighQuality
con	I-Claim	HighQuality
adefovir	I-Claim	HighQuality
dipivoxil	I-Claim	HighQuality
(	I-Claim	HighQuality
ADV	I-Claim	HighQuality
)	I-Claim	HighQuality
(	I-Claim	HighQuality
cambio	I-Claim	HighQuality
estable	I-Claim	HighQuality
)	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
crónica	I-Claim	HighQuality
(	I-Claim	HighQuality
CHB	I-Claim	HighQuality
)	I-Claim	HighQuality
resistente	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
LAM	I-Claim	HighQuality
y	I-Claim	HighQuality
ADN	I-Claim	HighQuality
indetectable	I-Claim	HighQuality
del	I-Claim	HighQuality
virus	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
(	I-Claim	HighQuality
VHB	I-Claim	HighQuality
)	I-Claim	HighQuality
no	I-Claim	HighQuality
está	I-Claim	HighQuality
clara.	I-Claim	HighQuality

En	O	-
este	O	-
ensayo	O	-
de	O	-
no	O	-
inferioridad,	O	-
los	O	-
pacientes	O	-
con	O	-
CHB	O	-
resistente	O	-
a	O	-
LAM	O	-
y	O	-
ADN	O	-
del	O	-
VHB	O	-
sérico	O	-
indetectable	O	-
(	O	-
<	O	-
20	O	-
UI/ml)	O	-
durante	O	-
>	O	-
6	O	-
meses	O	-
después	O	-
de	O	-
iniciar	O	-
el	O	-
tratamiento	O	-
de	O	-
combinación	O	-
LAM+ADV	O	-
fueron	O	-
aleatorizados	O	-
(	O	-
1:2	O	-
)	O	-
para	O	-
continuar	O	-
el	O	-
tratamiento	O	-
de	O	-
combinación	O	-
(	O	-
grupo	O	-
LAM+ADV,	O	-
n	O	-
=	O	-
58	O	-
)	O	-
o	O	-
para	O	-
cambiar	O	-
a	O	-
monoterapia	O	-
con	O	-
TDF	O	-
(	O	-
grupo	O	-
TDF,	O	-
n	O	-
=	O	-
111	O	-
).	O	-

Se	O	-
les	O	-
hizo	O	-
un	O	-
seguimiento	O	-
con	O	-
pruebas	O	-
de	O	-
bioquímica	O	-
sérica	O	-
y	O	-
medición	O	-
del	O	-
ADN	O	-
del	O	-
VHB	O	-
a	O	-
intervalos	O	-
de	O	-
12	O	-
semanas	O	-
durante	O	-
96	O	-
semanas.	O	-

La	O	-
variable	O	-
principal	O	-
de	O	-
valoración	O	-
de	O	-
este	O	-
estudio	O	-
fue	O	-
la	O	-
proporción	O	-
de	O	-
pacientes	O	-
con	O	-
reactivación	O	-
viral	O	-
a	O	-
la	O	-
semana	O	-
96.	O	-

Los	O	-
pacientes	O	-
con	O	-
CHB	O	-
incluidos	O	-
en	O	-
este	O	-
estudio	O	-
(	O	-
n	O	-
=	O	-
169	O	-
)	O	-
incluyeron	O	-
74	O	-
pacientes	O	-
con	O	-
cirrosis	O	-
hepática	O	-
compensada.	O	-

En	O	-
total,	O	-
9	O	-
pacientes	O	-
(	O	-
4	O	-
en	O	-
el	O	-
grupo	O	-
LAM+ADV	O	-
y	O	-
5	O	-
en	O	-
el	O	-
grupo	O	-
TDF	O	-
)	O	-
abandonaron	O	-
el	O	-
estudio.	O	-

Tras	B-Premise	HighQuality
un	I-Premise	HighQuality
período	I-Premise	HighQuality
medio	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
de	I-Premise	HighQuality
96	I-Premise	HighQuality
semanas,	I-Premise	HighQuality
la	I-Premise	HighQuality
proporción	I-Premise	HighQuality
de	I-Premise	HighQuality
reactivación	I-Premise	HighQuality
del	I-Premise	HighQuality
VHB	I-Premise	HighQuality
observada	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
6,8	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
4/58	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
LAM+ADV	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
4,5	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
5/111	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF	I-Premise	HighQuality
mediante	I-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
intención	I-Premise	HighQuality
de	I-Premise	HighQuality
tratar	I-Premise	HighQuality
(	I-Premise	HighQuality
diferencia,	I-Premise	HighQuality
-2,3	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
-9,84-5,24	I-Premise	HighQuality
%	I-Premise	HighQuality
).	I-Premise	HighQuality

Ninguno	B-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
sujetos	I-Premise	HighQuality
de	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
experimentó	I-Premise	HighQuality
reactivación	I-Premise	HighQuality
viral	I-Premise	HighQuality
basada	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
protocolo.	I-Premise	HighQuality

No	B-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
graves.	I-Premise	HighQuality

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
subgrupos	I-Premise	HighQuality
para	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
estimada	I-Premise	HighQuality
de	I-Premise	HighQuality
filtración	I-Premise	HighQuality
glomerular	I-Premise	HighQuality
(TFGe)	I-Premise	HighQuality
antes	I-Premise	HighQuality
y	I-Premise	HighQuality
después	I-Premise	HighQuality
del	I-Premise	HighQuality
tratamiento,	I-Premise	HighQuality
la	I-Premise	HighQuality
reducción	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
FRGe	I-Premise	HighQuality
sólo	I-Premise	HighQuality
se	I-Premise	HighQuality
observó	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF	I-Premise	HighQuality
con	I-Premise	HighQuality
cirrosis	I-Premise	HighQuality
(	I-Premise	HighQuality
85,22	I-Premise	HighQuality
vs.	I-Premise	HighQuality
79,83	I-Premise	HighQuality
mL/min/1,73	I-Premise	HighQuality
m2,	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,000	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Claim	HighQuality
cambio	I-Claim	HighQuality
estable	I-Claim	HighQuality
a	I-Claim	HighQuality
TDF	I-Claim	HighQuality
en	I-Claim	HighQuality
monoterapia	I-Claim	HighQuality
produjo	I-Claim	HighQuality
resultados	I-Claim	HighQuality
no	I-Claim	HighQuality
inferiores	I-Claim	HighQuality
a	I-Claim	HighQuality
las	I-Claim	HighQuality
96	I-Claim	HighQuality
semanas	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
los	I-Claim	HighQuality
resultados	I-Claim	HighQuality
obtenidos	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
combinado	I-Claim	HighQuality
LAM+ADV	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB	I-Claim	HighQuality
resistente	I-Claim	HighQuality
a	I-Claim	HighQuality
LAM	I-Claim	HighQuality
y	I-Claim	HighQuality
ADN	I-Claim	HighQuality
indetectable	I-Claim	HighQuality
del	I-Claim	HighQuality
VHB.	I-Claim	HighQuality

Sin	B-Claim	HighQuality
embargo,	I-Claim	HighQuality
la	I-Claim	HighQuality
monoterapia	I-Claim	HighQuality
con	I-Claim	HighQuality
TDF	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
cirrosis	I-Claim	HighQuality
requiere	I-Claim	HighQuality
una	I-Claim	HighQuality
estrecha	I-Claim	HighQuality
atención	I-Claim	HighQuality
con	I-Claim	HighQuality
respecto	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
renal.	I-Claim	HighQuality

Evaluar	O	-
la	O	-
seguridad	O	-
y	O	-
eficacia	O	-
a	O	-
largo	O	-
plazo	O	-
de	O	-
un	O	-
único	O	-
stent	O	-
de	O	-
microbypass	O	-
trabecular	O	-
con	O	-
cirugía	O	-
concomitante	O	-
de	O	-
cataratas	O	-
frente	O	-
a	O	-
la	O	-
cirugía	O	-
de	O	-
cataratas	O	-
sola	O	-
para	O	-
el	O	-
glaucoma	O	-
de	O	-
ángulo	O	-
abierto	O	-
de	O	-
leve	O	-
a	O	-
moderado.	O	-

Veintinueve	O	-
sitios	O	-
de	O	-
investigación,	O	-
Estados	O	-
Unidos.	O	-

Ensayo	O	-
clínico	O	-
multicéntrico	O	-
prospectivo	O	-
controlado	O	-
y	O	-
aleatorizado.	O	-

Los	O	-
ojos	O	-
con	O	-
glaucoma	O	-
de	O	-
leve	O	-
a	O	-
moderado	O	-
con	O	-
presión	O	-
intraocular	O	-
no	O	-
medicada	O	-
(PIO)	O	-
de	O	-
22	O	-
mm	O	-
Hg	O	-
o	O	-
superior	O	-
y	O	-
36	O	-
mm	O	-
Hg	O	-
o	O	-
inferior	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
para	O	-
someterse	O	-
a	O	-
cirugía	O	-
de	O	-
cataratas	O	-
con	O	-
implante	O	-
de	O	-
stent	O	-
de	O	-
microbypass	O	-
trabecular	O	-
iStent	O	-
(grupo	O	-
stent)	O	-
o	O	-
cirugía	O	-
de	O	-
cataratas	O	-
sola	O	-
(grupo	O	-
control	O	-
).	O	-

Los	O	-
pacientes	O	-
fueron	O	-
seguidos	O	-
durante	O	-
24	O	-
meses	O	-
en	O	-
el	O	-
postoperatorio.	O	-

La	B-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
fue	I-Premise	HighQuality
baja	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
a	I-Premise	HighQuality
lo	I-Premise	HighQuality
largo	I-Premise	HighQuality
de	I-Premise	HighQuality
24	I-Premise	HighQuality
meses	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento.	I-Premise	HighQuality

A	B-Premise	HighQuality
los	I-Premise	HighQuality
24	I-Premise	HighQuality
meses,	I-Premise	HighQuality
la	I-Premise	HighQuality
proporción	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
PIO	I-Premise	HighQuality
de	I-Premise	HighQuality
21	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
o	I-Premise	HighQuality
inferior	I-Premise	HighQuality
sin	I-Premise	HighQuality
medicamentos	I-Premise	HighQuality
hipotensos	I-Premise	HighQuality
oculares	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
stent	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
p=0,036	I-Premise	HighQuality
).	I-Premise	HighQuality

En	O	-
general,	O	-
la	B-Premise	HighQuality
PIO	I-Premise	HighQuality
media	I-Premise	HighQuality
fue	I-Premise	HighQuality
estable	I-Premise	HighQuality
entre	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
y	I-Premise	HighQuality
24	I-Premise	HighQuality
meses	I-Premise	HighQuality
(	I-Premise	HighQuality
17,0	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
±	I-Premise	HighQuality
2,8	I-Premise	HighQuality
[	I-Premise	HighQuality
DE	I-Premise	HighQuality
]	I-Premise	HighQuality
y	I-Premise	HighQuality
17,1	I-Premise	HighQuality
±	I-Premise	HighQuality
2,9	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
stent,	I-Premise	HighQuality
pero	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
(17,0	I-Premise	HighQuality
±	I-Premise	HighQuality
3,1	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
a	I-Premise	HighQuality
17,8	I-Premise	HighQuality
±	I-Premise	HighQuality
3,3	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

La	B-Premise	HighQuality
medicación	I-Premise	HighQuality
hipotensiva	I-Premise	HighQuality
ocular	I-Premise	HighQuality
fue	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
menor	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
del	I-Premise	HighQuality
stent	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
12	I-Premise	HighQuality
meses	I-Premise	HighQuality
;	I-Premise	HighQuality
también	I-Premise	HighQuality
fue	I-Premise	HighQuality
menor	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
24	I-Premise	HighQuality
meses,	I-Premise	HighQuality
aunque	I-Premise	HighQuality
la	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
ya	I-Premise	HighQuality
no	I-Premise	HighQuality
fue	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativa.	I-Premise	HighQuality

Los	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
un	I-Claim	HighQuality
solo	I-Claim	HighQuality
stent	I-Claim	HighQuality
de	I-Claim	HighQuality
microbypass	I-Claim	HighQuality
trabecular	I-Claim	HighQuality
combinado	I-Claim	HighQuality
y	I-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
cataratas	I-Claim	HighQuality
tuvieron	I-Claim	HighQuality
un	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
mejor	I-Claim	HighQuality
en	I-Claim	HighQuality
ningún	I-Claim	HighQuality
medicamento	I-Claim	HighQuality
durante	I-Claim	HighQuality
24	I-Claim	HighQuality
meses	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
cataratas	I-Claim	HighQuality
solos.	I-Claim	HighQuality

Ambos	B-Claim	HighQuality
grupos	I-Claim	HighQuality
tenían	I-Claim	HighQuality
un	I-Claim	HighQuality
perfil	I-Claim	HighQuality
de	I-Claim	HighQuality
seguridad	I-Claim	HighQuality
similar	I-Claim	HighQuality
favorable	I-Claim	HighQuality
a	I-Claim	HighQuality
largo	I-Claim	HighQuality
plazo.	I-Claim	HighQuality

Comparar	O	-
la	O	-
presión	O	-
intraocular	O	-
(	O	-
PIO	O	-
)	O	-
-reducción	O	-
del	O	-
efecto	O	-
y	O	-
la	O	-
seguridad	O	-
de	O	-
la	O	-
brimonidina	O	-
tópica	O	-
con	O	-
la	O	-
del	O	-
timolol,	O	-
y	O	-
estudiar	O	-
el	O	-
efecto	O	-
aditivo	O	-
de	O	-
la	O	-
brimonidina	O	-
tópica	O	-
a	O	-
análogos	O	-
de	O	-
la	O	-
prostaglandina	O	-
tópica	O	-
(	O	-
PG	O	-
)	O	-
en	O	-
475	O	-
pacientes	O	-
con	O	-
hipertensión	O	-
ocular	O	-
o	O	-
glaucoma	O	-
primario	O	-
de	O	-
ángulo	O	-
abierto.	O	-

El	O	-
criterio	O	-
de	O	-
valoración	O	-
principal	O	-
fue	O	-
el	O	-
cambio	O	-
medio	O	-
de	O	-
la	O	-
PIO	O	-
respecto	O	-
al	O	-
valor	O	-
basal	O	-
a	O	-
las	O	-
0	O	-
y	O	-
2	O	-
horas	O	-
en	O	-
la	O	-
semana	O	-
4.	O	-

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
medios	I-Premise	HighQuality
fueron	I-Premise	HighQuality
-4,7	I-Premise	HighQuality
+/-	I-Premise	HighQuality
2,1	I-Premise	HighQuality
(S.	I-Premise	HighQuality
D.	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
timolol	I-Premise	HighQuality
y	I-Premise	HighQuality
-4,0	I-Premise	HighQuality
+/-	I-Premise	HighQuality
2,0	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
brimonidina	I-Premise	HighQuality
(p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0138	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
entre	I-Premise	HighQuality
grupos	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
que	I-Premise	HighQuality
el	I-Premise	HighQuality
criterio	I-Premise	HighQuality
predeterminado	I-Premise	HighQuality
de	I-Premise	HighQuality
no	I-Premise	HighQuality
inferioridad	I-Premise	HighQuality
de	I-Premise	HighQuality
brimonidina	I-Premise	HighQuality
a	I-Premise	HighQuality
timolol.	I-Premise	HighQuality

Cuando	B-Premise	HighQuality
se	I-Premise	HighQuality
añadió	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
análogos	I-Premise	HighQuality
del	I-Premise	HighQuality
PG,	I-Premise	HighQuality
el	I-Premise	HighQuality
efecto	I-Premise	HighQuality
reductor	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
PIO	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
brimonidina	I-Premise	HighQuality
(	I-Premise	HighQuality
-2,9	I-Premise	HighQuality
+/-	I-Premise	HighQuality
1,8	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
)	I-Premise	HighQuality
fue	I-Premise	HighQuality
mayor	I-Premise	HighQuality
que	I-Premise	HighQuality
el	I-Premise	HighQuality
del	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
-2,1	I-Premise	HighQuality
+/-	I-Premise	HighQuality
1,8	I-Premise	HighQuality
mmHg	I-Premise	HighQuality
)	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0010	I-Premise	HighQuality
).	I-Premise	HighQuality

No	O	-
se	O	-
encontraron	O	-
efectos	O	-
adversos	O	-
apreciables.	O	-

La	B-Claim	HighQuality
brimonidina	I-Claim	HighQuality
tópica	I-Claim	HighQuality
mostró	I-Claim	HighQuality
un	I-Claim	HighQuality
efecto	I-Claim	HighQuality
reductor	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
aditivo	I-Claim	HighQuality
a	I-Claim	HighQuality
los	I-Claim	HighQuality
análogos	I-Claim	HighQuality
del	I-Claim	HighQuality
PG	I-Claim	HighQuality
tópico,	I-Claim	HighQuality
aunque	B-Claim	HighQuality
su	I-Claim	HighQuality
efecto	I-Claim	HighQuality
reductor	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
PIO	I-Claim	HighQuality
fue	I-Claim	HighQuality
inferior	I-Claim	HighQuality
al	I-Claim	HighQuality
timolol	I-Claim	HighQuality
tópico	I-Claim	HighQuality
en	I-Claim	HighQuality
monoterapia.	I-Claim	HighQuality

Comparar	O	-
la	O	-
presión	O	-
arterial	O	-
y	O	-
la	O	-
proporción	O	-
de	O	-
albúmina-creatinina	O	-
en	O	-
la	O	-
orina	O	-
con	O	-
el	O	-
tiempo	O	-
para	O	-
los	O	-
participantes	O	-
que	O	-
reciben	O	-
aflibercept,	O	-
bevacizumab,	O	-
o	O	-
ranibizumab.	O	-

Análisis	O	-
secundarios	O	-
planificados	O	-
de	O	-
un	O	-
ensayo	O	-
aleatorizado	O	-
que	O	-
compara	O	-
aflibercept,	O	-
bevacizumab	O	-
y	O	-
ranibizumab	O	-
para	O	-
edema	O	-
macular	O	-
diabético	O	-
(EMD	O	-
).	O	-

La	O	-
Red	O	-
de	O	-
Investigación	O	-
Clínica	O	-
de	O	-
Retinopatía	O	-
Diabética	O	-
(RCDR.net	O	-
)	O	-
inscribió	O	-
a	O	-
660	O	-
participantes	O	-
con	O	-
EMD	O	-
y	O	-
agudeza	O	-
visual	O	-
20/32	O	-
o	O	-
peor	O	-
en	O	-
al	O	-
menos	O	-
un	O	-
ojo.	O	-

Los	O	-
ojos	O	-
recibieron	O	-
inyecciones	O	-
intravítreas	O	-
de	O	-
2,0	O	-
mg	O	-
de	O	-
aflibercept,	O	-
1,25	O	-
mg	O	-
de	O	-
bevacizumab	O	-
o	O	-
0,3	O	-
mg	O	-
de	O	-
ranibizumab	O	-
según	O	-
un	O	-
protocolo	O	-
de	O	-
retratamiento	O	-
estructurado	O	-
durante	O	-
2	O	-
años.	O	-

Las	O	-
principales	O	-
medidas	O	-
de	O	-
resultado	O	-
fueron	O	-
(	O	-
1	O	-
)	O	-
un	O	-
cambio	O	-
en	O	-
la	O	-
presión	O	-
arterial	O	-
a	O	-
los	O	-
2	O	-
años,	O	-
y	O	-
(	O	-
2	O	-
)	O	-
un	O	-
cambio	O	-
en	O	-
la	O	-
relación	O	-
orina-creatinina	O	-
(	O	-
UACR	O	-
)	O	-
a	O	-
los	O	-
1	O	-
años.	O	-

Al	O	-
inicio,	O	-
95	O	-
participantes	O	-
(	O	-
14	O	-
%	O	-
)	O	-
tenían	O	-
presión	O	-
arterial	O	-
normal,	O	-
220	O	-
(	O	-
33	O	-
%	O	-
)	O	-
tenían	O	-
elevación	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
límite,	O	-
206	O	-
(	O	-
31	O	-
%	O	-
)	O	-
tenían	O	-
elevación	O	-
leve	O	-
de	O	-
la	O	-
presión	O	-
arterial	O	-
y	O	-
139	O	-
(	O	-
21	O	-
%	O	-
)	O	-
tenían	O	-
elevación	O	-
moderada	O	-
de	O	-
la	O	-
presión	O	-
arterial.	O	-

El	B-Premise	HighQuality
cambio	I-Premise	HighQuality
promedio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
media	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
hasta	I-Premise	HighQuality
2	I-Premise	HighQuality
años	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
-1,2	I-Premise	HighQuality
±	I-Premise	HighQuality
15,	I-Premise	HighQuality
-1,8	I-Premise	HighQuality
±	I-Premise	HighQuality
13,5,	I-Premise	HighQuality
-2,6	I-Premise	HighQuality
±	I-Premise	HighQuality
14,4	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
aflibercept,	I-Premise	HighQuality
bevacizumab	I-Premise	HighQuality
y	I-Premise	HighQuality
ranibizumab,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
global	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,69	I-Premise	HighQuality
).	I-Premise	HighQuality

Al	O	-
inicio	O	-
247	O	-
participantes	O	-
(	O	-
38	O	-
%	O	-
)	O	-
no	O	-
tenían	O	-
albuminuria	O	-
(	O	-
<	O	-
30	O	-
mg/g	O	-
),	O	-
195	O	-
(	O	-
30	O	-
%	O	-
)	O	-
tenían	O	-
microalbuminuria	O	-
(	O	-
30-300	O	-
mg/g	O	-
)	O	-
y	O	-
212	O	-
(	O	-
32	O	-
%	O	-
)	O	-
tenían	O	-
macroalbuminuria	O	-
(	O	-
>	O	-
300	O	-
mg/g	O	-
).	O	-

Los	B-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
categoría	I-Premise	HighQuality
UACR	I-Premise	HighQuality
no	I-Premise	HighQuality
fueron	I-Premise	HighQuality
diferentes	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
de	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
visita	I-Premise	HighQuality
de	I-Premise	HighQuality
52	I-Premise	HighQuality
semanas	I-Premise	HighQuality
(	I-Premise	HighQuality
global	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,29	I-Premise	HighQuality
).	I-Premise	HighQuality

No	B-Claim	HighQuality
parece	I-Claim	HighQuality
haber	I-Claim	HighQuality
diferencias	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
para	I-Claim	HighQuality
cambios	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
o	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
UACR	I-Claim	HighQuality
como	I-Claim	HighQuality
reflejo	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
renal	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
EMD	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
aflibercept,	I-Claim	HighQuality
bevacizumab,	I-Claim	HighQuality
o	I-Claim	HighQuality
ranibizumab.	I-Claim	HighQuality

La	B-Claim	HighQuality
terapia	I-Claim	HighQuality
de	I-Claim	HighQuality
privación	I-Claim	HighQuality
de	I-Claim	HighQuality
Andrógeno	I-Claim	HighQuality
es	I-Claim	HighQuality
un	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
común	I-Claim	HighQuality
en	I-Claim	HighQuality
hombres	I-Claim	HighQuality
con	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
de	I-Claim	HighQuality
próstata	I-Claim	HighQuality
que	I-Claim	HighQuality
puede	I-Claim	HighQuality
causar	I-Claim	HighQuality
fatiga,	I-Claim	HighQuality
disminución	I-Claim	HighQuality
funcional,	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
grasa	I-Claim	HighQuality
corporal,	I-Claim	HighQuality
y	I-Claim	HighQuality
pérdida	I-Claim	HighQuality
de	I-Claim	HighQuality
tejido	I-Claim	HighQuality
corporal	I-Claim	HighQuality
magro.	I-Claim	HighQuality

Estos	B-Claim	HighQuality
cambios	I-Claim	HighQuality
físicos	I-Claim	HighQuality
pueden	I-Claim	HighQuality
afectar	I-Claim	HighQuality
negativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
salud.	I-Claim	HighQuality

El	B-Claim	HighQuality
ejercicio	I-Claim	HighQuality
de	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
puede	I-Claim	HighQuality
ayudar	I-Claim	HighQuality
a	I-Claim	HighQuality
contrarrestar	I-Claim	HighQuality
algunos	I-Claim	HighQuality
de	I-Claim	HighQuality
estos	I-Claim	HighQuality
efectos	I-Claim	HighQuality
secundarios	I-Claim	HighQuality
al	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
fatiga,	I-Claim	HighQuality
elevar	I-Claim	HighQuality
el	I-Claim	HighQuality
estado	I-Claim	HighQuality
de	I-Claim	HighQuality
ánimo,	I-Claim	HighQuality
construir	I-Claim	HighQuality
masa	I-Claim	HighQuality
muscular	I-Claim	HighQuality
y	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
grasa	I-Claim	HighQuality
corporal.	I-Claim	HighQuality

En	O	-
un	O	-
estudio	O	-
de	O	-
dos	O	-
sitios,	O	-
155	O	-
hombres	O	-
con	O	-
cáncer	O	-
de	O	-
próstata	O	-
que	O	-
estaban	O	-
programados	O	-
para	O	-
recibir	O	-
terapia	O	-
de	O	-
privación	O	-
de	O	-
andrógenos	O	-
durante	O	-
al	O	-
menos	O	-
3	O	-
meses	O	-
después	O	-
del	O	-
reclutamiento	O	-
fueron	O	-
asignados	O	-
al	O	-
azar	O	-
a	O	-
un	O	-
grupo	O	-
de	O	-
intervención	O	-
que	O	-
participó	O	-
en	O	-
un	O	-
programa	O	-
de	O	-
ejercicio	O	-
de	O	-
resistencia	O	-
tres	O	-
veces	O	-
por	O	-
semana	O	-
durante	O	-
12	O	-
semanas	O	-
(	O	-
82	O	-
hombres	O	-
)	O	-
o	O	-
a	O	-
un	O	-
grupo	O	-
de	O	-
control	O	-
de	O	-
lista	O	-
de	O	-
espera	O	-
(	O	-
73	O	-
hombres	O	-
).	O	-

Los	O	-
principales	O	-
resultados	O	-
fueron	O	-
la	O	-
fatiga	O	-
y	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
específica	O	-
de	O	-
la	O	-
enfermedad,	O	-
evaluadas	O	-
mediante	O	-
cuestionarios	O	-
autoinformados	O	-
después	O	-
de	O	-
12	O	-
semanas.	O	-

Los	O	-
resultados	O	-
secundarios	O	-
fueron	O	-
aptitud	O	-
muscular	O	-
y	O	-
composición	O	-
corporal.	O	-

Los	B-Premise	HighQuality
hombres	I-Premise	HighQuality
asignados	I-Premise	HighQuality
al	I-Premise	HighQuality
ejercicio	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
menos	I-Premise	HighQuality
interferencia	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
fatiga	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
actividades	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
vida	I-Premise	HighQuality
diaria	I-Premise	HighQuality
(p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,002)	I-Premise	HighQuality
y	I-Premise	HighQuality
mayor	I-Premise	HighQuality
calidad	I-Premise	HighQuality
de	I-Premise	HighQuality
vida	I-Premise	HighQuality
(p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,001)	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
hombres	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

Los	B-Premise	HighQuality
hombres	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
intervención	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
niveles	I-Premise	HighQuality
superiores	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
parte	I-Premise	HighQuality
superior	I-Premise	HighQuality
del	I-Premise	HighQuality
cuerpo	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,009	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
parte	I-Premise	HighQuality
inferior	I-Premise	HighQuality
del	I-Premise	HighQuality
cuerpo	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
hombres	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

La	B-Premise	HighQuality
intervención	I-Premise	HighQuality
del	I-Premise	HighQuality
ejercicio	I-Premise	HighQuality
de	I-Premise	HighQuality
resistencia	I-Premise	HighQuality
de	I-Premise	HighQuality
12	I-Premise	HighQuality
semanas	I-Premise	HighQuality
no	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
la	I-Premise	HighQuality
composición	I-Premise	HighQuality
corporal	I-Premise	HighQuality
medida	I-Premise	HighQuality
por	I-Premise	HighQuality
cambios	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
peso	I-Premise	HighQuality
corporal,	I-Premise	HighQuality
índice	I-Premise	HighQuality
de	I-Premise	HighQuality
masa	I-Premise	HighQuality
corporal,	I-Premise	HighQuality
circunferencia	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
cintura	I-Premise	HighQuality
o	I-Premise	HighQuality
pliegues	I-Premise	HighQuality
cutáneos	I-Premise	HighQuality
subcutáneos.	I-Premise	HighQuality

El	B-Claim	HighQuality
ejercicio	I-Claim	HighQuality
de	I-Claim	HighQuality
resistencia	I-Claim	HighQuality
reduce	I-Claim	HighQuality
la	I-Claim	HighQuality
fatiga	I-Claim	HighQuality
y	I-Claim	HighQuality
mejora	I-Claim	HighQuality
la	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
aptitud	I-Claim	HighQuality
muscular	I-Claim	HighQuality
en	I-Claim	HighQuality
hombres	I-Claim	HighQuality
con	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
de	I-Claim	HighQuality
próstata	I-Claim	HighQuality
que	I-Claim	HighQuality
reciben	I-Claim	HighQuality
terapia	I-Claim	HighQuality
de	I-Claim	HighQuality
privación	I-Claim	HighQuality
andrógena.	I-Claim	HighQuality

Esta	B-Claim	HighQuality
forma	I-Claim	HighQuality
de	I-Claim	HighQuality
ejercicio	I-Claim	HighQuality
puede	I-Claim	HighQuality
ser	I-Claim	HighQuality
un	I-Claim	HighQuality
componente	I-Claim	HighQuality
importante	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
atención	I-Claim	HighQuality
de	I-Claim	HighQuality
apoyo	I-Claim	HighQuality
para	I-Claim	HighQuality
estos	I-Claim	HighQuality
pacientes.	I-Claim	HighQuality

Para	O	-
comparar	O	-
infusión	O	-
venosa	O	-
prolongada	O	-
(IPV	O	-
)	O	-
fluorouracilo	O	-
(	O	-
5-FU	O	-
)	O	-
con	O	-
PVI	O	-
5-FU	O	-
más	O	-
mitomicina	O	-
(MCM	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
cáncer	O	-
de	O	-
páncreas	O	-
avanzado	O	-
en	O	-
un	O	-
estudio	O	-
multicéntrico,	O	-
prospectivo	O	-
aleatorizado.	O	-

Doscientos	O	-
ocho	O	-
pacientes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
5-FU	O	-
de	O	-
VIP	O	-
(	O	-
300	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
/d	O	-
durante	O	-
un	O	-
máximo	O	-
de	O	-
24	O	-
semanas	O	-
)	O	-
o	O	-
5-FU	O	-
de	O	-
VIP	O	-
más	O	-
MMC	O	-
(	O	-
7	O	-
mg/m	O	-
(	O	-
2	O	-
)	O	-
cada	O	-
6	O	-
semanas	O	-
durante	O	-
cuatro	O	-
ciclos	O	-
).	O	-

Los	O	-
principales	O	-
puntos	O	-
finales	O	-
fueron	O	-
la	O	-
respuesta	O	-
tumoral,	O	-
la	O	-
supervivencia,	O	-
la	O	-
toxicidad	O	-
y	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(	O	-
CV	O	-
).	O	-

Los	O	-
dos	O	-
grupos	O	-
de	O	-
tratamiento	O	-
fueron	O	-
equilibrados	O	-
para	O	-
los	O	-
factores	O	-
demográficos	O	-
basales,	O	-
y	O	-
el	O	-
62	O	-
%	O	-
presentaron	O	-
enfermedad	O	-
metastásica.	O	-

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
global	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
8,4	I-Premise	HighQuality
%	I-Premise	HighQuality
(intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[IC	I-Premise	HighQuality
]	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
3,2	I-Premise	HighQuality
%	I-Premise	HighQuality
al	I-Premise	HighQuality
13,7	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
de	I-Premise	HighQuality
VIP	I-Premise	HighQuality
solo,	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
17,6	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
del	I-Premise	HighQuality
10,3	I-Premise	HighQuality
%	I-Premise	HighQuality
al	I-Premise	HighQuality
25,1	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
los	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
de	I-Premise	HighQuality
VIP	I-Premise	HighQuality
más	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,4	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
libre	I-Premise	HighQuality
de	I-Premise	HighQuality
fracaso	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
2,8	I-Premise	HighQuality
meses	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
del	I-Premise	HighQuality
IVP	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
3,8	I-Premise	HighQuality
meses	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
del	I-Premise	HighQuality
IVP	I-Premise	HighQuality
más	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
14,4).	I-Premise	HighQuality

La	B-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
fue	I-Premise	HighQuality
de	I-Premise	HighQuality
5,1	I-Premise	HighQuality
meses	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
de	I-Premise	HighQuality
VIP	I-Premise	HighQuality
y	I-Premise	HighQuality
de	I-Premise	HighQuality
6,5	I-Premise	HighQuality
meses	I-Premise	HighQuality
para	I-Premise	HighQuality
el	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
de	I-Premise	HighQuality
VIP	I-Premise	HighQuality
más	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,34).	I-Premise	HighQuality

Las	B-Premise	HighQuality
toxicidades	I-Premise	HighQuality
en	I-Premise	HighQuality
ambos	I-Premise	HighQuality
brazos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
leves.	I-Premise	HighQuality

Hubo	B-Premise	HighQuality
un	I-Premise	HighQuality
aumento	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
neutropenia	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
brazo	I-Premise	HighQuality
de	I-Premise	HighQuality
5-FU	I-Premise	HighQuality
más	I-Premise	HighQuality
MMC	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,01	I-Premise	HighQuality
),	I-Premise	HighQuality
aunque	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
observaron	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
infección.	I-Premise	HighQuality

Ningún	B-Premise	HighQuality
paciente	I-Premise	HighQuality
desarrolló	I-Premise	HighQuality
síndrome	I-Premise	HighQuality
urémico	I-Premise	HighQuality
hemolítico.	I-Premise	HighQuality

La	B-Claim	HighQuality
CV	I-Claim	HighQuality
global	I-Claim	HighQuality
mejoró	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
después	I-Claim	HighQuality
de	I-Claim	HighQuality
24	I-Claim	HighQuality
semanas	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
valor	I-Claim	HighQuality
basal	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
que	I-Claim	HighQuality
recibieron	I-Claim	HighQuality
5-FU	I-Claim	HighQuality
más	I-Claim	HighQuality
MMC,	I-Claim	HighQuality
aunque	B-Premise	LowQuality
no	I-Premise	LowQuality
hubo	I-Premise	LowQuality
diferencia	I-Premise	LowQuality
estadísticamente	I-Premise	LowQuality
significativa	I-Premise	LowQuality
en	I-Premise	LowQuality
la	I-Premise	LowQuality
CV	I-Premise	LowQuality
entre	I-Premise	LowQuality
los	I-Premise	LowQuality
brazos.	I-Premise	LowQuality

El	B-Claim	HighQuality
5-FU	I-Claim	HighQuality
de	I-Claim	HighQuality
PVI	I-Claim	HighQuality
más	I-Claim	HighQuality
MMC	I-Claim	HighQuality
resultó	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
respuesta	I-Claim	HighQuality
superior	I-Claim	HighQuality
en	I-Claim	HighQuality
comparación	I-Claim	HighQuality
con	I-Claim	HighQuality
el	I-Claim	HighQuality
5-FU	I-Claim	HighQuality
de	I-Claim	HighQuality
PVI	I-Claim	HighQuality
solo	I-Claim	HighQuality
en	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
de	I-Claim	HighQuality
páncreas	I-Claim	HighQuality
avanzado,	I-Claim	HighQuality
pero	B-Claim	HighQuality
esto	I-Claim	HighQuality
no	I-Claim	HighQuality
se	I-Claim	HighQuality
tradujo	I-Claim	HighQuality
en	I-Claim	HighQuality
una	I-Claim	HighQuality
ventaja	I-Claim	HighQuality
de	I-Claim	HighQuality
supervivencia.	I-Claim	HighQuality

Estos	B-Claim	HighQuality
resultados	I-Claim	HighQuality
enfatizan	I-Claim	HighQuality
la	I-Claim	HighQuality
importancia	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
en	I-Claim	HighQuality
este	I-Claim	HighQuality
entorno	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
valor	I-Claim	HighQuality
continuo	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
fluoropirimidinas	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
de	I-Claim	HighQuality
páncreas.	I-Claim	HighQuality

El	B-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
fractura	I-Claim	HighQuality
aumenta	I-Claim	HighQuality
en	I-Claim	HighQuality
individuos	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
tipo	I-Claim	HighQuality
2	I-Claim	HighQuality
(	I-Claim	HighQuality
T2D	I-Claim	HighQuality
).	I-Claim	HighQuality

Los	O	-
mecanismos	O	-
fisiopatológicos	O	-
que	O	-
acentúan	O	-
el	O	-
riesgo	O	-
de	O	-
fractura	O	-
en	O	-
T2D	O	-
son	O	-
enrevesados,	O	-
incorporando	O	-
factores	O	-
como	O	-
hiperglucemia,	O	-
insulinopenia,	O	-
y	O	-
antidiabéticos.	O	-

Los	O	-
objetivos	O	-
de	O	-
este	O	-
estudio	O	-
fueron	O	-
evaluar	O	-
si	O	-
diferentes	O	-
regímenes	O	-
de	O	-
insulina,	O	-
metformina	O	-
y	O	-
rosiglitazona	O	-
influyen	O	-
en	O	-
el	O	-
metabolismo	O	-
óseo.	O	-

Se	O	-
estudió	O	-
si	O	-
la	O	-
concentración	O	-
de	O	-
metformina	O	-
y	O	-
rosiglitazona	O	-
en	O	-
sangre	O	-
o	O	-
un	O	-
mejor	O	-
control	O	-
glucémico	O	-
alteraban	O	-
el	O	-
recambio	O	-
óseo.	O	-

Ensayo	O	-
clínico	O	-
de	O	-
dos	O	-
años	O	-
diseñado	O	-
para	O	-
investigar	O	-
los	O	-
efectos	O	-
del	O	-
tratamiento	O	-
antidiabético	O	-
en	O	-
371	O	-
pacientes	O	-
T2D.	O	-

Los	O	-
participantes	O	-
fueron	O	-
aleatorizados	O	-
a	O	-
insulina	O	-
humana	O	-
de	O	-
acción	O	-
corta	O	-
o	O	-
prolongada	O	-
(	O	-
no	O	-
ciega	O	-
)	O	-
y	O	-
luego	O	-
a	O	-
metformina	O	-
+	O	-
placebo,	O	-
rosiglitazona	O	-
+	O	-
placebo,	O	-
metformina	O	-
+	O	-
rosiglitazona	O	-
o	O	-
placebo	O	-
+	O	-
placebo	O	-
(	O	-
ciego	O	-
).	O	-

Los	O	-
marcadores	O	-
de	O	-
recambio	O	-
óseo	O	-
en	O	-
ayunas	O	-
(	O	-
BTM	O	-
)	O	-
que	O	-
representan	O	-
la	O	-
resorción	O	-
ósea	O	-
(	O	-
CTX	O	-
)	O	-
y	O	-
la	O	-
formación	O	-
(	O	-
PINP	O	-
)	O	-
incluyendo	O	-
HbA1c	O	-
se	O	-
midieron	O	-
al	O	-
inicio	O	-
y	O	-
después	O	-
de	O	-
3,	O	-
12	O	-
y	O	-
24	O	-
meses.	O	-

Las	O	-
concentraciones	O	-
plasmáticas	O	-
de	O	-
metformina	O	-
y	O	-
rosiglitazona	O	-
en	O	-
estado	O	-
estacionario	O	-
se	O	-
midieron	O	-
después	O	-
de	O	-
3,	O	-
6	O	-
y	O	-
9	O	-
meses	O	-
de	O	-
tratamiento.	O	-

Las	O	-
asociaciones	O	-
entre	O	-
tratamientos	O	-
y	O	-
BTM	O	-
durante	O	-
el	O	-
seguimiento	O	-
del	O	-
ensayo	O	-
fueron	O	-
analizadas	O	-
en	O	-
modelos	O	-
de	O	-
efectos	O	-
mixtos	O	-
que	O	-
incluyeron	O	-
ajustes	O	-
por	O	-
edad,	O	-
sexo,	O	-
IMC,	O	-
función	O	-
renal	O	-
y	O	-
medidas	O	-
repetidas	O	-
de	O	-
HbA1c.	O	-

Los	B-Premise	HighQuality
BTM	I-Premise	HighQuality
aumentaron	I-Premise	HighQuality
desde	I-Premise	HighQuality
el	I-Premise	HighQuality
inicio	I-Premise	HighQuality
hasta	I-Premise	HighQuality
el	I-Premise	HighQuality
mes	I-Premise	HighQuality
12	I-Premise	HighQuality
y	I-Premise	HighQuality
se	I-Premise	HighQuality
mantuvieron	I-Premise	HighQuality
más	I-Premise	HighQuality
altos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
mes	I-Premise	HighQuality
24,	I-Premise	HighQuality
con	I-Premise	HighQuality
CTX	I-Premise	HighQuality
y	I-Premise	HighQuality
PINP	I-Premise	HighQuality
aumentando	I-Premise	HighQuality
28,5	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
23,0	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
todos	I-Premise	HighQuality
:	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

La	B-Premise	HighQuality
asignación	I-Premise	HighQuality
de	I-Premise	HighQuality
regímenes	I-Premise	HighQuality
de	I-Premise	HighQuality
insulina	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
diferentes	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
BTM.	I-Premise	HighQuality

La	B-Premise	HighQuality
metformina	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
metformina	I-Premise	HighQuality
+	I-Premise	HighQuality
rosiglitazona,	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
la	I-Premise	HighQuality
rosiglitazona	I-Premise	HighQuality
sola,	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
formación	I-Premise	HighQuality
ósea	I-Premise	HighQuality
inferior	I-Premise	HighQuality
(	I-Premise	HighQuality
PINP	I-Premise	HighQuality
).	I-Premise	HighQuality

Ni	B-Premise	HighQuality
la	I-Premise	HighQuality
metformina	I-Premise	HighQuality
ni	I-Premise	HighQuality
las	I-Premise	HighQuality
concentraciones	I-Premise	HighQuality
plasmáticas	I-Premise	HighQuality
de	I-Premise	HighQuality
rosiglitazona	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
con	I-Premise	HighQuality
BTM.	I-Premise	HighQuality

HbA1c	B-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
inversamente	I-Premise	HighQuality
con	I-Premise	HighQuality
CTX	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
con	I-Premise	HighQuality
P1NP.	I-Premise	HighQuality

La	B-Claim	HighQuality
elección	I-Claim	HighQuality
del	I-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
insulina	I-Claim	HighQuality
no	I-Claim	HighQuality
influye	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
BTM,	I-Claim	HighQuality
el	B-Claim	HighQuality
tratamiento	I-Claim	HighQuality
con	I-Claim	HighQuality
metformina	I-Claim	HighQuality
puede	I-Claim	HighQuality
disminuir	I-Claim	HighQuality
los	I-Claim	HighQuality
BTM	I-Claim	HighQuality
y	O	-
la	B-Claim	HighQuality
mejoría	I-Claim	HighQuality
del	I-Claim	HighQuality
control	I-Claim	HighQuality
glucémico	I-Claim	HighQuality
puede	I-Claim	HighQuality
influir	I-Claim	HighQuality
en	I-Claim	HighQuality
la	I-Claim	HighQuality
actividad	I-Claim	HighQuality
de	I-Claim	HighQuality
resorción	I-Claim	HighQuality
ósea.	I-Claim	HighQuality

Investigar	O	-
el	O	-
efecto	O	-
clínico	O	-
y	O	-
la	O	-
seguridad	O	-
de	O	-
la	O	-
inyección	O	-
pegilada	O	-
de	O	-
acción	O	-
prolongada	O	-
de	O	-
interferón-α-2b	O	-
(	O	-
Peg-IFN-α-2b	O	-
)	O	-
(	O	-
forma	O	-
Y,	O	-
40	O	-
kD	O	-
)	O	-
(	O	-
180	O	-
μg/semana	O	-
)	O	-
en	O	-
el	O	-
tratamiento	O	-
de	O	-
pacientes	O	-
con	O	-
hepatitis	O	-
B	O	-
crónica	O	-
positiva	O	-
para	O	-
HBeAg	O	-
(	O	-
CHB	O	-
),	O	-
con	O	-
una	O	-
dosis	O	-
estándar	O	-
de	O	-
Peg-IFN-α-2a	O	-
como	O	-
control	O	-
positivo.	O	-

Este	O	-
estudio	O	-
fue	O	-
un	O	-
ensayo	O	-
clínico	O	-
de	O	-
fase	O	-
III	O	-
multicéntrico,	O	-
aleatorizado,	O	-
abierto	O	-
y	O	-
controlado	O	-
con	O	-
control	O	-
positivo.	O	-

Los	O	-
pacientes	O	-
con	O	-
CHB	O	-
HBeAg	O	-
positivos	O	-
elegibles	O	-
fueron	O	-
examinados	O	-
y	O	-
aleatorizados	O	-
a	O	-
Peg-IFN-α-2b	O	-
(forma	O	-
Y,	O	-
40	O	-
kD	O	-
)	O	-
grupo	O	-
de	O	-
ensayo	O	-
y	O	-
grupo	O	-
de	O	-
control	O	-
Peg-IFN-α-2a	O	-
con	O	-
una	O	-
relación	O	-
de	O	-
2:1.	O	-

El	O	-
curso	O	-
del	O	-
tratamiento	O	-
fue	O	-
de	O	-
48	O	-
semanas	O	-
y	O	-
los	O	-
pacientes	O	-
fueron	O	-
objeto	O	-
de	O	-
seguimiento	O	-
durante	O	-
24	O	-
semanas	O	-
después	O	-
de	O	-
la	O	-
retirada	O	-
del	O	-
fármaco.	O	-

Las	O	-
muestras	O	-
de	O	-
plasma	O	-
fueron	O	-
recolectadas	O	-
en	O	-
la	O	-
detección,	O	-
basal,	O	-
y	O	-
12,	O	-
24,	O	-
36,	O	-
48,	O	-
60,	O	-
y	O	-
72	O	-
semanas	O	-
para	O	-
la	O	-
detección	O	-
centralizada.	O	-

COBAS®	O	-
Ampliprep/COBAS®	O	-
TaqMan®	O	-
HBV	O	-
Test	O	-
se	O	-
utilizó	O	-
para	O	-
medir	O	-
el	O	-
nivel	O	-
de	O	-
ADN	O	-
del	O	-
VHB	O	-
por	O	-
PCR	O	-
cuantitativo	O	-
en	O	-
tiempo	O	-
real.	O	-

Para	O	-
medir	O	-
los	O	-
marcadores	O	-
del	O	-
VHB	O	-
(	O	-
HBsAg,	O	-
anti-HBs,	O	-
HBeAg,	O	-
anti-HBeBe,	O	-
anti-HBe	O	-
)	O	-
se	O	-
utilizó	O	-
inmunoensayo	O	-
de	O	-
electroquimioluminiscencia	O	-
con	O	-
kit	O	-
de	O	-
Elecsys.	O	-

Las	O	-
reacciones	O	-
adversas	O	-
se	O	-
registraron	O	-
en	O	-
detalle.	O	-

La	O	-
medida	O	-
del	O	-
resultado	O	-
primario	O	-
fue	O	-
la	O	-
tasa	O	-
de	O	-
seroconversión	O	-
de	O	-
HBeAg	O	-
después	O	-
del	O	-
seguimiento	O	-
de	O	-
24	O	-
semanas,	O	-
y	O	-
también	O	-
se	O	-
probó	O	-
la	O	-
no	O	-
inferioridad.	O	-

Se	O	-
calculó	O	-
la	O	-
diferencia	O	-
en	O	-
la	O	-
tasa	O	-
de	O	-
seroconversión	O	-
de	O	-
HBeAg	O	-
después	O	-
del	O	-
tratamiento	O	-
entre	O	-
el	O	-
grupo	O	-
de	O	-
ensayo	O	-
y	O	-
el	O	-
grupo	O	-
de	O	-
control	O	-
y	O	-
el	O	-
intervalo	O	-
de	O	-
confianza	O	-
bilateral	O	-
(IC	O	-
)	O	-
y	O	-
se	O	-
demostró	O	-
que	O	-
no	O	-
había	O	-
inferioridad	O	-
si	O	-
el	O	-
límite	O	-
inferior	O	-
de	O	-
IC	O	-
95	O	-
%	O	-
era	O	-
>	O	-
-10	O	-
%.	O	-

La	O	-
prueba	O	-
t,	O	-
prueba	O	-
chi-cuadrado,	O	-
o	O	-
prueba	O	-
de	O	-
la	O	-
suma	O	-
de	O	-
rango	O	-
se	O	-
utilizó	O	-
de	O	-
acuerdo	O	-
con	O	-
los	O	-
tipos	O	-
y	O	-
características	O	-
de	O	-
los	O	-
datos.	O	-

Se	O	-
incluyeron	O	-
855	O	-
pacientes	O	-
con	O	-
CHB	O	-
HBeAg	O	-
positivos	O	-
y	O	-
820	O	-
de	O	-
ellos	O	-
recibieron	O	-
tratamiento	O	-
(538	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
ensayo	O	-
y	O	-
282	O	-
en	O	-
el	O	-
grupo	O	-
de	O	-
control).	O	-

Los	B-Premise	HighQuality
datos	I-Premise	HighQuality
del	I-Premise	HighQuality
conjunto	I-Premise	HighQuality
completo	I-Premise	HighQuality
de	I-Premise	HighQuality
análisis	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
27,32	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
ensayo	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
22,70	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
de	I-Premise	HighQuality
tasas	I-Premise	HighQuality
del	I-Premise	HighQuality
4,63	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
-1,54	I-Premise	HighQuality
%	I-Premise	HighQuality
a	I-Premise	HighQuality
10,80	I-Premise	HighQuality
%,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,1493	I-Premise	HighQuality
).	I-Premise	HighQuality

Los	B-Premise	HighQuality
datos	I-Premise	HighQuality
del	I-Premise	HighQuality
conjunto	I-Premise	HighQuality
por	I-Premise	HighQuality
protocolo	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
seroconversión	I-Premise	HighQuality
de	I-Premise	HighQuality
HBeAg	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
semana	I-Premise	HighQuality
72	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
30,75	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
ensayo	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
27,14	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
de	I-Premise	HighQuality
tasas	I-Premise	HighQuality
del	I-Premise	HighQuality
3,61	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
-3,87	I-Premise	HighQuality
%	I-Premise	HighQuality
a	I-Premise	HighQuality
11,09	I-Premise	HighQuality
%,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,3436	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
de	I-Premise	HighQuality
IC	I-Premise	HighQuality
cumplió	I-Premise	HighQuality
los	I-Premise	HighQuality
criterios	I-Premise	HighQuality
de	I-Premise	HighQuality
no	I-Premise	HighQuality
inferioridad,	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
ensayo	I-Premise	HighQuality
no	I-Premise	HighQuality
fue	I-Premise	HighQuality
inferior	I-Premise	HighQuality
al	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control.	I-Premise	HighQuality

Los	B-Premise	HighQuality
dos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
presentaron	I-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
similares	I-Premise	HighQuality
de	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos,	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
graves	I-Premise	HighQuality
y	I-Premise	HighQuality
efectos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
comunes.	I-Premise	HighQuality

En	B-Claim	HighQuality
el	I-Claim	HighQuality
régimen	I-Claim	HighQuality
de	I-Claim	HighQuality
Peg-IFN-α	I-Claim	HighQuality
para	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
CHB	I-Claim	HighQuality
HBeAg	I-Claim	HighQuality
positivo,	I-Claim	HighQuality
el	I-Claim	HighQuality
nuevo	I-Claim	HighQuality
fármaco	I-Claim	HighQuality
Peg-IFN-α-2b	I-Claim	HighQuality
(	I-Claim	HighQuality
forma	I-Claim	HighQuality
Y,	I-Claim	HighQuality
40	I-Claim	HighQuality
kD	I-Claim	HighQuality
)	I-Claim	HighQuality
tiene	I-Claim	HighQuality
un	I-Claim	HighQuality
efecto	I-Claim	HighQuality
y	I-Claim	HighQuality
seguridad	I-Claim	HighQuality
comparables	I-Claim	HighQuality
al	I-Claim	HighQuality
fármaco	I-Claim	HighQuality
de	I-Claim	HighQuality
control	I-Claim	HighQuality
Peg-IFN-α-2a.	I-Claim	HighQuality

Los	B-Claim	HighQuality
datos	I-Claim	HighQuality
disponibles	I-Claim	HighQuality
indican	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
sodio	I-Claim	HighQuality
dietético	I-Claim	HighQuality
(	I-Claim	HighQuality
como	I-Claim	HighQuality
sal	I-Claim	HighQuality
)	I-Claim	HighQuality
se	I-Claim	HighQuality
relaciona	I-Claim	HighQuality
directamente	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
(	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial	I-Claim	HighQuality
).	I-Claim	HighQuality

La	O	-
mayoría	O	-
de	O	-
estos	O	-
hallazgos	O	-
son	O	-
de	O	-
estudios	O	-
que	O	-
carecen	O	-
de	O	-
datos	O	-
dietéticos	O	-
;	O	-
por	O	-
lo	O	-
tanto,	O	-
no	O	-
está	O	-
claro	O	-
si	O	-
esta	O	-
relación	O	-
sodio-BP	O	-
está	O	-
modulada	O	-
por	O	-
otros	O	-
factores	O	-
dietéticos.	O	-

Con	O	-
control	O	-
de	O	-
múltiples	O	-
factores	O	-
no	O	-
dietéticos,	O	-
pero	O	-
no	O	-
índice	O	-
de	O	-
masa	O	-
corporal,	O	-
hubo	O	-
relaciones	O	-
directas	O	-
con	O	-
la	O	-
PA	O	-
de	O	-
excreción	O	-
urinaria	O	-
de	O	-
sodio	O	-
de	O	-
24	O	-
horas	O	-
y	O	-
la	O	-
relación	O	-
orinal	O	-
de	O	-
sodio/potásico	O	-
entre	O	-
4680	O	-
hombres	O	-
y	O	-
mujeres	O	-
de	O	-
40	O	-
a	O	-
59	O	-
años	O	-
de	O	-
edad	O	-
(	O	-
17	O	-
muestras	O	-
de	O	-
población	O	-
en	O	-
China,	O	-
Japón,	O	-
Reino	O	-
Unido	O	-
y	O	-
Estados	O	-
Unidos	O	-
)	O	-
en	O	-
el	O	-
INTERMAP	O	-
(	O	-
Estudio	O	-
Internacional	O	-
sobre	O	-
Macro/Micronutrientes	O	-
y	O	-
Presión	O	-
Sanguínea	O	-
),	O	-
y	O	-
entre	O	-
sus	O	-
2195	O	-
participantes	O	-
estadounidenses,	O	-
por	O	-
ejemplo,	O	-
2	O	-
DE	O	-
mayor	O	-
excreción	O	-
urinaria	O	-
de	O	-
sodio	O	-
de	O	-
24	O	-
horas	O	-
(	O	-
118.7	O	-
mmol	O	-
)	O	-
asociada	O	-
con	O	-
la	O	-
PA	O	-
sistólica	O	-
3,7	O	-
mm	O	-
Hg	O	-
más	O	-
alta.	O	-

Estas	O	-
relaciones	O	-
sodio-BP	O	-
persistieron	O	-
con	O	-
el	O	-
control	O	-
de	O	-
13	O	-
macronutrientes,	O	-
12	O	-
vitaminas,	O	-
7	O	-
minerales,	O	-
y	O	-
18	O	-
aminoácidos,	O	-
para	O	-
ambos	O	-
sexos,	O	-
mayores	O	-
y	O	-
menores,	O	-
negros,	O	-
hispanos,	O	-
blancos,	O	-
y	O	-
estratos	O	-
socioeconómicos.	O	-

Con	O	-
control	O	-
del	O	-
índice	O	-
de	O	-
masa	O	-
corporal,	O	-
se	O	-
atenuaron	O	-
las	O	-
relaciones	O	-
sodio-BP	O	-
pero	O	-
no	O	-
sodio/potásico-BP.	O	-

El	B-Premise	HighQuality
peso	I-Premise	HighQuality
normal	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
participantes	I-Premise	HighQuality
obesos	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
relaciones	I-Premise	HighQuality
positivas	I-Premise	HighQuality
significativas	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
PA	I-Premise	HighQuality
de	I-Premise	HighQuality
sodio	I-Premise	HighQuality
urinario	I-Premise	HighQuality
;	I-Premise	HighQuality
las	I-Premise	HighQuality
relaciones	I-Premise	HighQuality
fueron	I-Premise	HighQuality
más	I-Premise	HighQuality
débiles	I-Premise	HighQuality
para	I-Premise	HighQuality
las	I-Premise	HighQuality
personas	I-Premise	HighQuality
con	I-Premise	HighQuality
sobrepeso.	I-Premise	HighQuality

A	B-Premise	HighQuality
niveles	I-Premise	HighQuality
más	I-Premise	HighQuality
bajos	I-Premise	HighQuality
pero	I-Premise	HighQuality
no	I-Premise	HighQuality
más	I-Premise	HighQuality
altos	I-Premise	HighQuality
de	I-Premise	HighQuality
excreción	I-Premise	HighQuality
de	I-Premise	HighQuality
sodio	I-Premise	HighQuality
de	I-Premise	HighQuality
24	I-Premise	HighQuality
horas,	I-Premise	HighQuality
la	I-Premise	HighQuality
ingesta	I-Premise	HighQuality
de	I-Premise	HighQuality
potasio	I-Premise	HighQuality
atascó	I-Premise	HighQuality
la	I-Premise	HighQuality
relación	I-Premise	HighQuality
sodio-BP.	I-Premise	HighQuality

La	B-Claim	HighQuality
asociación	I-Claim	HighQuality
adversa	I-Claim	HighQuality
del	I-Claim	HighQuality
sodio	I-Claim	HighQuality
dietético	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
PA	I-Claim	HighQuality
es	I-Claim	HighQuality
mínimamente	I-Claim	HighQuality
atenuada	I-Claim	HighQuality
por	I-Claim	HighQuality
otros	I-Claim	HighQuality
componentes	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
dieta	I-Claim	HighQuality
;	I-Claim	HighQuality
estos	B-Claim	HighQuality
hallazgos	I-Claim	HighQuality
subrayan	I-Claim	HighQuality
la	I-Claim	HighQuality
importancia	I-Claim	HighQuality
de	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
ingesta	I-Claim	HighQuality
de	I-Claim	HighQuality
sal	I-Claim	HighQuality
para	I-Claim	HighQuality
la	I-Claim	HighQuality
prevención	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
control	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
prehipertensión	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
hipertensión.	I-Claim	HighQuality

La	B-Claim	HighQuality
evidencia	I-Claim	HighQuality
ha	I-Claim	HighQuality
demostrado	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
reducción	I-Claim	HighQuality
de	I-Claim	HighQuality
sodio	I-Claim	HighQuality
a	I-Claim	HighQuality
largo	I-Claim	HighQuality
plazo	I-Claim	HighQuality
no	I-Claim	HighQuality
sólo	I-Claim	HighQuality
puede	I-Claim	HighQuality
reducir	I-Claim	HighQuality
la	I-Claim	HighQuality
presión	I-Claim	HighQuality
arterial,	I-Claim	HighQuality
sino	I-Claim	HighQuality
también	I-Claim	HighQuality
proporcionar	I-Claim	HighQuality
beneficios	I-Claim	HighQuality
cardiovasculares.	I-Claim	HighQuality

Hasta	O	-
la	O	-
fecha,	O	-
hay	O	-
poca	O	-
evidencia	O	-
relacionada	O	-
con	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
reducción	O	-
de	O	-
la	O	-
sal	O	-
en	O	-
la	O	-
hipertensión	O	-
sistólica	O	-
aislada	O	-
(	O	-
ISH	O	-
).	O	-
Un	O	-
total	O	-
de	O	-
126	O	-
pacientes	O	-
hipertensos	O	-
fueron	O	-
divididos	O	-
en	O	-
un	O	-
grupo	O	-
ISH	O	-
(	O	-
n	O	-
=	O	-
51	O	-
)	O	-
y	O	-
un	O	-
grupo	O	-
no-ISH	O	-
(	O	-
NISH	O	-
)	O	-
(	O	-
n	O	-
=	O	-
75	O	-
).	O	-

Los	O	-
miembros	O	-
de	O	-
cada	O	-
grupo	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
dietas	O	-
de	O	-
sal	O	-
baja	O	-
en	O	-
sodio	O	-
(	O	-
LSSalt	O	-
)	O	-
o	O	-
sal	O	-
normal	O	-
(	O	-
NSalt	O	-
)	O	-
durante	O	-
6	O	-
meses.	O	-

Su	O	-
presión	O	-
arterial	O	-
se	O	-
midió	O	-
cada	O	-
2	O	-
meses.	O	-

La	O	-
actividad	O	-
plasmática	O	-
sérica	O	-
renina-angiotensina,	O	-
los	O	-
ensayos	O	-
bioquímicos	O	-
en	O	-
sangre	O	-
y	O	-
las	O	-
mediciones	O	-
urinarias	O	-
se	O	-
determinaron	O	-
al	O	-
inicio	O	-
y	O	-
al	O	-
final	O	-
de	O	-
los	O	-
6	O	-
meses.	O	-

Al	B-Premise	HighQuality
final	I-Premise	HighQuality
del	I-Premise	HighQuality
estudio,	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
sistólica	I-Premise	HighQuality
media	I-Premise	HighQuality
(	I-Premise	HighQuality
PAS	I-Premise	HighQuality
)	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
ISH	I-Premise	HighQuality
LSSalt	I-Premise	HighQuality
había	I-Premise	HighQuality
disminuido	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
en	I-Premise	HighQuality
10,18	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
)	I-Premise	HighQuality
:	I-Premise	HighQuality
3,13	I-Premise	HighQuality
a	I-Premise	HighQuality
17,2,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,006	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
ISH	I-Premise	HighQuality
NSSalt,	I-Premise	HighQuality
mientras	O	-
que	O	-
la	B-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
media	I-Premise	HighQuality
sólo	I-Premise	HighQuality
había	I-Premise	HighQuality
disminuido	I-Premise	HighQuality
en	I-Premise	HighQuality
5,10	I-Premise	HighQuality
mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
(	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
:	I-Premise	HighQuality
-2,02	I-Premise	HighQuality
a	I-Premise	HighQuality
12,2,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
158	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
NISH	I-Premise	HighQuality
LSSalt	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
NISH	I-Premise	HighQuality
NSSalt.	I-Premise	HighQuality

La	B-Premise	HighQuality
presión	I-Premise	HighQuality
arterial	I-Premise	HighQuality
diastólica	I-Premise	HighQuality
media	I-Premise	HighQuality
(PAD	I-Premise	HighQuality
)	I-Premise	HighQuality
no	I-Premise	HighQuality
presentó	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
significativas	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos	I-Premise	HighQuality
ISH	I-Premise	HighQuality
y	I-Premise	HighQuality
NISH.	I-Premise	HighQuality

Después	B-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
intervención	I-Premise	HighQuality
con	I-Premise	HighQuality
LSSalt	I-Premise	HighQuality
no	I-Premise	HighQuality
se	I-Premise	HighQuality
encontró	I-Premise	HighQuality
una	I-Premise	HighQuality
activación	I-Premise	HighQuality
obvia	I-Premise	HighQuality
del	I-Premise	HighQuality
sistema	I-Premise	HighQuality
de	I-Premise	HighQuality
renina	I-Premise	HighQuality
angiotensina.	I-Premise	HighQuality

En	B-Premise	HighQuality
cuanto	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
excreción	I-Premise	HighQuality
urinaria	I-Premise	HighQuality
de	I-Premise	HighQuality
electrolitos	I-Premise	HighQuality
y	I-Premise	HighQuality
ensayos	I-Premise	HighQuality
bioquímicos	I-Premise	HighQuality
en	I-Premise	HighQuality
sangre,	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
con	I-Premise	HighQuality
LSSalt	I-Premise	HighQuality
tuvo	I-Premise	HighQuality
los	I-Premise	HighQuality
mismos	I-Premise	HighQuality
efectos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
ISH	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
NISH.	I-Premise	HighQuality

El	B-Claim	HighQuality
presente	I-Claim	HighQuality
estudio	I-Claim	HighQuality
mostró	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
PAS	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
ISH	I-Claim	HighQuality
se	I-Claim	HighQuality
redujo	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
intervención	I-Claim	HighQuality
de	I-Claim	HighQuality
LSSalt,	I-Claim	HighQuality
mientras	O	-
que	O	-
ni	B-Claim	HighQuality
la	I-Claim	HighQuality
PAS	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
NISH	I-Claim	HighQuality
ni	I-Claim	HighQuality
la	I-Claim	HighQuality
PAD	I-Claim	HighQuality
de	I-Claim	HighQuality
cualquiera	I-Claim	HighQuality
de	I-Claim	HighQuality
los	I-Claim	HighQuality
grupos	I-Claim	HighQuality
disminuyeron	I-Claim	HighQuality
de	I-Claim	HighQuality
manera	I-Claim	HighQuality
similar,	I-Claim	HighQuality
lo	I-Claim	HighQuality
que	I-Claim	HighQuality
indicó	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
ISH	I-Claim	HighQuality
eran	I-Claim	HighQuality
más	I-Claim	HighQuality
sensibles	I-Claim	HighQuality
a	I-Claim	HighQuality
la	I-Claim	HighQuality
restricción	I-Claim	HighQuality
de	I-Claim	HighQuality
sal.	I-Claim	HighQuality

Determinar	O	-
los	O	-
efectos	O	-
del	O	-
entrenamiento	O	-
de	O	-
ejercicio	O	-
sobre	O	-
la	O	-
función	O	-
cardiopulmonar	O	-
y	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(QOL	O	-
)	O	-
en	O	-
sobrevivientes	O	-
de	O	-
cáncer	O	-
de	O	-
mama	O	-
postmenopáusicas	O	-
que	O	-
habían	O	-
completado	O	-
cirugía,	O	-
radioterapia	O	-
y/o	O	-
quimioterapia	O	-
con	O	-
o	O	-
sin	O	-
uso	O	-
actual	O	-
de	O	-
terapia	O	-
hormonal.	O	-

Cincuenta	O	-
y	O	-
tres	O	-
sobrevivientes	O	-
de	O	-
cáncer	O	-
de	O	-
mama	O	-
postmenopáusico	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
un	O	-
grupo	O	-
de	O	-
ejercicio	O	-
(	O	-
n	O	-
=	O	-
25	O	-
)	O	-
o	O	-
control	O	-
(	O	-
n	O	-
=	O	-
28	O	-
).	O	-

El	O	-
grupo	O	-
de	O	-
ejercicios	O	-
entrenó	O	-
en	O	-
ergómetros	O	-
de	O	-
ciclo	O	-
tres	O	-
veces	O	-
por	O	-
semana	O	-
durante	O	-
15	O	-
semanas	O	-
a	O	-
una	O	-
potencia	O	-
de	O	-
salida	O	-
que	O	-
obtuvo	O	-
el	O	-
equivalente	O	-
ventilatorio	O	-
de	O	-
dióxido	O	-
de	O	-
carbono.	O	-

El	O	-
grupo	O	-
de	O	-
control	O	-
no	O	-
entrenó.	O	-

Los	O	-
principales	O	-
resultados	O	-
fueron	O	-
cambios	O	-
en	O	-
el	O	-
consumo	O	-
máximo	O	-
de	O	-
oxígeno	O	-
y	O	-
en	O	-
la	O	-
CV	O	-
global	O	-
desde	O	-
el	O	-
inicio	O	-
hasta	O	-
la	O	-
postintervención.	O	-

El	O	-
consumo	O	-
máximo	O	-
de	O	-
oxígeno	O	-
fue	O	-
evaluado	O	-
mediante	O	-
una	O	-
prueba	O	-
de	O	-
ejercicio	O	-
graduada	O	-
mediante	O	-
análisis	O	-
de	O	-
intercambio	O	-
de	O	-
gas.	O	-

En	O	-
general,	O	-
la	O	-
CV	O	-
se	O	-
evaluó	O	-
mediante	O	-
la	O	-
escala	O	-
de	O	-
la	O	-
Evaluación	O	-
Funcional	O	-
del	O	-
Cáncer	O	-
Terapia-Breast.	O	-

Cincuenta	O	-
y	O	-
dos	O	-
participantes	O	-
completaron	O	-
el	O	-
ensayo.	O	-

El	O	-
grupo	O	-
de	O	-
ejercicios	O	-
completó	O	-
el	O	-
98,4%	O	-
de	O	-
las	O	-
sesiones	O	-
de	O	-
ejercicios.	O	-

Los	O	-
valores	O	-
basales	O	-
para	O	-
el	O	-
consumo	O	-
máximo	O	-
de	O	-
oxígeno	O	-
(	O	-
P	O	-
=	O	-
254	O	-
)	O	-
y	O	-
la	O	-
CV	O	-
global	O	-
(	O	-
P	O	-
=	O	-
286	O	-
)	O	-
no	O	-
difirieron	O	-
entre	O	-
los	O	-
grupos.	O	-

El	B-Premise	HighQuality
consumo	I-Premise	HighQuality
máximo	I-Premise	HighQuality
de	I-Premise	HighQuality
oxígeno	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
en	I-Premise	HighQuality
0,24	I-Premise	HighQuality
L/min	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
ejercicio,	I-Premise	HighQuality
mientras	B-Premise	HighQuality
que	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
en	I-Premise	HighQuality
0,05	I-Premise	HighQuality
L/min	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
media,	I-Premise	HighQuality
0,29	I-Premise	HighQuality
L/min	I-Premise	HighQuality
;	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
],	I-Premise	HighQuality
0,18	I-Premise	HighQuality
a	I-Premise	HighQuality
0,40	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
CV	I-Premise	HighQuality
global	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
9,1	I-Premise	HighQuality
puntos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
ejercicio	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
0,3	I-Premise	HighQuality
puntos	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
diferencia	I-Premise	HighQuality
media,	I-Premise	HighQuality
8,8	I-Premise	HighQuality
puntos	I-Premise	HighQuality
;	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%,	I-Premise	HighQuality
3,6	I-Premise	HighQuality
a	I-Premise	HighQuality
14,0	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
correlaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
Pearson	I-Premise	HighQuality
indicaron	I-Premise	HighQuality
que	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
consumo	I-Premise	HighQuality
máximo	I-Premise	HighQuality
de	I-Premise	HighQuality
oxígeno	I-Premise	HighQuality
se	I-Premise	HighQuality
correlacionaba	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
cambio	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
CV	I-Premise	HighQuality
global	I-Premise	HighQuality
(	I-Premise	HighQuality
r	I-Premise	HighQuality
=	I-Premise	HighQuality
0,45	I-Premise	HighQuality
;	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,01	I-Premise	HighQuality
).	I-Premise	HighQuality

El	B-Claim	HighQuality
entrenamiento	I-Claim	HighQuality
físico	I-Claim	HighQuality
tuvo	I-Claim	HighQuality
efectos	I-Claim	HighQuality
beneficiosos	I-Claim	HighQuality
sobre	I-Claim	HighQuality
la	I-Claim	HighQuality
función	I-Claim	HighQuality
cardiopulmonar	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
CV	I-Claim	HighQuality
en	I-Claim	HighQuality
sobrevivientes	I-Claim	HighQuality
de	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
de	I-Claim	HighQuality
mama	I-Claim	HighQuality
postmenopáusicas.	I-Claim	HighQuality

Este	O	-
ensayo	O	-
clínico	O	-
aleatorizado,	O	-
doble	O	-
ciego,	O	-
controlado	O	-
con	O	-
placebo	O	-
evaluó	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
epoyetina	O	-
alfa	O	-
sobre	O	-
los	O	-
requisitos	O	-
de	O	-
transfusión,	O	-
los	O	-
parámetros	O	-
hematopoyéticos,	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
(QOL)	O	-
y	O	-
la	O	-
seguridad	O	-
en	O	-
pacientes	O	-
con	O	-
cáncer	O	-
anémico	O	-
que	O	-
reciben	O	-
quimioterapia	O	-
sin	O	-
platino.	O	-

El	O	-
estudio	O	-
también	O	-
exploró	O	-
una	O	-
posible	O	-
relación	O	-
entre	O	-
el	O	-
aumento	O	-
de	O	-
la	O	-
hemoglobina	O	-
y	O	-
la	O	-
supervivencia.	O	-

Trescientos	O	-
setenta	O	-
y	O	-
cinco	O	-
pacientes	O	-
con	O	-
neoplasias	O	-
hematológicas	O	-
sólidas	O	-
o	O	-
no	O	-
mieloides	O	-
y	O	-
niveles	O	-
de	O	-
hemoglobina	O	-
<	O	-
o	O	-
=	O	-
10,5	O	-
g/dl,	O	-
o	O	-
superiores	O	-
a	O	-
10,5	O	-
g/dl	O	-
pero	O	-
<	O	-
o	O	-
=	O	-
12.0	O	-
g/dl	O	-
después	O	-
de	O	-
una	O	-
disminución	O	-
de	O	-
hemoglobina	O	-
de	O	-
>	O	-
o	O	-
=	O	-
1,5	O	-
g/dl	O	-
por	O	-
ciclo	O	-
desde	O	-
el	O	-
inicio	O	-
de	O	-
la	O	-
quimioterapia,	O	-
fueron	O	-
aleatorizados	O	-
2:1	O	-
a	O	-
epoyetina	O	-
alfa	O	-
150	O	-
a	O	-
300	O	-
UI/kg	O	-
(	O	-
n	O	-
=	O	-
251	O	-
)	O	-
o	O	-
placebo	O	-
(	O	-
n	O	-
=	O	-
124	O	-
)	O	-
tres	O	-
veces	O	-
por	O	-
semana	O	-
por	O	-
vía	O	-
subcutánea	O	-
durante	O	-
12	O	-
a	O	-
24	O	-
semanas.	O	-

El	O	-
punto	O	-
final	O	-
primario	O	-
fue	O	-
la	O	-
proporción	O	-
de	O	-
pacientes	O	-
transfundidos	O	-
;	O	-
los	O	-
puntos	O	-
finales	O	-
secundarios	O	-
fueron	O	-
el	O	-
cambio	O	-
en	O	-
la	O	-
hemoglobina	O	-
y	O	-
la	O	-
CV.	O	-

El	O	-
protocolo	O	-
fue	O	-
modificado	O	-
antes	O	-
de	O	-
desencender	O	-
para	O	-
recolectar	O	-
y	O	-
evaluar	O	-
prospectivamente	O	-
los	O	-
datos	O	-
de	O	-
supervivencia	O	-
12	O	-
meses	O	-
después	O	-
de	O	-
que	O	-
el	O	-
último	O	-
paciente	O	-
completara	O	-
el	O	-
estudio.	O	-

La	B-Premise	HighQuality
epoyetina	I-Premise	HighQuality
alfa,	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
las	I-Premise	HighQuality
necesidades	I-Premise	HighQuality
de	I-Premise	HighQuality
transfusión	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0057	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
la	I-Premise	HighQuality
hemoglobina	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Para	B-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
con	I-Premise	HighQuality
epoyetina	I-Premise	HighQuality
alfa	I-Premise	HighQuality
frente	I-Premise	HighQuality
a	I-Premise	HighQuality
placebo,	I-Premise	HighQuality
la	I-Premise	HighQuality
mejora	I-Premise	HighQuality
de	I-Premise	HighQuality
todos	I-Premise	HighQuality
los	I-Premise	HighQuality
dominios	I-Premise	HighQuality
primarios	I-Premise	HighQuality
de	I-Premise	HighQuality
CV	I-Premise	HighQuality
específicos	I-Premise	HighQuality
para	I-Premise	HighQuality
cáncer	I-Premise	HighQuality
y	I-Premise	HighQuality
anemia,	I-Premise	HighQuality
incluido	I-Premise	HighQuality
el	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
energía,	I-Premise	HighQuality
la	I-Premise	HighQuality
capacidad	I-Premise	HighQuality
para	I-Premise	HighQuality
realizar	I-Premise	HighQuality
actividades	I-Premise	HighQuality
diarias	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
fatiga	I-Premise	HighQuality
fue	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,01	I-Premise	HighQuality
).	I-Premise	HighQuality

Aunque	O	-
el	O	-
estudio	O	-
no	O	-
fue	O	-
potenciado	O	-
para	O	-
la	O	-
supervivencia	O	-
como	O	-
punto	O	-
final,	O	-
las	B-Premise	HighQuality
estimaciones	I-Premise	HighQuality
de	I-Premise	HighQuality
Kaplan-Meier	I-Premise	HighQuality
mostraron	I-Premise	HighQuality
una	I-Premise	HighQuality
tendencia	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
global	I-Premise	HighQuality
favoreciendo	I-Premise	HighQuality
la	I-Premise	HighQuality
epoyetina	I-Premise	HighQuality
alfa	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
13,	I-Premise	HighQuality
prueba	I-Premise	HighQuality
de	I-Premise	HighQuality
rango	I-Premise	HighQuality
logarítmico	I-Premise	HighQuality
)	I-Premise	HighQuality
y	O	-
el	B-Premise	HighQuality
análisis	I-Premise	HighQuality
de	I-Premise	HighQuality
regresión	I-Premise	HighQuality
de	I-Premise	HighQuality
Cox	I-Premise	HighQuality
mostró	I-Premise	HighQuality
una	I-Premise	HighQuality
relación	I-Premise	HighQuality
de	I-Premise	HighQuality
riesgos	I-Premise	HighQuality
estimada	I-Premise	HighQuality
de	I-Premise	HighQuality
1,309	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,052	I-Premise	HighQuality
)	I-Premise	HighQuality
favoreciendo	I-Premise	HighQuality
la	I-Premise	HighQuality
epoyetina	I-Premise	HighQuality
alfa.	I-Premise	HighQuality

Las	B-Premise	HighQuality
reacciones	I-Premise	HighQuality
adversas	I-Premise	HighQuality
fueron	I-Premise	HighQuality
comparables	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

La	B-Claim	HighQuality
epoyetina	I-Claim	HighQuality
alfa	I-Claim	HighQuality
alivia	I-Claim	HighQuality
de	I-Claim	HighQuality
forma	I-Claim	HighQuality
segura	I-Claim	HighQuality
y	I-Claim	HighQuality
eficaz	I-Claim	HighQuality
la	I-Claim	HighQuality
anemia	I-Claim	HighQuality
y	I-Claim	HighQuality
mejora	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
la	I-Claim	HighQuality
CV	I-Claim	HighQuality
en	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
con	I-Claim	HighQuality
cáncer	I-Claim	HighQuality
que	I-Claim	HighQuality
reciben	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
sin	I-Claim	HighQuality
platino.	I-Claim	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
alentadores	I-Claim	HighQuality
con	I-Claim	HighQuality
respecto	I-Claim	HighQuality
al	I-Claim	HighQuality
aumento	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
supervivencia	I-Claim	HighQuality
justifican	I-Claim	HighQuality
otro	I-Claim	HighQuality
ensayo	I-Claim	HighQuality
diseñado	I-Claim	HighQuality
para	I-Claim	HighQuality
confirmar	I-Claim	HighQuality
estos	I-Claim	HighQuality
hallazgos.	I-Claim	HighQuality

Evaluar	O	-
prospectivamente	O	-
los	O	-
resultados	O	-
visuales	O	-
y	O	-
las	O	-
complicaciones	O	-
durante	O	-
y	O	-
después	O	-
de	O	-
la	O	-
cirugía	O	-
de	O	-
cataratas	O	-
con	O	-
o	O	-
sin	O	-
esclerostomía	O	-
profiláctica	O	-
en	O	-
ojos	O	-
nanoftálmicos	O	-
con	O	-
cataratas	O	-
visualmente	O	-
significativas.Sesenta	O	-
ojos	O	-
nanoftálmicos	O	-
de	O	-
60	O	-
pacientes	O	-
con	O	-
cataratas	O	-
visualmente	O	-
significativas	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
la	O	-
cirugía	O	-
de	O	-
cataratas	O	-
sola	O	-
(grupo	O	-
control,	O	-
n	O	-
=	O	-
31	O	-
)	O	-
o	O	-
cirugía	O	-
de	O	-
cataratas	O	-
con	O	-
esclerostomía	O	-
profiláctica	O	-
concomitante	O	-
(grupo	O	-
esclerostomía,	O	-
n	O	-
=	O	-
29	O	-
).	O	-

La	O	-
cirugía	O	-
se	O	-
realizó	O	-
mediante	O	-
facoemulsificación	O	-
o	O	-
cirugía	O	-
manual	O	-
de	O	-
cataratas	O	-
de	O	-
pequeña	O	-
incisión	O	-
(SICS	O	-
)	O	-
basada	O	-
en	O	-
la	O	-
puntuación	O	-
de	O	-
clasificación	O	-
LOCS	O	-
III.	O	-

Se	O	-
analizaron	O	-
las	O	-
diferencias	O	-
de	O	-
grupo	O	-
en	O	-
las	O	-
complicaciones	O	-
intraoperatorias	O	-
y	O	-
postoperatorias	O	-
y	O	-
se	O	-
evaluaron	O	-
los	O	-
factores	O	-
de	O	-
riesgo.	O	-

Se	B-Premise	HighQuality
observaron	I-Premise	HighQuality
menos	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
esclerostomía	I-Premise	HighQuality
(	I-Premise	HighQuality
5/29,	I-Premise	HighQuality
17,2%	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
control	I-Premise	HighQuality
(	I-Premise	HighQuality
12/31,	I-Premise	HighQuality
38,7%	I-Premise	HighQuality
),	I-Premise	HighQuality
aunque	I-Premise	HighQuality
las	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
fueron	I-Premise	HighQuality
marginalmente	I-Premise	HighQuality
significativas	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,065	I-Premise	HighQuality
).	I-Premise	HighQuality

Cuatro	B-Premise	HighQuality
grupos	I-Premise	HighQuality
control,	I-Premise	HighQuality
pero	I-Premise	HighQuality
sin	I-Premise	HighQuality
grupo	I-Premise	HighQuality
esclerostomía,	I-Premise	HighQuality
los	I-Premise	HighQuality
ojos	I-Premise	HighQuality
desarrollaron	I-Premise	HighQuality
efusiones	I-Premise	HighQuality
uveales	I-Premise	HighQuality
postoperatorias	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Premise	HighQuality
modelos	I-Premise	HighQuality
multivariables,	I-Premise	HighQuality
la	I-Premise	HighQuality
esclerostomía	I-Premise	HighQuality
disminuyó	I-Premise	HighQuality
las	I-Premise	HighQuality
probabilidades	I-Premise	HighQuality
de	I-Premise	HighQuality
complicación	I-Premise	HighQuality
intraoperatoria	I-Premise	HighQuality
o	I-Premise	HighQuality
postoperatoria	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
80	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
odds	I-Premise	HighQuality
ratio	I-Premise	HighQuality
[	I-Premise	HighQuality
OR	I-Premise	HighQuality
]	I-Premise	HighQuality
=	I-Premise	HighQuality
0,2,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
]	I-Premise	HighQuality
=	I-Premise	HighQuality
0,04-0,92,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,039	I-Premise	HighQuality
)	I-Premise	HighQuality
;	I-Premise	HighQuality
el	B-Premise	HighQuality
SICS	I-Premise	HighQuality
se	I-Premise	HighQuality
asoció	I-Premise	HighQuality
con	I-Premise	HighQuality
un	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
mayor	I-Premise	HighQuality
de	I-Premise	HighQuality
complicaciones	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
facoemulsificación	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
=	I-Premise	HighQuality
5,95,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
1,49-23,73,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,012	I-Premise	HighQuality
),	I-Premise	HighQuality
mientras	I-Premise	HighQuality
que	I-Premise	HighQuality
la	I-Premise	HighQuality
presión	I-Premise	HighQuality
intraocular	I-Premise	HighQuality
preoperatoria	I-Premise	HighQuality
alta	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
=	I-Premise	HighQuality
4,54,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,99-20,9,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,052	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
mayor	I-Premise	HighQuality
espesor	I-Premise	HighQuality
de	I-Premise	HighQuality
las	I-Premise	HighQuality
lentes	I-Premise	HighQuality
(	I-Premise	HighQuality
OR	I-Premise	HighQuality
=	I-Premise	HighQuality
3,38,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,88-12,91,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,075	I-Premise	HighQuality
)	I-Premise	HighQuality
demostraron	I-Premise	HighQuality
una	I-Premise	HighQuality
asociación	I-Premise	HighQuality
marginalmente	I-Premise	HighQuality
significativa.	I-Premise	HighQuality

La	B-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
cataratas	I-Claim	HighQuality
en	I-Claim	HighQuality
los	I-Claim	HighQuality
ojos	I-Claim	HighQuality
con	I-Claim	HighQuality
nanoftalmos	I-Claim	HighQuality
se	I-Claim	HighQuality
asocia	I-Claim	HighQuality
con	I-Claim	HighQuality
un	I-Claim	HighQuality
alto	I-Claim	HighQuality
riesgo	I-Claim	HighQuality
de	I-Claim	HighQuality
complicaciones	I-Claim	HighQuality
potencialmente	I-Claim	HighQuality
visuales.	I-Claim	HighQuality

Realizar	B-Claim	HighQuality
una	I-Claim	HighQuality
esclerostomía	I-Claim	HighQuality
profiláctica	I-Claim	HighQuality
simultánea	I-Claim	HighQuality
con	I-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
cataratas	I-Claim	HighQuality
reduce	I-Claim	HighQuality
las	I-Claim	HighQuality
tasas	I-Claim	HighQuality
de	I-Claim	HighQuality
complicaciones,	I-Claim	HighQuality
particularmente	I-Claim	HighQuality
las	I-Claim	HighQuality
efusiones	I-Claim	HighQuality
uveales.	I-Claim	HighQuality

La	B-Claim	HighQuality
cirugía	I-Claim	HighQuality
de	I-Claim	HighQuality
cataratas	I-Claim	HighQuality
en	I-Claim	HighQuality
etapas	I-Claim	HighQuality
anteriores	I-Claim	HighQuality
por	I-Claim	HighQuality
facoemulsificación	I-Claim	HighQuality
puede	I-Claim	HighQuality
ser	I-Claim	HighQuality
más	I-Claim	HighQuality
beneficiosa	I-Claim	HighQuality
que	I-Claim	HighQuality
someterse	I-Claim	HighQuality
a	I-Claim	HighQuality
SICS	I-Claim	HighQuality
manual.	I-Claim	HighQuality

Para	O	-
investigar	O	-
si	O	-
la	O	-
dosis-intensidad	O	-
relativa	O	-
de	O	-
la	O	-
quimioterapia	O	-
ciclofosfamida,	O	-
doxorrubicina,	O	-
vincristina	O	-
y	O	-
prednisona	O	-
(	O	-
CHOP	O	-
)	O	-
podría	O	-
mejorarse	O	-
mediante	O	-
la	O	-
administración	O	-
profiláctica	O	-
del	O	-
factor	O	-
estimulante	O	-
de	O	-
colonias	O	-
de	O	-
granulocitos	O	-
(	O	-
G-CSF	O	-
)	O	-
en	O	-
pacientes	O	-
de	O	-
edad	O	-
avanzada	O	-
con	O	-
linfoma	O	-
no	O	-
Hodgkin	O	-
agresivo	O	-
(	O	-
LNH	O	-
).	O	-

Los	O	-
pacientes	O	-
de	O	-
65	O	-
a	O	-
90	O	-
años	O	-
(mediana,	O	-
72	O	-
años	O	-
)	O	-
con	O	-
LNH	O	-
agresivo	O	-
en	O	-
estadio	O	-
II	O	-
a	O	-
IV	O	-
fueron	O	-
asignados	O	-
aleatoriamente	O	-
a	O	-
recibir	O	-
CHOP	O	-
estándar	O	-
cada	O	-
3	O	-
semanas	O	-
o	O	-
CHOP	O	-
más	O	-
G-CSF	O	-
cada	O	-
3	O	-
semanas	O	-
en	O	-
los	O	-
días	O	-
2	O	-
a	O	-
11	O	-
de	O	-
cada	O	-
ciclo.	O	-

En	B-Premise	HighQuality
389	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
elegibles,	I-Premise	HighQuality
las	I-Premise	HighQuality
intensidades	I-Premise	HighQuality
relativas	I-Premise	HighQuality
de	I-Premise	HighQuality
dosis	I-Premise	HighQuality
(	I-Premise	HighQuality
IDR	I-Premise	HighQuality
)	I-Premise	HighQuality
de	I-Premise	HighQuality
ciclofosfamida	I-Premise	HighQuality
(	I-Premise	HighQuality
mediana,	I-Premise	HighQuality
96,3	I-Premise	HighQuality
%	I-Premise	HighQuality
v	I-Premise	HighQuality
93,9	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,01	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
doxorrubicina	I-Premise	HighQuality
(	I-Premise	HighQuality
mediana,	I-Premise	HighQuality
95,4	I-Premise	HighQuality
%	I-Premise	HighQuality
v	I-Premise	HighQuality
93,3	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,4	I-Premise	HighQuality
)	I-Premise	HighQuality
fueron	I-Premise	HighQuality
mayores	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
más	I-Premise	HighQuality
G-CSF.	I-Premise	HighQuality

Las	B-Premise	HighQuality
tasas	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
completa	I-Premise	HighQuality
fueron	I-Premise	HighQuality
del	I-Premise	HighQuality
55	I-Premise	HighQuality
%	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
52	I-Premise	HighQuality
%	I-Premise	HighQuality
para	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
y	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
más	I-Premise	HighQuality
G-CSF,	I-Premise	HighQuality
respectivamente	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,63	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
supervivencia	I-Premise	HighQuality
global	I-Premise	HighQuality
actuarial	I-Premise	HighQuality
a	I-Premise	HighQuality
los	I-Premise	HighQuality
5	I-Premise	HighQuality
años	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
22	I-Premise	HighQuality
%	I-Premise	HighQuality
con	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
solo,	I-Premise	HighQuality
frente	I-Premise	HighQuality
al	I-Premise	HighQuality
24	I-Premise	HighQuality
%	I-Premise	HighQuality
con	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
más	I-Premise	HighQuality
G-CSF	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
=	I-Premise	HighQuality
0,76	I-Premise	HighQuality
),	I-Premise	HighQuality
con	I-Premise	HighQuality
una	I-Premise	HighQuality
mediana	I-Premise	HighQuality
de	I-Premise	HighQuality
seguimiento	I-Premise	HighQuality
de	I-Premise	HighQuality
33	I-Premise	HighQuality
meses.	I-Premise	HighQuality

Los	B-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
más	I-Premise	HighQuality
G-CSF	I-Premise	HighQuality
tuvieron	I-Premise	HighQuality
una	I-Premise	HighQuality
incidencia	I-Premise	HighQuality
idéntica	I-Premise	HighQuality
de	I-Premise	HighQuality
infecciones,	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
Organización	I-Premise	HighQuality
Mundial	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
Salud	I-Premise	HighQuality
grados	I-Premise	HighQuality
3	I-Premise	HighQuality
a	I-Premise	HighQuality
4	I-Premise	HighQuality
(	I-Premise	HighQuality
34	I-Premise	HighQuality
de	I-Premise	HighQuality
1.191	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
v	I-Premise	HighQuality
36	I-Premise	HighQuality
de	I-Premise	HighQuality
1.195	I-Premise	HighQuality
ciclos	I-Premise	HighQuality
).	I-Premise	HighQuality

Sólo	B-Premise	HighQuality
los	I-Premise	HighQuality
días	I-Premise	HighQuality
acumulados	I-Premise	HighQuality
con	I-Premise	HighQuality
antibióticos	I-Premise	HighQuality
fueron	I-Premise	HighQuality
menos	I-Premise	HighQuality
con	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
más	I-Premise	HighQuality
G-CSF	I-Premise	HighQuality
(	I-Premise	HighQuality
mediana,	I-Premise	HighQuality
0	I-Premise	HighQuality
v	I-Premise	HighQuality
6	I-Premise	HighQuality
días	I-Premise	HighQuality
;	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,006	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
con	I-Premise	HighQuality
CHOP	I-Premise	HighQuality
solo.	I-Premise	HighQuality

El	B-Premise	HighQuality
número	I-Premise	HighQuality
de	I-Premise	HighQuality
ingresos	I-Premise	HighQuality
hospitalarios	I-Premise	HighQuality
y	I-Premise	HighQuality
el	I-Premise	HighQuality
número	I-Premise	HighQuality
de	I-Premise	HighQuality
días	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
hospital	I-Premise	HighQuality
no	I-Premise	HighQuality
fueron	I-Premise	HighQuality
diferentes.	I-Premise	HighQuality

En	B-Claim	HighQuality
pacientes	I-Claim	HighQuality
de	I-Claim	HighQuality
edad	I-Claim	HighQuality
avanzada,	I-Claim	HighQuality
G-CSF	I-Claim	HighQuality
mejoró	I-Claim	HighQuality
el	I-Claim	HighQuality
RDI	I-Claim	HighQuality
de	I-Claim	HighQuality
CHOP,	I-Claim	HighQuality
pero	B-Premise	HighQuality
esto	I-Premise	HighQuality
no	I-Premise	HighQuality
llevó	I-Premise	HighQuality
a	I-Premise	HighQuality
una	I-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
completa	I-Premise	HighQuality
más	I-Premise	HighQuality
alta	I-Premise	HighQuality
o	I-Premise	HighQuality
mejor	I-Premise	HighQuality
supervivencia	I-Premise	HighQuality
global.	I-Premise	HighQuality

G-CSF	B-Claim	HighQuality
no	I-Claim	HighQuality
previno	I-Claim	HighQuality
infecciones	I-Claim	HighQuality
graves.	I-Claim	HighQuality

El	O	-
estudio	O	-
fue	O	-
diseñado	O	-
para	O	-
comparar	O	-
los	O	-
efectos	O	-
del	O	-
tratamiento	O	-
con	O	-
una	O	-
combinación	O	-
de	O	-
trastuzumab	O	-
(	O	-
Herceptin	O	-
;	O	-
Genentech,	O	-
Inc,	O	-
South	O	-
San	O	-
Francisco,	O	-
CA	O	-
)	O	-
y	O	-
quimioterapia	O	-
frente	O	-
a	O	-
quimioterapia	O	-
sola	O	-
en	O	-
la	O	-
calidad	O	-
de	O	-
vida	O	-
relacionada	O	-
con	O	-
la	O	-
salud	O	-
(	O	-
CVRS	O	-
)	O	-
en	O	-
pacientes	O	-
con	O	-
HER-2/neu	O	-
sobreexpresando,	O	-
cáncer	O	-
de	O	-
mama	O	-
metastásico.	O	-

Una	O	-
muestra	O	-
de	O	-
400	O	-
pacientes,	O	-
no	O	-
tratados	O	-
previamente	O	-
para	O	-
la	O	-
enfermedad	O	-
metastásica	O	-
y	O	-
aleatorizados	O	-
para	O	-
recibir	O	-
trastuzumab	O	-
más	O	-
quimioterapia	O	-
(	O	-
208	O	-
pacientes	O	-
)	O	-
o	O	-
quimioterapia	O	-
sola	O	-
(	O	-
192	O	-
pacientes	O	-
),	O	-
completó	O	-
el	O	-
cuestionario	O	-
de	O	-
calidad	O	-
de	O	-
vida	O	-
de	O	-
la	O	-
Organización	O	-
Europea	O	-
para	O	-
la	O	-
Investigación	O	-
y	O	-
el	O	-
Tratamiento	O	-
al	O	-
inicio	O	-
y	O	-
al	O	-
menos	O	-
en	O	-
una	O	-
ocasión	O	-
posterior	O	-
a	O	-
las	O	-
8,	O	-
20,	O	-
32,	O	-
44	O	-
y	O	-
56	O	-
semanas.	O	-

La	O	-
mejoría	O	-
o	O	-
empeoramiento	O	-
de	O	-
la	O	-
CVRS	O	-
se	O	-
definió	O	-
como	O	-
un	O	-
cambio	O	-
>	O	-
o	O	-
=	O	-
10	O	-
puntos	O	-
(rango,	O	-
0	O	-
a	O	-
100	O	-
puntos	O	-
)	O	-
en	O	-
los	O	-
puntajes	O	-
de	O	-
seis	O	-
dominios	O	-
preseleccionados	O	-
(	O	-
calidad	O	-
de	O	-
vida	O	-
global	O	-
[	O	-
CV	O	-
],	O	-
físico,	O	-
rol,	O	-
funcionamiento	O	-
social	O	-
y	O	-
emocional,	O	-
y	O	-
fatiga	O	-
).	O	-

La	O	-
CVRS	O	-
estable	O	-
se	O	-
definió	O	-
como	O	-
un	O	-
cambio	O	-
de	O	-
menos	O	-
de	O	-
10.	O	-
Se	O	-
aplicó	O	-
una	O	-
corrección	O	-
de	O	-
Bonferroni	O	-
para	O	-
múltiples	O	-
pruebas.	O	-

Tras	B-Premise	HighQuality
la	I-Premise	HighQuality
finalización	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
quimioterapia,	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
trastuzumab	I-Premise	HighQuality
y	I-Premise	HighQuality
quimioterapia	I-Premise	HighQuality
notificaron	I-Premise	HighQuality
una	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
significativa	I-Premise	HighQuality
de	I-Premise	HighQuality
la	I-Premise	HighQuality
fatiga	I-Premise	HighQuality
(	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
sus	I-Premise	HighQuality
puntuaciones	I-Premise	HighQuality
basales.	I-Premise	HighQuality

La	B-Premise	HighQuality
proporción	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
que	I-Premise	HighQuality
recibieron	I-Premise	HighQuality
el	I-Premise	HighQuality
tratamiento	I-Premise	HighQuality
combinado	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
CV	I-Premise	HighQuality
global	I-Premise	HighQuality
(p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,05	I-Premise	HighQuality
)	I-Premise	HighQuality
que	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
tratados	I-Premise	HighQuality
con	I-Premise	HighQuality
quimioterapia	I-Premise	HighQuality
sola.	I-Premise	HighQuality

Las	B-Premise	HighQuality
mayores	I-Premise	HighQuality
proporciones	I-Premise	HighQuality
del	I-Premise	HighQuality
grupo	I-Premise	HighQuality
de	I-Premise	HighQuality
terapia	I-Premise	HighQuality
combinada	I-Premise	HighQuality
también	I-Premise	HighQuality
lograron	I-Premise	HighQuality
una	I-Premise	HighQuality
mejoría	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
funcionamiento	I-Premise	HighQuality
físico	I-Premise	HighQuality
y	I-Premise	HighQuality
funcional	I-Premise	HighQuality
y	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
fatiga	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
quimioterapéutico,	I-Premise	HighQuality
pero	B-Premise	HighQuality
las	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
no	I-Premise	HighQuality
fueron	I-Premise	HighQuality
estadísticamente	I-Premise	HighQuality
significativas.	I-Premise	HighQuality

No	B-Premise	HighQuality
hubo	I-Premise	HighQuality
diferencias	I-Premise	HighQuality
en	I-Premise	HighQuality
las	I-Premise	HighQuality
proporciones	I-Premise	HighQuality
de	I-Premise	HighQuality
pacientes	I-Premise	HighQuality
en	I-Premise	HighQuality
los	I-Premise	HighQuality
dos	I-Premise	HighQuality
grupos	I-Premise	HighQuality
que	I-Premise	HighQuality
notificaron	I-Premise	HighQuality
empeoramiento.	I-Premise	HighQuality

Las	B-Claim	HighQuality
proporciones	I-Claim	HighQuality
estadísticamente	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
mayores	I-Claim	HighQuality
de	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
una	I-Claim	HighQuality
combinación	I-Claim	HighQuality
de	I-Claim	HighQuality
trastuzumab	I-Claim	HighQuality
y	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
notificaron	I-Claim	HighQuality
mejor	I-Claim	HighQuality
QOL	I-Claim	HighQuality
global	I-Claim	HighQuality
que	I-Claim	HighQuality
los	I-Claim	HighQuality
pacientes	I-Claim	HighQuality
tratados	I-Claim	HighQuality
con	I-Claim	HighQuality
quimioterapia	I-Claim	HighQuality
sola.	I-Claim	HighQuality

Las	O	-
mujeres	O	-
embarazadas	O	-
con	O	-
una	O	-
carga	O	-
viral	O	-
elevada	O	-
del	O	-
virus	O	-
de	O	-
la	O	-
hepatitis	O	-
B	O	-
(VHB)	O	-
tienen	O	-
riesgo	O	-
de	O	-
transmitir	O	-
infecciones	O	-
a	O	-
sus	O	-
bebés,	O	-
a	O	-
pesar	O	-
de	O	-
que	O	-
los	O	-
lactantes	O	-
reciben	O	-
inmunoglobulina	O	-
de	O	-
hepatitis	O	-
B.	O	-

En	O	-
este	O	-
ensayo	O	-
clínico	O	-
multicéntrico,	O	-
doble	O	-
ciego	O	-
realizado	O	-
en	O	-
Tailandia,	O	-
asignamos	O	-
al	O	-
azar	O	-
el	O	-
antígeno	O	-
de	O	-
hepatitis	O	-
B	O	-
e	O	-
(	O	-
HBeAg	O	-
)	O	-
a	O	-
mujeres	O	-
embarazadas	O	-
positivas	O	-
con	O	-
un	O	-
nivel	O	-
de	O	-
alanina	O	-
aminotransferasa	O	-
de	O	-
60	O	-
UI	O	-
o	O	-
menos	O	-
por	O	-
litro	O	-
para	O	-
recibir	O	-
tenofovir	O	-
disoproxil	O	-
fumarato	O	-
(	O	-
TDF	O	-
)	O	-
o	O	-
placebo	O	-
de	O	-
28	O	-
semanas	O	-
de	O	-
gestación	O	-
a	O	-
2	O	-
meses	O	-
después	O	-
del	O	-
parto.	O	-

Los	O	-
lactantes	O	-
recibieron	O	-
inmunoglobulina	O	-
de	O	-
hepatitis	O	-
B	O	-
al	O	-
nacer	O	-
y	O	-
vacuna	O	-
de	O	-
hepatitis	O	-
B	O	-
al	O	-
nacer	O	-
y	O	-
a	O	-
los	O	-
1,	O	-
2,	O	-
4	O	-
y	O	-
6	O	-
meses.	O	-

El	O	-
punto	O	-
final	O	-
primario	O	-
fue	O	-
un	O	-
antígeno	O	-
de	O	-
superficie	O	-
de	O	-
hepatitis	O	-
B	O	-
(	O	-
HBsAg	O	-
)	O	-
positivo	O	-
en	O	-
el	O	-
bebé,	O	-
confirmado	O	-
por	O	-
el	O	-
nivel	O	-
de	O	-
ADN	O	-
del	O	-
VHB	O	-
a	O	-
los	O	-
6	O	-
meses	O	-
de	O	-
edad.	O	-

Se	O	-
calculó	O	-
que	O	-
una	O	-
muestra	O	-
de	O	-
328	O	-
mujeres	O	-
proporcionaría	O	-
al	O	-
ensayo	O	-
una	O	-
potencia	O	-
del	O	-
90%	O	-
para	O	-
detectar	O	-
una	O	-
diferencia	O	-
de	O	-
al	O	-
menos	O	-
9	O	-
puntos	O	-
porcentuales	O	-
en	O	-
la	O	-
tasa	O	-
de	O	-
transmisión	O	-
(tasa	O	-
esperada,	O	-
3	O	-
%	O	-
en	O	-
el	O	-
grupo	O	-
TDF	O	-
vs.	O	-
12	O	-
%	O	-
en	O	-
el	O	-
grupo	O	-
placebo	O	-
).	O	-

De	O	-
enero	O	-
de	O	-
2013	O	-
a	O	-
agosto	O	-
de	O	-
2015,	O	-
se	O	-
inscribieron	O	-
331	O	-
mujeres	O	-
;	O	-
168	O	-
mujeres	O	-
fueron	O	-
asignadas	O	-
al	O	-
azar	O	-
al	O	-
grupo	O	-
TDF	O	-
y	O	-
163	O	-
al	O	-
grupo	O	-
placebo.	O	-

En	O	-
la	O	-
inscripción,	O	-
la	O	-
mediana	O	-
de	O	-
edad	O	-
gestacional	O	-
fue	O	-
de	O	-
28,3	O	-
semanas,	O	-
y	O	-
la	O	-
mediana	O	-
del	O	-
nivel	O	-
de	O	-
ADN	O	-
del	O	-
VHB	O	-
fue	O	-
de	O	-
8,0	O	-
log10	O	-
UI	O	-
por	O	-
mililitro.	O	-

Entre	O	-
322	O	-
partos	O	-
(	O	-
97	O	-
%	O	-
de	O	-
los	O	-
participantes	O	-
),	O	-
hubo	O	-
319	O	-
nacimientos	O	-
singleton,	O	-
dos	O	-
pares	O	-
gemelos,	O	-
y	O	-
un	O	-
bebé	O	-
muerto.	O	-

La	O	-
mediana	O	-
del	O	-
tiempo	O	-
desde	O	-
el	O	-
nacimiento	O	-
hasta	O	-
la	O	-
administración	O	-
de	O	-
la	O	-
inmunoglobulina	O	-
de	O	-
hepatitis	O	-
B	O	-
fue	O	-
de	O	-
1,3	O	-
horas,	O	-
y	O	-
la	O	-
mediana	O	-
del	O	-
tiempo	O	-
desde	O	-
el	O	-
nacimiento	O	-
hasta	O	-
la	O	-
administración	O	-
de	O	-
la	O	-
vacuna	O	-
de	O	-
hepatitis	O	-
B	O	-
fue	O	-
de	O	-
1,2	O	-
horas.	O	-

En	B-Premise	HighQuality
el	I-Premise	HighQuality
análisis	I-Premise	HighQuality
primario,	I-Premise	HighQuality
ninguno	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
147	I-Premise	HighQuality
lactantes	I-Premise	HighQuality
(	I-Premise	HighQuality
0	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
],	I-Premise	HighQuality
0	I-Premise	HighQuality
a	I-Premise	HighQuality
2	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF	I-Premise	HighQuality
fue	I-Premise	HighQuality
infectado,	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
3	I-Premise	HighQuality
de	I-Premise	HighQuality
147	I-Premise	HighQuality
(	I-Premise	HighQuality
2	I-Premise	HighQuality
%	I-Premise	HighQuality
;	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
IC,	I-Premise	HighQuality
0	I-Premise	HighQuality
a	I-Premise	HighQuality
6	I-Premise	HighQuality
)	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,12	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Premise	HighQuality
tasa	I-Premise	HighQuality
de	I-Premise	HighQuality
acontecimientos	I-Premise	HighQuality
adversos	I-Premise	HighQuality
no	I-Premise	HighQuality
difirió	I-Premise	HighQuality
significativamente	I-Premise	HighQuality
entre	I-Premise	HighQuality
los	I-Premise	HighQuality
grupos.	I-Premise	HighQuality

La	B-Premise	HighQuality
incidencia	I-Premise	HighQuality
de	I-Premise	HighQuality
un	I-Premise	HighQuality
nivel	I-Premise	HighQuality
de	I-Premise	HighQuality
alanina	I-Premise	HighQuality
aminotransferasa	I-Premise	HighQuality
materna	I-Premise	HighQuality
de	I-Premise	HighQuality
más	I-Premise	HighQuality
de	I-Premise	HighQuality
300	I-Premise	HighQuality
UI	I-Premise	HighQuality
por	I-Premise	HighQuality
litro	I-Premise	HighQuality
tras	I-Premise	HighQuality
la	I-Premise	HighQuality
interrupción	I-Premise	HighQuality
del	I-Premise	HighQuality
régimen	I-Premise	HighQuality
de	I-Premise	HighQuality
ensayo	I-Premise	HighQuality
fue	I-Premise	HighQuality
del	I-Premise	HighQuality
6	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
TDF	I-Premise	HighQuality
y	I-Premise	HighQuality
del	I-Premise	HighQuality
3	I-Premise	HighQuality
%	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
grupo	I-Premise	HighQuality
placebo	I-Premise	HighQuality
(p=0,29	I-Premise	HighQuality
).	I-Premise	HighQuality

En	B-Claim	HighQuality
un	I-Claim	HighQuality
contexto	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
que	I-Claim	HighQuality
la	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
transmisión	I-Claim	HighQuality
del	I-Claim	HighQuality
VHB	I-Claim	HighQuality
de	I-Claim	HighQuality
madre	I-Claim	HighQuality
a	I-Claim	HighQuality
hijo	I-Claim	HighQuality
fue	I-Claim	HighQuality
baja	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
administración	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
inmunoglobulina	I-Claim	HighQuality
de	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
y	I-Claim	HighQuality
la	I-Claim	HighQuality
vacuna	I-Claim	HighQuality
de	I-Claim	HighQuality
hepatitis	I-Claim	HighQuality
B	I-Claim	HighQuality
en	I-Claim	HighQuality
bebés	I-Claim	HighQuality
nacidos	I-Claim	HighQuality
de	I-Claim	HighQuality
madres	I-Claim	HighQuality
HBeAg	I-Claim	HighQuality
positivas,	I-Claim	HighQuality
el	I-Claim	HighQuality
uso	I-Claim	HighQuality
materno	I-Claim	HighQuality
adicional	I-Claim	HighQuality
de	I-Claim	HighQuality
TDF	I-Claim	HighQuality
no	I-Claim	HighQuality
dio	I-Claim	HighQuality
lugar	I-Claim	HighQuality
a	I-Claim	HighQuality
una	I-Claim	HighQuality
tasa	I-Claim	HighQuality
de	I-Claim	HighQuality
transmisión	I-Claim	HighQuality
significativamente	I-Claim	HighQuality
menor.	I-Claim	HighQuality

Para	O	-
evaluar	O	-
los	O	-
efectos	O	-
de	O	-
la	O	-
monitorización	O	-
continua	O	-
de	O	-
la	O	-
glucosa	O	-
(CGM	O	-
)	O	-
sobre	O	-
la	O	-
hipoglucemia	O	-
nocturna	O	-
y	O	-
diurna	O	-
en	O	-
personas	O	-
con	O	-
diabetes	O	-
tipo	O	-
1	O	-
tratadas	O	-
con	O	-
múltiples	O	-
inyecciones	O	-
diarias	O	-
de	O	-
insulina	O	-
(	O	-
MDI	O	-
)	O	-
;	O	-
también	O	-
se	O	-
evaluaron	O	-
factores	O	-
relacionados	O	-
con	O	-
las	O	-
diferencias	O	-
en	O	-
la	O	-
confianza	O	-
en	O	-
la	O	-
hipoglucemia	O	-
en	O	-
esta	O	-
población.	O	-

Se	O	-
realizaron	O	-
evaluaciones	O	-
a	O	-
partir	O	-
del	O	-
ensayo	O	-
aleatorizado	O	-
GOLD,	O	-
un	O	-
ensayo	O	-
clínico	O	-
abierto	O	-
multicéntrico	O	-
cruzado	O	-
aleatorizado	O	-
(	O	-
n	O	-
=	O	-
161	O	-
)	O	-
durante	O	-
69	O	-
semanas	O	-
en	O	-
el	O	-
que	O	-
se	O	-
comparó	O	-
la	O	-
CGM	O	-
con	O	-
la	O	-
automedición	O	-
de	O	-
glucosa	O	-
en	O	-
sangre	O	-
(	O	-
SMBG	O	-
)	O	-
en	O	-
personas	O	-
con	O	-
diabetes	O	-
tipo	O	-
1	O	-
tratadas	O	-
con	O	-
IDM.	O	-

Para	O	-
las	O	-
evaluaciones	O	-
se	O	-
utilizaron	O	-
la	O	-
CGM	O	-
enmascarada	O	-
y	O	-
el	O	-
cuestionario	O	-
de	O	-
confianza	O	-
de	O	-
la	O	-
hipoglucemia.	O	-

El	B-Premise	HighQuality
tiempo	I-Premise	HighQuality
con	I-Premise	HighQuality
hipoglucemia	I-Premise	HighQuality
nocturna,	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
<	I-Premise	HighQuality
70	I-Premise	HighQuality
mg/dl	I-Premise	HighQuality
se	I-Premise	HighQuality
redujeron	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
48	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
10,2	I-Premise	HighQuality
vs.	I-Premise	HighQuality
19,6	I-Premise	HighQuality
min	I-Premise	HighQuality
cada	I-Premise	HighQuality
noche,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
<	I-Premise	HighQuality
54	I-Premise	HighQuality
mg/dl	I-Premise	HighQuality
en	I-Premise	HighQuality
un	I-Premise	HighQuality
65	I-Premise	HighQuality
%.	I-Premise	HighQuality
(	I-Premise	HighQuality
3,1	I-Premise	HighQuality
vs	I-Premise	HighQuality
8,9	I-Premise	HighQuality
min,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Para	B-Premise	HighQuality
los	I-Premise	HighQuality
cortes	I-Premise	HighQuality
de	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
correspondientes,	I-Premise	HighQuality
la	I-Premise	HighQuality
hipoglucemia	I-Premise	HighQuality
diurna	I-Premise	HighQuality
se	I-Premise	HighQuality
redujo	I-Premise	HighQuality
un	I-Premise	HighQuality
40	I-Premise	HighQuality
%	I-Premise	HighQuality
(29	I-Premise	HighQuality
vs.	I-Premise	HighQuality
49	I-Premise	HighQuality
min,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
un	I-Premise	HighQuality
54	I-Premise	HighQuality
%	I-Premise	HighQuality
(	I-Premise	HighQuality
8	I-Premise	HighQuality
vs.	I-Premise	HighQuality
18	I-Premise	HighQuality
min.	I-Premise	HighQuality
,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
),	I-Premise	HighQuality
respectivamente.	I-Premise	HighQuality

En	B-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
SMBG,	I-Premise	HighQuality
el	I-Premise	HighQuality
uso	I-Premise	HighQuality
de	I-Premise	HighQuality
CGM	I-Premise	HighQuality
mejoró	I-Premise	HighQuality
la	I-Premise	HighQuality
confianza	I-Premise	HighQuality
relacionada	I-Premise	HighQuality
con	I-Premise	HighQuality
la	I-Premise	HighQuality
hipoglucemia	I-Premise	HighQuality
en	I-Premise	HighQuality
situaciones	I-Premise	HighQuality
sociales	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,016	I-Premise	HighQuality
)	I-Premise	HighQuality
y	I-Premise	HighQuality
la	I-Premise	HighQuality
confianza	I-Premise	HighQuality
en	I-Premise	HighQuality
evitar	I-Premise	HighQuality
más	I-Premise	HighQuality
ampliamente	I-Premise	HighQuality
problemas	I-Premise	HighQuality
graves	I-Premise	HighQuality
debido	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
hipoglucemia	I-Premise	HighQuality
(	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0020	I-Premise	HighQuality
).	I-Premise	HighQuality

Las	B-Premise	HighQuality
personas	I-Premise	HighQuality
también	I-Premise	HighQuality
reportaron	I-Premise	HighQuality
mayor	I-Premise	HighQuality
confianza	I-Premise	HighQuality
en	I-Premise	HighQuality
la	I-Premise	HighQuality
detección	I-Premise	HighQuality
y	I-Premise	HighQuality
respuesta	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
disminución	I-Premise	HighQuality
de	I-Premise	HighQuality
los	I-Premise	HighQuality
niveles	I-Premise	HighQuality
de	I-Premise	HighQuality
glucosa	I-Premise	HighQuality
en	I-Premise	HighQuality
sangre	I-Premise	HighQuality
(evitando	I-Premise	HighQuality
así	I-Premise	HighQuality
la	I-Premise	HighQuality
hipoglucemia	I-Premise	HighQuality
)	I-Premise	HighQuality
durante	I-Premise	HighQuality
el	I-Premise	HighQuality
uso	I-Premise	HighQuality
de	I-Premise	HighQuality
CGM	I-Premise	HighQuality
(P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,0033	I-Premise	HighQuality
)	I-Premise	HighQuality
e	O	-
indicaron	B-Premise	HighQuality
mayor	I-Premise	HighQuality
convicción	I-Premise	HighQuality
de	I-Premise	HighQuality
que	I-Premise	HighQuality
podrían	I-Premise	HighQuality
vivir	I-Premise	HighQuality
más	I-Premise	HighQuality
libremente	I-Premise	HighQuality
sus	I-Premise	HighQuality
vidas	I-Premise	HighQuality
a	I-Premise	HighQuality
pesar	I-Premise	HighQuality
del	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
hipoglucemia	I-Premise	HighQuality
(P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,022	I-Premise	HighQuality
).	I-Premise	HighQuality

La	B-Claim	HighQuality
CGM	I-Claim	HighQuality
redujo	I-Claim	HighQuality
el	I-Claim	HighQuality
tiempo	I-Claim	HighQuality
en	I-Claim	HighQuality
hipoglucemia	I-Claim	HighQuality
nocturna	I-Claim	HighQuality
y	I-Claim	HighQuality
diurna	I-Claim	HighQuality
en	I-Claim	HighQuality
personas	I-Claim	HighQuality
con	I-Claim	HighQuality
diabetes	I-Claim	HighQuality
tipo	I-Claim	HighQuality
1	I-Claim	HighQuality
tratadas	I-Claim	HighQuality
con	I-Claim	HighQuality
IDM	I-Claim	HighQuality
y	I-Claim	HighQuality
mejoró	I-Claim	HighQuality
la	I-Claim	HighQuality
confianza	I-Claim	HighQuality
relacionada	I-Claim	HighQuality
con	I-Claim	HighQuality
la	I-Claim	HighQuality
hipoglucemia,	I-Claim	HighQuality
especialmente	I-Claim	HighQuality
en	I-Claim	HighQuality
situaciones	I-Claim	HighQuality
sociales,	I-Claim	HighQuality
contribuyendo	I-Claim	HighQuality
así	I-Claim	HighQuality
a	I-Claim	HighQuality
un	I-Claim	HighQuality
mayor	I-Claim	HighQuality
bienestar	I-Claim	HighQuality
y	I-Claim	HighQuality
calidad	I-Claim	HighQuality
de	I-Claim	HighQuality
vida.	I-Claim	HighQuality

Para	O	-
investigar	O	-
los	O	-
factores	O	-
de	O	-
riesgo	O	-
asociados	O	-
con	O	-
la	O	-
progresión	O	-
del	O	-
campo	O	-
visual	O	-
en	O	-
el	O	-
Estudio	O	-
de	O	-
Tratamiento	O	-
del	O	-
Glaucoma	O	-
de	O	-
Baja	O	-
Presión,	O	-
un	O	-
ensayo	O	-
prospectivo	O	-
diseñado	O	-
para	O	-
comparar	O	-
los	O	-
efectos	O	-
del	O	-
tartrato	O	-
de	O	-
brimonidina	O	-
agonista	O	-
alfa2-adrenérgico	O	-
0,2	O	-
%	O	-
con	O	-
el	O	-
maleato	O	-
de	O	-
timolol	O	-
antagonista	O	-
beta-adrenérgico	O	-
0,5	O	-
%	O	-
sobre	O	-
la	O	-
función	O	-
visual	O	-
en	O	-
el	O	-
glaucoma	O	-
de	O	-
baja	O	-
presión.	O	-

Estudio	O	-
prospectivo	O	-
de	O	-
cohortes.	O	-

Tratamiento	O	-
del	O	-
glaucoma	O	-
a	O	-
baja	O	-
presión	O	-
Se	O	-
incluyeron	O	-
pacientes	O	-
del	O	-
estudio	O	-
con	O	-
≥5	O	-
pruebas	O	-
de	O	-
campo	O	-
visual	O	-
durante	O	-
el	O	-
seguimiento.	O	-

La	O	-
progresión	O	-
se	O	-
determinó	O	-
mediante	O	-
el	O	-
análisis	O	-
de	O	-
regresión	O	-
lineal	O	-
puntual,	O	-
definido	O	-
como	O	-
los	O	-
mismos	O	-
3	O	-
o	O	-
más	O	-
lugares	O	-
de	O	-
campo	O	-
visual	O	-
con	O	-
una	O	-
pendiente	O	-
más	O	-
negativa	O	-
que	O	-
-1,0	O	-
dB/año	O	-
en	O	-
P	O	-
<	O	-
5	O	-
%,	O	-
en	O	-
3	O	-
pruebas	O	-
consecutivas.	O	-

Los	O	-
factores	O	-
de	O	-
riesgo	O	-
ocular	O	-
y	O	-
sistémico	O	-
fueron	O	-
analizados	O	-
utilizando	O	-
el	O	-
modelo	O	-
de	O	-
riesgos	O	-
proporcionales	O	-
Cox	O	-
y	O	-
posteriormente	O	-
probados	O	-
para	O	-
la	O	-
independencia	O	-
en	O	-
un	O	-
modelo	O	-
multivariado.	O	-

Se	O	-
analizó	O	-
un	O	-
total	O	-
de	O	-
253	O	-
ojos	O	-
de	O	-
127	O	-
sujetos	O	-
(edad	O	-
media,	O	-
64,7	O	-
10,9	O	-
años;	O	-
seguimiento	O	-
medio,	O	-
40,6	O	-
12	O	-
meses).	O	-

Los	B-Premise	HighQuality
ojos	I-Premise	HighQuality
aleatorizados	I-Premise	HighQuality
a	I-Premise	HighQuality
timolol	I-Premise	HighQuality
progresaron	I-Premise	HighQuality
más	I-Premise	HighQuality
rápido	I-Premise	HighQuality
que	I-Premise	HighQuality
los	I-Premise	HighQuality
aleatorizados	I-Premise	HighQuality
a	I-Premise	HighQuality
brimonidina	I-Premise	HighQuality
(tasas	I-Premise	HighQuality
medias	I-Premise	HighQuality
de	I-Premise	HighQuality
progresión,	I-Premise	HighQuality
-0,38	I-Premise	HighQuality
0,9	I-Premise	HighQuality
vs	I-Premise	HighQuality
0,02	I-Premise	HighQuality
0,7	I-Premise	HighQuality
dB/y,	I-Premise	HighQuality
p	I-Premise	HighQuality
<	I-Premise	HighQuality
0,01	I-Premise	HighQuality
).	I-Premise	HighQuality

En	O	-
el	O	-
modelo	O	-
multivariado	O	-
final	O	-
de	O	-
ajuste	O	-
para	O	-
todas	O	-
las	O	-
covariables	O	-
probadas,	O	-
edad	B-Premise	HighQuality
avanzada	I-Premise	HighQuality
(hazard	I-Premise	HighQuality
ratio	I-Premise	HighQuality
[	I-Premise	HighQuality
HR	I-Premise	HighQuality
]	I-Premise	HighQuality
=	I-Premise	HighQuality
1,41/decade	I-Premise	HighQuality
mayor,	I-Premise	HighQuality
intervalo	I-Premise	HighQuality
de	I-Premise	HighQuality
confianza	I-Premise	HighQuality
del	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
[	I-Premise	HighQuality
IC	I-Premise	HighQuality
]	I-Premise	HighQuality
=	I-Premise	HighQuality
1,05	I-Premise	HighQuality
a	I-Premise	HighQuality
1,90,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,022	I-Premise	HighQuality
),	I-Premise	HighQuality
uso	I-Premise	HighQuality
de	I-Premise	HighQuality
antihipertensivos	I-Premise	HighQuality
sistémicos	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
=	I-Premise	HighQuality
2,53,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
1,32	I-Premise	HighQuality
a	I-Premise	HighQuality
4,87,	I-Premise	HighQuality
P	I-Premise	HighQuality
=	I-Premise	HighQuality
0,005	I-Premise	HighQuality
),	I-Premise	HighQuality
y	I-Premise	HighQuality
presión	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
perfusión	I-Premise	HighQuality
ocular	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
=	I-Premise	HighQuality
1,21/mm	I-Premise	HighQuality
Hg	I-Premise	HighQuality
menor,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
1,12	I-Premise	HighQuality
a	I-Premise	HighQuality
1,31,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
)	I-Premise	HighQuality
se	I-Premise	HighQuality
asociaron	I-Premise	HighQuality
con	I-Premise	HighQuality
progresión	I-Premise	HighQuality
mientras	O	-
que	O	-
la	B-Premise	HighQuality
aleatorización	I-Premise	HighQuality
a	I-Premise	HighQuality
la	I-Premise	HighQuality
brimonidina	I-Premise	HighQuality
reveló	I-Premise	HighQuality
un	I-Premise	HighQuality
efecto	I-Premise	HighQuality
protector	I-Premise	HighQuality
(	I-Premise	HighQuality
HR	I-Premise	HighQuality
=	I-Premise	HighQuality
0,26,	I-Premise	HighQuality
IC	I-Premise	HighQuality
95	I-Premise	HighQuality
%	I-Premise	HighQuality
=	I-Premise	HighQuality
0,12	I-Premise	HighQuality
a	I-Premise	HighQuality
0,55,	I-Premise	HighQuality
P	I-Premise	HighQuality
<	I-Premise	HighQuality
0,001	I-Premise	HighQuality
).	I-Premise	HighQuality

Mientras	O	-
que	O	-
la	B-Premise	HighQuality
aleatorización	I-Premise	HighQuality
a	I-Premise	HighQuality
brimonidina	I-Premise	HighQuality
0,2	I-Premise	HighQuality
%	I-Premise	HighQuality
fue	I-Premise	HighQuality
protectora	I-Premise	HighQuality
en	I-Premise	HighQuality
comparación	I-Premise	HighQuality
con	I-Premise	HighQuality
timolol	I-Premise	HighQuality
0,5	I-Premise	HighQuality
%,	I-Premise	HighQuality
la	B-Premise	HighQuality
menor	I-Premise	HighQuality
presión	I-Premise	HighQuality
media	I-Premise	HighQuality
de	I-Premise	HighQuality
perfusión	I-Premise	HighQuality
ocular	I-Premise	HighQuality
aumentó	I-Premise	HighQuality
el	I-Premise	HighQuality
riesgo	I-Premise	HighQuality
de	I-Premise	HighQuality
alcanzar	I-Premise	HighQuality
un	I-Premise	HighQuality
resultado	I-Premise	HighQuality
de	I-Premise	HighQuality
progresión	I-Premise	HighQuality
en	I-Premise	HighQuality
el	I-Premise	HighQuality
Estudio	I-Premise	HighQuality
de	I-Premise	HighQuality
Tratamiento	I-Premise	HighQuality
de	I-Premise	HighQuality
Glaucoma	I-Premise	HighQuality
de	I-Premise	HighQuality
Baja	I-Premise	HighQuality
Presión.	I-Premise	HighQuality

Esto	B-Claim	HighQuality
sugiere	I-Claim	HighQuality
que	I-Claim	HighQuality
el	I-Claim	HighQuality
efecto	I-Claim	HighQuality
beneficioso	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
aleatorización	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
brazo	I-Claim	HighQuality
de	I-Claim	HighQuality
brimonidina	I-Claim	HighQuality
fue	I-Claim	HighQuality
independiente	I-Claim	HighQuality
de	I-Claim	HighQuality
las	I-Claim	HighQuality
posibles	I-Claim	HighQuality
diferencias	I-Claim	HighQuality
en	I-Claim	HighQuality
las	I-Claim	HighQuality
presiones	I-Claim	HighQuality
de	I-Claim	HighQuality
perfusión	I-Claim	HighQuality
ocular	I-Claim	HighQuality
entre	I-Claim	HighQuality
los	I-Claim	HighQuality
dos	I-Claim	HighQuality
brazos	I-Claim	HighQuality
de	I-Claim	HighQuality
tratamiento.	I-Claim	HighQuality

Los	B-Claim	HighQuality
resultados	I-Claim	HighQuality
actuales	I-Claim	HighQuality
y	I-Claim	HighQuality
el	I-Claim	HighQuality
gran	I-Claim	HighQuality
número	I-Claim	HighQuality
de	I-Claim	HighQuality
abandonos	I-Claim	HighQuality
en	I-Claim	HighQuality
el	I-Claim	HighQuality
grupo	I-Claim	HighQuality
de	I-Claim	HighQuality
brimonidina	I-Claim	HighQuality
0,2	I-Claim	HighQuality
%	I-Claim	HighQuality
sugieren	I-Claim	HighQuality
que	I-Claim	HighQuality
es	I-Claim	HighQuality
necesaria	I-Claim	HighQuality
más	I-Claim	HighQuality
investigación	I-Claim	HighQuality
antes	I-Claim	HighQuality
de	I-Claim	HighQuality
alterar	I-Claim	HighQuality
los	I-Claim	HighQuality
paradigmas	I-Claim	HighQuality
de	I-Claim	HighQuality
la	I-Claim	HighQuality
práctica	I-Claim	HighQuality
clínica.	I-Claim	HighQuality

